organonitrogen heterocyclic antibiotic - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	organonitrogen heterocyclic antibiotic	go back to main search page
Accession:	CHEBI:25558	browse the term
Synonyms:	related_synonym:	organonitrogen heterocyclic antibiotics

show annotations for term's descendants Sort by:
Rat (3036 ) Mouse (3125 ) Human (3060 ) Chinchilla (0 ) Bonobo (0 ) Dog (9 ) Squirrel (0 ) Pig (6 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (3036)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 3

increases expression
multiple interactions

ISO

Anisomycin results in increased expression of ABCC3 mRNA
SB 203580 inhibits the reaction [Anisomycin results in increased expression of ABCC3 mRNA]

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

actin alpha 2, smooth muscle

multiple interactions

ISO

Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

advanced glycosylation end product-specific receptor

increases expression

ISO

Anisomycin results in increased expression of AGER protein

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

argonaute RISC catalytic component 2

increases phosphorylation

ISO

Anisomycin results in increased phosphorylation of AGO2 protein

NCBI chr 7:106,907,209...106,994,124
Ensembl chr 7:106,918,125...106,993,980

G

aryl hydrocarbon receptor

multiple interactions
decreases expression

ISO

Anisomycin promotes the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein]
Anisomycin results in decreased expression of AHR protein

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

activity-regulated cytoskeleton-associated protein

decreases expression

ISO

anisomycin decreases expression of Arc protein in dorsal striatum

RGD

NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:108,444,692...108,451,220

G

activating transcription factor 1

increases phosphorylation
multiple interactions

ISO

Anisomycin results in increased phosphorylation of ATF1 protein
[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Anisomycin results in increased phosphorylation of ATF1 protein]; SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of ATF1 protein]

NCBI chr 7:133,240,774...133,283,488
Ensembl chr 7:133,241,197...133,283,485

G

activating transcription factor 2

increases phosphorylation
multiple interactions

ISO

Anisomycin results in increased phosphorylation of ATF2 protein
pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of ATF2 protein]

PMID:12663670 PMID:28975372

NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745

G

activating transcription factor 3

multiple interactions
increases expression

ISO

[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of ATF3 mRNA]

PMID:19101521 PMID:22003189

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

autophagy related 13

decreases expression

ISO

Anisomycin results in decreased expression of ATG13 protein

NCBI chr 3:98,102,831...98,136,741
Ensembl chr 3:98,101,552...98,136,743

G

autophagy related 4B, cysteine peptidase

decreases expression

ISO

Anisomycin results in decreased expression of ATG4B protein

NCBI chr 9:101,729,772...101,761,456
Ensembl chr 9:101,726,782...101,761,622

G

BTB domain and CNC homolog 2

increases expression

ISO

Anisomycin results in increased expression of BACH2 mRNA

NCBI chr 5:51,428,802...51,779,030
Ensembl chr 5:51,434,870...51,774,234

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

Anisomycin promotes the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

EXP

[Colistin co-treated with Anisomycin] results in increased phosphorylation of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

beclin 1

multiple interactions

EXP

Anisomycin promotes the reaction [Colistin results in increased expression of BECN1 protein]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

BH3 interacting domain death agonist

multiple interactions

ISO

Anisomycin results in increased cleavage of and results in increased activity of BID protein

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

baculoviral IAP repeat-containing 5

multiple interactions

ISO

Anisomycin promotes the reaction [(+)-JQ1 compound results in decreased expression of BIRC5 protein]

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

caspase 3

multiple interactions
increases expression

ISO
EXP

Anisomycin promotes the reaction [Indomethacin results in increased activity of CASP3 protein]; Anisomycin results in increased cleavage of and results in increased activity of CASP3 protein
Anisomycin results in increased expression of CASP3 protein modified form
[Colistin co-treated with Anisomycin] results in increased cleavage of CASP3 protein; Anisomycin inhibits the reaction [gamma-glutamylcysteine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of CASP3 protein]]
Anisomycin promotes the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]

PMID:17341418 PMID:18241849 PMID:28842171 PMID:29944914 PMID:33684387 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 6

multiple interactions

ISO

Anisomycin promotes the reaction [Indomethacin results in increased activity of CASP6 protein]

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

caspase 8

increases activity

ISO

Anisomycin results in increased activity of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

multiple interactions

ISO
EXP

Anisomycin promotes the reaction [Indomethacin results in increased activity of CASP9 protein]
Anisomycin inhibits the reaction [gamma-glutamylcysteine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of CASP9 protein]]

PMID:17341418 PMID:34767868

Ensembl chr 5:159,391,188...159,409,648

G

caveolin 1

multiple interactions
increases phosphorylation

ISO

wogonin inhibits the reaction [Anisomycin results in increased phosphorylation of CAV1 protein]

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

C-C motif chemokine ligand 2

decreases expression

ISO

Anisomycin results in decreased expression of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 4

decreases expression

ISO

Anisomycin results in decreased expression of CCL4 protein

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 5

decreases expression

ISO

Anisomycin results in decreased expression of CCL5 protein

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

CD55 molecule (Cromer blood group)

increases expression

ISO

Anisomycin results in increased expression of CD55 mRNA

NCBI chr13:44,409,574...44,438,913
Ensembl chr13:44,409,587...44,438,107

G

Cd69 molecule

increases expression

ISO

Anisomycin results in increased expression of CD69 mRNA

NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:164,411,485...164,419,509

G

claudin 1

multiple interactions

ISO

Anisomycin inhibits the reaction [TES protein inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of CLDN1 protein]]

NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529

G

collagen type I alpha 1 chain

multiple interactions

ISO

Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

cAMP responsive element binding protein 1

increases phosphorylation
multiple interactions

ISO

Anisomycin results in increased phosphorylation of CREB1 protein
SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of CREB1 protein]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

CREB binding protein

increases expression

ISO

Anisomycin results in increased expression of CREBBP mRNA

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

citrate synthase

multiple interactions

ISO

Anisomycin affects the reaction [triethylene glycol dimethacrylate affects the activity of CS protein]

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

C-X-C motif chemokine ligand 1

multiple interactions
increases expression

ISO

[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL1 mRNA]

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 3

increases expression
multiple interactions

ISO

Anisomycin results in increased expression of CXCL1 mRNA
[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL1 mRNA]

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

ISO

Anisomycin results in increased expression of CYP1A1 mRNA
[Anisomycin co-treated with Tetrachlorodibenzodioxin] results in increased expression of CYP1A1 mRNA

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

ISO

Anisomycin inhibits the reaction [Tretinoin results in increased expression of CYP26A1 mRNA]

NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657

G

cytochrome P450, family 2, subfamily a, polypeptide 3

multiple interactions

ISO

1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [[Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2A7 mRNA]; [Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2A7 mRNA

NCBI chr 1:91,299,584...91,307,650
Ensembl chr 1:91,299,561...91,307,649

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2B6 mRNA
Anisomycin promotes the reaction [[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with NR1I3 protein] results in increased expression of CYP2B6 mRNA]

NCBI chr 1:90,780,468...90,859,852

G

DNA-damage inducible transcript 3

increases expression

ISO

Anisomycin results in increased expression of DDIT3 mRNA

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

dual specificity phosphatase 6

decreases expression

ISO

Anisomycin results in decreased expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

dual specificity phosphatase 8

multiple interactions

ISO

DUSP8 protein inhibits the reaction [Anisomycin results in increased phosphorylation of JUN protein]; DUSP8 protein inhibits the reaction [Anisomycin results in increased phosphorylation of NR3C1 protein]

NCBI chr 1:206,596,912...206,613,728
Ensembl chr 1:206,598,942...206,612,441

G

early growth response 1

multiple interactions
increases expression

ISO

SB 203580 inhibits the reaction [Anisomycin results in increased expression of EGR1 mRNA]

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

eukaryotic translation initiation factor 4E

increases phosphorylation
multiple interactions

ISO

Anisomycin results in increased phosphorylation of EIF4E protein
SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of EIF4E protein]

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105

G

ETS transcription factor ELK1

increases phosphorylation
multiple interactions

ISO

Anisomycin results in increased phosphorylation of ELK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Anisomycin results in increased phosphorylation of ELK1 protein]; pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of ELK1 protein]

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249

G

ecotropic viral integration site 2A

increases expression

ISO

Anisomycin results in increased expression of EVI2A mRNA

NCBI chr10:64,983,727...64,987,627
Ensembl chr10:64,983,705...64,999,516

G

Fas cell surface death receptor

increases localization

ISO

Anisomycin results in increased localization of FAS protein

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Anisomycin results in increased expression of FOS mRNA

PMID:12660819 PMID:18241849

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Anisomycin results in increased expression of FOSB mRNA

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477

G

forkhead box O1

multiple interactions

ISO

Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in decreased phosphorylation of FOXO1 protein]]; Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased expression of FOXO1 protein]]

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

ghrelin and obestatin prepropeptide

multiple interactions

ISO

Anisomycin inhibits the reaction [GHRL protein inhibits the reaction [Uranium results in decreased expression of and results in decreased secretion of TNFRSF11B protein]]; Anisomycin inhibits the reaction [GHRL protein inhibits the reaction [Uranium results in increased expression of and results in increased secretion of TNFSF11 protein]]

NCBI chr 4:148,421,315...148,431,128
Ensembl chr 4:148,421,315...148,425,969

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions

EXP

anisomycin inhibits the reaction [CNQX increases expression of Gria1 protein in nucleus accumbens cultured cells]

RGD

NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions

EXP

anisomycin inhibits the reaction [CNQX increases expression of Gria2 protein in nucleus accumbens cultured cells]

RGD

NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616

G

homeobox A1

multiple interactions

ISO

Anisomycin promotes the reaction [Tretinoin results in increased expression of HOXA1 mRNA]

NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209

G

heat shock protein family A (Hsp70) member 5

decreases expression

ISO

Anisomycin results in decreased expression of HSPA5 mRNA; Anisomycin results in decreased expression of HSPA5 protein

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

heat shock protein family A (Hsp70) member 9

multiple interactions

EXP

Anisomycin inhibits the reaction [Cocaine results in increased expression of HSPA9 protein]

NCBI chr18:26,810,004...26,832,958
Ensembl chr18:26,804,774...26,828,398

G

intercellular adhesion molecule 1

multiple interactions

ISO

Anisomycin inhibits the reaction [TNF protein results in increased expression of and affects the localization of ICAM1 protein]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon gamma

multiple interactions

EXP

Anisomycin inhibits the reaction [neohesperidin results in decreased secretion of IFNG protein]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor 1

multiple interactions

ISO

Anisomycin promotes the reaction [IGF1 protein results in increased phosphorylation of JUN protein]

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

interleukin 1 beta

increases expression
multiple interactions

ISO

Anisomycin results in increased expression of IL1B protein
Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]]
Anisomycin inhibits the reaction [rutecarpine inhibits the reaction [Glucose results in increased expression of IL1B protein]]

PMID:15019843 PMID:36928891 PMID:39237074

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 27

multiple interactions

EXP

Anisomycin inhibits the reaction [neohesperidin results in increased secretion of IL27 protein]

NCBI chr 1:190,603,684...190,609,292
Ensembl chr 1:190,603,522...190,609,258

G

interleukin 4

multiple interactions

EXP

Anisomycin inhibits the reaction [neohesperidin results in increased secretion of IL4 protein]

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 6

multiple interactions

ISO
EXP

Anisomycin inhibits the reaction [rutecarpine inhibits the reaction [Glucose results in increased expression of IL6 protein]]
Anisomycin inhibits the reaction [neohesperidin results in decreased secretion of IL6 protein]
Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 mRNA]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein]]

PMID:33604646 PMID:36928891 PMID:39237074

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 receptor

decreases expression

ISO

Anisomycin results in decreased expression of IL6R protein modified form

NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases phosphorylation
increases expression

ISO
EXP

Anisomycin promotes the reaction [IGF1 protein results in increased phosphorylation of JUN protein]; DUSP8 protein inhibits the reaction [Anisomycin results in increased phosphorylation of JUN protein]
Anisomycin results in increased expression of JUN mRNA

PMID:9751194 PMID:11278392 PMID:15019843 PMID:18241849 PMID:21815634 More...

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

JunD proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Anisomycin results in increased expression of JUND mRNA

NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148

G

MAF bZIP transcription factor F

increases expression

ISO

Anisomycin results in increased expression of MAFF mRNA

NCBI chr 7:112,792,787...112,804,139
Ensembl chr 7:112,791,416...112,804,147

G

mitogen-activated protein kinase kinase kinase 20

multiple interactions

ISO

MAP3K20 protein promotes the reaction [Anisomycin results in increased phosphorylation of and results in increased activity of MAPK8 protein]; quinoline analog inhibits the reaction [MAP3K20 protein promotes the reaction [Anisomycin results in increased phosphorylation of and results in increased activity of MAPK8 protein]]

NCBI chr 3:77,538,146...77,697,540
Ensembl chr 3:77,537,956...77,697,538

G

mitogen activated protein kinase 1

multiple interactions
increases expression
increases phosphorylation
increases activity

ISO
EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Anisomycin results in increased phosphorylation of MAPK1 protein]; Anisomycin promotes the reaction [thymoquinone results in increased phosphorylation of MAPK1 protein]
Anisomycin results in increased expression of MAPK1 protein modified form
Anisomycin results in increased activity of MAPK1 protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Anisomycin results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Anisomycin results in increased phosphorylation of MAPK1 protein]

PMID:9671412 PMID:11551972 PMID:12660819 PMID:15772366 PMID:25233930 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 10

multiple interactions
increases activity

ISO

Dicumarol inhibits the reaction [Anisomycin results in increased activity of MAPK10 protein]

NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,802,295...7,094,100

G

mitogen activated protein kinase 14

multiple interactions
increases phosphorylation

ISO
EXP

Anisomycin results in increased phosphorylation of and results in increased activity of MAPK14 protein
Anisomycin results in increased phosphorylation of MAPK14 protein
MAPK14 protein affects the reaction [Anisomycin results in increased activity of MAPKAPK2 protein]

PMID:10704466 PMID:15961565 PMID:16038797 PMID:16364386

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

multiple interactions
increases expression
increases phosphorylation

ISO
EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Anisomycin results in increased phosphorylation of MAPK3 protein]; Anisomycin promotes the reaction [thymoquinone results in increased phosphorylation of MAPK3 protein]
Anisomycin results in increased expression of MAPK3 protein modified form
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Anisomycin results in increased phosphorylation of MAPK3 protein]

PMID:12660819 PMID:15772366 PMID:25233930 PMID:34173702

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

increases phosphorylation
increases activity
multiple interactions

ISO
EXP

Anisomycin results in increased phosphorylation of MAPK8 protein
Anisomycin results in increased activity of MAPK8 protein
Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK8 protein]]; Anisomycin inhibits the reaction [rutecarpine inhibits the reaction [Glucose results in increased phosphorylation of MAPK8 protein]]; Anisomycin results in increased phosphorylation of and results in increased activity of MAPK8 protein; MAP3K20 protein promotes the reaction [Anisomycin results in increased phosphorylation of and results in increased activity of MAPK8 protein]; quinoline analog inhibits the reaction [MAP3K20 protein promotes the reaction [Anisomycin results in increased phosphorylation of and results in increased activity of MAPK8 protein]]
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Anisomycin results in increased phosphorylation of MAPK8 protein]

PMID:12902192 PMID:12967334 PMID:15737997 PMID:15772366 PMID:15961565 More...

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 9

multiple interactions
increases phosphorylation

ISO

4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Anisomycin results in increased phosphorylation of MAPK9 protein]

PMID:12967334 PMID:15772366 PMID:16038797 PMID:33075463

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

MAPK activated protein kinase 2

increases activity
multiple interactions

ISO

Anisomycin results in increased activity of MAPKAPK2 protein
MAPK14 protein affects the reaction [Anisomycin results in increased activity of MAPKAPK2 protein]

NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326

G

MAPK interacting serine/threonine kinase 1

increases activity
multiple interactions

ISO

Anisomycin results in increased activity of MKNK1 protein
SB 203580 inhibits the reaction [Anisomycin results in increased activity of MKNK1 protein]

NCBI chr 5:134,554,881...134,594,392
Ensembl chr 5:134,554,943...134,594,393

G

mitochondrial ribosomal protein S30

increases expression

ISO

Anisomycin results in increased expression of MRPS30 mRNA

NCBI chr 2:52,189,049...52,196,136
Ensembl chr 2:52,189,058...52,195,904

G

MYC proto-oncogene, bHLH transcription factor

increases expression

ISO

Anisomycin results in increased expression of MYC mRNA

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

neurofilament heavy chain

decreases degradation

EXP

Anisomycin results in decreased degradation of NEFH mRNA

NCBI chr14:84,044,428...84,054,413
Ensembl chr14:84,044,023...84,054,417

G

neurofilament light chain

decreases degradation

EXP

Anisomycin results in decreased degradation of NEFL mRNA

NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515

G

neurofilament medium chain

decreases degradation

EXP

Anisomycin results in decreased degradation of NEFM mRNA

NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163

G

nucleotide-binding oligomerization domain containing 2

multiple interactions

ISO

[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of ATF3 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL1 mRNA]; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [Anisomycin results in increased expression of CXCL8 mRNA]

NCBI chr19:34,555,832...34,596,281
Ensembl chr19:34,555,832...34,722,846

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

ISO

1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [[Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2A7 mRNA]; [Anisomycin co-treated with 1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with NR1I3 protein] results in increased expression of CYP2C9 mRNA; [Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2A7 mRNA; Anisomycin promotes the reaction [[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with NR1I3 protein] results in increased expression of CYP2B6 mRNA]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Anisomycin co-treated with NR1I3 protein] results in increased expression of CYP2B6 mRNA

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

nuclear receptor subfamily 3, group C, member 1

increases phosphorylation
multiple interactions

ISO

Anisomycin results in increased phosphorylation of NR3C1 protein
DUSP8 protein inhibits the reaction [Anisomycin results in increased phosphorylation of NR3C1 protein]

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

poly (ADP-ribose) polymerase 1

multiple interactions

EXP

[Colistin co-treated with Anisomycin] results in increased cleavage of PARP1 protein; Anisomycin inhibits the reaction [gamma-glutamylcysteine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of PARP1 protein]]

PMID:28842171 PMID:34767868

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression

ISO

Anisomycin results in increased expression of PMAIP1 mRNA

NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382

G

periostin

increases expression

EXP

Anisomycin results in increased expression of POSTN mRNA

NCBI chr 2:140,677,774...140,709,304
Ensembl chr 2:140,677,754...140,709,300

G

protein tyrosine phosphatase, non-receptor type 5

multiple interactions

EXP

Anisomycin inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein]

NCBI chr 1:106,756,896...106,817,369
Ensembl chr 1:106,756,896...106,816,828

G

retinoic acid receptor, beta

multiple interactions

ISO

Anisomycin promotes the reaction [Tretinoin results in increased expression of RARB mRNA]

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased phosphorylation of RELA protein]]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

ret proto-oncogene

decreases expression

EXP

Anisomycin results in decreased expression of RET protein

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556

G

ras homolog family member H

increases expression

ISO

Anisomycin results in increased expression of RHOH mRNA

NCBI chr14:42,694,860...42,725,690
Ensembl chr14:42,693,413...42,749,967

G

RAR-related orphan receptor A

increases expression

ISO

Anisomycin results in increased expression of RORA mRNA

NCBI chr 8:78,182,710...78,915,730
Ensembl chr 8:78,182,620...78,915,730

G

retinoid X receptor alpha

increases phosphorylation
multiple interactions

ISO

Anisomycin results in increased phosphorylation of RXRA protein
pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of RXRA protein]

PMID:16038797 PMID:16184197

NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417

G

sequestosome 1

multiple interactions

EXP
ISO

Anisomycin promotes the reaction [Colistin results in increased degradation of SQSTM1 protein]
Anisomycin promotes the reaction [triethylene glycol dimethacrylate results in increased expression of SQSTM1 protein]

PMID:28842171 PMID:33684387

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

serum response factor

increases phosphorylation
multiple interactions

ISO

Anisomycin results in increased phosphorylation of SRF protein
SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of SRF protein]

NCBI chr 9:21,924,050...21,933,338
Ensembl chr 9:21,924,076...21,933,337

G

steroidogenic acute regulatory protein

multiple interactions

ISO

Anisomycin promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Anisomycin results in increased expression of and results in increased stability of STAR mRNA

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

testin LIM domain protein

multiple interactions

ISO

Anisomycin inhibits the reaction [TES protein inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of CLDN1 protein]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of TJP1 protein]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 mRNA]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF mRNA]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]]

NCBI chr 4:46,331,257...46,369,782
Ensembl chr 4:46,331,257...46,369,780

G

transforming growth factor, beta 1

multiple interactions

ISO

Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in decreased phosphorylation of FOXO1 protein]]; Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]]; Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]]; Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased expression of FOXO1 protein]]; Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK8 protein]]; Anisomycin inhibits the reaction [1-hydroxyalantolactone inhibits the reaction [TGFB1 protein results in increased phosphorylation of RELA protein]]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tight junction protein 1

multiple interactions

ISO

Anisomycin inhibits the reaction [TES protein inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of TJP1 protein]]

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

tumor necrosis factor

increases expression
multiple interactions

ISO
EXP

Anisomycin results in increased expression of TNF mRNA
Anisomycin inhibits the reaction [neohesperidin results in decreased secretion of TNF protein]
Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF mRNA]]; Anisomycin inhibits the reaction [TES protein inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]]
Anisomycin inhibits the reaction [rutecarpine inhibits the reaction [Glucose results in increased expression of TNF protein]]; Anisomycin inhibits the reaction [TNF protein results in increased expression of and affects the localization of ICAM1 protein]

PMID:18241849 PMID:21448188 PMID:33604646 PMID:36928891 PMID:39237074

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 11B

multiple interactions

ISO

Anisomycin inhibits the reaction [GHRL protein inhibits the reaction [Uranium results in decreased expression of and results in decreased secretion of TNFRSF11B protein]]

NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075

G

TNF superfamily member 11

multiple interactions

ISO

Anisomycin inhibits the reaction [GHRL protein inhibits the reaction [Uranium results in increased expression of and results in increased secretion of TNFSF11 protein]]

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

TNF superfamily member 9

increases expression
decreases expression

ISO

Anisomycin results in increased expression of TNFSF9 mRNA
Anisomycin results in decreased expression of TNFSF9 mRNA

PMID:18241849 PMID:24247028

NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:2,030,953...2,033,339

G

tumor protein p53

multiple interactions

EXP

Anisomycin promotes the reaction [Colistin results in increased expression of TP53 protein]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

thioredoxin interacting protein

increases expression

ISO

Anisomycin results in increased expression of TXNIP mRNA

NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731

G

unc-51 like autophagy activating kinase 1

decreases expression

ISO

Anisomycin results in decreased expression of ULK1 protein

NCBI chr12:51,511,492...51,537,746
Ensembl chr12:51,511,492...51,537,746

G

ubiquitin specific peptidase 30

increases expression

ISO

Anisomycin results in increased expression of USP30 mRNA

NCBI chr12:48,161,905...48,215,878
Ensembl chr12:48,161,908...48,215,968

G

vascular endothelial growth factor A

decreases expression

ISO

Anisomycin results in decreased expression of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

X-box binding protein 1

decreases splicing

ISO

Anisomycin results in decreased splicing of XBP1 mRNA

NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1 member B10

increases expression

ISO

Amoxicillin results in increased expression of AKR1B10 mRNA

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

ISO
EXP

Amoxicillin results in decreased phosphorylation of AKT1 protein
amoxicillin inhibits the reaction [Ethanol decreases phosphorylation of Akt1 protein in the prefrontal cortex

CTD
RGD

PMID:36529298 PMID:26168897

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

anti-Mullerian hormone

increases expression

ISO

Amoxicillin results in increased expression of AMH mRNA

NCBI chr 7:9,557,451...9,559,867
Ensembl chr 7:9,557,451...9,559,867

G

aquaporin 5

decreases expression

EXP

Amoxicillin results in decreased expression of AQP5 protein

NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:132,601,059...132,605,062

G

caspase 3

increases expression

ISO

Amoxicillin results in increased expression of CASP3 mRNA; Amoxicillin results in increased expression of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

catalase

decreases activity

EXP

Amoxicillin results in decreased activity of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-X-C motif chemokine ligand 10

decreases expression

ISO

Amoxicillin results in decreased expression of CXCL10 mRNA

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

ISO

Amoxicillin results in decreased expression of CYP11A1 mRNA

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 11, subfamily b, polypeptide 3

increases expression

ISO

Amoxicillin results in increased expression of CYP11B2

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

ISO

Amoxicillin results in decreased expression of CYP17A1 mRNA

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases expression

ISO

Amoxicillin results in increased expression of CYP19A1

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 2, subfamily c, polypeptide 79

multiple interactions
decreases activity

ISO

Amoxicillin inhibits the reaction [CYP2C8 protein results in decreased methylation of Aminopyrine]
Amoxicillin results in decreased activity of CYP2C8 protein

G

GDNF family receptor alpha 1

decreases expression

ISO

Amoxicillin results in decreased expression of GFRA1 mRNA

NCBI chr 1:267,325,297...267,557,037
Ensembl chr 1:267,326,817...267,556,501

G

glutathione-disulfide reductase

decreases activity

ISO

Amoxicillin results in decreased activity of GSR protein

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

mitogen activated protein kinase 1

decreases phosphorylation

ISO

Amoxicillin results in decreased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation

ISO

Amoxicillin results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

marker of proliferation Ki-67

decreases expression

ISO

Amoxicillin results in decreased expression of MKI67 mRNA; Amoxicillin results in decreased expression of MKI67 protein

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

Amoxicillin results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 5, group A, member 1

decreases expression

ISO

Amoxicillin results in decreased expression of NR5A1 mRNA

NCBI chr 3:42,874,505...42,896,109
Ensembl chr 3:42,875,221...42,896,046

G

proliferating cell nuclear antigen

decreases expression

ISO

Amoxicillin results in decreased expression of PCNA mRNA; Amoxicillin results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

RT1 class II, locus Bb

affects expression

ISO

Amoxicillin affects the expression of HLA-DQB1 mRNA

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118

G

solute carrier family 1 member 2

multiple interactions

EXP

amoxicillin inhibits the reaction [ethanol decreases expression of Slc1a2 protein in prefrontal cortex]
amoxicillin inhibits the reaction [ethanol decreases expression of Slc1a2 protein in nucleus accumbens]

RGD

PMID:26168897 PMID:27199635

RGD:598147077, RGD:598154609

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 51 member A

increases expression

ISO

Amoxicillin results in increased expression of SLC51A mRNA

NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539

G

solute carrier family 7 member 11

multiple interactions

EXP

amoxicillin inhibits the reaction [ethanol decreases expression of Slc7a11 protein in nucleus accumbens and prefrontal cortex]

RGD

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

sulfiredoxin 1

increases expression

ISO

Amoxicillin results in increased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

steroidogenic acute regulatory protein

decreases expression

ISO

Amoxicillin results in decreased expression of STAR mRNA; Amoxicillin results in decreased expression of STAR protein

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

zinc finger and BTB domain containing 16

decreases expression

ISO

Amoxicillin results in decreased expression of ZBTB16 mRNA; Amoxicillin results in decreased expression of ZBTB16 protein

NCBI chr 8:57,885,886...58,073,507
Ensembl chr 8:57,891,081...58,073,507

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

ISO

[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCA1 mRNA

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily B member 11

multiple interactions

ISO

[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB11 mRNA

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB1A mRNA

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 2

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

decreases expression
multiple interactions

ISO

Ampicillin results in decreased expression of ABCC3 mRNA
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC3 mRNA

PMID:21632981 PMID:36464106

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 4

increases transport

ISO

ABCC4 protein results in increased transport of Ampicillin

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

ATP binding cassette subfamily G member 2

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

ATP binding cassette subfamily G member 5

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA

NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376

G

acetyl-CoA carboxylase alpha

multiple interactions

ISO

[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of ACACA protein]

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

acetyl-CoA carboxylase beta

multiple interactions

ISO

[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of ACACB protein]

NCBI chr12:48,026,394...48,138,214
Ensembl chr12:48,026,394...48,138,214

G

acetyl-CoA acetyltransferase 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2 protein

NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095

G

acetyl-CoA acetyltransferase 2-like 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2L1 protein

NCBI chr 1:50,341,596...50,376,961
Ensembl chr 1:50,359,869...50,376,959

G

angiotensin converting enzyme 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACE2 protein

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

advanced glycosylation end product-specific receptor

decreases expression

ISO

Ampicillin results in decreased expression of AGER mRNA

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

alpha-2-HS-glycoprotein

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of AHSG protein

NCBI chr11:91,625,975...91,632,583
Ensembl chr11:91,625,975...91,634,039

G

aldo-keto reductase family 1 member B10

decreases expression

ISO

Ampicillin results in decreased expression of AKR1B10 mRNA

PMID:21632981 PMID:26198647

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

G

aldo-keto reductase family 1, member C2

decreases expression

ISO

Ampicillin results in decreased expression of AKR1C2 mRNA

NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686

G

AKT serine/threonine kinase 1

increases phosphorylation

EXP

ampicillin cotreated ethanol increases phosphorylation of Akt1 protein in nucleus accumbens and prefrontal cortex

RGD

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldolase, fructose-bisphosphate A

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOA protein

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

aldolase, fructose-bisphosphate B

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOB protein

NCBI chr 5:68,684,541...68,697,582
Ensembl chr 5:68,684,542...68,716,740

G

angiomotin

increases expression

ISO

Ampicillin results in increased expression of AMOT mRNA

NCBI chr X:113,778,990...113,837,846
Ensembl chr X:113,781,526...113,837,482

G

amylase 2a3

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of AMY2A3 protein

NCBI chr 2:204,005,840...204,014,412
Ensembl chr 2:204,005,840...204,014,413

G

ankyrin repeat domain 1

increases expression

ISO

Ampicillin results in increased expression of ANKRD1 mRNA

NCBI chr 1:243,228,460...243,237,014
Ensembl chr 1:243,228,448...243,263,751

G

aquaporin 3 (Gill blood group)

decreases expression

ISO

Ampicillin results in decreased expression of AQP3 mRNA

NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685

G

arginase 1

increases expression

ISO

Ampicillin results in increased expression of ARG1 mRNA

NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713

G

arginase 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ARG2 protein

NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:103,668,988...103,694,375

G

Rho GDP dissociation inhibitor alpha

increases expression

ISO

Ampicillin results in increased expression of ARHGDIA mRNA

NCBI chr10:106,352,858...106,356,347
Ensembl chr10:106,353,491...106,356,347

G

actin related protein 2/3 complex, subunit 3

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ARPC3 protein

NCBI chr12:39,833,569...39,847,436
Ensembl chr12:39,833,569...39,847,436

G

arrestin domain containing 3

decreases expression

ISO

Ampicillin results in decreased expression of ARRDC3 mRNA

NCBI chr 2:12,873,202...12,885,716
Ensembl chr 2:12,873,202...12,885,875

G

arrestin domain containing 4

decreases expression

ISO

Ampicillin results in decreased expression of ARRDC4 mRNA

NCBI chr 1:131,779,436...131,793,438
Ensembl chr 1:131,779,437...131,793,565

G

N-acylsphingosine amidohydrolase 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ASAH1 protein

NCBI chr16:57,669,927...57,701,349
Ensembl chr16:57,669,750...57,718,305

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

ISO

Ampicillin results in decreased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP1A1 protein

NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP2A3 protein

NCBI chr10:58,079,710...58,111,279
Ensembl chr10:58,079,852...58,111,278

G

ATP synthase membrane subunit f

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5MF protein

NCBI chr12:14,535,435...14,542,007
Ensembl chr12:14,522,832...14,542,709

G

ATP synthase peripheral stalk subunit d

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PD protein

NCBI chr10:101,156,673...101,161,926
Ensembl chr10:101,156,673...101,162,954

G

ATP synthase peripheral stalk subunit F6

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PF protein

NCBI chr11:37,368,045...37,375,721
Ensembl chr11:37,368,042...37,375,466

G

Beta-1,3-galactosyltransferase 5

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of B3GALT5 protein

NCBI chr11:49,053,959...49,100,398
Ensembl chr11:49,006,560...49,101,283

G

BCL2 associated X, apoptosis regulator

increases response to substance

ISO

BAX results in increased susceptibility to Ampicillin

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BPI fold containing family B, member 2

increases expression

ISO

Ampicillin results in increased expression of BPIFB2 mRNA

NCBI chr 3:162,818,223...162,837,219
Ensembl chr 3:162,818,223...162,837,210

G

carbonic anhydrase 9

increases expression

ISO

Ampicillin results in increased expression of CA9 mRNA

NCBI chr 5:62,559,024...62,565,626
Ensembl chr 5:62,558,823...62,565,626

G

calreticulin

increases expression

ISO

Ampicillin results in increased expression of CALR mRNA

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236

G

cellular communication network factor 1

increases expression

ISO

Ampicillin results in increased expression of CCN1 mRNA

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cell cycle progression 1

decreases expression

ISO

Ampicillin results in decreased expression of CCPG1 mRNA

NCBI chr 8:82,600,677...82,633,082
Ensembl chr 8:82,600,536...82,660,246

G

CD40 molecule

increases expression

ISO

Ampicillin results in increased expression of CD40 mRNA

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

carboxylesterase 1D

increases expression

ISO

Ampicillin results in increased expression of CES1 mRNA

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carbohydrate sulfotransferase 15

increases expression

ISO

Ampicillin results in increased expression of CHST15 mRNA

NCBI chr 1:196,458,978...196,540,088
Ensembl chr 1:196,460,425...196,491,444

G

creatine kinase B

increases expression

ISO

Ampicillin results in increased expression of CKB mRNA

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478

G

chloride channel accessory 4

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLCA4 protein

NCBI chr 2:236,543,975...236,565,096
Ensembl chr 2:236,544,201...236,563,435

G

claudin 5

multiple interactions

ISO

[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 protein]

NCBI chr11:95,717,172...95,718,598
Ensembl chr11:95,717,176...95,719,322

G

claudin 7

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLDN7 protein

NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905

G

calmegin

decreases expression

ISO

Ampicillin results in decreased expression of CLGN mRNA

NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325

G

chloride intracellular channel 3

increases expression

ISO

Ampicillin results in increased expression of CLIC3 mRNA

NCBI chr 3:28,670,176...28,672,166
Ensembl chr 3:28,670,229...28,675,723

G

carboxymethylenebutenolidase homolog

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CMBL protein

NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880

G

carnosine dipeptidase 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CNDP2 protein

NCBI chr18:80,314,799...80,331,900
Ensembl chr18:80,314,801...80,331,900

G

cytochrome c oxidase subunit 5A

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX5A protein

NCBI chr 8:66,818,284...66,829,691
Ensembl chr 8:66,818,196...66,830,279

G

cytochrome c oxidase subunit 6B1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX6B1 protein

NCBI chr 1:95,002,513...95,011,516
Ensembl chr 1:95,001,707...95,011,431
Ensembl chr 5:95,001,707...95,011,431

G

cytochrome c oxidase subunit 6C

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX6C2 protein

NCBI chr 7:69,014,410...69,027,145
Ensembl chr 7:69,014,417...69,027,166

G

cytochrome c oxidase subunit 7A2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX7A2 protein

NCBI chr 8:89,597,051...89,611,032
Ensembl chr14:55,514,261...55,514,512
Ensembl chr 8:55,514,261...55,514,512

G

ceruloplasmin

increases expression

ISO

Ampicillin results in increased expression of CP mRNA

NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087

G

cAMP responsive element binding protein 3-like 3

decreases expression

ISO

Ampicillin results in decreased expression of CREB3L3 mRNA

NCBI chr 7:9,273,320...9,281,755
Ensembl chr 7:9,273,338...9,281,778

G

colony stimulating factor 2

multiple interactions

ISO

[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of CSF2 protein

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

cystatin A

decreases expression

ISO

Ampicillin results in decreased expression of CSTA mRNA

NCBI chr11:78,125,813...78,136,818
Ensembl chr11:78,125,800...78,136,822

G

cathepsin A

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CTSA protein

NCBI chr 3:173,988,443...173,994,320
Ensembl chr 3:173,988,460...173,995,539

G

C-X-C motif chemokine ligand 2

increases expression

ISO

Ampicillin results in increased expression of CXCL2 mRNA

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases expression

ISO

Ampicillin results in decreased expression of CYP1A1 mRNA

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 24, subfamily a, polypeptide 1

decreases expression

ISO

Ampicillin results in decreased expression of CYP24A1 mRNA

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, subfamily 2, polypeptide 11

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2C11 mRNA

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853

G

cytochrome P450, family 2, subfamily d, polypeptide 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2D2 mRNA

NCBI chr 7:115,815,212...115,819,281
Ensembl chr 7:115,815,212...115,819,281

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2E1 mRNA

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP3A2 mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA]; [Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of CYP7A1 protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA

PMID:36464106 PMID:37211107

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

ISO

[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

dickkopf WNT signaling pathway inhibitor 1

increases expression

ISO

Ampicillin results in increased expression of DKK1 mRNA

NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650

G

dual specificity phosphatase 1

increases expression

ISO

Ampicillin results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 7

increases expression

ISO

Ampicillin results in increased expression of DUSP7 mRNA

NCBI chr 8:115,888,091...115,895,126
Ensembl chr 8:115,887,892...115,895,126

G

endothelin 1

increases expression

ISO

Ampicillin results in increased expression of EDN1 mRNA

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

epithelial cell adhesion molecule

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EPCAM protein

NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702

G

endothelial cell-specific molecule 1

decreases expression

ISO

Ampicillin results in decreased expression of ESM1 mRNA

NCBI chr 2:46,609,253...46,617,991
Ensembl chr 2:46,609,204...46,617,990

G

electron transfer flavoprotein subunit alpha

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ETFA protein

NCBI chr 8:64,731,192...64,787,965
Ensembl chr 8:64,731,193...64,788,080

G

ezrin

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EZR protein

NCBI chr 1:49,373,033...49,416,573
Ensembl chr 1:49,373,035...49,416,573

G

fatty acid synthase

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

filamin A interacting protein 1-like

increases expression

ISO

Ampicillin results in increased expression of FILIP1L mRNA

NCBI chr11:56,403,467...56,646,422
Ensembl chr11:56,410,582...56,646,402

G

FXYD domain-containing ion transport regulator 1

increases expression

ISO

Ampicillin results in increased expression of FXYD1 mRNA

NCBI chr 1:95,414,556...95,418,645
Ensembl chr 1:95,414,557...95,418,591

G

glutamate-cysteine ligase, catalytic subunit

decreases expression

ISO

Ampicillin results in decreased expression of GCLC mRNA

PMID:21632981 PMID:26198647

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

decreases expression
increases expression

ISO

Ampicillin results in decreased expression of GCLM mRNA
Ampicillin results in increased expression of GCLM mRNA

PMID:21632981 PMID:22609641

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

glutamine-fructose-6-phosphate transaminase 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein

NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,615,370...34,662,419

G

GIPC PDZ domain containing family, member 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GIPC2 protein

NCBI chr 2:243,690,742...243,770,199
Ensembl chr 2:243,690,748...243,770,199

G

G protein subunit gamma 12

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GNG12 protein

NCBI chr 4:97,340,830...97,464,422
Ensembl chr 4:97,340,472...97,464,476

G

glycerol-3-phosphate acyltransferase 3

decreases expression

ISO

Ampicillin results in decreased expression of GPAT3 mRNA

PMID:21632981 PMID:26198647

NCBI chr14:9,018,762...9,072,552

G

G protein-coupled bile acid receptor 1

multiple interactions

ISO

[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of GPBAR1 protein]

NCBI chr 9:83,309,895...83,312,397
Ensembl chr 9:83,311,246...83,315,608

G

glutamic--pyruvic transaminase

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GPX1 protein

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glutathione S-transferase alpha 3

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTA3 mRNA

NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654

G

glutathione S-transferase mu 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTM2 mRNA

NCBI chr 2:198,312,179...198,316,962

G

hexosaminidase subunit beta

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of HEXB protein

NCBI chr 2:30,218,608...30,238,771
Ensembl chr 2:30,218,608...30,238,771

G

high mobility group box 1

increases expression

ISO

Ampicillin results in increased expression of HMGB1 protein

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

heme oxygenase 1

increases expression

ISO

Ampicillin results in increased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heterogeneous nuclear ribonucleoprotein H2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HNRNPH2 protein

NCBI chr X:102,074,175...102,080,115
Ensembl chr X:102,074,179...102,081,025

G

homeo box D1

increases expression

ISO

Ampicillin results in increased expression of HOXD1 mRNA

NCBI chr 3:80,073,041...80,075,180
Ensembl chr 3:80,073,041...80,075,180

G

haptoglobin

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HP protein

NCBI chr19:54,449,151...54,453,701
Ensembl chr19:54,446,217...54,467,518

G

interferon-related developmental regulator 1

decreases expression

ISO

Ampicillin results in decreased expression of IFRD1 mRNA

NCBI chr 6:62,996,560...63,044,996
Ensembl chr 6:62,996,562...63,016,131

G

insulin-like growth factor binding protein 3

increases expression

ISO

Ampicillin results in increased expression of IGFBP3 mRNA

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

interleukin 18

multiple interactions

ISO

[Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol S results in increased expression of IL18 protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased secretion of IL18 protein]

PMID:35390362 PMID:38908815

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 beta

multiple interactions
increases expression

EXP
ISO

Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]]; Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]]
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of IL1B protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA]
Ampicillin results in increased expression of IL1B mRNA

PMID:21893697 PMID:24747151 PMID:35390362

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

Jun dimerization protein 2

decreases expression

ISO

Ampicillin results in decreased expression of JDP2 mRNA

NCBI chr 6:110,988,927...111,033,392
Ensembl chr 6:110,992,806...111,033,392

G

JunD proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Ampicillin results in increased expression of JUND mRNA

NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148

G

kininogen 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAP1 protein

NCBI chr11:91,418,470...91,440,841
Ensembl chr11:91,414,207...91,441,259

G

keratin 16

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of KRT16 protein

NCBI chr10:85,669,276...85,672,211
Ensembl chr10:85,669,276...85,672,211

G

low density lipoprotein receptor

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

lysyl oxidase

increases expression

ISO

Ampicillin results in increased expression of LOX mRNA

NCBI chr18:48,162,889...48,175,640
Ensembl chr18:48,165,688...48,239,810

G

lipin 1

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA

NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991

G

lysozyme 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of LYZ2 protein

NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011

G

mitogen activated protein kinase 3

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MYC associated zinc finger protein

increases expression

ISO

Ampicillin results in increased expression of MAZ mRNA

NCBI chr 1:191,060,271...191,065,722
Ensembl chr 1:191,060,280...191,065,339

G

myeloperoxidase

multiple interactions

EXP

Ampicillin inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:11686837 PMID:11991626 PMID:18306037

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

MTSS I-BAR domain containing 2

increases expression

ISO

Ampicillin results in increased expression of MTSS2 mRNA

NCBI chr19:55,602,180...55,623,955
Ensembl chr19:55,602,498...55,623,950

G

MYD88, innate immune signal transduction adaptor

multiple interactions

ISO

[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 protein]

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

myosin heavy chain 14

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MYH14 protein

NCBI chr 1:104,232,778...104,295,369
Ensembl chr 1:104,232,778...104,323,404

G

NADH:ubiquinone oxidoreductase subunit A13

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFA13 protein

NCBI chr16:19,560,526...19,567,500
Ensembl chr 7:32,257,006...32,257,492

G

NADH:ubiquinone oxidoreductase subunit AB1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFAB1 protein

NCBI chr 1:186,075,933...186,091,843
Ensembl chr 1:186,057,113...186,089,373

G

NHERF family PDZ scaffold protein 2

increases expression

ISO

Ampicillin results in increased expression of NHERF2 mRNA

NCBI chr10:14,167,005...14,177,519
Ensembl chr10:14,167,005...14,177,593

G

nitric oxide synthase 2

multiple interactions

EXP

Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 mRNA]]; Ampicillin inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; Ampicillin inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]

PMID:11686837 PMID:12568917 PMID:15610444 PMID:16944022 PMID:18306037 More...

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

NPC intracellular cholesterol transporter 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of NPC2 protein

NCBI chr 6:110,128,325...110,149,245
Ensembl chr 6:110,128,325...110,150,004

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

Ampicillin results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

ISO

[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of NR0B2 protein]

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

ISO

[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of NR1H4 protein]

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

occludin

multiple interactions

ISO

[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN protein]

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

proliferation-associated 2G4

increases expression

ISO

Ampicillin results in increased expression of PA2G4 mRNA

NCBI chr 7:1,569,326...1,576,794
Ensembl chr 7:1,569,327...1,576,802

G

poly(A) binding protein, cytoplasmic 1-like

decreases expression

ISO

Ampicillin results in decreased expression of PABPC1L mRNA

NCBI chr 3:173,111,856...173,145,389
Ensembl chr 3:173,112,904...173,146,038

G

pyruvate dehydrogenase phosphatase catalytic subunit 2

increases expression

ISO

Ampicillin results in increased expression of PDP2 mRNA

NCBI chr19:392,858...400,529
Ensembl chr19:392,183...400,902

G

pyridoxal kinase

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PDXK protein

NCBI chr20:10,209,975...10,232,012
Ensembl chr20:10,209,832...10,233,780

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

increases expression

ISO

Ampicillin results in increased expression of PFKFB3 mRNA

NCBI chr17:71,893,320...71,974,526
Ensembl chr17:71,893,416...71,975,052

G

profilin 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PFN1 protein

NCBI chr10:55,863,882...55,866,587
Ensembl chr10:55,863,881...55,868,611

G

phosphoglycerate mutase 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PGAM1 protein

NCBI chr 1:250,673,152...250,680,762
Ensembl chr 1:250,673,049...250,690,203

G

progastricsin

increases expression

ISO

Ampicillin results in increased expression of PGC mRNA

NCBI chr 9:20,755,002...20,763,220
Ensembl chr 9:20,755,002...20,763,220

G

phosphogluconate dehydrogenase

decreases activity

EXP

Ampicillin results in decreased activity of PGD protein

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

pirin

increases expression

ISO

Ampicillin results in increased expression of PIR mRNA

NCBI chr X:33,740,428...33,851,049
Ensembl chr X:33,740,429...33,851,049

G

pyruvate kinase M1/2

increases expression

ISO

Ampicillin results in increased expression of PKM mRNA

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396

G

phospholipid phosphatase related 1

increases expression

ISO

Ampicillin results in increased expression of PLPPR1 mRNA

NCBI chr 5:68,232,963...68,520,784
Ensembl chr 5:68,232,963...68,592,444

G

phosphomannomutase 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PMM2 protein

NCBI chr10:7,468,371...7,489,574
Ensembl chr10:7,468,372...7,489,554

G

paraoxonase 1

decreases activity

ISO

Ampicillin results in decreased activity of PON1 protein

PMID:16880604 PMID:31581362

NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924

G

protein phosphatase 1 catalytic subunit alpha

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein

NCBI chr 1:210,914,576...210,918,193
Ensembl chr 1:210,914,567...210,918,193

G

protein phosphatase 1 catalytic subunit beta

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CB protein

NCBI chr 6:29,681,099...29,712,835
Ensembl chr 6:29,681,100...29,712,924

G

protein phosphatase 1 catalytic subunit gamma

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CC protein

NCBI chr12:40,043,822...40,061,301
Ensembl chr12:40,043,822...40,061,341

G

proteasome 20S subunit alpha 3

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PSMA3 protein

NCBI chr 6:95,219,714...95,239,745
Ensembl chr 6:95,219,629...95,241,032

G

prostaglandin reductase 1

decreases expression

ISO

Ampicillin results in decreased expression of PTGR1 mRNA

NCBI chr 5:78,579,060...78,597,671
Ensembl chr 5:78,579,057...78,597,811

G

prostaglandin-endoperoxide synthase 2

multiple interactions

EXP

Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 mRNA]]; Ampicillin inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA]

PMID:15610444 PMID:21893697

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

parathymosin

increases expression

ISO

Ampicillin results in increased expression of PTMS mRNA

NCBI chr 4:159,408,647...159,412,837
Ensembl chr 4:159,408,649...159,415,212

G

RAS like proto-oncogene B

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RALB protein

NCBI chr13:33,140,834...33,176,997
Ensembl chr13:33,140,835...33,176,998

G

RAN, member RAS oncogene family

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RAN protein

NCBI chr12:33,311,155...33,314,339
Ensembl chr12:33,311,158...33,314,317

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

regulator of cell cycle

increases expression

ISO

Ampicillin results in increased expression of RGCC mRNA

NCBI chr15:61,071,574...61,084,408
Ensembl chr15:61,071,574...61,084,408

G

reactive intermediate imine deaminase A homolog

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RIDA protein

NCBI chr 7:67,576,586...67,590,493
Ensembl chr 7:67,576,586...67,590,692

G

ribosomal protein L30

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPL30 protein

NCBI chr 7:67,533,420...67,536,555
Ensembl chr 7:67,465,332...67,536,555

G

ribophorin II

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPN2 protein

NCBI chr 3:166,361,955...166,409,272
Ensembl chr 3:166,362,049...166,409,922

G

ribosomal protein S23

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS23 protein

NCBI chr 2:23,814,517...23,816,087
Ensembl chr 2:23,814,497...23,816,088

G

ribosomal protein S27-like

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS27L protein

NCBI chr 8:76,443,658...76,448,593
Ensembl chr12:33,713,661...33,714,130
Ensembl chr 8:33,713,661...33,714,130

G

RT1 class II, locus DMb

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RT1-DMB protein

NCBI chr20:4,695,009...4,702,560
Ensembl chr20:4,695,010...4,702,246

G

S100 calcium binding protein A10

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A10 protein

NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103

G

S100 calcium binding protein A11

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A11 protein

NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:181,875,130...181,880,541

G

S100 calcium binding protein A9

increases expression

ISO

Ampicillin results in increased expression of S100A9 mRNA

NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870

G

sterile alpha motif domain containing 1

increases expression

ISO

Ampicillin results in increased expression of SAMD1 mRNA

NCBI chr19:41,055,898...41,059,243
Ensembl chr19:41,055,442...41,059,475

G

scavenger receptor class B, member 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of SCARB2 protein

NCBI chr14:15,842,583...15,894,123
Ensembl chr14:15,842,515...15,896,671

G

stearoyl-CoA desaturase

multiple interactions

ISO

[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of SCD1 protein]

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

serpin family B member 6A

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SERPINB6 protein

NCBI chr17:31,076,811...31,195,035
Ensembl chr17:31,158,622...31,196,545

G

serum/glucocorticoid regulated kinase 2

decreases expression

ISO

Ampicillin results in decreased expression of SGK2 mRNA

NCBI chr 3:172,063,625...172,089,000
Ensembl chr 3:172,063,776...172,089,011

G

serine hydroxymethyltransferase 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SHMT2 protein

NCBI chr 7:65,244,247...65,249,580
Ensembl chr 7:65,244,247...65,249,567

G

solute carrier family 1 member 2

increases expression

ISO
EXP

Ampicillin results in increased expression of SLC1A2 protein
ampicillin cotreated ethanol increases expression of Slc1a2 protein in nucleus accumbens and prefrontal cortex

CTD
RGD

PMID:17138558 PMID:25813713

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 22, member 15

decreases expression

ISO

Ampicillin results in decreased expression of SLC22A15 mRNA

NCBI chr 2:191,987,409...192,049,859
Ensembl chr 2:191,987,409...192,047,362

G

solute carrier family 22 member 7

multiple interactions

ISO

[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SLC22A7 mRNA

NCBI chr 9:22,044,672...22,052,051
Ensembl chr 9:22,045,435...22,051,681

G

solute carrier family 25 member 20

multiple interactions

EXP

Ampicillin binds to and results in decreased activity of SLC25A20 protein; Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

G

solute carrier family 2 member 3

increases expression

ISO

Ampicillin results in increased expression of SLC2A3 mRNA

NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186

G

solute carrier family 3 member 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SLC3A1 protein

NCBI chr 6:15,361,037...15,396,695
Ensembl chr 6:15,361,046...15,394,775

G

solute carrier family 6 member 14

increases expression

ISO

Ampicillin results in increased expression of SLC6A14 mRNA

NCBI chr X:117,109,063...117,169,522
Ensembl chr X:117,108,947...117,169,828

G

solute carrier family 6 member 8

increases expression

ISO

Ampicillin results in increased expression of SLC6A8 mRNA

NCBI chr X:156,536,017...156,545,321
Ensembl chr X:156,536,017...156,545,321

G

solute carrier family 7 member 11

decreases expression

ISO

Ampicillin results in decreased expression of SLC7A11 mRNA

PMID:21632981 PMID:26198647

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

small integral membrane protein 14

decreases expression

ISO

Ampicillin results in decreased expression of SMIM14 mRNA

NCBI chr14:43,136,754...43,180,622
Ensembl chr14:43,136,867...43,183,416

G

sphingomyelin phosphodiesterase 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SMPD2 protein

NCBI chr20:46,568,627...46,571,741
Ensembl chr20:46,568,629...46,571,741

G

squalene epoxidase

multiple interactions

ISO

[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SQLE mRNA

NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:92,757,409...92,773,050

G

sterol regulatory element binding transcription factor 1

multiple interactions

ISO

[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA]; [Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of SREBF1 protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA

PMID:36464106 PMID:37211107

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

sterol regulatory element binding transcription factor 2

multiple interactions

ISO

[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF2 mRNA

NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:115,543,290...115,600,943

G

sulfiredoxin 1

decreases expression

ISO

Ampicillin results in decreased expression of SRXN1 mRNA

PMID:21632981 PMID:26198647

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

transgelin

increases expression

ISO

Ampicillin results in increased expression of TAGLN mRNA

NCBI chr 8:55,121,647...55,127,121
Ensembl chr 8:55,121,301...55,127,563

G

threonyl-tRNA synthetase 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TARS1 protein

NCBI chr 2:62,095,978...62,114,802
Ensembl chr 2:62,087,763...62,114,802

G

TIMP metallopeptidase inhibitor 1

decreases expression

ISO

Ampicillin results in decreased expression of TIMP1 mRNA

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

tight junction protein 1

multiple interactions

ISO

[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 protein]

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

toll-like receptor 4

multiple interactions

ISO

[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 protein]; TLR4 gene mutant form results in decreased susceptibility to [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin]

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

transmembrane 9 superfamily member 2

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TM9SF2 protein

NCBI chr15:105,606,082...105,660,715
Ensembl chr15:105,606,118...105,660,714

G

transmembrane p24 trafficking protein 10

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TMED10 protein

NCBI chr 6:110,722,887...110,757,743
Ensembl chr 6:110,722,889...110,757,777

G

tumor necrosis factor

multiple interactions

EXP
ISO

Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF mRNA]]; Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]]
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of TNF protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein]

PMID:21893697 PMID:31442584 PMID:35390362

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tropomyosin 4

increases expression

ISO

Ampicillin results in increased expression of TPM4 mRNA

NCBI chr16:17,718,442...17,732,483
Ensembl chr16:17,717,230...17,732,494

G

TNF receptor associated factor 6

multiple interactions

ISO

[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 protein]

NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328

G

tripartite motif-containing 16

increases expression

ISO

Ampicillin results in increased expression of TRIM16 mRNA

NCBI chr10:47,985,235...48,008,242
Ensembl chr10:47,958,677...48,051,136

G

tweety family member 3

increases expression

ISO

Ampicillin results in increased expression of TTYH3 mRNA

NCBI chr12:19,110,973...19,139,379
Ensembl chr12:19,110,824...19,139,371

G

tubulin, alpha-like 3

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TUBAL3 protein

NCBI chr17:71,233,194...71,245,297
Ensembl chr17:71,232,851...71,245,337

G

tubulin, beta 1 class VI

increases expression

ISO

Ampicillin results in increased expression of TUBB1 mRNA

NCBI chr 3:183,666,189...183,675,656
Ensembl chr 3:183,666,242...183,674,795

G

tubulin, epsilon 1

decreases expression

ISO

Ampicillin results in decreased expression of TUBE1 mRNA

NCBI chr20:44,105,405...44,124,947
Ensembl chr20:44,107,022...44,125,271

G

twinfilin actin-binding protein 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TWF1 protein

NCBI chr 7:127,595,210...127,607,821
Ensembl chr 7:127,595,210...127,607,105

G

thioredoxin domain containing 5

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TXNDC5 protein

NCBI chr17:26,495,467...26,523,608
Ensembl chr17:26,490,047...26,523,597

G

ubiquinol-cytochrome c reductase core protein 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRC1 protein

NCBI chr 8:118,468,223...118,479,968
Ensembl chr 8:118,468,200...118,479,964

G

ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRFS1 protein

NCBI chr17:34,173,787...34,190,952
Ensembl chr17:34,173,833...34,190,950

G

ubiquinol-cytochrome c reductase hinge protein

multiple interactions

EXP

[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRH protein

NCBI chr 5:134,782,687...134,790,882
Ensembl chr 5:134,782,255...134,790,926

G

vascular endothelial growth factor A

multiple interactions

EXP

Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of VEGFA mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of VEGFA mRNA]]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

very low density lipoprotein receptor

decreases expression

ISO

Ampicillin results in decreased expression of VLDLR mRNA

NCBI chr 1:234,239,769...234,272,150
Ensembl chr 1:234,240,121...234,272,154

Ampicillin Sodium Mixture With Sulbactam Sodium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

advanced glycosylation end product-specific receptor

multiple interactions

EXP

Amp/Sul inhibits the reaction [ethanol increases expression of Ager protein in the shell of nucleus accumbens]

RGD

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

EXP

Amp/Sul inhibits the reaction [ethanol decreases expression of Grin2b protein in the core of nucleus accumbens]

RGD

NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570

G

glutamate metabotropic receptor 5

multiple interactions

EXP

Amp/Sul inhibits the reaction [ethanol decreases expression of Grm5 protein in the shell of nucleus accumbens]

RGD

NCBI chr 1:150,722,711...151,297,585
Ensembl chr 1:150,733,678...151,296,649

G

high mobility group box 1

multiple interactions

EXP

Amp/Sul inhibits the reaction [ethanol increases expression of Hmgb1 protein in the shell of nucleus accumbens]

RGD

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

solute carrier family 1 member 2

multiple interactions

EXP

Amp/Sul inhibits the reaction [ethanol decreases expression of Slc1a2 protein in the shell of nucleus accumbens]

RGD

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

tumor necrosis factor

multiple interactions

EXP

Amp/Sul inhibits the reaction [ethanol increases expression of TNFa protein in the shell of nucleus accumbens]

RGD

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of ABCB11 mRNA

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

aldo-keto reductase family 1 member B10

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

G

AKT serine/threonine kinase 1

multiple interactions

EXP

Augmentin inhibits the reaction [Ethanol decreases phosphorylation of Akt1 protein in the prefrontal cortex

RGD

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

caspase 3

increases activity

EXP

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 9

increases activity

EXP

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

cytochrome c, somatic

increases secretion

EXP

Amoxicillin-Potassium Clavulanate Combination results in increased secretion of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP7A1 mRNA

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

fibroblast growth factor 19

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of FGF19 mRNA

NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267

G

glucose-6-phosphate dehydrogenase

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of G6PD mRNA

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

glutamate-cysteine ligase, catalytic subunit

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

gamma-glutamyltransferase 1

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GGT1 protein

NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050

G

glutamic-oxaloacetic transaminase 1

increases activity

EXP

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GOT1 protein

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glutamic--pyruvic transaminase

increases activity

EXP

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GPT protein

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 2

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GPX2 mRNA

NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862

G

glutathione-disulfide reductase

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

malic enzyme 1

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of ME1 mRNA

NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275

G

nuclear receptor subfamily 0, group B, member 2

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of NR0B2 mRNA

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

solute carrier family 10 member 1

decreases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 1 member 2

increases expression
multiple interactions

EXP

Augmentin cotreated with ethanol increases expression of Slc1a2 in prefrontal cortex and nucleus accumbens
Augmentin inhibits the reaction [ethanol decreases expression of Slc1a2 protein in nucleus accumbens]
Augmentin inhibits the reaction [ethanol decreases expression of Slc1a2 protein in prefrontal cortex]

RGD

PMID:27993695 PMID:27199635 PMID:26168897

RGD:598147066, RGD:598154609, RGD:598147077

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 51 member A

decreases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA

NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539

G

solute carrier family 7 member 11

increases expression
multiple interactions
increases expression

ISO
EXP

Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA
Augmentin inhibits the reaction [ethanol decreases expression of Slc7a11 protein in nucleus accumbens and prefrontal cortex]
Augmentin cotreated with ethanol increases expression of Slc7a11 in prefrontal cortex and nucleus accumbens

CTD
RGD

PMID:34767876 PMID:27199635 PMID:27993695

RGD:598154609, RGD:598147066

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

transketolase

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TKT mRNA

NCBI chr16:5,729,381...5,755,170
Ensembl chr16:5,729,991...5,756,431

G

thioredoxin reductase 1

increases expression

ISO

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

increases expression

ISO

Aztreonam results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily G member 5

increases expression

ISO

Aztreonam results in increased expression of ABCG5 mRNA

NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376

G

ATP binding cassette subfamily G member 8

increases expression

ISO

Aztreonam results in increased expression of ABCG8 mRNA

NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:15,698,448...15,717,730

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

ISO

Aztreonam results in decreased expression of NPC1L1 mRNA

NCBI chr14:85,285,387...85,305,050
Ensembl chr14:85,285,390...85,305,050

G

nuclear receptor subfamily 5, group A, member 2

increases expression

ISO

Aztreonam results in increased expression of NR5A2 mRNA

NCBI chr13:50,865,253...50,985,107
Ensembl chr13:50,867,920...50,984,938

G

RT1 class II, locus Ha

affects expression

ISO

Aztreonam affects the expression of HLA-DPA1 mRNA

NCBI chr20:4,762,425...4,772,439
Ensembl chr20:4,763,033...4,772,141

G

solute carrier family 10 member 1

increases expression

ISO

Aztreonam results in increased expression of SLC10A1 mRNA

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 10 member 2

decreases expression

ISO

Aztreonam results in decreased expression of SLC10A2 mRNA

NCBI chr16:91,088,089...91,111,025
Ensembl chr16:91,076,423...91,111,025

G

SLC51 subunit beta

decreases expression

ISO

Aztreonam results in decreased expression of SLC51B mRNA

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

balofloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

benzylpenicillin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

increases activity
multiple interactions

EXP
ISO

Penicillin G results in increased activity of ABCC2 protein
Penicillin G promotes the reaction [ABCC2 protein affects the transport of estradiol-17 beta-glucuronide]

PMID:12702717 PMID:15904671

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 4

increases transport

ISO

ABCC4 protein results in increased transport of Penicillin G

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

acetyl-CoA carboxylase alpha

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of ACACA mRNA
Penicillin G results in increased expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

ATP citrate lyase

increases expression
multiple interactions

ISO

Penicillin G results in increased expression of ACLY mRNA
[Penicillin G co-treated with Erythromycin] results in increased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

alpha-fetoprotein

affects expression
decreases expression

ISO

Penicillin G affects the expression of AFP mRNA
Penicillin G results in decreased expression of AFP mRNA

PMID:24737281 PMID:25137620 PMID:26272751

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

annexin A8

decreases expression

ISO

Penicillin G results in decreased expression of ANXA8 mRNA

NCBI chr16:9,403,267...9,418,317
Ensembl chr16:9,403,353...9,418,310

G

activating transcription factor 3

increases expression

ISO

Penicillin G results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of CCL2 mRNA
Penicillin G results in increased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine receptor 2

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of CCR2 mRNA

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059

G

CD36 molecule

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of CD36 mRNA
Penicillin G results in increased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142

G

CD86 molecule

increases expression

ISO

Penicillin G results in increased expression of CD86 protein

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

cerberus 1, DAN family BMP antagonist

increases expression

ISO

Penicillin G results in increased expression of CER1 mRNA

NCBI chr 5:102,352,364...102,355,720
Ensembl chr 5:102,352,368...102,355,720

G

carboxylesterase 1D

increases expression

ISO

Penicillin G results in increased expression of CES1 mRNA

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carnitine palmitoyltransferase 1A

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

C-reactive protein

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of CRP mRNA

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

citrate synthase

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of CS mRNA
Penicillin G results in increased expression of CS mRNA

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

decorin

decreases expression

ISO

Penicillin G results in decreased expression of DCN mRNA

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

defensin beta 1

decreases expression
multiple interactions

ISO

Penicillin G results in decreased expression of DEFB1 mRNA
[Penicillin G co-treated with Erythromycin] results in decreased expression of DEFB1 mRNA

NCBI chr16:77,001,326...77,016,068
Ensembl chr16:77,001,326...77,016,068

G

diacylglycerol O-acyltransferase 1

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of DGAT1 mRNA

NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016

G

diacylglycerol O-acyltransferase 2

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of DGAT2 mRNA

NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:162,866,237...162,896,566

G

fatty acid binding protein 1

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of FABP1 mRNA

NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113

G

fatty acid synthase

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of FASN mRNA
Penicillin G results in increased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

frizzled-related protein

decreases expression

ISO

Penicillin G results in decreased expression of FRZB mRNA

NCBI chr 3:85,739,162...85,772,168
Ensembl chr 3:85,739,165...85,772,096

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

Penicillin G results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

glycerol-3-phosphate acyltransferase, mitochondrial

increases expression
multiple interactions

ISO

Penicillin G results in increased expression of GPAM mRNA
[Penicillin G co-treated with Erythromycin] results in increased expression of GPAM mRNA

NCBI chr 1:264,111,599...264,176,112
Ensembl chr 1:264,113,813...264,175,911

G

histone deacetylase 7

increases expression

ISO

Penicillin G results in increased expression of HDAC7 mRNA

NCBI chr 7:130,803,013...130,841,181
Ensembl chr 7:130,803,013...130,841,017

G

interferon gamma

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of IFNG mRNA
Penicillin G results in increased expression of IFNG mRNA

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor 2

decreases expression

ISO

Penicillin G results in decreased expression of IGF2 mRNA

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

insulin-like growth factor binding protein 5

decreases expression

ISO

Penicillin G results in decreased expression of IGFBP5 mRNA

NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390

G

interleukin 18

increases expression

ISO

Penicillin G results in increased expression of IL18 protein

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 alpha

increases expression
multiple interactions

ISO

Penicillin G results in increased expression of IL1A mRNA
[Penicillin G co-treated with Erythromycin] results in increased expression of IL1A mRNA

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

increases expression

ISO

Penicillin G results in increased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of IL6 mRNA

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Penicillin G results in increased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

kinase insert domain receptor

increases expression
decreases expression

ISO

Penicillin G results in increased expression of KDR mRNA
Penicillin G results in decreased expression of KDR mRNA

PMID:25137620 PMID:26272751

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

lipopolysaccharide binding protein

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of LBP mRNA

NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:167,373,924...167,401,518

G

mesoderm posterior bHLH transcription factor 1

decreases expression

ISO

Penicillin G results in decreased expression of MESP1 mRNA

NCBI chr 1:143,147,671...143,149,189
Ensembl chr 1:143,147,671...143,149,189

G

matrix metallopeptidase 1

decreases expression

ISO

Penicillin G results in decreased expression of MMP1 mRNA

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

microsomal triglyceride transfer protein

increases expression
multiple interactions

ISO

Penicillin G results in increased expression of MTTP mRNA
[Penicillin G co-treated with Erythromycin] results in increased expression of MTTP mRNA

NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650

G

mucin 2, oligomeric mucus/gel-forming

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in decreased expression of MUC2 mRNA

NCBI chr 1:206,225,775...206,261,280
Ensembl chr 1:206,229,035...206,261,280

G

MYC proto-oncogene, bHLH transcription factor

increases expression

ISO

Penicillin G results in increased expression of MYC mRNA

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

neurofilament medium chain

affects expression

ISO

Penicillin G affects the expression of NEFM mRNA

NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163

G

nestin

increases expression
affects expression

EXP
ISO

Penicillin G results in increased expression of NES protein
Penicillin G affects the expression of NES mRNA

PMID:16137769 PMID:16369854 PMID:25137620

NCBI chr 2:175,735,715...175,745,631
Ensembl chr 2:175,736,551...175,746,228

G

nuclear factor kappa B subunit 1

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of NFKB1 mRNA
Penicillin G results in increased expression of NFKB1 mRNA

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

Penicillin G results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

phosphogluconate dehydrogenase

decreases activity

EXP

Penicillin G results in decreased activity of PGD protein

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

pirin

increases expression

ISO

Penicillin G results in increased expression of PIR mRNA

NCBI chr X:33,740,428...33,851,049
Ensembl chr X:33,740,429...33,851,049

G

patatin-like phospholipase domain containing 6

decreases expression

ISO

Penicillin G results in decreased expression of PNPLA6 mRNA

NCBI chr12:6,372,284...6,401,632
Ensembl chr12:6,372,293...6,401,631

G

regenerating family member 3 gamma

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in decreased expression of REG3G mRNA

NCBI chr 4:112,482,183...112,484,738
Ensembl chr 4:112,482,183...112,484,738

G

resistin like beta

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in decreased expression of RETNLB mRNA

NCBI chr11:65,446,433...65,448,319
Ensembl chr11:65,446,434...65,448,319

G

stearoyl-CoA desaturase

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of SCD1 mRNA
Penicillin G results in increased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

sonic hedgehog signaling molecule

increases expression

ISO

Penicillin G results in increased expression of SHH mRNA

NCBI chr 4:7,687,872...7,697,025
Ensembl chr 4:7,687,846...7,697,901

G

solute carrier family 22 member 12

multiple interactions

ISO

Potassium promotes the reaction [SLC22A12 protein results in increased uptake of Penicillin G]

NCBI chr 1:213,274,266...213,282,793
Ensembl chr 1:213,274,275...213,281,380

G

solute carrier family 22 member 20

multiple interactions

ISO

Penicillin G inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]

NCBI chr 1:212,686,691...212,703,163
Ensembl chr 1:212,686,691...212,703,163

G

solute carrier family 22 member 6

multiple interactions

ISO

Penicillin G inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]

NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311

G

solute carrier family 22 member 8

multiple interactions
increases uptake

EXP
ISO

Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Ranitidine]; Probenecid inhibits the reaction [SLC22A8 protein results in increased uptake of Penicillin G]; tranilast inhibits the reaction [SLC22A8 protein results in increased uptake of Penicillin G]
resveratrol inhibits the reaction [SLC22A8 protein results in increased uptake of Penicillin G]

PMID:10224140 PMID:15319347 PMID:17255469 PMID:27377006 PMID:35019195

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

G

solute carrier family 27 member 2

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of SLC27A2 mRNA

NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581

G

solute carrier organic anion transporter family, member 3a1

multiple interactions

ISO

Penicillin G promotes the reaction [SLCO3A1 protein results in increased uptake of simvastatin acid]

NCBI chr 1:137,516,037...137,797,836
Ensembl chr 1:137,505,158...137,797,836

G

sterol regulatory element binding transcription factor 1

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of SREBF1 mRNA

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

toll-like receptor 4

multiple interactions

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of TLR4 mRNA

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

tumor necrosis factor

multiple interactions
increases expression

ISO

[Penicillin G co-treated with Erythromycin] results in increased expression of TNF mRNA
Penicillin G results in increased expression of TNF mRNA

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tripartite motif-containing 16

increases expression

ISO

Penicillin G results in increased expression of TRIM16 mRNA

NCBI chr10:47,985,235...48,008,242
Ensembl chr10:47,958,677...48,051,136

G

transthyretin

decreases expression

ISO

Penicillin G results in decreased expression of TTR mRNA

NCBI chr18:12,216,684...12,225,972
Ensembl chr18:12,216,732...12,225,969

G

Wnt family member 3

increases expression

ISO

Penicillin G results in increased expression of WNT3 mRNA

NCBI chr10:89,180,224...89,224,195
Ensembl chr10:89,216,801...89,224,195

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acylaminoacyl-peptide hydrolase

multiple interactions
decreases activity

ISO

Carbapenems inhibits the reaction [APEH protein results in increased metabolism of valproic acid glucuronide]
Carbapenems results in decreased activity of APEH protein

NCBI chr 8:117,652,390...117,661,502
Ensembl chr 8:117,652,393...117,661,711

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

ISO

Cefaclor inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Cefaclor results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

ISO

Cefaclor results in increased expression of CYP3A4 mRNA; Cefaclor results in increased expression of CYP3A4 protein

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

solute carrier family 22 member 6

multiple interactions

ISO

Cefaclor inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]

NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311

G

solute carrier family 22 member 8

increases uptake
multiple interactions

ISO

SLC22A8 protein results in increased uptake of Cefaclor
Cefaclor inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

ISO

Cefadroxil results in increased expression of CYP3A4 mRNA; Cefadroxil results in increased expression of CYP3A4 protein

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

RT1 class Ib, locus M3, gene 1

affects expression

ISO

Cefadroxil affects the expression of HLA-G mRNA

NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

increases expression

EXP

Cephaloridine results in increased expression of AADAC mRNA

NCBI chr 2:146,293,449...146,351,061
Ensembl chr 2:146,313,279...146,324,525

G

aminoadipate-semialdehyde synthase

decreases expression

EXP

Cephaloridine results in decreased expression of AASS mRNA

NCBI chr 4:52,572,146...52,628,811
Ensembl chr 4:52,572,147...52,657,600

G

ATP-binding cassette, sub-family B member 1B

increases expression

EXP

Cephaloridine results in increased expression of ABCB1B mRNA

NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567

G

ATP binding cassette subfamily C member 2

increases expression

EXP

Cephaloridine results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

aminocarboxymuconate semialdehyde decarboxylase

decreases expression

EXP

Cephaloridine results in decreased expression of ACMSD mRNA

NCBI chr13:41,752,894...41,798,427
Ensembl chr13:41,752,875...41,798,427

G

acyl-CoA thioesterase 5

decreases expression

EXP

Cephaloridine results in decreased expression of ACOT5 mRNA

NCBI chr 6:109,433,062...109,439,846
Ensembl chr 6:109,453,391...109,461,035
Ensembl chr 6:109,453,391...109,461,035

G

acyl-CoA thioesterase 9

increases expression

EXP

Cephaloridine results in increased expression of ACOT9 mRNA

NCBI chr X:43,922,943...43,973,311
Ensembl chr X:43,914,923...43,973,205

G

acyl-CoA synthetase medium-chain family member 5

decreases expression

EXP

Cephaloridine results in decreased expression of ACSM5 mRNA

NCBI chr 1:183,302,241...183,328,175
Ensembl chr 1:183,294,105...183,329,925

G

ADAM metallopeptidase domain 8

decreases expression

EXP

Cephaloridine results in decreased expression of ADAM8 mRNA

NCBI chr 1:204,206,206...204,218,988
Ensembl chr 1:204,206,199...204,218,485

G

adhesion G protein-coupled receptor E1

increases expression

EXP

Cephaloridine results in increased expression of ADGRE1 mRNA

NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,329,438...2,484,959

G

adenosine A2a receptor

increases expression

EXP

Cephaloridine results in increased expression of ADORA2A mRNA

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802

G

adrenoceptor alpha 1D

increases expression

EXP

Cephaloridine results in increased expression of ADRA1D mRNA

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

aftiphilin

decreases expression

EXP

Cephaloridine results in decreased expression of AFTPH mRNA

NCBI chr14:99,072,761...99,127,006
Ensembl chr14:99,072,761...99,126,727

G

aldo-keto reductase family 1 member B1

increases expression

EXP

Cephaloridine results in increased expression of AKR1B1 mRNA

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315

G

aldo-keto reductase family 1 member B15

increases expression

EXP

Cephaloridine results in increased expression of AKR1B8 mRNA

NCBI chr 4:63,964,421...63,976,995
Ensembl chr 4:63,960,880...63,978,349

G

aldo-keto reductase family 1 member C8

increases expression

EXP

Cephaloridine results in increased expression of AKR1CL mRNA

NCBI chr17:71,091,398...71,117,985
Ensembl chr17:71,083,080...71,117,957

G

aldo-keto reductase family 1, member D1

increases expression

EXP

Cephaloridine results in increased expression of AKR1D1 mRNA

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540

G

5'-aminolevulinate synthase 1

increases expression

EXP

Cephaloridine results in increased expression of ALAS1 mRNA

NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642

G

aldehyde dehydrogenase 3 family, member A1

increases expression

EXP

Cephaloridine results in increased expression of ALDH3A1 mRNA

NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151

G

aldehyde dehydrogenase 3 family, member B1

increases expression

EXP

Cephaloridine results in increased expression of ALDH3B1 mRNA

NCBI chr 1:210,574,545...210,605,188
Ensembl chr 1:210,573,661...210,610,538

G

aldolase, fructose-bisphosphate A

affects expression

EXP

Cephaloridine affects the expression of ALDOA mRNA

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

APC membrane recruitment protein 2

decreases expression

EXP

Cephaloridine results in decreased expression of AMER2 mRNA

NCBI chr15:38,701,509...38,711,817
Ensembl chr15:38,701,657...38,705,633

G

adhesion molecule with Ig like domain 2

increases expression

EXP

Cephaloridine results in increased expression of AMIGO2 mRNA

NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218

G

adenosine monophosphate deaminase 1

increases expression

EXP

Cephaloridine results in increased expression of AMPD1 mRNA

NCBI chr 2:193,287,219...193,308,446
Ensembl chr 2:193,287,265...193,308,443

G

adenosine monophosphate deaminase 3

increases expression

EXP

Cephaloridine results in increased expression of AMPD3 mRNA

NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608

G

angiopoietin-like 4

increases expression

EXP

Cephaloridine results in increased expression of ANGPTL4 mRNA

NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681

G

anillin, actin binding protein

decreases expression

EXP

Cephaloridine results in decreased expression of ANLN mRNA

NCBI chr 8:29,134,222...29,197,513
Ensembl chr 8:29,134,222...29,197,513

G

annexin A13

decreases expression

EXP

Cephaloridine results in decreased expression of ANXA13 mRNA

NCBI chr 7:91,773,844...91,826,386
Ensembl chr 7:91,770,861...91,826,386

G

annexin A7

increases expression

EXP

Cephaloridine results in increased expression of ANXA7 mRNA

NCBI chr15:3,869,180...3,897,827
Ensembl chr15:3,870,974...3,898,891

G

amyloid P component, serum

decreases expression

EXP

Cephaloridine results in decreased expression of APCS mRNA

NCBI chr13:87,905,532...87,906,508
Ensembl chr13:87,905,532...87,928,824

G

apolipoprotein A4

increases expression

EXP

Cephaloridine results in increased expression of APOA4 mRNA

NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164

G

apolipoprotein B

increases expression

EXP

Cephaloridine results in increased expression of APOB mRNA

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

apolipoprotein C2

increases expression

EXP

Cephaloridine results in increased expression of APOC2 mRNA

NCBI chr 1:88,457,397...88,462,365
Ensembl chr 1:88,457,396...88,463,438

G

apolipoprotein L domain containing 1

decreases expression

EXP

Cephaloridine results in decreased expression of APOLD1 mRNA

NCBI chr 4:169,499,728...169,557,075
Ensembl chr 4:169,549,679...169,559,176

G

ARFGEF family member 3

decreases expression

EXP

Cephaloridine results in decreased expression of ARFGEF3 mRNA

NCBI chr 1:15,058,574...15,223,742
Ensembl chr 1:15,058,579...15,223,742

G

Rho GTPase activating protein 35

decreases expression

EXP

Cephaloridine results in decreased expression of ARHGAP35 mRNA

NCBI chr 1:86,330,566...86,447,414
Ensembl chr 1:86,330,566...86,447,414

G

AT-rich interaction domain 5A

increases expression

EXP

Cephaloridine results in increased expression of ARID5A mRNA

NCBI chr 9:46,030,513...46,058,729
Ensembl chr 9:46,030,548...46,045,363

G

anti-silencing function 1B histone chaperone

increases expression

EXP

Cephaloridine results in increased expression of ASF1B mRNA

NCBI chr19:41,085,786...41,100,352
Ensembl chr19:41,086,114...41,100,352

G

ASH1 like histone lysine methyltransferase

decreases expression

EXP

Cephaloridine results in decreased expression of ASH1L mRNA

NCBI chr 2:176,644,393...176,780,848
Ensembl chr 2:176,644,924...176,780,847

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

EXP

Cephaloridine results in increased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

ATPase family, AAA domain containing 1

increases expression

EXP

Cephaloridine results in increased expression of ATAD1 mRNA

NCBI chr 1:239,957,329...240,023,792
Ensembl chr 1:239,957,882...240,009,822

G

ATPase family, AAA domain containing 2

increases expression

EXP

Cephaloridine results in increased expression of ATAD2 mRNA

NCBI chr 7:91,523,626...91,566,238
Ensembl chr 7:91,523,626...91,566,238

G

activating transcription factor 3

decreases expression

EXP

Cephaloridine results in decreased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

atlastin GTPase 1

increases expression

EXP

Cephaloridine results in increased expression of ATL1 mRNA

NCBI chr 6:94,113,149...94,210,955
Ensembl chr 6:94,112,877...94,211,219

G

ATPase phospholipid transporting 11C

decreases expression

EXP

Cephaloridine results in decreased expression of ATP11C mRNA

NCBI chr X:143,600,763...143,788,407
Ensembl chr X:143,600,767...143,788,432

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

increases expression

EXP

Cephaloridine results in increased expression of ATP12A mRNA

NCBI chr15:34,559,209...34,583,866
Ensembl chr15:34,559,209...34,583,866

G

aurora kinase B

decreases expression

EXP

Cephaloridine results in decreased expression of AURKB mRNA

NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285

G

Beta-1,3-galactosyltransferase 2

decreases expression

EXP

Cephaloridine results in decreased expression of B3GALT2 mRNA

NCBI chr13:57,939,724...57,948,735
Ensembl chr13:57,930,539...57,956,539

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

decreases expression

EXP

Cephaloridine results in decreased expression of B3GNT7 mRNA

NCBI chr 9:94,404,197...94,408,148
Ensembl chr 9:94,404,135...94,408,147

G

BAG cochaperone 3

increases expression

EXP

Cephaloridine results in increased expression of BAG3 mRNA

NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280

G

BCL2-antagonist/killer 1

increases expression

EXP

Cephaloridine results in increased expression of BAK1 mRNA

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BRCA1 associated RING domain 1

increases expression

EXP

Cephaloridine results in increased expression of BARD1 mRNA

NCBI chr 9:80,069,960...80,144,167
Ensembl chr 9:80,069,960...80,176,873

G

basic leucine zipper ATF-like transcription factor

increases expression

EXP

Cephaloridine results in increased expression of BATF mRNA

NCBI chr 6:111,084,717...111,107,052
Ensembl chr 6:111,084,717...111,107,052

G

Bcl2-like 1

affects expression

EXP

Cephaloridine affects the expression of BCL2L1 mRNA

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

brain expressed X-linked 2

increases expression

EXP

Cephaloridine results in increased expression of BEX1 mRNA

NCBI chr X:103,811,458...103,812,986
Ensembl chr X:103,808,935...103,812,092

G

brain expressed, X-linked 4

increases expression

EXP

Cephaloridine results in increased expression of BEX4 mRNA

NCBI chr X:103,923,609...103,925,041
Ensembl chr X:103,923,338...103,925,496

G

basic helix-loop-helix family, member e41

increases expression

EXP

Cephaloridine results in increased expression of BHLHE41 mRNA

NCBI chr 4:180,565,003...180,569,415
Ensembl chr 4:180,565,003...180,569,355

G

baculoviral IAP repeat-containing 3

increases expression

EXP

Cephaloridine results in increased expression of BIRC3 mRNA

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

biliverdin reductase B

increases expression

EXP

Cephaloridine results in increased expression of BLVRB mRNA

NCBI chr 1:91,866,258...91,883,921
Ensembl chr 1:91,866,258...91,884,225

G

bactericidal/permeability-increasing protein

increases expression

EXP

Cephaloridine results in increased expression of BPI mRNA

NCBI chr 3:167,329,513...167,356,217
Ensembl chr 3:167,329,530...167,356,396

G

BRCA1 interacting DNA helicase 1

increases expression

EXP

Cephaloridine results in increased expression of BRIP1 mRNA

NCBI chr10:71,402,035...71,528,083
Ensembl chr10:71,401,151...71,575,206

G

barttin CLCNK type accessory subunit beta

increases expression

EXP

Cephaloridine results in increased expression of BSND mRNA

NCBI chr 5:126,480,590...126,489,389
Ensembl chr 5:126,480,592...126,489,389

G

BTG anti-proliferation factor 2

decreases expression

EXP

Cephaloridine results in decreased expression of BTG2 mRNA

NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690

G

BUB1 mitotic checkpoint serine/threonine kinase B

decreases expression

EXP

Cephaloridine results in decreased expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

similar to human chromosome 16 open reading frame 89

increases expression

EXP

Cephaloridine results in increased expression of C10H16ORF89 mRNA

NCBI chr10:10,856,320...10,877,515
Ensembl chr10:10,868,419...10,877,515

G

C1q and TNF related 1

increases expression

EXP

Cephaloridine results in increased expression of C1QTNF1 mRNA

NCBI chr10:104,159,021...104,180,253
Ensembl chr10:104,158,886...104,180,251

G

complement C5

decreases expression

EXP

Cephaloridine results in decreased expression of C5 mRNA

NCBI chr 3:38,668,174...38,759,468
Ensembl chr 3:38,668,174...38,759,468

G

complement C6

increases expression

EXP

Cephaloridine results in increased expression of C6 mRNA

NCBI chr 2:55,573,596...55,648,857
Ensembl chr 2:55,573,653...55,649,120

G

calcium voltage-gated channel subunit alpha1 H

increases expression

EXP

Cephaloridine results in increased expression of CACNA1H mRNA

NCBI chr10:14,894,630...14,952,317
Ensembl chr10:14,894,641...14,952,771

G

calcium voltage-gated channel auxiliary subunit gamma 3

increases expression

EXP

Cephaloridine results in increased expression of CACNG3 mRNA

NCBI chr 1:186,632,334...186,728,220
Ensembl chr 1:186,632,323...186,728,214

G

calbindin 1

increases expression

EXP

Cephaloridine results in increased expression of CALB1 mRNA

NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160

G

calbindin 2

decreases expression

EXP

Cephaloridine results in decreased expression of CALB2 mRNA

NCBI chr19:55,023,849...55,050,858
Ensembl chr19:55,023,838...55,057,952

G

calreticulin

increases expression

EXP

Cephaloridine results in increased expression of CALR mRNA

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236

G

CaM kinase-like vesicle-associated

increases expression

EXP

Cephaloridine results in increased expression of CAMKV mRNA

NCBI chr 8:117,505,439...117,519,785
Ensembl chr 8:117,505,408...117,519,797

G

calnexin

increases expression

EXP

Cephaloridine results in increased expression of CANX mRNA

NCBI chr10:35,124,941...35,157,954
Ensembl chr10:35,124,941...35,157,857

G

catalase

affects expression

EXP

Cephaloridine affects the expression of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 17

increases expression

EXP

Cephaloridine results in increased expression of CCL17 mRNA

NCBI chr19:10,208,120...10,218,340
Ensembl chr19:10,208,120...10,209,895

G

C-C motif chemokine ligand 19

increases expression

EXP

Cephaloridine results in increased expression of CCL19 mRNA

NCBI chr 5:61,759,220...61,761,164
Ensembl chr 5:61,759,220...61,772,022

G

C-C motif chemokine ligand 20

increases expression

EXP

Cephaloridine results in increased expression of CCL20 mRNA

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736

G

C-C motif chemokine ligand 28

increases expression

EXP

Cephaloridine results in increased expression of CCL28 mRNA

NCBI chr 2:53,334,071...53,358,709
Ensembl chr 2:53,334,071...53,358,709

G

C-C motif chemokine ligand 3

decreases expression

EXP

Cephaloridine results in decreased expression of CCL3 mRNA

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

decreases expression

EXP

Cephaloridine results in decreased expression of CCL4 mRNA

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

cellular communication network factor 2

decreases expression

EXP

Cephaloridine results in decreased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cyclin A2

decreases expression

EXP

Cephaloridine results in decreased expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

decreases expression

EXP

Cephaloridine results in decreased expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin B2

decreases expression

EXP

Cephaloridine results in decreased expression of CCNB2 mRNA

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682

G

cyclin E1

increases expression

EXP

Cephaloridine results in increased expression of CCNE1 mRNA

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

cyclin E2

increases expression

EXP

Cephaloridine results in increased expression of CCNE2 mRNA

NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:29,082,703...29,094,882

G

CD52 molecule

decreases expression

EXP

Cephaloridine results in decreased expression of CD52 mRNA

NCBI chr 5:151,603,537...151,605,096
Ensembl chr 5:151,603,524...151,605,086

G

Cd72 molecule

increases expression

EXP

Cephaloridine results in increased expression of CD72 mRNA

NCBI chr 5:62,493,155...62,500,779
Ensembl chr 5:62,493,161...62,500,519

G

CD86 molecule

increases expression

EXP

Cephaloridine results in increased expression of CD86 mRNA

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

cell division cycle 42

decreases expression

EXP

Cephaloridine results in decreased expression of CDC42 mRNA

NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:154,839,631...154,876,627

G

cell division cycle 45

increases expression

EXP

Cephaloridine results in increased expression of CDC45 mRNA

NCBI chr11:95,689,702...95,714,980
Ensembl chr11:95,689,919...95,714,981

G

cell division cycle 6

increases expression

EXP

Cephaloridine results in increased expression of CDC6 mRNA

NCBI chr10:84,360,361...84,374,239
Ensembl chr10:84,360,381...84,374,241

G

cell division cycle associated 2

decreases expression

EXP

Cephaloridine results in decreased expression of CDCA2 mRNA

NCBI chr15:46,071,360...46,117,524
Ensembl chr15:46,071,360...46,116,639

G

cyclin-dependent kinase 1

decreases expression

EXP

Cephaloridine results in decreased expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin dependent kinase like 1

decreases expression

EXP

Cephaloridine results in decreased expression of CDKL1 mRNA

NCBI chr 6:93,960,157...94,005,207
Ensembl chr 6:93,959,911...94,006,115

G

cyclin-dependent kinase inhibitor 1A

decreases expression

EXP

Cephaloridine results in decreased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

decreases expression

EXP

Cephaloridine results in decreased expression of CDKN1B mRNA

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

chromatin licensing and DNA replication factor 1

increases expression

EXP

Cephaloridine results in increased expression of CDT1 mRNA

NCBI chr19:67,529,249...67,534,195
Ensembl chr19:67,529,201...67,534,194

G

CEA cell adhesion molecule 16, tectorial membrane component

increases expression

EXP

Cephaloridine results in increased expression of CEACAM16 mRNA

NCBI chr 1:88,642,925...88,652,821
Ensembl chr 1:88,642,925...88,652,821

G

centromere protein K

increases expression

EXP

Cephaloridine results in increased expression of CENPK mRNA

NCBI chr 2:37,094,163...37,155,158
Ensembl chr 2:37,094,248...37,119,488

G

centromere protein Q

increases expression

EXP

Cephaloridine results in increased expression of CENPQ mRNA

NCBI chr 9:27,454,339...27,469,371
Ensembl chr 9:27,454,252...27,469,366

G

carboxylesterase 1E

decreases expression

EXP

Cephaloridine results in decreased expression of CES1E mRNA

NCBI chr19:30,006,173...30,042,628
Ensembl chr19:30,006,153...30,042,626

G

carboxylesterase 2G

decreases expression

EXP

Cephaloridine results in decreased expression of CES2G mRNA

NCBI chr19:49,856,670...49,865,034
Ensembl chr19:49,856,549...49,864,282

G

carboxylesterase-like 1

decreases expression

EXP

Cephaloridine results in decreased expression of CESL1 mRNA

NCBI chr19:38,554,365...38,612,663

G

cilia and flagella associated protein 263

increases expression

EXP

Cephaloridine results in increased expression of CCDC113 mRNA

NCBI chr19:9,503,062...9,522,957
Ensembl chr19:9,503,066...9,522,957

G

chromatin assembly factor 1 subunit A

increases expression

EXP

Cephaloridine results in increased expression of CHAF1A mRNA

NCBI chr 9:961,225...987,825
Ensembl chr 9:961,084...987,868

G

chromatin assembly factor 1 subunit B

increases expression

EXP

Cephaloridine results in increased expression of CHAF1B mRNA

NCBI chr11:46,670,560...46,690,739
Ensembl chr11:46,670,630...46,690,733

G

chromodomain helicase DNA binding protein 4

decreases expression

EXP

Cephaloridine results in decreased expression of CHD4 mRNA

NCBI chr 4:159,584,623...159,617,867
Ensembl chr 4:159,584,654...159,617,866

G

chromodomain helicase DNA binding protein 6

decreases expression

EXP

Cephaloridine results in decreased expression of CHD6 mRNA

NCBI chr 3:170,016,204...170,177,480
Ensembl chr 3:170,016,204...170,177,558

G

checkpoint kinase 1

increases expression

EXP

Cephaloridine results in increased expression of CHEK1 mRNA

NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359

G

carbohydrate sulfotransferase 7

decreases expression

EXP

Cephaloridine results in decreased expression of CHST7 mRNA

NCBI chr X:4,949,810...4,986,372
Ensembl chr X:4,938,757...4,986,907

G

chromosome transmission fidelity factor 18

increases expression

EXP

Cephaloridine results in increased expression of CHTF18 mRNA

NCBI chr10:15,247,525...15,255,573
Ensembl chr10:15,246,362...15,255,685

G

cartilage intermediate layer protein

decreases expression

EXP

Cephaloridine results in decreased expression of CILP mRNA

NCBI chr 8:74,671,696...74,687,420
Ensembl chr 8:74,671,534...74,687,409

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

increases expression

EXP

Cephaloridine results in increased expression of CITED2 mRNA

NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782

G

cytoskeleton associated protein 2

decreases expression

EXP

Cephaloridine results in decreased expression of CKAP2 mRNA

NCBI chr16:76,542,114...76,567,297
Ensembl chr16:76,542,104...76,567,352

G

claudin 14

increases expression

EXP

Cephaloridine results in increased expression of CLDN14 mRNA

NCBI chr11:46,701,940...46,799,049
Ensembl chr11:46,701,940...46,799,096

G

calsyntenin 2

decreases expression

EXP

Cephaloridine results in decreased expression of CLSTN2 mRNA

NCBI chr 8:106,899,894...107,516,402
Ensembl chr 8:106,899,894...107,040,053

G

c-Maf-inducing protein

decreases expression

EXP

Cephaloridine results in decreased expression of CMIP mRNA

NCBI chr19:62,213,402...62,419,443
Ensembl chr19:62,213,365...62,417,500

G

carnosine dipeptidase 1

decreases expression

EXP

Cephaloridine results in decreased expression of CNDP1 mRNA

NCBI chr18:80,254,499...80,305,845
Ensembl chr18:80,255,784...80,282,643

G

collagen type IV alpha 4 chain

decreases expression

EXP

Cephaloridine results in decreased expression of COL4A4 mRNA

NCBI chr 9:91,281,324...91,323,577
Ensembl chr 9:91,203,670...91,323,577

G

collagen type VII alpha 1 chain

increases expression

EXP

Cephaloridine results in increased expression of COL7A1 mRNA

NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:118,483,364...118,517,439

G

carnitine palmitoyltransferase 1B

increases expression

EXP

Cephaloridine results in increased expression of CPT1B mRNA

NCBI chr 7:122,370,974...122,380,473
Ensembl chr 7:122,370,444...122,380,036

G

cellular retinoic acid binding protein 1

increases expression

EXP

Cephaloridine results in increased expression of CRABP1 mRNA

NCBI chr 8:64,047,431...64,055,469
Ensembl chr 8:64,047,060...64,055,470

G

CREB binding protein

decreases expression

EXP

Cephaloridine results in decreased expression of CREBBP mRNA

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

cryptochrome circadian regulator 1

increases expression

EXP

Cephaloridine results in increased expression of CRY1 mRNA

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

C-X-C motif chemokine ligand 1

decreases expression

EXP

Cephaloridine results in decreased expression of CXCL1 mRNA

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 10

increases expression

EXP

Cephaloridine results in increased expression of CXCL10 mRNA

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

C-X-C motif chemokine ligand 13

increases expression

EXP

Cephaloridine results in increased expression of CXCL13 mRNA

NCBI chr14:13,912,858...13,917,920
Ensembl chr14:13,912,858...13,917,920

G

C-X-C motif chemokine ligand 14

increases expression

EXP

Cephaloridine results in increased expression of CXCL14 mRNA

NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,323,143...8,331,172

G

CXXC finger protein 4

decreases expression

EXP

Cephaloridine results in decreased expression of CXXC4 mRNA

NCBI chr 2:225,329,044...225,363,347

G

cytochrome b5 type A

increases expression

EXP

Cephaloridine results in increased expression of CYB5A mRNA

NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094
Ensembl chr18:14,453,966...14,455,094

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression

EXP

Cephaloridine results in increased expression of CYP1B1 mRNA

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 24, subfamily a, polypeptide 1

decreases expression

EXP

Cephaloridine results in decreased expression of CYP24A1 mRNA

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, subfamily 2, polypeptide 11

decreases expression

EXP

Cephaloridine results in decreased expression of CYP2C mRNA

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853

G

cytochrome P450 family 7 subfamily B member 1

increases expression

EXP

Cephaloridine results in increased expression of CYP7B1 mRNA

NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804

G

dCTP pyrophosphatase 1

increases expression

EXP

Cephaloridine results in increased expression of DCTPP1 mRNA

NCBI chr 1:191,307,933...191,311,326
Ensembl chr 1:191,307,935...191,313,405

G

dCTP pyrophosphatase 1, pseudogene 2

increases expression

EXP

Cephaloridine results in increased expression of DCTPP1-PS2 mRNA

NCBI chr16:1,400,142...1,400,652

G

dopa decarboxylase

decreases expression

EXP

Cephaloridine results in decreased expression of DDC mRNA

NCBI chr14:90,592,304...90,682,830
Ensembl chr14:90,592,304...90,682,806

G

DNA-damage-inducible transcript 4

decreases expression

EXP

Cephaloridine results in decreased expression of DDIT4 mRNA

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037

G

DNA-damage-inducible transcript 4-like

increases expression

EXP

Cephaloridine results in increased expression of DDIT4L mRNA

NCBI chr 2:228,800,831...228,804,478
Ensembl chr 2:228,801,705...228,806,225

G

DExD-box helicase 39A

increases expression

EXP

Cephaloridine results in increased expression of DDX39A mRNA

NCBI chr19:41,323,465...41,331,413
Ensembl chr19:41,322,836...41,332,306

G

DEAD-box helicase 6

decreases expression

EXP

Cephaloridine results in decreased expression of DDX6 mRNA

NCBI chr 8:53,827,661...53,864,538
Ensembl chr 8:53,827,835...53,860,977

G

2,4-dienoyl-CoA reductase 2

decreases expression

EXP

Cephaloridine results in decreased expression of DECR2 mRNA

NCBI chr10:15,609,389...15,617,779
Ensembl chr10:15,611,092...15,617,397

G

dehydrogenase/reductase member 2 like 1

increases expression

EXP

Cephaloridine results in increased expression of DHRS2L1 mRNA

NCBI chr15:32,605,149...32,608,039
Ensembl chr15:32,605,149...32,608,039

G

DLG associated protein 1

increases expression

EXP

Cephaloridine results in increased expression of DLGAP1 mRNA

NCBI chr 9:117,304,144...118,173,463
Ensembl chr 9:117,614,061...118,173,463

G

dynein, axonemal, heavy chain 7

decreases expression

EXP

Cephaloridine results in decreased expression of DNAH7 mRNA

NCBI chr 9:62,454,838...62,760,504
Ensembl chr 9:62,454,838...62,756,730

G

dynein, axonemal, heavy chain 9

decreases expression

EXP

Cephaloridine results in decreased expression of DNAH9 mRNA

NCBI chr10:50,996,796...51,363,977
Ensembl chr10:50,996,796...51,363,963

G

deoxyribonuclease 1L3

increases expression

EXP

Cephaloridine results in increased expression of DNASE1L3 mRNA

NCBI chr15:19,351,683...19,378,536
Ensembl chr15:19,352,493...19,378,531

G

2'-deoxynucleoside 5'-phosphate N-hydrolase 1

increases expression

EXP

Cephaloridine results in increased expression of DNPH1 mRNA

NCBI chr 9:21,978,894...21,981,631
Ensembl chr 9:21,978,894...21,981,631

G

DNA replication fork stabilization factor DONSON

increases expression

EXP

Cephaloridine results in increased expression of DONSON mRNA

NCBI chr11:44,405,794...44,419,099
Ensembl chr11:44,405,804...44,418,791

G

double PHD fingers 1

increases expression

EXP

Cephaloridine results in increased expression of DPF1 mRNA

NCBI chr 1:93,729,683...93,743,425
Ensembl chr 1:93,726,970...93,743,425

G

DNA replication and sister chromatid cohesion 1

increases expression

EXP

Cephaloridine results in increased expression of DSCC1 mRNA

NCBI chr 7:88,372,349...88,390,815
Ensembl chr 7:88,372,146...88,387,973

G

desmoglein 2

increases expression

EXP

Cephaloridine results in increased expression of DSG2 mRNA

NCBI chr18:12,121,287...12,179,590
Ensembl chr18:12,121,181...12,179,590

G

deltex E3 ubiquitin ligase 4

increases expression

EXP

Cephaloridine results in increased expression of DTX4 mRNA

NCBI chr 1:218,882,391...218,969,837
Ensembl chr 1:218,832,284...218,917,130

G

dual specificity phosphatase 6

affects expression

EXP

Cephaloridine affects the expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

dual specificity phosphatase 7

decreases expression

EXP

Cephaloridine results in decreased expression of DUSP7 mRNA

NCBI chr 8:115,888,091...115,895,126
Ensembl chr 8:115,887,892...115,895,126

G

dual specificity phosphatase 9

increases expression

EXP

Cephaloridine results in increased expression of DUSP9 mRNA

NCBI chr X:156,503,237...156,507,162
Ensembl chr X:156,503,190...156,507,161

G

E2F transcription factor 8

increases expression

EXP

Cephaloridine results in increased expression of E2F8 mRNA

NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:107,701,985...107,720,009

G

erythroid differentiation regulatory factor 1

decreases expression

EXP

Cephaloridine results in decreased expression of EDRF1 mRNA

NCBI chr 1:197,869,873...197,908,693
Ensembl chr 1:197,870,962...197,908,731

G

eukaryotic translation elongation factor 2

increases expression

EXP

Cephaloridine results in increased expression of EEF2 mRNA

NCBI chr 7:9,183,836...9,196,255
Ensembl chr 7:9,183,961...9,189,544

G

early growth response 1

decreases expression

EXP

Cephaloridine results in decreased expression of EGR1 mRNA

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

early growth response 2

decreases expression

EXP

Cephaloridine results in decreased expression of EGR2 mRNA

NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748

G

eukaryotic translation initiation factor 4H

increases expression

EXP

Cephaloridine results in increased expression of EIF4H mRNA

NCBI chr12:27,719,527...27,736,350
Ensembl chr12:27,719,321...27,736,346

G

E74 like ETS transcription factor 3

increases expression

EXP

Cephaloridine results in increased expression of ELF3 mRNA

NCBI chr13:49,242,265...49,247,102
Ensembl chr13:49,242,267...49,247,380

G

embigin

increases expression

EXP

Cephaloridine results in increased expression of EMB mRNA

NCBI chr 2:50,803,468...50,858,001
Ensembl chr 2:50,801,973...50,862,920

G

essential meiotic structure-specific endonuclease 1

decreases expression

EXP

Cephaloridine results in decreased expression of EME1 mRNA

NCBI chr10:80,083,585...80,092,450
Ensembl chr10:80,083,585...80,092,301

G

ectodermal-neural cortex 1

increases expression

EXP

Cephaloridine results in increased expression of ENC1 mRNA

NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721

G

enolase 2

increases expression

EXP

Cephaloridine results in increased expression of ENO2 mRNA

NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220

G

endosomal transmembrane epsin interactor 1

increases expression

EXP

Cephaloridine results in increased expression of ENTREP1 mRNA

NCBI chr 1:231,018,987...231,073,474
Ensembl chr 1:231,018,987...231,102,708

G

extra spindle pole bodies like 1, separase

decreases expression

EXP

Cephaloridine results in decreased expression of ESPL1 mRNA

NCBI chr 7:135,302,460...135,329,570
Ensembl chr 7:135,302,716...135,329,570

G

exonuclease 1

increases expression

EXP

Cephaloridine results in increased expression of EXO1 mRNA

NCBI chr13:90,341,947...90,366,861
Ensembl chr13:90,342,018...90,366,861

G

coagulation factor XIII B chain

decreases expression

EXP

Cephaloridine results in decreased expression of F13B mRNA

NCBI chr13:53,681,639...53,707,114
Ensembl chr13:53,681,622...53,707,300

G

FAM111 trypsin like peptidase A

decreases expression

EXP

Cephaloridine results in decreased expression of FAM111A mRNA

NCBI chr 1:219,065,542...219,081,213
Ensembl chr 1:219,065,601...219,081,211

G

FA complementation group D2

increases expression

EXP

Cephaloridine results in increased expression of FANCD2 mRNA

NCBI chr 4:148,234,633...148,299,035
Ensembl chr 4:148,234,708...148,299,035

G

fibulin 1

increases expression

EXP

Cephaloridine results in increased expression of FBLN1 mRNA

NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965

G

fructose-bisphosphatase 2

increases expression

EXP

Cephaloridine results in increased expression of FBP2 mRNA

NCBI chr17:2,241,767...2,259,371
Ensembl chr17:2,241,975...2,259,366

G

F-box protein 5

increases expression

EXP

Cephaloridine results in increased expression of FBXO5 mRNA

NCBI chr 1:44,601,412...44,607,781
Ensembl chr 1:44,601,412...44,607,781

G

Fc gamma receptor 2A

increases expression

EXP

Cephaloridine results in increased expression of FCGR2A mRNA

NCBI chr13:85,813,516...85,830,269
Ensembl chr13:85,855,437...85,864,394
Ensembl chr13:85,855,437...85,864,394

G

Fc gamma receptor 2B

increases expression

EXP

Cephaloridine results in increased expression of FCGR2B mRNA

NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517

G

Fc gamma receptor 3A

increases expression

EXP

Cephaloridine results in increased expression of FCGR3A mRNA

NCBI chr13:85,782,636...85,792,656
Ensembl chr13:85,782,490...85,792,651

G

ficolin B

increases expression

EXP

Cephaloridine results in increased expression of FCNB mRNA

NCBI chr 3:31,791,750...31,800,188
Ensembl chr 3:31,791,750...31,800,188

G

flap structure-specific endonuclease 1

increases expression

EXP

Cephaloridine results in increased expression of FEN1 mRNA

NCBI chr 1:216,270,016...216,274,873
Ensembl chr 1:216,269,163...216,275,016

G

fibrinogen beta chain

increases expression

EXP

Cephaloridine results in increased expression of FGB mRNA

NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434

G

fibroblast growth factor 17

increases expression

EXP

Cephaloridine results in increased expression of FGF17 mRNA

NCBI chr15:52,118,141...52,132,083
Ensembl chr15:52,121,191...52,132,016

G

fibrinogen-like 2

increases expression

EXP

Cephaloridine results in increased expression of FGL2 mRNA

NCBI chr 4:14,602,762...14,608,405
Ensembl chr 4:14,602,771...14,608,405

G

FH2 domain containing 1

increases expression

EXP

Cephaloridine results in increased expression of FHDC1 mRNA

NCBI chr 2:172,088,987...172,127,838
Ensembl chr 2:172,089,010...172,125,956

G

filamin A interacting protein 1

decreases expression

EXP

Cephaloridine results in decreased expression of FILIP1 mRNA

NCBI chr 8:89,641,509...89,836,772
Ensembl chr 8:89,644,579...89,802,771

G

folate hydrolase 1

decreases expression

EXP

Cephaloridine results in decreased expression of FOLH1 mRNA

NCBI chr 1:149,828,286...149,914,313
Ensembl chr 1:149,840,760...149,914,035

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression

EXP

Cephaloridine results in decreased expression of FOS mRNA

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

forkhead box E1

decreases expression

EXP

Cephaloridine results in decreased expression of FOXE1 mRNA

NCBI chr 5:65,425,630...65,428,438
Ensembl chr 5:65,425,630...65,428,438

G

forkhead box Q1

increases expression

EXP

Cephaloridine results in increased expression of FOXQ1 mRNA

NCBI chr17:33,121,454...33,124,087
Ensembl chr17:33,121,545...33,123,720

G

FYVE and coiled-coil domain autophagy adaptor 1

decreases expression

EXP

Cephaloridine results in decreased expression of FYCO1 mRNA

NCBI chr 8:132,289,538...132,356,810
Ensembl chr 8:132,289,539...132,356,451

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

EXP

Cephaloridine results in decreased expression of G6PC1 mRNA

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033

G

glucose-6-phosphate dehydrogenase

increases expression

EXP

Cephaloridine results in increased expression of G6PD mRNA

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

growth arrest and DNA-damage-inducible, alpha

increases expression

EXP

Cephaloridine results in increased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

polypeptide N-acetylgalactosaminyltransferase 13

increases expression

EXP

Cephaloridine results in increased expression of GALNT13 mRNA

NCBI chr 3:59,312,628...59,969,633
Ensembl chr 3:59,383,516...59,965,379

G

glucosidase, alpha; neutral C

decreases expression

EXP

Cephaloridine results in decreased expression of GANC mRNA

NCBI chr 3:127,807,132...127,858,995
Ensembl chr 3:127,807,441...127,859,859

G

golgi associated RAB2 interactor family member 4

increases expression

EXP

Cephaloridine results in increased expression of GARIN4 mRNA

NCBI chr13:105,274,107...105,276,287
Ensembl chr13:105,274,106...105,276,286

G

glucosylceramidase beta 3

decreases expression

EXP

Cephaloridine results in decreased expression of GBA3 mRNA

NCBI chr14:64,787,601...64,934,043
Ensembl chr14:64,787,601...64,934,043

G

guanine deaminase

increases expression

EXP

Cephaloridine results in increased expression of GDA mRNA

NCBI chr 1:228,333,401...228,408,901
Ensembl chr 1:228,333,364...228,409,348

G

growth differentiation factor 15

decreases expression

EXP

Cephaloridine results in decreased expression of GDF15 mRNA

NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022

G

GDNF family receptor alpha 2

decreases expression

EXP

Cephaloridine results in decreased expression of GFRA2 mRNA

NCBI chr15:52,351,499...52,443,369
Ensembl chr15:52,351,514...52,477,782

G

GINS complex subunit 2

increases expression

EXP

Cephaloridine results in increased expression of GINS2 mRNA

NCBI chr19:65,535,492...65,548,270
Ensembl chr19:65,535,492...65,548,052

G

GINS complex subunit 4

increases expression

EXP

Cephaloridine results in increased expression of GINS4 mRNA

NCBI chr16:75,489,990...75,502,455
Ensembl chr16:75,490,126...75,505,000

G

glycosylation dependent cell adhesion molecule 1

increases expression

EXP

Cephaloridine results in increased expression of GLYCAM1 mRNA

NCBI chr 7:136,559,039...136,561,299
Ensembl chr 7:136,559,039...136,561,299

G

geminin, DNA replication inhibitor

increases expression

EXP

Cephaloridine results in increased expression of GMNN mRNA

NCBI chr17:40,729,760...40,738,077
Ensembl chr17:40,729,824...40,738,068

G

G protein subunit alpha 14

increases expression

EXP

Cephaloridine results in increased expression of GNA14 mRNA

NCBI chr 1:223,141,802...223,324,210
Ensembl chr 1:223,141,802...223,324,210

G

glycoprotein nmb

increases expression

EXP

Cephaloridine results in increased expression of GPNMB mRNA

NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:79,341,021...79,380,240

G

G protein-coupled receptor 135

decreases expression

EXP

Cephaloridine results in decreased expression of GPR135 mRNA

NCBI chr 6:96,363,466...96,366,594
Ensembl chr 6:96,362,867...96,382,988

G

G protein-coupled receptor 19

increases expression

EXP

Cephaloridine results in increased expression of GPR19 mRNA

NCBI chr 4:169,442,278...169,468,805
Ensembl chr 4:169,436,658...169,471,249

G

glutathione peroxidase 2

increases expression

EXP

Cephaloridine results in increased expression of GPX2 mRNA

NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862

G

glutamate ionotropic receptor AMPA type subunit 3

decreases expression

EXP

Cephaloridine results in decreased expression of GRIA3 mRNA

NCBI chr X:125,103,975...125,369,690
Ensembl chr X:125,103,782...125,369,679

G

glutathione-disulfide reductase

increases expression

EXP

Cephaloridine results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase alpha 2

increases expression

EXP

Cephaloridine results in increased expression of GSTA2 mRNA

NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092

G

glutathione S-transferase alpha 5

increases expression

EXP

Cephaloridine results in increased expression of GSTA5 mRNA

NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765

G

glutathione S-transferase mu 1

increases expression

EXP

Cephaloridine results in increased expression of GSTM1 mRNA

PMID:18172885 PMID:18500788

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569

G

glutathione S-transferase pi 1

increases expression

EXP

Cephaloridine results in increased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

glucoside xylosyltransferase 1

decreases expression

EXP

Cephaloridine results in decreased expression of GXYLT1 mRNA

NCBI chr 7:126,280,349...126,320,803
Ensembl chr 7:126,280,349...126,314,237

G

H1.1 linker histone, cluster member

increases expression

EXP

Cephaloridine results in increased expression of H1F1 mRNA

NCBI chr17:41,762,278...41,794,876

G

hydroxyacyl-CoA dehydrogenase

decreases expression

EXP

Cephaloridine results in decreased expression of HADH mRNA

NCBI chr 2:222,462,049...222,504,446
Ensembl chr 2:222,462,049...222,504,446

G

HAUS augmin-like complex, subunit 8

increases expression

EXP

Cephaloridine results in increased expression of HAUS8 mRNA

NCBI chr16:17,964,813...17,979,313
Ensembl chr16:17,964,814...17,979,192

G

hepatitis A virus cellular receptor 1

increases expression

EXP

Cephaloridine results in increased expression of HAVCR1 mRNA

PMID:18500788 PMID:20305092

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

HCK proto-oncogene, Src family tyrosine kinase

increases expression

EXP

Cephaloridine results in increased expression of HCK mRNA

NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935

G

heme binding protein 1

increases expression

EXP

Cephaloridine results in increased expression of HEBP1 mRNA

NCBI chr 4:169,705,665...169,735,199
Ensembl chr 4:169,705,668...169,735,199

G

heme binding protein 2

increases expression

EXP

Cephaloridine results in increased expression of HEBP2 mRNA

NCBI chr 1:15,014,729...15,021,523
Ensembl chr 1:15,014,729...15,021,523

G

helicase, lymphoid specific

increases expression

EXP

Cephaloridine results in increased expression of HELLS mRNA

NCBI chr 1:246,113,580...246,159,230
Ensembl chr 1:246,114,096...246,159,228

G

HEPACAM family member 2

increases expression

EXP

Cephaloridine results in increased expression of HEPACAM2 mRNA

NCBI chr 4:32,400,523...32,435,936
Ensembl chr 4:32,400,558...32,435,512

G

hemojuvelin BMP co-receptor

decreases expression

EXP

Cephaloridine results in decreased expression of HJV mRNA

NCBI chr 2:186,754,801...186,758,708
Ensembl chr 2:186,754,811...186,758,867

G

H2.0-like homeobox

decreases expression

EXP

Cephaloridine results in decreased expression of HLX mRNA

NCBI chr13:98,811,852...98,817,264
Ensembl chr13:98,811,856...98,817,264

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

decreases expression

EXP

Cephaloridine results in decreased expression of HMGCS2 mRNA

NCBI chr 2:188,564,348...188,590,872
Ensembl chr 2:188,547,767...188,592,242

G

heme oxygenase 1

increases expression

EXP

Cephaloridine results in increased expression of HMOX1 mRNA

PMID:18172885 PMID:18500788

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

H6 family homeobox 3

increases expression

EXP

Cephaloridine results in increased expression of HMX3 mRNA

NCBI chr 1:195,743,411...195,745,375
Ensembl chr 1:195,743,271...195,746,444

G

heterogeneous nuclear ribonucleoprotein A1

increases expression

EXP

Cephaloridine results in increased expression of HNRNPA1 mRNA

NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:136,253,278...136,260,085

G

heterogeneous nuclear ribonucleoprotein A1, pseudogene 28

increases expression

EXP

Cephaloridine results in increased expression of HNRNPA1-PS28 mRNA

NCBI chr X:112,548,677...112,549,706

G

histidine-rich glycoprotein

decreases expression

EXP

Cephaloridine results in decreased expression of HRG mRNA

NCBI chr11:91,559,087...91,573,982
Ensembl chr11:91,559,091...91,573,982

G

hydroxysteroid (17-beta) dehydrogenase 2

decreases expression

EXP

Cephaloridine results in decreased expression of HSD17B2 mRNA

NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

increases expression

EXP

Cephaloridine results in increased expression of HSD3B1 mRNA

NCBI chr 2:188,858,574...188,864,694

G

heat shock protein 90 alpha family class A member 1

increases expression

EXP

Cephaloridine results in increased expression of HSP90AA1 mRNA

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499

G

heat shock protein family A (Hsp70) member 1A

increases expression

EXP

Cephaloridine results in increased expression of HSPA1A mRNA

NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979

G

heat shock protein family A (Hsp70) member 1B

increases expression

EXP

Cephaloridine results in increased expression of HSPA1B mRNA

NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979

G

heat shock protein family H (Hsp110) member 1

increases expression

EXP

Cephaloridine results in increased expression of HSPH1 mRNA

NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891

G

HIV-1 Tat interactive protein 2

increases expression

EXP

Cephaloridine results in increased expression of HTATIP2 mRNA

NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815

G

5-hydroxytryptamine (serotonin) receptor 5B

increases expression

EXP

Cephaloridine results in increased expression of HTR5B mRNA

NCBI chr13:35,239,662...35,252,586
Ensembl chr13:35,239,662...35,252,586

G

intercellular adhesion molecule 1

increases expression

EXP

Cephaloridine results in increased expression of ICAM1 mRNA

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

isopentenyl-diphosphate delta isomerase 2 like 3

decreases expression

EXP

Cephaloridine results in decreased expression of IDI2L3 mRNA

NCBI chr17:66,243,932...66,258,028

G

immediate early response 3

decreases expression

EXP

Cephaloridine results in decreased expression of IER3 mRNA

NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377

G

interferon induced transmembrane protein 10

increases expression

EXP

Cephaloridine results in increased expression of IFITM10 mRNA

NCBI chr 1:206,936,979...206,954,594
Ensembl chr 1:206,936,444...206,954,629

G

interferon induced transmembrane protein 6

increases expression

EXP

Cephaloridine results in increased expression of IFITM6 mRNA

NCBI chr 1:205,546,648...205,547,920

G

interleukin 18

increases expression

EXP

Cephaloridine results in increased expression of IL18 mRNA

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 beta

decreases expression

EXP

Cephaloridine results in decreased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 20 receptor subunit alpha

decreases expression

EXP

Cephaloridine results in decreased expression of IL20RA mRNA

NCBI chr 1:16,243,683...16,313,229
Ensembl chr 1:16,243,801...16,313,221

G

inhibin subunit beta B

decreases expression

EXP

Cephaloridine results in decreased expression of INHBB mRNA

NCBI chr13:33,083,671...33,089,373
Ensembl chr13:33,083,671...33,089,609

G

inositol-trisphosphate 3-kinase A

increases expression

EXP

Cephaloridine results in increased expression of ITPKA mRNA

NCBI chr 3:127,179,841...127,188,405
Ensembl chr 3:127,179,808...127,188,414

G

inositol-trisphosphate 3-kinase B

increases expression

EXP

Cephaloridine results in increased expression of ITPKB mRNA

NCBI chr13:94,601,072...94,696,180
Ensembl chr13:94,601,167...94,696,179

G

jade family PHD finger 2

decreases expression

EXP

Cephaloridine results in decreased expression of JADE2 mRNA

NCBI chr10:36,576,187...36,625,129
Ensembl chr10:36,576,187...36,623,532

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

EXP

Cephaloridine results in increased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

JunB proto-oncogene, AP-1 transcription factor subunit

decreases expression
increases expression

EXP

Cephaloridine results in decreased expression of JUNB mRNA
Cephaloridine results in increased expression of JUNB mRNA

PMID:18172885 PMID:18500788

NCBI chr19:40,081,126...40,082,910
Ensembl chr19:40,073,541...40,085,218

G

kelch repeat and BTB domain containing 11

decreases expression

EXP

Cephaloridine results in decreased expression of KBTBD11 mRNA

NCBI chr16:81,318,596...81,340,334
Ensembl chr16:81,313,093...81,340,390

G

potassium voltage-gated channel subfamily H member 1

increases expression

EXP

Cephaloridine results in increased expression of KCNH1 mRNA

NCBI chr13:106,253,101...106,555,712
Ensembl chr13:106,253,213...106,555,710

G

potassium inwardly-rectifying channel, subfamily J, member 15

decreases expression

EXP

Cephaloridine results in decreased expression of KCNJ15 mRNA

NCBI chr11:48,046,953...48,091,285
Ensembl chr11:48,035,655...48,092,457

G

potassium channel tetramerization domain containing 1

increases expression

EXP

Cephaloridine results in increased expression of KCTD1 mRNA

NCBI chr18:6,396,947...6,591,026
Ensembl chr18:6,396,947...6,515,191

G

alpha-ketoglutarate dehydrogenase subunit 4

increases expression

EXP

Cephaloridine results in increased expression of KGD4 mRNA

NCBI chr 2:33,604,611...33,614,988
Ensembl chr 2:33,604,613...33,615,095

G

kinesin family member 18A

decreases expression

EXP

Cephaloridine results in decreased expression of KIF18A mRNA

NCBI chr 3:116,219,007...116,279,378
Ensembl chr 3:116,219,007...116,279,227

G

kinesin family member 2C

decreases expression

EXP

Cephaloridine results in decreased expression of KIF2C mRNA

NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:135,873,925...135,899,212

G

KLF transcription factor 7

decreases expression

EXP

Cephaloridine results in decreased expression of KLF7 mRNA

NCBI chr 9:72,927,485...73,020,167
Ensembl chr 9:72,933,136...73,020,056

G

kelch-like family member 25

decreases expression

EXP

Cephaloridine results in decreased expression of KLHL25 mRNA

NCBI chr 1:139,134,655...139,159,898
Ensembl chr 1:139,122,977...139,165,970

G

kinetochore-localized astrin/SPAG5 binding protein

decreases expression

EXP

Cephaloridine results in decreased expression of KNSTRN mRNA

NCBI chr 3:126,254,633...126,274,412
Ensembl chr 3:126,254,663...126,274,418

G

kinetochore associated 1

increases expression

EXP

Cephaloridine results in increased expression of KNTC1 mRNA

NCBI chr12:38,429,925...38,500,564
Ensembl chr12:38,429,925...38,500,457

G

laminin subunit alpha 2

decreases expression

EXP

Cephaloridine results in decreased expression of LAMA2 mRNA

NCBI chr 1:19,492,126...20,140,056
Ensembl chr 1:19,244,599...20,140,056

G

laminin subunit beta 3

increases expression

EXP

Cephaloridine results in increased expression of LAMB3 mRNA

NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081

G

leucyl-tRNA synthetase 1

decreases expression

EXP

Cephaloridine results in decreased expression of LARS1 mRNA

NCBI chr18:34,452,567...34,507,030
Ensembl chr18:34,452,561...34,506,938

G

ligand dependent nuclear receptor corepressor

decreases expression

EXP

Cephaloridine results in decreased expression of LCOR mRNA

NCBI chr 1:250,247,965...250,354,985
Ensembl chr 1:250,247,934...250,354,985

G

leukocyte cell-derived chemotaxin 2

decreases expression

EXP

Cephaloridine results in decreased expression of LECT2 mRNA

NCBI chr17:8,050,034...8,056,256
Ensembl chr17:8,050,034...8,056,256

G

galectin 2

increases expression

EXP

Cephaloridine results in increased expression of LGALS2 mRNA

NCBI chr 7:112,283,630...112,290,228
Ensembl chr 7:112,282,822...112,285,392

G

galectin 3

increases expression

EXP

Cephaloridine results in increased expression of LGALS3 mRNA

NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737

G

LIM homeobox 3

decreases expression

EXP

Cephaloridine results in decreased expression of LHX3 mRNA

NCBI chr 3:29,424,620...29,432,637
Ensembl chr 3:29,424,620...29,432,637

G

DNA ligase 1

increases expression

EXP

Cephaloridine results in increased expression of LIG1 mRNA

NCBI chr 1:83,243,043...83,281,707
Ensembl chr 1:83,219,545...83,281,708

G

lamin B1

decreases expression

EXP

Cephaloridine results in decreased expression of LMNB1 mRNA

NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283

G

LRAT domain containing 1

increases expression

EXP

Cephaloridine results in increased expression of LRATD1 mRNA

NCBI chr 6:42,646,515...42,650,988
Ensembl chr 6:42,640,190...42,651,204

G

leucine rich repeat neuronal 3

decreases expression

EXP

Cephaloridine results in decreased expression of LRRN3 mRNA

NCBI chr 6:64,216,164...64,247,293
Ensembl chr 6:64,215,878...64,247,614

G

MAF bZIP transcription factor

decreases expression

EXP

Cephaloridine results in decreased expression of MAF mRNA

NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378

G

mitogen-activated protein kinase kinase kinase 1

increases expression

EXP

Cephaloridine results in increased expression of MAP3K1 mRNA

NCBI chr 2:45,081,889...45,150,555
Ensembl chr 2:45,081,889...45,149,897

G

mitogen activated protein kinase kinase kinase 12

decreases expression

EXP

Cephaloridine results in decreased expression of MAP3K12 mRNA

NCBI chr 7:135,507,082...135,527,396
Ensembl chr 7:135,508,790...135,515,137

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
increases activity

EXP

Thymic Factor, Circulating inhibits the reaction [Cephaloridine results in increased phosphorylation of MAPK1 protein]
Cephaloridine results in increased activity of MAPK1 protein

PMID:16154539 PMID:16272694

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases activity
multiple interactions
increases phosphorylation

EXP

Cephaloridine results in increased activity of MAPK3 protein
Thymic Factor, Circulating inhibits the reaction [Cephaloridine results in increased phosphorylation of MAPK3 protein]

PMID:16154539 PMID:16272694

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8 interacting protein 3

increases expression

EXP

Cephaloridine results in increased expression of MAPK8IP3 mRNA

NCBI chr10:14,422,936...14,463,387
Ensembl chr10:14,422,936...14,462,812

G

MBL associated serine protease 2

increases expression

EXP

Cephaloridine results in increased expression of MASP2 mRNA

NCBI chr 5:164,319,017...164,332,686
Ensembl chr 5:164,308,991...164,332,705

G

minichromosome maintenance complex component 2

increases expression

EXP

Cephaloridine results in increased expression of MCM2 mRNA

NCBI chr 4:122,903,679...122,918,205
Ensembl chr 4:122,903,682...122,918,094

G

minichromosome maintenance complex component 3

increases expression

EXP

Cephaloridine results in increased expression of MCM3 mRNA

NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746

G

minichromosome maintenance complex component 5

increases expression

EXP

Cephaloridine results in increased expression of MCM5 mRNA

NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758

G

minichromosome maintenance complex component 6

increases expression

EXP

Cephaloridine results in increased expression of MCM6 mRNA

NCBI chr13:42,379,161...42,404,352
Ensembl chr13:42,379,162...42,465,467

G

minichromosome maintenance complex component 7

increases expression

EXP

Cephaloridine results in increased expression of MCM7 mRNA

NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771

G

minichromosome maintenance 8 homologous recombination repair factor

increases expression

EXP

Cephaloridine results in increased expression of MCM8 mRNA

NCBI chr 3:140,539,590...140,569,891
Ensembl chr 3:140,539,647...140,569,891

G

mesoderm posterior bHLH transcription factor 1

decreases expression

EXP

Cephaloridine results in decreased expression of MESP1 mRNA

NCBI chr 1:143,147,671...143,149,189
Ensembl chr 1:143,147,671...143,149,189

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

EXP

Cephaloridine results in increased expression of MET mRNA

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

monoglyceride lipase

decreases expression

EXP

Cephaloridine results in decreased expression of MGLL mRNA

NCBI chr 4:122,749,436...122,851,440
Ensembl chr 4:122,749,436...122,851,440

G

marker of proliferation Ki-67

decreases expression

EXP

Cephaloridine results in decreased expression of MKI67 mRNA

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

matrix metallopeptidase 12

increases expression

EXP

Cephaloridine results in increased expression of MMP12 mRNA

NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478

G

matrix metallopeptidase 16

increases expression

EXP

Cephaloridine results in increased expression of MMP16 mRNA

NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:36,109,265...36,353,252

G

meiotic nuclear divisions 1

increases expression

EXP

Cephaloridine results in increased expression of MND1 mRNA

NCBI chr 2:171,731,523...171,794,124
Ensembl chr 2:171,731,523...171,794,095

G

meiosis-specific nuclear structural 1

decreases expression

EXP

Cephaloridine results in decreased expression of MNS1 mRNA

NCBI chr 8:82,029,587...82,050,276
Ensembl chr 8:82,029,587...82,050,274

G

mercaptopyruvate sulfurtransferase

decreases expression

EXP

Cephaloridine results in decreased expression of MPST mRNA

NCBI chr 7:111,836,079...111,843,651
Ensembl chr 7:111,835,587...111,843,650

G

MPV17 mitochondrial inner membrane protein like

decreases expression

EXP

Cephaloridine results in decreased expression of MPV17L mRNA

NCBI chr10:2,495,605...2,532,448
Ensembl chr10:2,495,607...2,532,448

G

metallothionein 1A

decreases expression

EXP

Cephaloridine results in decreased expression of MT1A mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

increases expression

EXP

Cephaloridine results in increased expression of MTHFD1L mRNA

NCBI chr 1:42,849,424...43,038,313
Ensembl chr 1:42,849,374...43,038,309

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

increases expression

EXP

Cephaloridine results in increased expression of MTHFD2 mRNA

NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350

G

myomesin 3

increases expression

EXP

Cephaloridine results in increased expression of MYOM3 mRNA

NCBI chr 5:153,276,306...153,326,847
Ensembl chr 5:153,276,261...153,326,839

G

nuclear receptor co-repressor 2

decreases expression

EXP

Cephaloridine results in decreased expression of NCOR2 mRNA

NCBI chr12:37,127,736...37,289,612
Ensembl chr12:37,127,686...37,289,612

G

NIMA-related kinase 6

increases expression

EXP

Cephaloridine results in increased expression of NEK6 mRNA

NCBI chr 3:42,693,994...42,766,026
Ensembl chr 3:42,693,971...42,767,773

G

nuclear factor, interleukin 3 regulated

increases expression

EXP

Cephaloridine results in increased expression of NFIL3 mRNA

NCBI chr17:12,432,376...12,447,605
Ensembl chr17:12,432,198...12,450,826

G

NFKB inhibitor alpha

decreases expression

EXP

Cephaloridine results in decreased expression of NFKBIA mRNA

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

NFKB inhibitor zeta

decreases expression

EXP

Cephaloridine results in decreased expression of NFKBIZ mRNA

NCBI chr11:58,251,720...58,279,767
Ensembl chr11:58,251,721...58,279,767

G

nerve growth factor receptor

increases expression

EXP

Cephaloridine results in increased expression of NGFR mRNA

NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305

G

NHP2 ribonucleoprotein

increases expression

EXP

Cephaloridine results in increased expression of NHP2 mRNA

NCBI chr10:36,378,020...36,381,362
Ensembl chr10:36,377,997...36,381,354

G

ninjurin 2

increases expression

EXP

Cephaloridine results in increased expression of NINJ2 mRNA

NCBI chr 4:154,978,660...155,080,860
Ensembl chr 4:155,073,295...155,080,860

G

nipsnap homolog 3B

increases expression

EXP

Cephaloridine results in increased expression of NIPSNAP3B mRNA

NCBI chr 5:72,446,945...72,465,090
Ensembl chr 5:72,432,957...72,465,544

G

NME/NM23 nucleoside diphosphate kinase 4

decreases expression

EXP

Cephaloridine results in decreased expression of NME4 mRNA

NCBI chr10:15,619,106...15,622,961
Ensembl chr10:15,619,106...15,623,098

G

NOP56 ribonucleoprotein

increases expression

EXP

Cephaloridine results in increased expression of NOP56 mRNA

NCBI chr 3:137,926,187...137,934,971
Ensembl chr 3:137,929,646...137,934,959

G

NAD(P)H quinone dehydrogenase 1

increases expression

EXP

Cephaloridine results in increased expression of NQO1 mRNA

PMID:18172885 PMID:18500788

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 1, group D, member 1

increases expression

EXP

Cephaloridine results in increased expression of NR1D1 mRNA

NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812

G

nurim

increases expression

EXP

Cephaloridine results in increased expression of NRM mRNA

NCBI chr20:2,893,126...2,897,725
Ensembl chr20:2,882,369...2,896,605

G

nudix hydrolase 11

increases expression

EXP

Cephaloridine results in increased expression of NUDT11 mRNA

NCBI chr X:18,998,587...19,005,208
Ensembl chr X:18,998,461...19,005,208

G

nudix hydrolase 4

increases expression

EXP

Cephaloridine results in increased expression of NUDT10 mRNA

NCBI chr 7:32,074,978...32,091,491
Ensembl chr 7:32,075,002...32,091,491

G

opioid related nociceptin receptor 1

increases expression

EXP

Cephaloridine results in increased expression of OPRL1 mRNA

NCBI chr 3:189,209,495...189,225,406
Ensembl chr 3:189,212,175...189,217,426

G

olfactory receptor family 10 subfamily J member 3B

increases expression

EXP

Cephaloridine results in increased expression of OR10J3B mRNA

NCBI chr13:88,212,909...88,213,850
Ensembl chr13:88,212,909...88,213,850

G

olfactory receptor family 13 subfamily L member 2

decreases expression

EXP

Cephaloridine results in decreased expression of OR13L2 mRNA

NCBI chr 2:187,645,780...187,646,742
Ensembl chr 2:187,645,780...187,646,742

G

olfactory receptor family 14 subfamily A member 258

decreases expression

EXP

Cephaloridine results in decreased expression of OR14A258 mRNA

NCBI chr 1:149,373,596...149,374,546
Ensembl chr 1:149,373,596...149,374,546

G

olfactory receptor family 2 subfamily W member 6

increases expression

EXP

Cephaloridine results in increased expression of OR2W6 mRNA

NCBI chr17:47,596,741...47,603,138

G

olfactory receptor family 52 subfamily B member 2

increases expression

EXP

Cephaloridine results in increased expression of OR52B2 mRNA

NCBI chr 1:169,107,360...169,108,328
Ensembl chr 1:169,107,360...169,108,328

G

olfactory receptor family 52 subfamily K member 1

decreases expression

EXP

Cephaloridine results in decreased expression of OR52K1 mRNA

NCBI chr 1:166,449,318...166,450,262
Ensembl chr 1:166,449,318...166,450,262

G

olfactory receptor family 52 subfamily Z member 12

decreases expression

EXP

Cephaloridine results in decreased expression of OR52Z12 mRNA

NCBI chr 1:167,345,560...167,346,525
Ensembl chr 1:167,345,560...167,346,525

G

origin recognition complex, subunit 6

increases expression

EXP

Cephaloridine results in increased expression of ORC6 mRNA

NCBI chr19:37,931,085...37,938,856
Ensembl chr19:37,931,090...37,938,856

G

oxysterol binding protein-like 8

decreases expression

EXP

Cephaloridine results in decreased expression of OSBPL8 mRNA

NCBI chr 7:48,483,259...48,636,151
Ensembl chr 7:48,483,022...48,636,151

G

oncostatin M receptor

increases expression

EXP

Cephaloridine results in increased expression of OSMR mRNA

NCBI chr 2:57,634,517...57,688,802
Ensembl chr 2:57,634,517...57,688,561

G

oxoglutarate receptor 1

increases expression

EXP

Cephaloridine results in increased expression of OXGR1 mRNA

NCBI chr15:103,551,338...103,573,611
Ensembl chr15:103,552,861...103,553,874

G

peptidyl arginine deiminase 6

increases expression

EXP

Cephaloridine results in increased expression of PADI6 mRNA

NCBI chr 5:158,304,118...158,320,508
Ensembl chr 5:158,304,921...158,320,508

G

partner and localizer of BRCA2

increases expression

EXP

Cephaloridine results in increased expression of PALB2 mRNA

NCBI chr 1:186,096,312...186,120,284
Ensembl chr 1:186,096,312...186,120,302

G

PAS domain containing serine/threonine kinase

increases expression

EXP

Cephaloridine results in increased expression of PASK mRNA

NCBI chr 9:101,291,673...101,333,288
Ensembl chr 9:101,291,676...101,332,504

G

PDZ binding kinase

decreases expression

EXP

Cephaloridine results in decreased expression of PBK mRNA

NCBI chr15:44,198,506...44,209,572
Ensembl chr15:44,198,544...44,209,570

G

protocadherin 7

decreases expression

EXP

Cephaloridine results in decreased expression of PCDH7 mRNA

NCBI chr14:56,684,817...57,114,976
Ensembl chr14:56,687,725...57,112,665

G

protocadherin 9

decreases expression

EXP

Cephaloridine results in decreased expression of PCDH9 mRNA

NCBI chr15:75,748,472...76,646,644
NCBI chr15:76,078,024...76,127,778
Ensembl chr15:75,749,278...76,645,302

G

phosphoenolpyruvate carboxykinase 1

decreases expression

EXP

Cephaloridine results in decreased expression of PCK1 mRNA

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

PCNA clamp associated factor

increases expression

EXP

Cephaloridine results in increased expression of PCLAF mRNA

NCBI chr 8:75,311,028...75,328,108
Ensembl chr 8:75,315,707...75,328,106

G

proliferating cell nuclear antigen

increases expression

EXP

Cephaloridine results in increased expression of PCNA mRNA

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

protein disulfide isomerase family A, member 4

increases expression

EXP

Cephaloridine results in increased expression of PDIA4 mRNA

NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:78,134,144...78,153,191

G

profilin 3

decreases expression

EXP

Cephaloridine results in decreased expression of PFN3 mRNA

NCBI chr17:9,222,729...9,223,256
Ensembl chr17:9,222,719...9,223,249

G

pipecolic acid and sarcosine oxidase

increases expression

EXP

Cephaloridine results in increased expression of PIPOX mRNA

NCBI chr10:63,267,946...63,281,556
Ensembl chr10:63,267,972...63,282,273

G

pirin

increases expression

EXP

Cephaloridine results in increased expression of PIR mRNA

NCBI chr X:33,740,428...33,851,049
Ensembl chr X:33,740,429...33,851,049

G

PKHD1 ciliary IPT domain containing fibrocystin/polyductin

decreases expression

EXP

Cephaloridine results in decreased expression of PKHD1 mRNA

NCBI chr 9:30,040,466...30,533,834
Ensembl chr 9:30,046,038...30,533,935

G

protein kinase, membrane associated tyrosine/threonine 1

increases expression

EXP

Cephaloridine results in increased expression of PKMYT1 mRNA

NCBI chr10:13,252,805...13,263,584
Ensembl chr10:13,252,816...13,264,263

G

phospholipase A1 member A

increases expression

EXP

Cephaloridine results in increased expression of PLA1A mRNA

NCBI chr11:75,825,626...75,863,296
Ensembl chr11:75,825,585...75,878,165

G

pleckstrin 2

increases expression

EXP

Cephaloridine results in increased expression of PLEK2 mRNA

NCBI chr 6:103,434,156...103,452,457
Ensembl chr 6:103,434,156...103,452,371

G

pleckstrin homology domain containing A5

decreases expression

EXP

Cephaloridine results in decreased expression of PLEKHA5 mRNA

NCBI chr 4:175,065,011...175,234,672
Ensembl chr 4:175,065,183...175,234,672

G

polo-like kinase 1

decreases expression

EXP

Cephaloridine results in decreased expression of PLK1 mRNA

NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:186,147,658...186,157,637

G

DNA polymerase alpha 2, accessory subunit

increases expression

EXP

Cephaloridine results in increased expression of POLA2 mRNA

NCBI chr 1:212,656,500...212,680,667
Ensembl chr 1:212,656,501...212,680,542

G

DNA polymerase delta 1, catalytic subunit

increases expression

EXP

Cephaloridine results in increased expression of POLD1 mRNA

NCBI chr 1:104,161,984...104,178,074
Ensembl chr 1:104,162,016...104,172,982

G

DNA polymerase epsilon, catalytic subunit

increases expression

EXP

Cephaloridine results in increased expression of POLE mRNA

NCBI chr12:52,005,155...52,053,761
Ensembl chr12:52,005,155...52,053,662

G

inorganic pyrophosphatase 1

increases expression

EXP

Cephaloridine results in increased expression of PPA1 mRNA

NCBI chr20:30,132,088...30,160,492
Ensembl chr20:30,133,504...30,160,489

G

protein phosphatase, Mg2+/Mn2+ dependent, 1J

increases expression

EXP

Cephaloridine results in increased expression of PPM1J mRNA

NCBI chr 2:194,966,854...194,972,228
Ensembl chr 2:194,966,950...194,972,227

G

protein phosphatase 1, regulatory subunit 15A

decreases expression

EXP

Cephaloridine results in decreased expression of PPP1R15A mRNA

NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774

G

protein regulator of cytokinesis 1

decreases expression

EXP

Cephaloridine results in decreased expression of PRC1 mRNA

NCBI chr 1:143,659,312...143,681,019
Ensembl chr 1:143,659,481...143,681,012

G

DNA primase subunit 1

increases expression

EXP

Cephaloridine results in increased expression of PRIM1 mRNA

NCBI chr 7:1,031,436...1,047,134

G

protein kinase cAMP-dependent type I regulatory subunit beta

increases expression

EXP

Cephaloridine results in increased expression of PRKAR1B mRNA

NCBI chr12:20,606,066...20,738,766
Ensembl chr12:20,618,757...20,738,766

G

proline dehydrogenase 2

decreases expression

EXP

Cephaloridine results in decreased expression of PRODH2 mRNA

NCBI chr 1:94,881,000...94,894,609
Ensembl chr 1:94,881,061...94,894,609

G

paired related homeobox 1

decreases expression

EXP

Cephaloridine results in decreased expression of PRRX1 mRNA

NCBI chr13:78,136,783...78,205,379
Ensembl chr13:78,136,783...78,204,058

G

serine protease 35

decreases expression

EXP

Cephaloridine results in decreased expression of PRSS35 mRNA

NCBI chr 8:96,594,460...96,610,992
Ensembl chr 8:96,590,571...96,613,024

G

proteasome 20S subunit beta 4

increases expression

EXP

Cephaloridine results in increased expression of PSMB4 mRNA

NCBI chr 2:185,131,787...185,134,561
Ensembl chr 2:185,131,786...185,135,287

G

polypyrimidine tract binding protein 1

increases expression

EXP

Cephaloridine results in increased expression of PTBP1 mRNA

NCBI chr 7:10,493,199...10,502,957
Ensembl chr 7:10,493,200...10,502,957

G

prostaglandin reductase 1

increases expression

EXP

Cephaloridine results in increased expression of PTGR1 mRNA

NCBI chr 5:78,579,060...78,597,671
Ensembl chr 5:78,579,057...78,597,811

G

protein tyrosine phosphatase, non-receptor type 11

decreases expression

EXP

Cephaloridine results in decreased expression of PTPN11 mRNA

NCBI chr12:41,026,079...41,085,577
Ensembl chr12:41,043,785...41,085,577

G

protein tyrosine phosphatase, receptor type, B

decreases expression

EXP

Cephaloridine results in decreased expression of PTPRB mRNA

NCBI chr 7:53,816,197...53,920,760
Ensembl chr 7:53,816,097...53,920,760

G

protein tyrosine phosphatase, receptor type N2

increases expression

EXP

Cephaloridine results in increased expression of PTPRN2 mRNA

NCBI chr 6:143,582,568...144,334,573
Ensembl chr 6:143,582,547...144,336,744

G

peptidyl-tRNA hydrolase 1 homolog

increases expression

EXP

Cephaloridine results in increased expression of PTRH1 mRNA

NCBI chr 3:36,462,575...36,475,605
Ensembl chr 3:36,462,575...36,476,139

G

PVR cell adhesion molecule

increases expression

EXP

Cephaloridine results in increased expression of PVR mRNA

NCBI chr 1:88,689,235...88,704,641
Ensembl chr 1:88,688,981...88,704,630

G

RAB11 family interacting protein 3

decreases expression

EXP

Cephaloridine results in decreased expression of RAB11FIP3 mRNA

NCBI chr10:15,507,151...15,591,173
Ensembl chr10:15,507,151...15,591,173

G

RAB31, member RAS oncogene family

decreases expression

EXP

Cephaloridine results in decreased expression of RAB31 mRNA

NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:112,693,597...112,828,092

G

RAD18 E3 ubiquitin protein ligase

increases expression

EXP

Cephaloridine results in increased expression of RAD18 mRNA

NCBI chr 4:147,291,463...147,376,904
Ensembl chr 4:147,291,276...147,376,869

G

RB transcriptional corepressor 1

affects activity

EXP

Cephaloridine affects the activity of RB1 protein

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

retinol binding protein 2

increases expression

EXP

Cephaloridine results in increased expression of RBP2 mRNA

NCBI chr 8:107,958,670...107,983,850

G

rabenosyn, RAB effector

decreases expression

EXP

Cephaloridine results in decreased expression of RBSN mRNA

NCBI chr 4:126,239,354...126,269,702
Ensembl chr 4:126,239,902...126,266,904

G

retinol dehydrogenase 16

decreases expression

EXP

Cephaloridine results in decreased expression of RDH2 mRNA

NCBI chr 7:65,499,763...65,510,304

G

RecQ like helicase 4

increases expression

EXP

Cephaloridine results in increased expression of RECQL4 mRNA

NCBI chr 7:110,304,092...110,311,426
Ensembl chr 7:110,304,094...110,311,258

G

RELA proto-oncogene, NF-kB subunit

affects activity

EXP

Cephaloridine affects the activity of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

replication factor C subunit 3

increases expression

EXP

Cephaloridine results in increased expression of RFC3 mRNA

NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340

G

replication factor C subunit 4

increases expression

EXP

Cephaloridine results in increased expression of RFC4 mRNA

NCBI chr11:91,254,273...91,268,727
Ensembl chr11:91,254,243...91,268,730

G

regucalcin

decreases expression

EXP

Cephaloridine results in decreased expression of RGN mRNA

PMID:8584014 PMID:18500788

NCBI chr X:4,172,537...4,190,112
Ensembl chr X:4,172,537...4,190,251

G

regulator of G-protein signaling 11

increases expression

EXP

Cephaloridine results in increased expression of RGS11 mRNA

NCBI chr10:15,727,279...15,735,536
Ensembl chr10:15,727,279...15,735,536

G

Rh family, C glycoprotein

increases expression

EXP

Cephaloridine results in increased expression of RHCG mRNA

NCBI chr 1:142,941,046...142,965,242
Ensembl chr 1:142,941,048...142,965,376

G

Rho-related BTB domain containing 1

decreases expression

EXP

Cephaloridine results in decreased expression of RHOBTB1 mRNA

NCBI chr20:19,326,197...19,455,182
Ensembl chr20:19,326,212...19,402,057

G

rhophilin, Rho GTPase binding protein 2

increases expression

EXP

Cephaloridine results in increased expression of RHPN2 mRNA

NCBI chr 1:97,128,054...97,188,803
Ensembl chr 1:97,127,697...97,188,803

G

reactive intermediate imine deaminase A homolog

decreases expression

EXP

Cephaloridine results in decreased expression of RIDA mRNA

NCBI chr 7:67,576,586...67,590,493
Ensembl chr 7:67,576,586...67,590,692

G

Rho family GTPase 1

increases expression

EXP

Cephaloridine results in increased expression of RND1 mRNA

NCBI chr 7:131,700,321...131,707,392
Ensembl chr 7:131,700,321...131,707,392

G

ring finger protein 227

increases expression

EXP

Cephaloridine results in increased expression of RNF227 mRNA

NCBI chr10:54,559,862...54,561,823
Ensembl chr10:54,559,739...54,561,818

G

ribosomal protein L23A

increases expression

EXP

Cephaloridine results in increased expression of RPL23A mRNA

NCBI chr10:63,574,732...63,577,511
Ensembl chr10:63,574,732...63,581,606

G

ribosomal protein L23a, pseudogene 6

increases expression

EXP

Cephaloridine results in increased expression of RPL23A-PS6 mRNA

NCBI chr 1:3,874,949...3,875,451

G

ribosomal protein L23A like 1

increases expression

EXP

Cephaloridine results in increased expression of RPL23AL1 mRNA

NCBI chr 2:40,186,356...40,186,893
Ensembl chr 2:40,185,013...40,189,038

G

ribosomal protein L32 like 4

decreases expression

EXP

Cephaloridine results in decreased expression of RPL32L4 mRNA

NCBI chr 8:93,571,155...93,572,183

G

ribonucleotide reductase regulatory subunit M2

decreases expression

EXP

Cephaloridine results in decreased expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

RUNX1 partner transcriptional co-repressor 1

decreases expression

EXP

Cephaloridine results in decreased expression of RUNX1T1 mRNA

NCBI chr 5:31,984,946...32,136,878
Ensembl chr 5:31,984,855...32,132,855

G

retinoid X receptor gamma

increases expression

EXP

Cephaloridine results in increased expression of RXRG mRNA

NCBI chr13:82,276,330...82,318,097
Ensembl chr13:82,276,291...82,318,095

G

secretoglobin, family 3A, member 1

increases expression

EXP

Cephaloridine results in increased expression of SCGB3A1 mRNA

NCBI chr10:34,469,166...34,470,473
Ensembl chr10:34,468,002...34,470,583

G

secretoglobin, family 3A, member 2

increases expression

EXP

Cephaloridine results in increased expression of SCGB3A2 mRNA

NCBI chr18:36,183,745...36,186,667
Ensembl chr18:36,183,698...36,186,742

G

secretin

increases expression

EXP

Cephaloridine results in increased expression of SCT mRNA

NCBI chr 1:205,812,435...205,813,246
Ensembl chr 1:205,812,435...205,813,246

G

secreted and transmembrane 1B

increases expression

EXP

Cephaloridine results in increased expression of SECTM1A mRNA

NCBI chr10:106,822,397...106,832,105
Ensembl chr10:106,822,397...106,832,104

G

selenoprotein P

decreases expression

EXP

Cephaloridine results in decreased expression of SELENOP mRNA

NCBI chr 2:54,225,736...54,236,022
Ensembl chr 2:54,225,152...54,236,019

G

semaphorin 4C

decreases expression

EXP

Cephaloridine results in decreased expression of SEMA4C mRNA

NCBI chr 9:46,287,540...46,298,041
Ensembl chr 9:46,287,542...46,297,998

G

septin 10

decreases expression

EXP

Cephaloridine results in decreased expression of SEPTIN10 mRNA

NCBI chr20:27,644,862...27,737,817
Ensembl chr20:27,643,876...27,737,902

G

SH2B adaptor protein 2

increases expression

EXP

Cephaloridine results in increased expression of SH2B2 mRNA

NCBI chr12:26,063,812...26,093,468
Ensembl chr12:26,064,486...26,093,467

G

SH3-domain binding protein 2

increases expression

EXP

Cephaloridine results in increased expression of SH3BP2 mRNA

NCBI chr14:80,400,685...80,437,887
Ensembl chr14:80,400,685...80,437,906

G

shroom family member 4

decreases expression

EXP

Cephaloridine results in decreased expression of SHROOM4 mRNA

NCBI chr X:18,537,371...18,748,665
Ensembl chr X:18,540,913...18,748,700

G

sialic acid binding Ig-like lectin 5

increases expression

EXP

Cephaloridine results in increased expression of SIGLEC5 mRNA

NCBI chr 1:102,904,705...102,913,281
Ensembl chr 1:102,904,578...102,913,281

G

spindle and kinetochore associated complex subunit 1

decreases expression

EXP

Cephaloridine results in decreased expression of SKA1 mRNA

NCBI chr18:70,069,957...70,080,303
Ensembl chr18:70,069,957...70,080,398

G

solute carrier family 15 member 3

increases expression

EXP

Cephaloridine results in increased expression of SLC15A3 mRNA

NCBI chr 1:216,906,836...216,932,046
Ensembl chr 1:216,916,675...216,932,045

G

solute carrier family 16, member 12

decreases expression

EXP

Cephaloridine results in decreased expression of SLC16A12 mRNA

NCBI chr 1:241,597,165...241,674,821
Ensembl chr 1:241,599,066...241,674,743

G

solute carrier family 16, member 14

decreases expression

EXP

Cephaloridine results in decreased expression of SLC16A14 mRNA

NCBI chr 9:93,558,144...93,585,396
Ensembl chr 9:93,558,144...93,585,396

G

solute carrier family 1 member 5

increases expression

EXP

Cephaloridine results in increased expression of SLC1A5 mRNA

NCBI chr 1:86,584,949...86,599,052
Ensembl chr 1:86,584,949...86,599,054

G

solute carrier family 22, member 23

decreases expression

EXP

Cephaloridine results in decreased expression of SLC22A23 mRNA

NCBI chr17:30,749,445...30,915,139
Ensembl chr17:30,749,445...30,915,139

G

solute carrier family 22 member 5

decreases expression

EXP

Cephaloridine results in decreased expression of SLC22A5 mRNA

NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077

G

solute carrier family 22 member 6

increases import
multiple interactions
increases uptake

EXP
ISO

SLC22A6 protein results in increased import of Cephaloridine
Cephaloridine inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]
SLC22A6 protein results in increased uptake of Cephaloridine

PMID:10594788 PMID:16098483

NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311

G

solute carrier family 22 member 8

increases uptake
multiple interactions

ISO

SLC22A8 protein results in increased uptake of Cephaloridine
Cephaloridine inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

G

solute carrier family 35 member D2

increases expression

EXP

Cephaloridine results in increased expression of SLC35D2 mRNA

NCBI chr17:992,153...1,025,476
Ensembl chr17:993,646...1,025,475

G

solute carrier family 39 member 4

increases expression

EXP

Cephaloridine results in increased expression of SLC39A4 mRNA

NCBI chr 7:110,214,017...110,218,202
Ensembl chr 7:110,214,017...110,218,202

G

solute carrier family 41 member 2

increases expression

EXP

Cephaloridine results in increased expression of SLC41A2 mRNA

NCBI chr 7:22,271,298...22,378,764
Ensembl chr 7:22,271,313...22,378,764

G

solute carrier family 46, member 3

increases expression

EXP

Cephaloridine results in increased expression of SLC46A3 mRNA

NCBI chr12:12,176,776...12,193,256
Ensembl chr12:12,176,807...12,193,255

G

solute carrier family 4 member 4

decreases expression

EXP

Cephaloridine results in decreased expression of SLC4A4 mRNA

NCBI chr14:19,125,394...19,577,379
Ensembl chr14:19,129,264...19,577,435

G

solute carrier family 5 member 3

increases expression

EXP

Cephaloridine results in increased expression of SLC5A3 mRNA

NCBI chr11:44,799,787...44,802,233
Ensembl chr11:44,790,297...44,818,157

G

solute carrier family 7 member 10

increases expression

EXP

Cephaloridine results in increased expression of SLC7A10 mRNA

NCBI chr 1:96,966,030...96,982,020
Ensembl chr 1:96,966,076...96,982,018

G

solute carrier family 7 member 5

increases expression

EXP

Cephaloridine results in increased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412

G

solute carrier family 7 member 7

decreases expression

EXP

Cephaloridine results in decreased expression of SLC7A7 mRNA

NCBI chr15:31,792,122...31,852,732
Ensembl chr15:31,792,125...31,835,683

G

solute carrier family 8 member A1

decreases expression

EXP

Cephaloridine results in decreased expression of SLC8A1 mRNA

NCBI chr 6:18,975,498...19,299,704
Ensembl chr 6:18,946,798...19,287,964

G

secretory leukocyte peptidase inhibitor

increases expression

EXP

Cephaloridine results in increased expression of SLPI mRNA

NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822

G

SET and MYND domain containing 1

increases expression

EXP

Cephaloridine results in increased expression of SMYD1 mRNA

NCBI chr 4:104,757,281...104,811,307
Ensembl chr 4:104,760,475...104,870,081

G

small nuclear RNA activating complex, polypeptide 2

increases expression

EXP

Cephaloridine results in increased expression of SNAPC2 mRNA

NCBI chr12:7,403,650...7,406,840
Ensembl chr12:7,403,469...7,406,840

G

suppressor of cytokine signaling 3

decreases expression

EXP

Cephaloridine results in decreased expression of SOCS3 mRNA

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

Spetex-2B protein

increases expression

EXP

Cephaloridine results in increased expression of SPETEX2B mRNA

NCBI chr15:5,806,975...5,810,125
Ensembl chr15:5,806,975...5,810,255

G

Spetex-2D protein

increases expression

EXP

Cephaloridine results in increased expression of SPETEX2D mRNA

NCBI chr15:5,880,984...5,883,252
Ensembl chr15:5,880,859...5,883,451

G

sphingosine kinase 1

increases expression

EXP

Cephaloridine results in increased expression of SPHK1 mRNA

NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082

G

serine peptidase inhibitor, Kazal type 1

decreases expression

EXP

Cephaloridine results in decreased expression of SPINK1 mRNA

NCBI chr18:36,121,626...36,133,596
Ensembl chr18:36,076,399...36,133,545

G

SRP receptor subunit alpha

decreases expression

EXP

Cephaloridine results in decreased expression of SRPRA mRNA

NCBI chr 8:41,818,199...41,824,292
Ensembl chr 8:41,818,229...41,824,280

G

signal transducer and activator of transcription 3

increases expression

EXP

Cephaloridine results in increased expression of STAT3 mRNA

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

serine/threonine kinase 35

increases expression

EXP

Cephaloridine results in increased expression of STK35 mRNA

NCBI chr 3:137,465,884...137,498,554
Ensembl chr 3:137,470,110...137,498,940

G

signaling receptor and transporter of retinol STRA6

decreases expression

EXP

Cephaloridine results in decreased expression of STRA6 mRNA

NCBI chr 8:67,444,757...67,464,719
Ensembl chr 8:67,444,742...67,464,720

G

sulfotransferase family 1C member 2A

decreases expression

EXP

Cephaloridine results in decreased expression of SULT1C2 mRNA; Cephaloridine results in decreased expression of SULT1C2A mRNA

NCBI chr 9:7,075,873...7,103,316
Ensembl chr 9:7,066,905...7,244,132

G

sulfotransferase family 4A, member 1

increases expression

EXP

Cephaloridine results in increased expression of SULT4A1 mRNA

NCBI chr 7:117,096,064...117,120,714
Ensembl chr 7:117,096,064...117,120,083

G

surfeit 6

decreases expression

EXP

Cephaloridine results in decreased expression of SURF6 mRNA

NCBI chr 3:30,619,525...30,630,388
Ensembl chr 3:30,619,530...30,630,247

G

sushi domain containing 2

decreases expression

EXP

Cephaloridine results in decreased expression of SUSD2 mRNA

NCBI chr20:13,016,960...13,024,264
Ensembl chr20:13,016,907...13,024,264

G

spectrin repeat containing nuclear envelope protein 1

decreases expression

EXP

Cephaloridine results in decreased expression of SYNE1 mRNA

NCBI chr 1:43,917,640...44,388,802
Ensembl chr 1:43,895,994...44,388,721

G

spectrin repeat containing nuclear envelope protein 2

decreases expression

EXP

Cephaloridine results in decreased expression of SYNE2 mRNA

NCBI chr 6:100,272,729...100,586,364
Ensembl chr 6:100,272,729...100,583,723

G

synaptotagmin-like 5

increases expression

EXP

Cephaloridine results in increased expression of SYTL5 mRNA

NCBI chr X:15,461,215...15,702,660
Ensembl chr X:15,460,472...15,550,471

G

tachykinin precursor 3

increases expression

EXP

Cephaloridine results in increased expression of TAC2 mRNA

NCBI chr 7:65,447,817...65,454,427
Ensembl chr 7:65,447,817...65,454,427

G

T-box transcription factor 3

decreases expression

EXP

Cephaloridine results in decreased expression of TBX3 mRNA

NCBI chr12:42,540,378...42,555,490
Ensembl chr12:42,540,378...42,554,171

G

transcription factor 12

decreases expression

EXP

Cephaloridine results in decreased expression of TCF12 mRNA

NCBI chr 8:81,371,201...81,682,337
Ensembl chr 8:81,373,321...81,679,922

G

transcription factor 19

increases expression

EXP

Cephaloridine results in increased expression of TCF19 mRNA

NCBI chr20:3,223,464...3,227,569
Ensembl chr20:3,223,324...3,230,060

G

transferrin receptor

increases expression

EXP

Cephaloridine results in increased expression of TFRC mRNA

NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318

G

TOPBP1-interacting checkpoint and replication regulator

increases expression

EXP

Cephaloridine results in increased expression of TICRR mRNA

NCBI chr 1:143,006,989...143,048,836
Ensembl chr 1:143,006,924...143,049,133

G

timeless circadian regulator

increases expression

EXP

Cephaloridine results in increased expression of TIMELESS mRNA

NCBI chr 7:1,239,388...1,263,344
Ensembl chr 7:1,239,450...1,263,337

G

TIMP metallopeptidase inhibitor 1

increases expression

EXP

Cephaloridine results in increased expression of TIMP1 mRNA

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

toll-like receptor 2

increases expression

EXP

Cephaloridine results in increased expression of TLR2 mRNA

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

transmembrane protein 163

increases expression

EXP

Cephaloridine results in increased expression of TMEM163 mRNA

NCBI chr13:41,520,595...41,693,938
Ensembl chr13:41,520,359...41,693,938

G

transmembrane protein 252

decreases expression

EXP

Cephaloridine results in decreased expression of TMEM252 mRNA

NCBI chr 1:231,743,396...231,748,360
Ensembl chr 1:231,743,233...231,748,358

G

transmembrane protein 270

increases expression

EXP

Cephaloridine results in increased expression of TMEM270 mRNA

NCBI chr12:27,430,092...27,435,243
Ensembl chr12:27,429,985...27,435,242

G

transmembrane protein 63c

increases expression

EXP

Cephaloridine results in increased expression of TMEM63C mRNA

NCBI chr 6:112,398,308...112,469,732
Ensembl chr 6:112,399,118...112,469,729

G

transmembrane protein 86A

decreases expression

EXP

Cephaloridine results in decreased expression of TMEM86A mRNA

NCBI chr 1:106,732,168...106,736,518
Ensembl chr 1:106,661,042...106,736,516

G

TNF receptor superfamily member 12A

increases expression

EXP

Cephaloridine results in increased expression of TNFRSF12A mRNA

NCBI chr10:13,211,670...13,213,666
Ensembl chr10:13,211,673...13,213,704

G

TNF receptor superfamily member 1A

increases expression

EXP

Cephaloridine results in increased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

tensin 1

decreases expression

EXP

Cephaloridine results in decreased expression of TNS1 mRNA

NCBI chr 9:82,941,068...83,152,007
Ensembl chr 9:82,941,068...83,152,007

G

tensin 4

increases expression

EXP

Cephaloridine results in increased expression of TNS4 mRNA

NCBI chr10:84,518,179...84,537,558
Ensembl chr10:84,518,180...84,537,558

G

tonsoku-like, DNA repair protein

increases expression

EXP

Cephaloridine results in increased expression of TONSL mRNA

NCBI chr 7:110,226,696...110,241,459
Ensembl chr 7:110,225,525...110,241,397

G

DNA topoisomerase II alpha

decreases expression

EXP

Cephaloridine results in decreased expression of TOP2A mRNA

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

tryptophan hydroxylase 1

increases expression

EXP

Cephaloridine results in increased expression of TPH1 mRNA

NCBI chr 1:106,293,695...106,314,628
Ensembl chr 1:106,085,953...106,312,484

G

tribbles pseudokinase 3

increases expression

EXP

Cephaloridine results in increased expression of TRIB3 mRNA

NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802

G

TLR4 interactor with leucine-rich repeats

decreases expression

EXP

Cephaloridine results in decreased expression of TRIL mRNA

NCBI chr 4:84,252,781...84,257,626
Ensembl chr 4:84,239,028...84,260,209

G

transient receptor potential cation channel, subfamily C, member 6

increases expression

EXP

Cephaloridine results in increased expression of TRPC6 mRNA

NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304

G

testis specific X-linked gene

increases expression

EXP

Cephaloridine results in increased expression of TSX mRNA

NCBI chr X:72,493,147...72,503,653
Ensembl chr X:72,489,226...72,503,653

G

tetratricopeptide repeat domain 39A

increases expression

EXP

Cephaloridine results in increased expression of TTC39A mRNA

NCBI chr 5:129,379,560...129,441,779
Ensembl chr 5:129,380,753...129,433,372

G

Ttk protein kinase

decreases expression

EXP

Cephaloridine results in decreased expression of TTK mRNA

NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:93,634,319...93,672,664

G

tubulin tyrosine ligase like 2

increases expression

EXP

Cephaloridine results in increased expression of TTLL2 mRNA

NCBI chr 1:55,515,931...55,524,240
Ensembl chr 1:55,515,397...55,524,071

G

tubulin, beta 3 class III

increases expression

EXP

Cephaloridine results in increased expression of TUBB3 mRNA

NCBI chr19:68,365,687...68,374,741
Ensembl chr19:68,365,587...68,374,740

G

tubulin, beta 6 class V

increases expression

EXP

Cephaloridine results in increased expression of TUBB6 mRNA

NCBI chr18:63,213,287...63,222,926
Ensembl chr18:63,213,279...63,224,303

G

thymidylate synthetase

increases expression

EXP

Cephaloridine results in increased expression of TYMS mRNA

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097

G

ubiquitin D

increases expression

EXP

Cephaloridine results in increased expression of UBD mRNA

NCBI chr20:1,390,734...1,392,685
Ensembl chr20:1,390,600...1,413,965

G

ubiquitin-conjugating enzyme E2C

decreases expression

EXP

Cephaloridine results in decreased expression of UBE2C mRNA

NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678

G

ubiquitin-conjugating enzyme E2L 6

increases expression

EXP

Cephaloridine results in increased expression of UBE2L6 mRNA

NCBI chr 3:90,279,705...90,294,721
Ensembl chr 3:90,279,668...90,294,717

G

ubiquitin-like 7

increases expression

EXP

Cephaloridine results in increased expression of UBL7 mRNA

NCBI chr 8:67,217,151...67,236,224
Ensembl chr 8:67,216,527...67,236,224

G

ubiquitin C-terminal hydrolase L1

increases expression

EXP

Cephaloridine results in increased expression of UCHL1 mRNA

NCBI chr14:41,838,859...41,849,743
Ensembl chr14:41,838,861...41,849,417

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression

EXP

Cephaloridine results in increased expression of UGT1A2 mRNA

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A6a

increases expression

EXP

Cephaloridine results in increased expression of UGT1A6 mRNA

NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase 2 family, polypeptide B35

increases expression

EXP

Cephaloridine results in increased expression of UGT2B36 mRNA

NCBI chr14:21,208,389...21,245,893
Ensembl chr14:21,208,430...21,246,694

G

UDP-glucuronosyltransferase 2 family, member 37

increases expression

EXP

Cephaloridine results in increased expression of UGT2B37 mRNA

NCBI chr14:21,172,136...21,188,768
Ensembl chr14:21,172,133...21,190,661

G

UDP glucuronosyltransferase family 2 member B7

increases expression

EXP

Cephaloridine results in increased expression of UGT2B7 mRNA

NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451

G

U2AF homology motif kinase 1

increases expression

EXP

Cephaloridine results in increased expression of UHMK1 mRNA

NCBI chr13:84,929,418...84,949,194
Ensembl chr13:84,922,829...84,949,061

G

U2AF homology motif kinase 1l1

increases expression

EXP

Cephaloridine results in increased expression of UHMK1L1 mRNA

NCBI chr17:43,147,379...43,149,342

G

uridine phosphorylase 1

increases expression

EXP

Cephaloridine results in increased expression of UPP1 mRNA

NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034

G

ubiquitin specific peptidase 24

decreases expression

EXP

Cephaloridine results in decreased expression of USP24 mRNA

NCBI chr 5:126,309,396...126,439,147
Ensembl chr 5:126,309,597...126,439,135

G

vascular cell adhesion molecule 1

increases expression

EXP

Cephaloridine results in increased expression of VCAM1 mRNA

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

V-set pre-B cell surrogate light chain 3

increases expression

EXP

Cephaloridine results in increased expression of VPREB3 mRNA

NCBI chr20:12,716,862...12,720,108

G

WD repeat and HMG-box DNA binding protein 1

increases expression

EXP

Cephaloridine results in increased expression of WDHD1 mRNA

NCBI chr15:22,957,492...23,002,820
Ensembl chr15:22,958,069...23,002,820

G

zinc finger CCCH type containing 13

decreases expression

EXP

Cephaloridine results in decreased expression of ZC3H13 mRNA

NCBI chr15:57,016,686...57,081,201
Ensembl chr15:57,016,781...57,081,201

G

zinc finger DHHC-type palmitoyltransferase 18

decreases expression

EXP

Cephaloridine results in decreased expression of ZDHHC18 mRNA

NCBI chr 5:151,105,303...151,143,843
Ensembl chr 5:151,105,201...151,143,769

G

zinc finger AN1-type containing 2A

decreases expression

EXP

Cephaloridine results in decreased expression of ZFAND2A mRNA

NCBI chr12:20,275,435...20,286,513
Ensembl chr12:20,275,450...20,286,513

G

zinc finger protein 367

increases expression

EXP

Cephaloridine results in increased expression of ZFP367 mRNA

NCBI chr17:970,896...990,025
Ensembl chr17:970,741...990,029

G

zinc finger protein 36, C3H type-like 3

increases expression

EXP

Cephaloridine results in increased expression of ZFP36L3 mRNA

NCBI chr X:138,573,127...138,576,456
Ensembl chr X:138,573,127...138,576,456

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of ABCB11 mRNA

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily C member 2

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

Cephalothin results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

caspase 3

multiple interactions

ISO

Cephalothin results in increased cleavage of and results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

fibroblast growth factor 19

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of FGF15 mRNA

NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of NPC1L1 mRNA

NCBI chr14:85,285,387...85,305,050
Ensembl chr14:85,285,390...85,305,050

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of NR5A2 mRNA

NCBI chr13:50,865,253...50,985,107
Ensembl chr13:50,867,920...50,984,938

G

solute carrier family 10 member 1

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of SLC10A1 mRNA

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 25 member 20

multiple interactions

EXP

Cephalothin binds to and results in decreased activity of SLC25A20 protein; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

G

SLC51 subunit beta

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in decreased expression of SLC51B mRNA

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

G

solute carrier organic anion transporter family member 1B2

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of SLCO1B2 mRNA

NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083

G

tumor protein p53

increases expression

ISO

Cephalothin results in increased expression of TP53 protein

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

vitamin D receptor

multiple interactions

ISO

[Cephalothin co-treated with Neomycin] results in increased expression of VDR mRNA

NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation

EXP

cefazolin cotreated ethanol increases phosphorylation of Akt1 protein in nucleus accumbens and prefrontal cortex

RGD

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

dihydrofolate reductase

decreases activity

ISO

Cefazolin results in decreased activity of DHFR protein

NCBI chr 2:25,320,895...25,346,004

G

glutathione-disulfide reductase

multiple interactions
increases expression

ISO

Cefazolin results in increased expression of and results in decreased activity of GSR protein
Cefazolin results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

RT1 class II, locus DOa

affects expression

ISO

Cefazolin affects the expression of HLA-DOA mRNA

NCBI chr20:4,755,287...4,758,491
Ensembl chr20:4,755,499...4,758,478

G

RT1 class Ib, locus M3, gene 1

affects expression

ISO

Cefazolin affects the expression of HLA-G mRNA

NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366

G

solute carrier family 1 member 2

increases expression

EXP

cefazolin cotreated ethanol increases expression of Slc1a2 protein in nucleus accumbens and prefrontal cortex

RGD

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 22 member 8

increases uptake

ISO

SLC22A8 protein results in increased uptake of Cefazolin

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

G

solute carrier family 25 member 20

multiple interactions

EXP

Cefazolin binds to and results in decreased activity of SLC25A20 protein; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 6

multiple interactions
increases uptake

ISO

cefdinir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]
SLC22A6 protein results in increased uptake of cefdinir

NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311

G

solute carrier family 22 member 8

multiple interactions
increases uptake

ISO

cefdinir inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]
SLC22A8 protein results in increased uptake of cefdinir

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Rho GTPase activating protein 45

affects expression

ISO

cefepime affects the expression of ARHGAP45 mRNA

NCBI chr 7:10,325,515...10,340,955
Ensembl chr 7:10,325,539...10,341,890

G

catalase

multiple interactions

ISO

cefepime inhibits the reaction [Amikacin results in decreased activity of CAT protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

dihydrofolate reductase

decreases activity

ISO

cefepime results in decreased activity of DHFR protein

NCBI chr 2:25,320,895...25,346,004

G

phosphogluconate dehydrogenase

decreases activity

EXP

cefepime results in decreased activity of PGD protein

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

RT1 class II, locus Db1

affects expression

ISO

cefepime affects the expression of HLA-DRB1 mRNA

NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,550,596...4,560,165

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RAB8A, member RAS oncogene family

multiple interactions
increases uptake

ISO

[RAB8A protein results in increased localization of SLC15A1 protein] which results in increased uptake of Cefixime
RAB8A protein results in increased uptake of Cefixime

NCBI chr16:17,688,049...17,709,412
Ensembl chr16:17,688,050...17,709,477

G

solute carrier family 15 member 1

multiple interactions
increases uptake

ISO

[RAB8A protein results in increased localization of SLC15A1 protein] which results in increased uptake of Cefixime
SLC15A1 protein results in increased uptake of Cefixime

NCBI chr15:104,944,461...104,991,316
Ensembl chr15:104,944,463...104,989,369

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ISO

ABCC4 protein results in increased transport of Cefmetazole

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 25 member 20

multiple interactions

EXP

Cefonicid binds to and results in decreased activity of SLC25A20 protein; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation

EXP

cefoperazone cotreated ethanol increases phosphorylation of Akt1 protein in nucleus accumbens and prefrontal cortex

RGD

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

solute carrier family 1 member 2

increases expression
multiple interactions

EXP

cefoperazone co-treated with ethanol increases expression of Slc1a2 protein in nucleus accumbens and prefrontal cortex
[cefoperazone co-treated with ethanol] results in increased expression of Slc1a2 protein in prefrontal cortex and nucleus accumbens
cefoperazone cotreated ethanol increases expression of Slc1a2 protein in nucleus accumbens and prefrontal cortex

RGD

PMID:26790351 PMID:25619881 PMID:25813713

RGD:598136399, RGD:598154596, RGD:598147069

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 22 member 7

multiple interactions

ISO

Cefoperazone inhibits the reaction [SLC22A7 protein results in increased uptake of Glutarates]

NCBI chr 9:22,044,672...22,052,051
Ensembl chr 9:22,045,435...22,051,681

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

Cefotaxime results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

interleukin 10

multiple interactions

ISO

Cefotaxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

phosphogluconate dehydrogenase

decreases activity

EXP

Cefotaxime results in decreased activity of PGD protein

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

RT1 class I, locus CE5

affects expression

ISO

Cefotaxime affects the expression of HLA-F mRNA

NCBI chr20:3,407,880...3,484,130

G

tumor protein p53

increases expression

ISO

Cefotaxime results in increased expression of TP53 protein

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

Cefotetan results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 6

multiple interactions

ISO

Cefotiam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]

NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311

G

solute carrier family 22 member 8

increases uptake
multiple interactions

ISO

SLC22A8 protein results in increased uptake of Cefotiam
Cefotiam inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interferon gamma

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911

G

interleukin 10

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL10 mRNA]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 1 beta

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

MYD88, innate immune signal transduction adaptor

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

RT1 class I, locus CE16

affects expression

ISO

Cefoxitin affects the expression of HLA-A mRNA

NCBI chr20:3,261,656...3,265,548

G

RT1 class II, locus Ha

affects expression

ISO

Cefoxitin affects the expression of HLA-DPA1 mRNA

NCBI chr20:4,762,425...4,772,439
Ensembl chr20:4,763,033...4,772,141

G

transforming growth factor, beta 1

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

toll-like receptor 2

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

tumor necrosis factor

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor associated factor 6

multiple interactions

ISO

[Gentamicins co-treated with Vancomycin co-treated with Cefoxitin co-treated with Metronidazole] inhibits the reaction [Fluorides results in increased expression of TRAF6 mRNA]

NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

prolactin

increases expression

ISO

Cefpodoxime results in increased expression of PRL protein

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

defensin beta 5

multiple interactions

ISO

Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of and results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of DEFB4A protein]

PMID:27397760 PMID:28720485

NCBI chr16:77,315,424...77,317,828
Ensembl chr16:77,315,424...77,317,828

G

interleukin 1 beta

multiple interactions

ISO

Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

toll-like receptor 2

multiple interactions

ISO

Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR2 protein]

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

toll-like receptor 4

multiple interactions

ISO

Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR4 protein]

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

tumor necrosis factor

multiple interactions

ISO

Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in increased secretion of TNF protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

ceftazidime pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ISO

ABCC4 protein results in increased transport of Ceftazidime

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

dihydrofolate reductase

decreases activity

ISO

Ceftazidime results in decreased activity of DHFR protein

NCBI chr 2:25,320,895...25,346,004

G

heat shock transcription factor 1

decreases activity

ISO

Ceftazidime results in decreased activity of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

G

interleukin 10

multiple interactions

ISO

Ceftazidime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 1 member 2

increases expression

EXP

ceftezole co-treated with ethanol increases expression of Slc1a2 protein in nucleus accumbens and prefrontal cortex

RGD

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 15 member 1

multiple interactions

ISO

[Zinc results in decreased activity of SLC15A1 protein] which results in decreased uptake of ceftibuten

NCBI chr15:104,944,461...104,991,316
Ensembl chr15:104,944,463...104,989,369

G

solute carrier family 22 member 6

increases uptake
multiple interactions

ISO

SLC22A6 protein results in increased uptake of ceftibuten
ceftibuten inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]

NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311

G

solute carrier family 22 member 8

increases uptake
multiple interactions

ISO

SLC22A8 protein results in increased uptake of ceftibuten
ceftibuten inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

dihydrofolate reductase

decreases activity

ISO

Ceftizoxime results in decreased activity of DHFR protein

NCBI chr 2:25,320,895...25,346,004

G

solute carrier family 22 member 6

multiple interactions
increases uptake

ISO

Ceftizoxime inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]
SLC22A6 protein results in increased uptake of Ceftizoxime

NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311

G

solute carrier family 22 member 8

increases uptake
multiple interactions

ISO

SLC22A8 protein results in increased uptake of Ceftizoxime
Ceftizoxime inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin converting enzyme 2

decreases expression

EXP

Ceftriaxone results in decreased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

actin, beta

increases expression

EXP

Ceftriaxone results in increased expression of ACTB mRNA

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

beta-secretase 1

decreases expression

EXP

Ceftriaxone results in decreased expression of BACE1 mRNA

NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:55,038,823...55,064,918

G

catalase

decreases expression
multiple interactions

ISO
EXP

Ceftriaxone results in decreased expression of CAT protein
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]]

PMID:19442074 PMID:25053526

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

dihydrofolate reductase

decreases activity

ISO

Ceftriaxone results in decreased activity of DHFR protein

NCBI chr 2:25,320,895...25,346,004

G

endothelin converting enzyme 1

increases expression

EXP

Ceftriaxone results in increased expression of ECE1 mRNA

NCBI chr 5:155,361,031...155,462,723
Ensembl chr 5:155,360,639...155,462,719

G

erythropoietin

increases expression

EXP

Ceftriaxone results in increased expression of EPO mRNA

NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions

EXP

Ceftriaxone inhibits the reaction [Cocaine increases expression of Gria1 protein in the nucleus accumbens]

RGD

NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309

G

insulin degrading enzyme

increases expression

EXP

Ceftriaxone results in increased expression of IDE mRNA

NCBI chr 1:244,415,495...244,516,925
Ensembl chr 1:244,416,343...244,514,526

G

interleukin 1 beta

multiple interactions

EXP

Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

membrane metallo-endopeptidase

increases expression

EXP

Ceftriaxone results in increased expression of MME mRNA

NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:149,872,291...149,953,463

G

RELA proto-oncogene, NF-kB subunit

increases expression

EXP

ceftriaxone increases expression of Rela protein in dorsal striatum

RGD

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

solute carrier family 1 member 2

multiple interactions
increases expression

EXP

Ceftriaxone inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of SLC1A2 protein]; Ceftriaxone inhibits the reaction [Cocaine results in decreased expression of SLC1A2 protein]; Ceftriaxone inhibits the reaction [JZL195 results in decreased expression of and affects the folding of SLC1A2 protein]; Ceftriaxone promotes the reaction [Kainic Acid results in increased expression of SLC1A2 protein]
ceftriaxone increases expression of Slc1a2 protein in hippocampus
ceftriaxone inhibits the reaction [ethanol decreases expression of Slc1a2 protein in the shell of nucleus accumbens]
[ceftriaxone co-treated with ethanol] results in increased expression of Slc1a2 protein in prefrontal cortex and nucleus accumbens
Ceftriaxone cotreated with ethanol increases expression of Slc1a2 protein in nucleus accumbens, amygdala and prefrontal cortex
Ceftriaxone cotreated ethanol increases expression of Slc1a2 protein in nucleus accumbens and prefrontal cortex
ceftriaxone increases expression of Slc1a2 protein in prefrontal cortex and nucleus accumbens
Ceftriaxone results in increased expression of SLC1A2 protein

CTD
RGD

PMID:19625514 PMID:19717140 PMID:28257918 PMID:29045497 PMID:29432698 More...

RGD:598150313, RGD:598276809, RGD:598150309, RGD:598150065, RGD:598148181, RGD:598108052

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 2 member 1

multiple interactions

EXP

[ceftriaxone co-treated with ethanol] results in increased expression of Slc2a1 protein in prefrontal cortex

RGD

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 7 member 11

multiple interactions
increases expression

EXP

Ceftriaxone inhibits the reaction [Cocaine results in decreased expression of SLC7A11 protein]
Ceftriaxone increases expression of Slc7a11 protein in dorsal striatum
[ceftriaxone co-treated with ethanol] results in increased expression of Slc7a11 protein in prefrontal cortex and nucleus accumbens
Ceftriaxone cotreated with ethanol increases expression of Slc7a11 protein in nucleus accumbens, amydgala and prefrontal cortex

CTD
RGD

PMID:19717140 PMID:31100299 PMID:25619881 PMID:24535561

RGD:598150313, RGD:598154596, RGD:598150065

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

tumor necrosis factor

multiple interactions

EXP

Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

decreases activity

EXP

Cefuroxime results in decreased activity of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

interleukin 10

multiple interactions

ISO

Cefuroxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

NFE2 like bZIP transcription factor 2

decreases activity

ISO

Cefuroxime results in decreased activity of NFE2L2 protein

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear receptor subfamily 1, group I, member 3

decreases activity

ISO

Cefuroxime results in decreased activity of NR1I3 protein

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

peroxisome proliferator activated receptor alpha

decreases activity

ISO

Cefuroxime results in decreased activity of PPARA protein

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

RT1 class Ia, locus A2

affects expression

ISO

Cefuroxime affects the expression of HLA-E mRNA

NCBI chr20:4,872,720...4,876,425

G

RT1 class II, locus Bb

affects expression

ISO

Cefuroxime affects the expression of HLA-DQB1 mRNA

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RT1 class II, locus Ha

affects expression

ISO

Cephalexin affects the expression of HLA-DPA1 mRNA

NCBI chr20:4,762,425...4,772,439
Ensembl chr20:4,763,033...4,772,141

G

solute carrier family 15 member 1

increases transport

EXP

SLC15A1 protein results in increased transport of Cephalexin

NCBI chr15:104,944,461...104,991,316
Ensembl chr15:104,944,463...104,989,369

cephalosporin C

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ISO

ABCC4 protein results in increased transport of cephalosporin C

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 15 member 1

multiple interactions

ISO

[Zinc results in decreased activity of SLC15A1 protein] which results in decreased uptake of Cephradine

NCBI chr15:104,944,461...104,991,316
Ensembl chr15:104,944,463...104,989,369

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

decreases expression

ISO

Ciprofloxacin results in decreased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

increases expression

ISO

Ciprofloxacin results in increased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 4

increases export
multiple interactions
increases expression

ISO

ABCC4 protein results in increased export of Ciprofloxacin
[Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin
Ciprofloxacin results in increased expression of ABCC4 mRNA; Ciprofloxacin results in increased expression of ABCC4 protein
[Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin; Gemfibrozil inhibits the reaction [[Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin]

PMID:19307362 PMID:22162766

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

ATP binding cassette subfamily G member 2

increases expression

ISO

Ciprofloxacin results in increased expression of ABCG2 protein

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

AKT serine/threonine kinase 1

increases phosphorylation

ISO

Ciprofloxacin results in increased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 1 family, member A1

increases expression

ISO

Ciprofloxacin results in increased expression of ALDH1A1 protein

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases localization
increases expression

ISO

BCL2 protein inhibits the reaction [Ciprofloxacin results in increased localization of BAX protein]
Ciprofloxacin results in increased expression of BAX protein

PMID:10741713 PMID:11832715 PMID:11875713 PMID:12632069

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO

[Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Ciprofloxacin results in increased localization of BAX protein]

PMID:11832715 PMID:12063570

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

caspase 3

multiple interactions
increases activity

ISO
EXP

Ciprofloxacin results in increased cleavage of and results in increased activity of CASP3 protein
Ciprofloxacin results in increased activity of CASP3 protein

PMID:10741713 PMID:11832715 PMID:11875713 PMID:12632069 PMID:30273099

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases activity

ISO

Ciprofloxacin results in increased activity of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases activity

ISO
EXP

Ciprofloxacin results in increased activity of CASP9 protein

PMID:11875713 PMID:30273099

Ensembl chr 5:159,391,188...159,409,648

G

catalase

decreases activity
multiple interactions

EXP

Ciprofloxacin results in decreased activity of CAT protein
Quercetin inhibits the reaction [Ciprofloxacin results in decreased activity of CAT protein]

PMID:25902267 PMID:25929518

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

caveolin 1

increases expression

ISO

Ciprofloxacin results in increased expression of CAV1 protein

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

cyclin B1

decreases expression
increases expression

ISO
EXP

Ciprofloxacin results in decreased expression of CCNB1 protein
Ciprofloxacin results in increased expression of CCNB1 mRNA; Ciprofloxacin results in increased expression of CCNB1 protein

PMID:10741713 PMID:18512786

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin E1

decreases expression

ISO

Ciprofloxacin results in decreased expression of CCNE1 protein

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

CD44 molecule

increases expression

ISO

Ciprofloxacin results in increased expression of CD44 protein

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424

G

cyclin-dependent kinase 1

increases expression

EXP

Ciprofloxacin results in increased expression of CDK1 mRNA; Ciprofloxacin results in increased expression of CDK1 protein

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin dependent kinase 2

decreases phosphorylation

ISO

Ciprofloxacin results in decreased phosphorylation of CDK2 protein

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase inhibitor 1A

decreases expression

ISO

Ciprofloxacin results in decreased expression of CDKN1A; Ciprofloxacin results in decreased expression of CDKN1A protein

PMID:10741713 PMID:12063570 PMID:12632069

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

CCAAT/enhancer binding protein delta

multiple interactions

ISO

Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA]

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

checkpoint kinase 1

increases expression

EXP

Ciprofloxacin results in increased expression of CHEK1 protein

NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359

G

colony stimulating factor 2

increases expression

ISO

Ciprofloxacin results in increased expression of CSF2 protein

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

C-X-C motif chemokine ligand 2

decreases expression

ISO

Ciprofloxacin results in decreased expression of CXCL2 protein

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

cytochrome c, somatic

increases secretion

EXP

Ciprofloxacin results in increased secretion of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
decreases activity

ISO

[Ciprofloxacin results in decreased activity of CYP1A2 protein] which results in increased abundance of Clozapine; [Ciprofloxacin results in decreased activity of CYP1A2 protein] which results in increased abundance of norclozapine; Ciprofloxacin inhibits the reaction [CYP1A2 protein affects the metabolism of tizanidine]; Ciprofloxacin inhibits the reaction [CYP1A2 protein results in decreased methylation of Caffeine]

PMID:11145498 PMID:11151749 PMID:15592331 PMID:18816299

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, subfamily 2, polypeptide 11

decreases expression

EXP

Ciprofloxacin results in decreased expression of CYP2C11 mRNA

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

ISO

Ciprofloxacin results in decreased activity of CYP3A4 protein

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

decreases expression

EXP

Ciprofloxacin results in decreased expression of CYP3A23-3A1 mRNA

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

dihydroorotate dehydrogenase

multiple interactions
decreases activity

EXP

Ciprofloxacin inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]
Ciprofloxacin results in decreased activity of DHODH protein

NCBI chr19:54,460,636...54,483,049
Ensembl chr19:54,468,690...54,514,496

G

fibroblast growth factor 19

decreases expression

ISO

Ciprofloxacin results in decreased expression of FGF15 mRNA

NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267

G

glucose-6-phosphate dehydrogenase

increases response to substance

ISO

G6PD protein mutant form results in increased susceptibility to Ciprofloxacin

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

glutamic-oxaloacetic transaminase 1

increases activity

EXP

Ciprofloxacin results in increased activity of GOT1 protein

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glutamic--pyruvic transaminase

multiple interactions
increases activity

ISO
EXP

[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein]
Ciprofloxacin results in increased activity of GPT protein

PMID:29679711 PMID:30273099

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

interferon gamma

multiple interactions
decreases expression

ISO
EXP

Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]
[Ciprofloxacin co-treated with Cyclosporine] results in increased expression of IFNG mRNA; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IFNG protein]]
Ciprofloxacin results in decreased expression of IFNG protein

PMID:16006447 PMID:16968468 PMID:18337667 PMID:19401694

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 10

multiple interactions

ISO
EXP

Ciprofloxacin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]
Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Mitogens results in increased expression of IL10 protein]]

PMID:16939481 PMID:19401694

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 1 alpha

multiple interactions

ISO

Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions
decreases expression

ISO
EXP

Ciprofloxacin affects the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Ciprofloxacin promotes the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP3 protein]
Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]
Ciprofloxacin results in decreased expression of IL1B protein

PMID:9267955 PMID:11052920 PMID:12428247 PMID:16148020 PMID:18197910 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 2

multiple interactions

EXP

Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IL2 protein]]

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 3

increases expression

ISO

Ciprofloxacin results in increased expression of IL3 mRNA; Ciprofloxacin results in increased expression of IL3 protein

NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810

G

interleukin 4

decreases expression

ISO

Ciprofloxacin results in decreased expression of IL4 protein

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 6

multiple interactions

ISO
EXP

Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA]
Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Mitogens results in increased expression of IL6 protein]]; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IL6 protein]]

PMID:9267955 PMID:11052920 PMID:19401694

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

Ciprofloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

lipocalin 2

multiple interactions

ISO

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842

G

mitogen activated protein kinase 1

increases phosphorylation

ISO

Ciprofloxacin results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases phosphorylation

ISO

Ciprofloxacin results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

myoglobin

multiple interactions

ISO

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein

NCBI chr 7:110,640,511...110,647,742
Ensembl chr 7:110,640,512...110,647,958

G

MCL1 apoptosis regulator, BCL2 family member

increases expression

ISO

Ciprofloxacin results in increased expression of MCL1 protein

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

microRNA 133b

multiple interactions

ISO

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA

NCBI chr 9:30,594,582...30,594,665
Ensembl chr 9:30,594,582...30,594,665

G

microRNA 206

multiple interactions

ISO

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA

NCBI chr 9:30,590,697...30,590,780
Ensembl chr 9:30,590,697...30,590,780

G

melanocyte inducing transcription factor

decreases expression

ISO

Ciprofloxacin results in decreased expression of MITF protein

NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790

G

matrix metallopeptidase 1

multiple interactions
increases expression

ISO

Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]
Ciprofloxacin results in increased expression of MMP1 mRNA

PMID:12428247 PMID:16148020

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 13

multiple interactions
decreases expression

ISO

Ciprofloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]
Ciprofloxacin results in decreased expression of MMP13 mRNA

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

matrix metallopeptidase 2

increases expression
increases activity

EXP

Ciprofloxacin results in increased expression of MMP2 mRNA
Ciprofloxacin results in increased activity of MMP2 protein

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 3

multiple interactions
increases expression

ISO

Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP3 protein]
Ciprofloxacin results in increased expression of MMP3 mRNA

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826

G

matrix metallopeptidase 9

increases activity
increases expression

EXP

Ciprofloxacin results in increased activity of MMP9 protein
Ciprofloxacin results in increased expression of MMP9 mRNA

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

myeloperoxidase

multiple interactions

EXP

Ciprofloxacin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

Nanog homeobox

increases expression

ISO

Ciprofloxacin results in increased expression of NANOG protein

NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061

G

nucleotide-binding oligomerization domain containing 2

decreases response to substance

ISO

NOD2 gene SNP results in decreased susceptibility to Ciprofloxacin

NCBI chr19:34,555,832...34,596,281
Ensembl chr19:34,555,832...34,722,846

G

nuclear receptor subfamily 0, group B, member 2

increases expression

ISO

Ciprofloxacin results in increased expression of NR0B2 mRNA

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

poly (ADP-ribose) polymerase 1

increases cleavage

ISO

Ciprofloxacin results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

phosphogluconate dehydrogenase

decreases activity

EXP

Ciprofloxacin results in decreased activity of PGD protein

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

polo-like kinase 1

increases expression

EXP

Ciprofloxacin results in increased expression of PLK1 protein

NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:186,147,658...186,157,637

G

paraoxonase 1

decreases activity

ISO

Ciprofloxacin results in decreased activity of PON1 protein

PMID:16880604 PMID:31581362

NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924

G

POU class 5 homeobox 1

increases expression

ISO

Ciprofloxacin results in increased expression of POU5F1 protein

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598

G

prominin 1

increases expression

ISO

Ciprofloxacin results in increased expression of PROM1 protein

NCBI chr14:71,202,303...71,307,008
Ensembl chr14:71,202,336...71,307,002

G

RT1 class Ia, locus A2

affects expression

ISO

Ciprofloxacin affects the expression of HLA-E mRNA

NCBI chr20:4,872,720...4,876,425

G

RT1 class II, locus Db1

affects expression

ISO

Ciprofloxacin affects the expression of HLA-DRB1 mRNA

NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,550,596...4,560,165

G

RT1 class Ib, locus M3, gene 1

affects expression

ISO

Ciprofloxacin affects the expression of HLA-G mRNA

NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366

G

solute carrier family 2 member 1

affects localization
decreases expression

ISO

Ciprofloxacin affects the localization of SLC2A1 mRNA
Ciprofloxacin results in decreased expression of SLC2A1 mRNA

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

SLC51 subunit beta

decreases expression

ISO

Ciprofloxacin results in decreased expression of SLC51B mRNA

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

G

solute carrier organic anion transporter family member 1B2

increases expression

ISO

Ciprofloxacin results in increased expression of SLCO1B2 mRNA

NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083

G

snail family transcriptional repressor 1

decreases expression

ISO

Ciprofloxacin results in decreased expression of SNAI1 protein

NCBI chr 3:176,667,476...176,671,965

G

snail family transcriptional repressor 2

decreases expression

ISO

Ciprofloxacin results in decreased expression of SNAI2 protein

NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349

G

SRY-box transcription factor 2

decreases expression

ISO

Ciprofloxacin results in decreased expression of SOX2 protein

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350

G

transforming growth factor, beta 1

increases expression
multiple interactions

ISO
EXP

Ciprofloxacin results in increased expression of TGFB1 mRNA
[Ciprofloxacin co-treated with Cyclosporine] results in decreased expression of TGFB1 mRNA

PMID:18337667 PMID:19371339

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tumor necrosis factor

multiple interactions
decreases expression

ISO
EXP

Ciprofloxacin affects the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA]; Ciprofloxacin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Ciprofloxacin promotes the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]
[Ciprofloxacin co-treated with Cyclosporine] results in decreased expression of TNF mRNA; [irinotecan co-treated with Ciprofloxacin] promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of TNF protein]]
Ciprofloxacin results in decreased expression of TNF protein

PMID:9267955 PMID:11052920 PMID:16939481 PMID:16968468 PMID:18197910 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

DNA topoisomerase I

multiple interactions

ISO

[Ciprofloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein

NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327

G

DNA topoisomerase II alpha

affects binding
multiple interactions

ISO

Ciprofloxacin binds to TOP2A protein
[Ciprofloxacin binds to TOP2A protein] inhibits the reaction [Etoposide binds to TOP2A protein]; [Ciprofloxacin binds to TOP2A protein] inhibits the reaction [F14512 binds to TOP2A protein]

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

xin actin-binding repeat containing 1

multiple interactions

ISO

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA

NCBI chr 8:128,625,111...128,635,011
Ensembl chr 8:128,611,641...128,653,565

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

ISO
EXP

Cloxacillin results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

caspase 3

increases activity
multiple interactions

ISO

Cloxacillin results in increased activity of CASP3 protein
[Cloxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Cloxacillin co-treated with IL1B protein] results in increased activity of CASP3 protein; [Cloxacillin co-treated with IL6 protein] results in increased activity of CASP3 protein; [Cloxacillin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Cloxacillin results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

interleukin 1 beta

multiple interactions

ISO

[Cloxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Cloxacillin co-treated with IL1B protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Cloxacillin results in increased activity of CASP3 protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

[Cloxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Cloxacillin co-treated with IL6 protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Cloxacillin results in increased activity of CASP3 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

tumor necrosis factor

multiple interactions

ISO

[Cloxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Cloxacillin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Cloxacillin results in increased activity of CASP3 protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases expression
multiple interactions

ISO
EXP

Cycloheximide results in increased expression of ABCB1 mRNA
Cycloheximide inhibits the reaction [[Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [[Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein]; Cycloheximide inhibits the reaction [tetrabromobisphenol A results in increased expression of and results in increased activity of ABCB1A protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein]
Cycloheximide promotes the reaction [Reserpine results in increased expression of ABCB1 mRNA]

PMID:7476894 PMID:18474546 PMID:30830211

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily B member 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ABCB4 mRNA]

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in increased expression of ABCC3 mRNA
Cycloheximide results in increased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 5

multiple interactions
decreases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of ABCC5 mRNA
Cycloheximide results in decreased expression of ABCC5 mRNA

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655

G

acyl-CoA synthetase long-chain family member 3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ACSL3 mRNA

NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:87,563,601...87,613,097

G

acyl-CoA synthetase long-chain family member 6

multiple interactions

EXP

Cycloheximide inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of ACSL6 mRNA]

NCBI chr10:38,940,668...38,999,515
Ensembl chr10:38,940,747...39,002,873

G

ADAM metallopeptidase domain 17

decreases stability
multiple interactions

ISO

Cycloheximide results in decreased stability of ADAM17 protein
cordycepin inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]; N(6),N(6)-dimethyladenosine inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]

NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344

G

ADAM metallopeptidase domain 9

multiple interactions

ISO

Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of ADAM9 protein]

NCBI chr16:73,725,186...73,804,284
Ensembl chr16:73,725,114...73,804,646

G

adrenomedullin

multiple interactions
increases expression

ISO

Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of ADM mRNA]
Cycloheximide results in increased expression of ADM mRNA

NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371

G

adenosine A2B receptor

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ADORA2B mRNA

NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091

G

adrenoceptor beta 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of ADRB2 mRNA; Cycloheximide results in increased expression of ADRB2 protein
[Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA; Cycloheximide inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; N(6)-benzoyl-cyclic AMP promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]

PMID:22483689 PMID:24705868

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

argonaute RISC catalytic component 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA]

NCBI chr 5:143,913,957...143,998,746
Ensembl chr 5:143,926,501...143,998,737

G

aryl hydrocarbon receptor

multiple interactions
increases localization
decreases expression

ISO

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein]
[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Tretinoin co-treated with Cycloheximide] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]
Cycloheximide results in increased localization of AHR protein

PMID:9145908 PMID:10777561 PMID:12002481 PMID:12147270 PMID:15385644 More...

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

A-kinase anchoring protein 5

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP5 mRNA]

NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:100,790,148...100,796,620

G

A-kinase anchoring protein 6

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP6 mRNA]

NCBI chr 6:75,919,350...76,359,667
Ensembl chr 6:75,919,513...76,355,036

G

aldo-keto reductase family 1, member C3

multiple interactions

ISO

Cycloheximide inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein]

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

EXP
ISO

Cycloheximide inhibits the reaction [[Hydrogen Peroxide co-treated with sodium arsenite] results in increased phosphorylation of AKT1 protein]
Cycloheximide results in increased phosphorylation of AKT1 protein

PMID:12472888 PMID:28634229

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 1 family, member A3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH1A3 mRNA

NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777

G

aldehyde dehydrogenase 3 family, member A1

multiple interactions
affects expression

EXP
ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ALDH3A1 mRNA; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of ALDH3A1 mRNA]
Cycloheximide affects the expression of ALDH3A1 mRNA

PMID:1953764 PMID:39580082

NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151

G

aldehyde dehydrogenase 3 family, member A2

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH3A2 mRNA

NCBI chr10:46,427,789...46,448,449
Ensembl chr10:46,407,993...46,448,648

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ALOX5AP mRNA]

NCBI chr12:10,785,254...10,809,295
Ensembl chr12:10,785,257...10,817,038

G

alkaline phosphatase, intestinal

decreases activity
multiple interactions

ISO
EXP

Cycloheximide results in decreased activity of ALPI protein
Cycloheximide inhibits the reaction [Fish Oils results in increased activity of ALPI protein]

PMID:15599000 PMID:20362602

NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:95,221,314...95,224,780

G

anti-Mullerian hormone receptor type 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AMHR2 mRNA]

NCBI chr 7:135,454,517...135,470,183
Ensembl chr 7:135,457,922...135,471,104

G

ankyrin 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ANK2 mRNA]

NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:218,052,555...218,537,259

G

ankyrin repeat domain 27

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ANKRD27 mRNA

NCBI chr 1:97,387,997...97,440,501
Ensembl chr 1:97,388,099...97,440,501

G

amine oxidase, copper containing 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased activity of AOC1 protein]

PMID:2860926 PMID:6218830

NCBI chr 4:79,143,126...79,162,705
Ensembl chr 4:79,143,126...79,162,704

G

apoptotic peptidase activating factor 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of APAF1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of APAF1 mRNA

NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772

G

aquaporin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of AQP1 mRNA]

NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504

G

aquaporin 4

multiple interactions

EXP

[Lactic Acid co-treated with Cycloheximide] results in increased expression of AQP4 protein

NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098

G

amphiregulin

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in increased expression of AREG mRNA
Cycloheximide results in increased expression of AREG mRNA

PMID:15072547 PMID:15228094

NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641

G

armadillo repeat containing 5

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ARMC5 mRNA

NCBI chr 1:192,250,580...192,257,347
Ensembl chr 1:192,249,939...192,257,348

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

ISO

[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]

PMID:12002481 PMID:20570689

NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546

G

ankyrin repeat and SOCS box-containing 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ASB1 mRNA

NCBI chr 9:99,566,852...99,588,321
Ensembl chr 9:99,567,867...99,583,907

G

asparagine synthetase (glutamine-hydrolyzing)

multiple interactions

EXP

Cycloheximide inhibits the reaction [Methotrexate results in increased activity of ASNS protein]

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

activating transcription factor 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein]

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

activating transcription factor 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]]; Cycloheximide inhibits the reaction [Capsaicin results in increased expression of ATF4 protein]
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein]

PMID:18533110 PMID:23593480 PMID:24057571

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

autophagy related 13

decreases expression

ISO

Cycloheximide results in decreased expression of ATG13 protein

NCBI chr 3:98,102,831...98,136,741
Ensembl chr 3:98,101,552...98,136,743

G

ATPase copper transporting alpha

multiple interactions
decreases expression

EXP

cupric chloride inhibits the reaction [Cycloheximide results in decreased expression of ATP7A protein]

NCBI chr X:75,159,635...75,267,094
Ensembl chr X:75,159,782...75,267,093

G

arginine vasopressin receptor 1A

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AVPR1A mRNA]

NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:59,999,738...60,003,837

G

BTB domain and CNC homolog 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of BACH1 protein
tetrachlorobenzoquinone promotes the reaction [Cycloheximide results in decreased expression of BACH1 protein]

NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277

G

BRCA1 associated deubiquitinase 1

multiple interactions

ISO

BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein]

NCBI chr16:6,453,126...6,461,952
Ensembl chr16:6,452,974...6,461,952

G

BCL2 associated X, apoptosis regulator

multiple interactions

EXP

Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

gamma-butyrobetaine hydroxylase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BBOX1 mRNA]

NCBI chr 3:117,277,226...117,326,383
Ensembl chr 3:117,277,226...117,326,064

G

BCL2, apoptosis regulator

multiple interactions

ISO

BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]

PMID:11726273 PMID:22343715 PMID:34303041

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of BCL2L1 protein alternative form
Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein]

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 14

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of BCL2L14 mRNA

NCBI chr 4:168,948,919...168,989,450
Ensembl chr 4:168,948,946...168,990,079

G

3-hydroxybutyrate dehydrogenase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BDH1 mRNA]

NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636

G

beclin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of BECN1 protein]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

bone gamma-carboxyglutamate protein

multiple interactions

ISO

Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of BGLAP mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of BGLAP mRNA]

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

BH3 interacting domain death agonist

multiple interactions

ISO

[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; Cycloheximide inhibits the reaction [vorinostat results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]

PMID:11535817 PMID:12925536

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

BCL2 interacting protein 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein]

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

BRCA1, DNA repair associated

multiple interactions

ISO

Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA]
BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein]; Cycloheximide inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA]

PMID:10344722 PMID:29576526 PMID:37414201

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763

G

BRCA2, DNA repair associated

multiple interactions

ISO

Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA]

NCBI chr12:4,895,092...4,939,340
Ensembl chr12:4,895,447...4,936,194

G

calbindin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CALB1 mRNA]

NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160

G

calcium modulating ligand

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CAMLG mRNA]

NCBI chr17:8,997,868...9,009,140
Ensembl chr17:8,997,272...9,009,012

G

caspase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of CASP1 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of CASP1 protein modified form]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP1 mRNA]

PMID:11007951 PMID:26901245

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

multiple interactions
increases activity

ISO
EXP

[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; IFI6 protein inhibits the reaction [Cycloheximide results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]
Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Cryptoxanthins promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]
obeticholic acid promotes the reaction [Cycloheximide results in increased activity of CASP3 protein]

PMID:12760867 PMID:12925536 PMID:14502240 PMID:15537749 PMID:15685448 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP4 mRNA]

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727

G

caspase 7

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tretinoin results in increased expression of CASP7 mRNA]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]

PMID:12760867 PMID:16166294

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

multiple interactions
increases activity

ISO

[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]
Cycloheximide results in increased activity of CASP8 protein

PMID:12760867 PMID:12925536 PMID:15924153 PMID:18222423

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

multiple interactions
increases activity

ISO

[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]
Cycloheximide results in increased activity of CASP9 protein

PMID:12925536 PMID:14502240 PMID:18222423

Ensembl chr 5:159,391,188...159,409,648

G

catalase

multiple interactions

EXP

Cycloheximide inhibits the reaction [Clofibrate results in increased expression of CAT protein]; Cycloheximide inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CAT protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cation channel, sperm associated 4

affects response to substance

ISO

CATSPER4 gene SNP affects the susceptibility to Cycloheximide

NCBI chr 5:151,711,415...151,731,083
Ensembl chr 5:151,711,194...151,730,750

G

caveolin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of CAV1 mRNA]

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

Cbl proto-oncogene

multiple interactions

ISO

CBL protein affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]

NCBI chr 8:53,384,656...53,468,067
Ensembl chr 8:53,384,656...53,468,067

G

chromobox 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CBX1 mRNA

NCBI chr10:82,266,746...82,286,431
Ensembl chr10:82,266,759...82,287,242

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

ISO

Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]

PMID:21146893 PMID:22121136

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 5

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of CCL5 mRNA
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]

PMID:21146893 PMID:22121136

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

cellular communication network factor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Acetylcysteine results in increased expression of CCN1 protein]

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cellular communication network factor 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of CCN2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cellular communication network factor 3

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of CCN3 mRNA
Cycloheximide results in increased expression of CCN3 mRNA

NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581

G

cellular communication network factor 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased expression of CCN4 mRNA]

NCBI chr 7:100,534,578...100,566,287
Ensembl chr 7:100,534,505...100,563,094

G

cyclin A2

multiple interactions
decreases expression

ISO

[Cycloheximide co-treated with Estradiol] results in increased expression of CCNA2 mRNA
Cycloheximide results in decreased expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin D1

multiple interactions
decreases expression

ISO
EXP

[gingerol co-treated with Cycloheximide] results in increased degradation of CCND1 protein; Cycloheximide inhibits the reaction [CXCL8 protein results in increased expression of CCND1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]]
Cycloheximide results in decreased expression of CCND1 mRNA

PMID:17606477 PMID:18058799 PMID:25923732 PMID:27853917

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D3

affects expression
multiple interactions

ISO

Cycloheximide affects the expression of CCND3 mRNA
Cycloheximide affects the reaction [Estradiol affects the expression of CCND3 mRNA]

NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033

G

chaperonin containing TCP1 subunit 5

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCT5 mRNA

NCBI chr 2:84,302,621...84,313,773
Ensembl chr 2:84,302,623...84,313,779

G

CD38 molecule

multiple interactions

ISO

Cycloheximide affects the reaction [Tretinoin results in increased expression of CD38 mRNA]

NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505

G

CD3 epsilon subunit of T-cell receptor complex

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD3E mRNA]

NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:54,200,617...54,211,876

G

CD44 molecule

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of CD44 protein]

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424

G

Cd47 molecule

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD47 mRNA]

NCBI chr11:64,374,816...64,438,763
Ensembl chr11:64,377,926...64,438,272

G

Cd63 molecule

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD63 mRNA]

NCBI chr 7:1,909,538...1,924,937
Ensembl chr 7:1,922,169...1,924,938

G

CD8 subunit alpha

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CD8A mRNA

NCBI chr 4:104,924,116...104,928,353
Ensembl chr 4:104,900,833...104,928,358

G

CDC42 small effector 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of CDC42SE2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CDC42SE2 mRNA

NCBI chr10:39,337,269...39,405,772
Ensembl chr 1:100,424,547...100,424,801
Ensembl chr10:100,424,547...100,424,801

G

cell division cycle associated 5

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of CDCA5 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CDCA5 mRNA

NCBI chr 1:212,807,863...212,821,313
Ensembl chr 1:212,804,014...212,821,309

G

cell division cycle associated 7 like

multiple interactions

ISO

Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of CDCA7L protein]

NCBI chr 6:144,936,885...144,982,844
Ensembl chr 6:144,908,171...144,982,843

G

cadherin 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Cycloheximide promotes the reaction [necrostatin-1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]]

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cyclin dependent kinase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of CDK2 mRNA]

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
decreases expression

ISO
EXP

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of CDKN1A mRNA]; Cycloheximide inhibits the reaction [Troglitazone results in increased expression of CDKN1A protein]; Furazolidone promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein]
Cycloheximide promotes the reaction [Dexamethasone results in decreased expression of CDKN1A protein]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CDKN1A mRNA]
Cycloheximide inhibits the reaction [manganese chloride results in increased expression of CDKN1A protein]
Cycloheximide results in decreased expression of CDKN1A mRNA; Cycloheximide results in decreased expression of CDKN1A protein

PMID:10441511 PMID:12690110 PMID:22542671 PMID:24211769 PMID:26687534 More...

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 2A

increases expression

ISO

Cycloheximide results in increased expression of CDKN2A mRNA

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

CASP8 and FADD-like apoptosis regulator

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of CFLAR protein; Cycloheximide results in decreased expression of CFLAR protein alternative form; Cycloheximide results in decreased expression of CFLAR protein modified form
shogaol promotes the reaction [Cycloheximide results in decreased expression of CFLAR protein modified form]

PMID:12663669 PMID:15924153 PMID:16077199 PMID:16951203 PMID:25619640

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

CF transmembrane conductance regulator

affects expression

EXP

Cycloheximide affects the expression of CFTR mRNA

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

cholinergic receptor, muscarinic 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dihydrotestosterone results in decreased expression of CHRM1 mRNA]

NCBI chr 1:214,996,180...215,012,136
Ensembl chr 1:214,995,872...215,020,602

G

cytokine inducible SH2-containing protein

increases expression

ISO

Cycloheximide results in increased expression of CISH mRNA

NCBI chr 8:116,850,969...116,855,917
Ensembl chr 8:116,850,773...116,855,986

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CITED2 mRNA

NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782

G

creatine kinase B

multiple interactions

EXP

Cycloheximide inhibits the reaction [Estradiol results in increased expression of CKB protein]; Cycloheximide inhibits the reaction [Methoxychlor results in increased expression of CKB protein]

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478

G

chloride voltage-gated channel 3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CLCN3 mRNA

NCBI chr16:34,138,004...34,210,984
Ensembl chr16:34,137,952...34,210,984

G

cannabinoid receptor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dronabinol results in increased expression of CNR1 mRNA]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]
Cycloheximide results in decreased expression of and affects the localization of CNR1 protein

PMID:17041005 PMID:22258905 PMID:27513693

NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252

G

collagen type X alpha 1 chain

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tretinoin results in increased expression of COL10A1 mRNA]

NCBI chr20:39,737,536...39,744,518
Ensembl chr20:39,716,822...39,751,440

G

collagen type I alpha 1 chain

multiple interactions

ISO

Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of COL1A1 mRNA]

PMID:15962303 PMID:17203194

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

cAMP responsive element binding protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

CDP-L-ribitol pyrophosphorylase A

affects response to substance

ISO

CRPPA gene SNP affects the susceptibility to Cycloheximide

NCBI chr 6:58,847,550...59,124,309
Ensembl chr 6:58,848,621...59,181,406

G

crystallin, lambda 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CRYL1 mRNA

NCBI chr15:35,542,628...35,661,563
Ensembl chr15:35,542,628...35,661,563

G

colony stimulating factor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc results in increased expression of CSF1 mRNA]

PMID:12112025 PMID:17295206 PMID:18636177

NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468

G

colony stimulating factor 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein]

PMID:9606035 PMID:10645887

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

casein kinase 1, delta

multiple interactions

ISO

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA]

NCBI chr10:106,713,497...106,754,953
Ensembl chr10:106,694,279...106,754,953

G

casein kinase 2 beta

multiple interactions
decreases degradation

ISO

Diethylhexyl Phthalate inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]; TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]

NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525

G

catenin beta 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of CTNNB1 protein
CBL protein affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]; Phenobarbital affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]; Tetrachlorodibenzodioxin promotes the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]

PMID:27693619 PMID:39880321

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cathepsin B

multiple interactions

EXP

Cycloheximide inhibits the reaction [Azithromycin results in increased activity of CTSB protein]

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478

G

cullin 2

multiple interactions

ISO

CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]

NCBI chr17:58,864,274...58,905,447
Ensembl chr17:58,864,274...58,905,132

G

C-X-C motif chemokine ligand 10

multiple interactions

ISO

Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome c, somatic

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CYCS mRNA]

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

EXP

Cycloheximide results in decreased expression of CYP11A1 protein

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity
decreases expression

ISO
EXP

Cycloheximide results in decreased activity of CYP19A1 protein
Cycloheximide results in decreased expression of CYP19A1 protein

PMID:16480277 PMID:21126571

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 1

affects expression
multiple interactions
increases expression

EXP
ISO

Cycloheximide affects the expression of CYP1A1 mRNA
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Piperonyl Butoxide co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Copper results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Mercury results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Dactinomycin promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]
3'-methoxy-4'-nitroflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; [Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with Tetrachlorodibenzodioxin] results in increased expression of CYP1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; beta-Naphthoflavone promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide affects the reaction [Tetrachlorodibenzodioxin affects the expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide promotes the reaction [[Benzo(a)pyrene co-treated with Calcitriol] results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Skatole results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Tetrachlorodibenzodioxin affects the reaction [Cycloheximide affects the expression of CYP1A1 mRNA]

PMID:1321828 PMID:1849469 PMID:1934297 PMID:2985607 PMID:8647108 More...

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO

Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
affects expression
multiple interactions

ISO
EXP

Cycloheximide results in increased expression of CYP1B1 mRNA
Cycloheximide affects the expression of CYP1B1 mRNA
Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of CYP1B1 protein]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Cycloheximide results in increased expression of CYP1B1 mRNA]
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1B1 mRNA; Cycloheximide affects the reaction [Tetrachlorodibenzodioxin affects the expression of CYP1B1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Tetrachlorodibenzodioxin affects the reaction [Cycloheximide affects the expression of CYP1B1 mRNA]

PMID:9145908 PMID:19684285 PMID:21867498 PMID:39580082

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions

ISO

alpha-naphthoflavone inhibits the reaction [Cycloheximide promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]]; Cycloheximide inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases degradation

ISO
EXP

(4-amidinophenyl)methanesulfonyl fluoride inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; acetonitrile inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Biotin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Carbon Tetrachloride promotes the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Cycloheximide promotes the reaction [Carbon Tetrachloride results in increased degradation of CYP2E1 protein]; Dimethyl Sulfoxide inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Edetic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Egtazic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Ethanol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; fomepizole inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Glycerol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; leupeptin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]
Cycloheximide inhibits the reaction [pyridine results in increased activity of CYP2E1 protein]; Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP2E1 protein]

PMID:1968335 PMID:8531136 PMID:9143349

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily f, polypeptide 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]

NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
decreases expression

EXP
ISO

Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A2 mRNA]
Cycloheximide results in decreased expression of CYP3A4 mRNA

PMID:11181506 PMID:21466820

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A23-3A1 mRNA]

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

dystroglycan 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DAG1 mRNA]

NCBI chr 8:117,769,517...117,834,347
Ensembl chr 8:117,769,517...117,782,199

G

decorin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DCN mRNA]

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

DNA-damage inducible transcript 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [plumbagin results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DNA-damage-inducible transcript 4

increases expression
multiple interactions

EXP

Cycloheximide results in increased expression of DDIT4 protein
[EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037

G

DEAF1 transcription factor

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DEAF1 mRNA

NCBI chr 1:205,831,428...205,865,106
Ensembl chr 1:205,831,336...205,865,106

G

delta(4)-desaturase, sphingolipid 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DEGS1 mRNA]

NCBI chr13:96,478,645...96,485,302
Ensembl chr13:96,478,646...96,485,302

G

iodothyronine deiodinase 2

multiple interactions
decreases activity

ISO

[Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [2,2',4,4',5-brominated diphenyl ether metabolite results in decreased activity of DIO2 protein]; [Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased activity of DIO2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]]; lactacystin inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]

PMID:11425850 PMID:26004626

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

iodothyronine deiodinase 3

multiple interactions

EXP

Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased activity of DIO3 protein]

NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:135,107,074...135,107,985

G

DnaJ heat shock protein family (Hsp40) member B5

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DNAJB5 mRNA]

NCBI chr 5:61,972,637...61,981,887
Ensembl chr 5:61,972,706...61,981,860

G

deoxyribonuclease 1L3

increases expression

ISO

Cycloheximide results in increased expression of DNASE1L3 protein

NCBI chr15:19,351,683...19,378,536
Ensembl chr15:19,352,493...19,378,531

G

dynamin 1-like

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of DNM1L mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DNM1L mRNA

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420

G

DNA methyltransferase 3 alpha

multiple interactions

EXP

[Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

endothelin 1

multiple interactions

ISO

[Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type A

multiple interactions

EXP

[Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA mRNA; [Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA protein; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA protein]

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

endothelin receptor type B

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]

PMID:20561571 PMID:20716444

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

epidermal growth factor

multiple interactions

EXP

[EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]

PMID:12632255 PMID:22689575

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

increases expression
multiple interactions

ISO
EXP

Cycloheximide results in increased expression of EGFR mRNA
Cycloheximide promotes the reaction [Arsenic Trioxide results in decreased expression of EGFR protein]
Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein]

PMID:15228094 PMID:26368632 PMID:30237564

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

early growth response 2

increases expression

ISO

Cycloheximide results in increased expression of EGR2 mRNA

NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748

G

eukaryotic translation initiation factor 2A

multiple interactions

ISO

Cycloheximide inhibits the reaction [epimedokoreanin B results in increased phosphorylation of EIF2A protein]; Cycloheximide inhibits the reaction [Orlistat results in increased phosphorylation of EIF2A protein]

PMID:17283163 PMID:36027945

NCBI chr 2:144,911,247...144,944,705
Ensembl chr 2:144,911,153...144,945,201

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

EXP
ISO

Cycloheximide inhibits the reaction [dimethylarsinous acid results in increased phosphorylation of EIF2AK3 protein]
Cycloheximide inhibits the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [1,12-benzoperylene results in increased expression of EIF2AK3 mRNA]]

PMID:22425709 PMID:35182551

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268

G

eukaryotic translation initiation factor 2 subunit alpha

increases expression
increases phosphorylation
multiple interactions

ISO

Cycloheximide results in increased expression of EIF2S1 mRNA
Cycloheximide results in increased phosphorylation of EIF2S1 protein
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of EIF2S1 mRNA

PMID:19684285 PMID:24315374

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

eukaryotic translation initiation factor 4E

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]]
Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]

PMID:22689575 PMID:25923732

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]; Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein]

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

eukaryotic translation initiation factor 4 gamma 1

multiple interactions

EXP

Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein]

NCBI chr11:93,726,322...93,746,387
Ensembl chr11:93,726,322...93,746,367

G

eukaryotic translation initiation factor 4 gamma, 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of EIF4G3 mRNA]

NCBI chr 5:155,481,378...155,702,194
Ensembl chr 5:155,481,378...155,702,194

G

eukaryotic translation initiation factor 5

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of EIF5 mRNA

NCBI chr 6:136,410,333...136,418,827
Ensembl chr 6:136,407,440...136,418,821

G

ELAV like RNA binding protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]

NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631

G

E74 like ETS transcription factor 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELF4 mRNA]

NCBI chr X:132,465,290...132,508,175
Ensembl chr X:132,468,539...132,478,689

G

ETS transcription factor ELK1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of ELK1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ELK1 mRNA

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249

G

elastin

multiple interactions

EXP

Cycloheximide inhibits the reaction [Okadaic Acid results in decreased expression of ELN mRNA]

NCBI chr12:27,604,983...27,648,413
Ensembl chr12:27,604,680...27,648,413

G

ELOVL fatty acid elongase 3

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of ELOVL3 mRNA
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of ELOVL3 mRNA]

NCBI chr 1:254,938,731...254,942,559
Ensembl chr 1:254,938,731...254,942,559

G

ectodermal-neural cortex 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of ENC1 mRNA

NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721

G

endonuclease G

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ENDOG mRNA]

NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573

G

endothelial PAS domain protein 1

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]; MALAT1 mRNA inhibits the reaction [Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]]
Cycloheximide results in decreased expression of EPAS1 protein

PMID:23958427 PMID:26735578

NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729

G

erythropoietin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]

NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725

G

epiphycan

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EPYC mRNA]

NCBI chr 7:34,323,332...34,360,845
Ensembl chr 7:34,323,273...34,361,032

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
increases degradation
decreases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA; Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]; PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein]
Cycloheximide results in decreased expression of ERBB2 mRNA; Cycloheximide results in decreased expression of ERBB2 protein

PMID:15072547 PMID:15228094 PMID:20379846 PMID:25866362

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

erb-b2 receptor tyrosine kinase 3

decreases expression

ISO

Cycloheximide results in decreased expression of ERBB3 mRNA

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120

G

epiregulin

increases expression

ISO

Cycloheximide results in increased expression of EREG mRNA

NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of ERN1 protein]

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

estrogen receptor 1

multiple interactions
decreases expression

ISO

bisphenol A promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; Estradiol promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; naringenin inhibits the reaction [Cycloheximide results in decreased expression of ESR1 protein]

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions

ISO

Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]]

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

estrogen related receptor, alpha

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of ESRRA protein
HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein]

NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811

G

exostosin glycosyltransferase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EXT2 mRNA]

NCBI chr 3:100,120,776...100,253,424
Ensembl chr 3:100,120,776...100,253,596

G

coagulation factor XII

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of F12 mRNA]

NCBI chr17:9,212,819...9,220,664
Ensembl chr17:9,212,819...9,220,664

G

coagulation factor II, thrombin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

coagulation factor III, tissue factor

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tretinoin results in decreased expression of F3 mRNA]

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

Fas cell surface death receptor

multiple interactions
increases response to substance

ISO

Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein]
Cycloheximide results in increased susceptibility to FAS protein

PMID:8932996 PMID:12760867

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FASLG mRNA]
[Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein

PMID:11007951 PMID:19833194

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fatty acid synthase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Calcitriol results in decreased expression of FASN mRNA]

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

fibrillarin

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FBL mRNA

NCBI chr 1:92,597,407...92,606,507
Ensembl chr 1:92,597,258...92,606,506

G

F-box and WD repeat domain containing 7

multiple interactions

ISO

Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein]
FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]

PMID:24457827 PMID:25897075

NCBI chr 2:172,447,738...172,609,591
Ensembl chr 2:172,447,738...172,609,591

G

fibrinogen alpha chain

decreases expression

EXP

Cycloheximide results in decreased expression of FGA protein

NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577

G

fibrinogen beta chain

decreases expression

EXP

Cycloheximide results in decreased expression of FGB protein

NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434

G

fibroblast growth factor 2

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA]

PMID:9798919 PMID:15654655

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

Fibroblast growth factor receptor 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855

G

fibrinogen-like 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FGL2 mRNA]

NCBI chr 4:14,602,762...14,608,405
Ensembl chr 4:14,602,771...14,608,405

G

fragile histidine triad diadenosine triphosphatase

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FHIT mRNA

NCBI chr15:16,365,401...17,872,901
Ensembl chr15:16,747,338...17,872,621

G

four and a half LIM domains 1

multiple interactions

EXP

Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]

NCBI chr X:139,592,794...139,652,290
Ensembl chr X:139,592,604...139,652,282

G

Fms related receptor tyrosine kinase 3

decreases expression

ISO

Cycloheximide results in decreased expression of FLT3 protein mutant form

NCBI chr12:12,660,035...12,735,584
Ensembl chr12:12,659,946...12,735,581

G

flavin containing dimethylaniline monoxygenase 3

increases expression

ISO

Cycloheximide results in increased expression of FMO3 mRNA

NCBI chr13:77,838,899...77,868,869
Ensembl chr13:77,842,602...77,861,256

G

fragile X messenger ribonucleoprotein 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FMR1 mRNA

NCBI chr X:152,284,857...152,322,686
Ensembl chr X:152,284,841...152,322,675

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

ISO
EXP

Cycloheximide inhibits the reaction [Estradiol results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Genistein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of FOS protein]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA]
Cycloheximide results in increased expression of FOS mRNA
Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]
[Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA; Cadmium Chloride promotes the reaction [Cycloheximide results in increased expression of FOS mRNA]; Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of FOS protein]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [[Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA]

PMID:1696944 PMID:9094091 PMID:9417049 PMID:9650640 PMID:12632255 More...

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

fyn-related Src family tyrosine kinase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FRK mRNA]

NCBI chr20:39,820,441...39,926,065
Ensembl chr20:39,820,295...39,926,362

G

follistatin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FST mRNA]

NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:47,856,345...47,863,491

G

ferritin heavy chain 1

multiple interactions
decreases expression

ISO

[Antimony Potassium Tartrate results in increased abundance of Antimony] promotes the reaction [Cycloheximide results in decreased expression of FTH1 protein]

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214

G

ferritin light chain 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of FTL protein
[Antimony Potassium Tartrate results in increased abundance of Antimony] promotes the reaction [Cycloheximide results in decreased expression of FTL protein]

NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915
Ensembl chr 2:45,399,355...45,399,915
Ensembl chr 1:45,399,355...45,399,915

G

fucosyltransferase 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FUT4 mRNA]

NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436

G

frizzled class receptor 7

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FZD7 mRNA]

NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585

G

glucose-6-phosphate dehydrogenase

multiple interactions

EXP

Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of G6PD protein]

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

polypeptide N-acetylgalactosaminyltransferase 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GALNT1 mRNA

NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588

G

growth arrest-specific 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GAS1 mRNA]

NCBI chr17:4,487,716...4,490,701
Ensembl chr17:4,484,283...4,497,657

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLC mRNA]; Cycloheximide inhibits the reaction [diphenylarsinic acid results in increased expression of GCLC protein]
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]

PMID:17628625 PMID:19328227 PMID:24437944

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

multiple interactions

ISO

Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLM mRNA]

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

growth differentiation factor 15

multiple interactions

ISO

Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 mRNA]; Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 protein]; Cycloheximide inhibits the reaction [troglitazone results in increased expression of GDF15 mRNA]

PMID:14662774 PMID:18801729

NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022

G

gap junction protein, alpha 1

multiple interactions
decreases expression

EXP

9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Cycloheximide results in decreased expression of GJA1 protein]; Cycloheximide promotes the reaction [Benzo(a)pyrene results in decreased expression of GJA1 protein]

PMID:34283317 PMID:36863560

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689

G

glycosylphosphatidylinositol anchor attachment 1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of GPAA1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of GPAA1 mRNA

NCBI chr 7:109,932,556...109,936,139
Ensembl chr 7:109,932,544...109,936,138

G

G protein-coupled receptor 37

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GPR37 mRNA]

NCBI chr 4:55,104,355...55,126,420
Ensembl chr 4:55,104,365...55,126,494

G

glutathione peroxidase 4

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of GPX4 protein
triptolide promotes the reaction [Cycloheximide results in decreased expression of GPX4 protein]

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

glutamate metabotropic receptor 5

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA]; Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein]

NCBI chr 1:150,722,711...151,297,585
Ensembl chr 1:150,733,678...151,296,649

G

granulin precursor

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GRN mRNA

NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,886,122...87,893,936

G

glycogen synthase kinase 3 beta

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GSK3B mRNA]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

glutathione S-transferase alpha 2

multiple interactions
decreases expression

ISO

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]]; Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]
Cycloheximide results in decreased expression of GSTA1 mRNA

NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092

G

heparin-binding EGF-like growth factor

increases expression

ISO

Cycloheximide results in increased expression of HBEGF mRNA

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

histone deacetylase 6

multiple interactions

ISO

HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein]

NCBI chr X:17,222,538...17,244,373
Ensembl chr X:17,222,856...17,244,370

G

hypoxia inducible factor 1 subunit alpha

increases degradation
decreases expression
multiple interactions

ISO
EXP

Cycloheximide results in increased degradation of HIF1A protein
Cycloheximide results in decreased expression of HIF1A protein
Cycloheximide promotes the reaction [methylmercuric chloride results in decreased expression of HIF1A protein]
[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with Oxygen deficiency] affects the expression of HIF1A protein; [Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein; Butyric Acid promotes the reaction [Cycloheximide results in decreased expression of HIF1A protein]; Cycloheximide affects the reaction [[Apigenin co-treated with Oxygen deficiency] affects the expression of HIF1A protein]; Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased stability of HIF1A protein]; Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of HIF1A protein]; Cycloheximide inhibits the reaction [zinc chloride results in increased expression of HIF1A protein alternative form]; Cycloheximide promotes the reaction [Cobalt results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [sodium arsenite inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; genipin affects the reaction [[Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose co-treated with Cycloheximide] results in decreased expression of HIF1A protein]; scutellarin promotes the reaction [Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; sodium arsenite inhibits the reaction [Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Polystyrenes analog results in increased expression of HIF1A protein]

PMID:11641398 PMID:11739637 PMID:19958256 PMID:20524035 PMID:22537771 More...

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

heme oxygenase 1

multiple interactions
decreases expression

ISO
EXP

Cycloheximide inhibits the reaction [Curcumin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]; Cycloheximide results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein]
Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]
Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [puerarin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Triterpenes analog results in increased expression of HMOX1 protein]

PMID:9747510 PMID:12441344 PMID:12472888 PMID:15118350 PMID:15588712 More...

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heterogeneous nuclear ribonucleoprotein H2

increases expression

ISO

Cycloheximide results in increased expression of HNRNPH2 mRNA

NCBI chr X:102,074,175...102,080,115
Ensembl chr X:102,074,179...102,081,025

G

heterogeneous nuclear ribonucleoprotein K

multiple interactions

EXP

Cycloheximide inhibits the reaction [Glycine results in increased expression of HNRNPK protein]

NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,268,385...6,280,565

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

ISO

Cycloheximide promotes the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [tributyltin results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [triphenyltin chloride results in increased expression of HSD11B2 mRNA]

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

heat shock transcription factor 1

decreases activity

ISO

Cycloheximide results in decreased activity of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

G

heat shock protein family A (Hsp70) member 5

multiple interactions

EXP
ISO

Cycloheximide inhibits the reaction [GIF 0010 results in increased expression of HSPA5 mRNA]; Cycloheximide inhibits the reaction [lead acetate results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Mercuric Chloride results in increased expression of HSPA5 protein]
Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [plumbagin results in increased expression of HSPA5 protein]

PMID:9742210 PMID:17915553 PMID:26784903 PMID:31276663 PMID:34560123

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

HIV-1 Tat interactive protein 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of HTATIP2 mRNA]

NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815

G

intercellular adhesion molecule 1

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]
Cycloheximide results in decreased expression of ICAM1 protein

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

immediate early response 3

multiple interactions

ISO

[afimoxifene co-treated with Cycloheximide] results in increased expression of IER3 mRNA

NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377

G

interferon gamma

multiple interactions

ISO

[Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein]

PMID:12070711 PMID:16087364

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

intraflagellar transport 27

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IFT27 mRNA]

NCBI chr 7:111,619,145...111,635,129
Ensembl chr 7:111,619,077...111,634,936

G

insulin-like growth factor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [IGF1 protein affects the metabolism of 1,2-diacylglycerol]
IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]

PMID:2120207 PMID:26687534

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 2 mRNA binding protein 3

multiple interactions

ISO

Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein]

NCBI chr 4:79,391,367...79,525,923
Ensembl chr 4:79,393,067...79,525,730

G

insulin-like growth factor binding protein 4

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of IGFBP4 mRNA
[Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA

NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473

G

interleukin 10

multiple interactions
decreases response to substance
increases expression

ISO
EXP

Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]
IL10 protein results in decreased susceptibility to Cycloheximide
Cycloheximide results in increased expression of IL10 mRNA

PMID:19395591 PMID:22183712

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 17A

multiple interactions

ISO

Cycloheximide inhibits the reaction [Glucose results in increased secretion of IL17A protein]

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 18

multiple interactions

EXP

Cycloheximide inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 alpha

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1A mRNA
Cycloheximide results in increased expression of IL1A mRNA

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions
increases expression

ISO
EXP

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1B mRNA; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL1B protein]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL1B protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of IL1B protein modified form]
Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]
Cycloheximide results in increased expression of IL1B mRNA

PMID:8071060 PMID:9606035 PMID:11112151 PMID:11286988 PMID:19684285 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 5

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of IL5 protein
T0901317 inhibits the reaction [Cycloheximide results in decreased expression of IL5 protein]

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

multiple interactions
increases expression
decreases secretion
increases secretion

ISO

Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL6 protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]
Cycloheximide results in decreased secretion of IL6 protein

PMID:8071060 PMID:11216681 PMID:12185005 PMID:21146893 PMID:24771768

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 cytokine family signal transducer

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL6ST mRNA]

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182

G

insulin 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin 2

multiple interactions

ISO

[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

IQ motif containing GTPase activating protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IQGAP1 mRNA]

NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043

G

insulin receptor substrate 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of IRS1 mRNA
[Cycloheximide co-treated with Estradiol] results in increased expression of IRS1 mRNA

NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538

G

integrin subunit beta 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB3 mRNA]

NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800

G

integrin subunit beta 6

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB6 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA]

PMID:11007951 PMID:21303922

NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:65,456,713...65,530,333

G

inositol-tetrakisphosphate 1-kinase

multiple interactions

ISO

ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]

NCBI chr 6:127,475,589...127,609,320
Ensembl chr 6:127,476,808...127,609,062

G

inositol 1,4,5-trisphosphate receptor, type 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Ethanol results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITPR1 mRNA]

PMID:11007951 PMID:17241155

NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504

G

influenza virus NS1A binding protein

multiple interactions

ISO

Cycloheximide inhibits the reaction [Doxorubicin results in decreased expression of IVNS1ABP mRNA]

NCBI chr13:65,977,069...65,996,685
Ensembl chr13:65,977,045...65,997,547

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases stability
increases phosphorylation
multiple interactions

EXP
ISO

Cycloheximide results in increased stability of JUN protein
Cycloheximide results in increased phosphorylation of JUN protein
Cycloheximide promotes the reaction [Cadmium results in increased expression of JUN mRNA]
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein]

PMID:1696944 PMID:9751194 PMID:12169099 PMID:23593480

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

KN motif and ankyrin repeat domains 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KANK1 mRNA

NCBI chr 1:232,381,720...232,500,834
Ensembl chr 1:232,445,658...232,500,839

G

KIAA0930 homolog

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KIAA0930 mRNA

NCBI chr 7:117,947,898...117,987,601
Ensembl chr 7:117,947,898...117,987,636

G

kininogen 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein]

NCBI chr11:91,317,354...91,340,148
Ensembl chr11:91,317,355...91,340,148

G

KRAS proto-oncogene, GTPase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA]

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

kringle containing transmembrane protein 1

affects response to substance

ISO

KREMEN1 gene SNP affects the susceptibility to Cycloheximide

NCBI chr14:84,295,931...84,361,534
Ensembl chr14:84,297,700...84,361,614

G

keratin 13

multiple interactions

ISO

[afimoxifene co-treated with Cycloheximide] results in increased expression of KRT13 mRNA

NCBI chr10:85,552,287...85,556,499
Ensembl chr10:85,552,287...85,556,499

G

keratinocyte associated protein 2

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KRTCAP2 mRNA

NCBI chr 2:176,952,167...176,956,163
Ensembl chr 2:176,949,809...176,956,163

G

LCK proto-oncogene, Src family tyrosine kinase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA]

NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267

G

low density lipoprotein receptor

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [Quercetin results in increased expression of LDLR protein]
Cycloheximide results in decreased expression of LDLR protein

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

leptin

multiple interactions

ISO

LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein]

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

leptin receptor

multiple interactions
decreases expression

ISO

LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein]

NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215

G

galectin 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of LGALS3 protein]

NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737

G

luteinizing hormone subunit beta

multiple interactions

EXP

Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA]

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

LIM domain 7

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LMO7 mRNA]

NCBI chr15:84,981,689...85,184,554
Ensembl chr15:84,981,735...85,184,551

G

leupaxin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LPXN mRNA]

NCBI chr 1:219,353,319...219,387,743
Ensembl chr 1:219,353,708...219,387,742

G

MAF1 homolog, negative regulator of RNA polymerase III

increases degradation
multiple interactions

ISO

Cycloheximide results in increased degradation of MAF1 protein
Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein]; CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]

NCBI chr 7:109,955,876...109,958,909
Ensembl chr 7:109,955,282...109,958,910

G

mitogen activated protein kinase kinase 1

multiple interactions
increases activity

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cycloheximide results in increased expression of MAP2K1 mRNA]
Cycloheximide results in increased activity of MAP2K1 protein

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

ISO
EXP

Cycloheximide results in increased phosphorylation of MAPK1 protein
Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide promotes the reaction [[sodium arsenite co-treated with Hydrogen Peroxide] results in increased phosphorylation of MAPK1 protein]
Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]]

PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 14

multiple interactions

ISO

Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of MAPK14 protein]

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

ISO
EXP

Cycloheximide results in increased phosphorylation of MAPK3 protein
Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide promotes the reaction [sodium arsenite promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]]
Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]]

PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 7

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MAPK7 mRNA; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAPK7 mRNA]
Cycloheximide results in increased expression of MAPK7 mRNA

PMID:11007951 PMID:19684285

NCBI chr10:46,669,721...46,675,768
Ensembl chr10:46,669,721...46,675,806

G

MAPK activated protein kinase 3

affects response to substance

ISO

MAPKAPK3 gene SNP affects the susceptibility to Cycloheximide

NCBI chr 8:116,808,429...116,842,228
Ensembl chr 8:116,808,429...116,842,228

G

myelin basic protein

affects expression

EXP

Cycloheximide affects the expression of MBP mRNA

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions
decreases expression

ISO

[Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [Resveratrol co-treated with Clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MCL1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]

PMID:14982947 PMID:21880625 PMID:24924397 PMID:25408576 PMID:25923732 More...

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

midkine

multiple interactions

ISO

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of MDK mRNA]

NCBI chr 3:98,356,789...98,358,960
Ensembl chr 3:98,356,789...98,358,743

G

microRNA 21

multiple interactions
increases expression

ISO

Cycloheximide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [Estradiol results in decreased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA]
Cycloheximide results in increased expression of MIR21 mRNA

PMID:19264808 PMID:23052036

NCBI chr10:71,902,600...71,902,691

G

melanocyte inducing transcription factor

multiple interactions

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein]; [Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein

NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790

G

matrix metallopeptidase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MMP1 mRNA]

PMID:15075337 PMID:19136476

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 13

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of MMP13 mRNA
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of MMP13 mRNA]
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MMP13 mRNA

PMID:16350840 PMID:19684285

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

matrix metallopeptidase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of MMP2 mRNA]

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

motor neuron and pancreas homeobox 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MNX1 mRNA]

NCBI chr 4:6,541,645...6,546,604
Ensembl chr 4:6,541,645...6,546,604

G

N-methylpurine-DNA glycosylase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MPG mRNA]

NCBI chr10:15,900,697...15,906,981
Ensembl chr10:15,899,635...15,907,052

G

mitochondrial ribosomal protein S7

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of MRPS7 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of MRPS7 mRNA

NCBI chr10:101,342,642...101,345,790
Ensembl chr10:101,342,421...101,346,082

G

mutS homolog 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MSH3 mRNA]

NCBI chr 2:25,179,400...25,320,857
Ensembl chr 2:25,179,400...25,321,102

G

macrophage scavenger receptor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA]

NCBI chr16:59,421,250...59,507,070
Ensembl chr16:59,421,057...59,507,070

G

metallothionein 1A

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of MT1 mRNA
2-tert-butylhydroquinone promotes the reaction [Cycloheximide results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]; MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA]

PMID:14998373 PMID:19276070

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

mitochondrial carrier 2

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTCH2 mRNA

NCBI chr 3:97,286,388...97,306,028
Ensembl chr 3:97,285,894...97,307,327

G

mitochondrial transcription termination factor 3

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of MTERF3 protein
Ammonium Chloride inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]

NCBI chr 7:65,711,654...65,729,926
Ensembl chr 7:65,711,662...65,729,895

G

metal-regulatory transcription factor 1

multiple interactions

ISO

MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA]

NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810

G

myotubularin related protein 7

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of MTMR7 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTMR7 mRNA

NCBI chr16:58,344,755...58,435,682
Ensembl chr16:58,344,767...58,436,615

G

max dimerization protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MXD1 mRNA]

NCBI chr 4:120,654,731...120,678,972
Ensembl chr 4:120,654,731...120,675,129

G

Max dimerization protein 3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MXD3 mRNA

NCBI chr17:9,306,552...9,310,278
Ensembl chr17:9,302,321...9,310,278

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

ISO
EXP

arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]
Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of MYC protein]
Cycloheximide promotes the reaction [Cadmium results in increased expression of MYC mRNA]

PMID:1696944 PMID:23593480 PMID:24457827 PMID:31285264

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

myosin light chain kinase

multiple interactions

ISO

Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]

NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659

G

myosin ID

affects response to substance

ISO

MYO1D gene SNP affects the susceptibility to Cycloheximide

NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958

G

NBR1, autophagy cargo receptor

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of NBR1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NBR1 mRNA

NCBI chr10:86,978,024...87,006,664
Ensembl chr10:86,977,885...87,007,012

G

N-myc downstream regulated 1

multiple interactions
decreases expression

ISO

Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of NDRG1 protein]

NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913

G

NEDD4 E3 ubiquitin protein ligase

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of NEDD4 protein
Melatonin promotes the reaction [Cycloheximide results in decreased expression of NEDD4 protein]

NCBI chr 8:82,264,751...82,349,642
Ensembl chr 8:82,264,649...82,349,633

G

neurofilament heavy chain

decreases expression
decreases degradation

EXP

Cycloheximide results in decreased expression of NEFH mRNA
Cycloheximide results in decreased degradation of NEFH mRNA

PMID:1280263 PMID:19146868

NCBI chr14:84,044,428...84,054,413
Ensembl chr14:84,044,023...84,054,417

G

neurofilament light chain

decreases expression
decreases degradation

EXP

Cycloheximide results in decreased expression of NEFL mRNA
Cycloheximide results in decreased degradation of NEFL mRNA

PMID:1280263 PMID:19146868

NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515

G

neurofilament medium chain

decreases degradation

EXP

Cycloheximide results in decreased degradation of NEFM mRNA

NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163

G

NIMA-related kinase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NEK2 mRNA]

NCBI chr13:105,936,809...105,950,054
Ensembl chr13:105,936,788...105,950,056

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression

ISO

[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Cycloheximide] results in increased expression of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of NFE2L2 protein]; Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]; exenatide inhibits the reaction [Cycloheximide results in decreased expression of NFE2L2 protein]
[SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; Curcumin inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]

PMID:12441344 PMID:14510636 PMID:15322212 PMID:22019695 PMID:22197970 More...

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

affects localization
multiple interactions
increases expression

ISO

Cycloheximide affects the localization of NFKB1 protein
FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]
Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]

PMID:16637064 PMID:21146893 PMID:24457827

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NFKB inhibitor alpha

multiple interactions
decreases expression
increases degradation

ISO

Cycloheximide inhibits the reaction [Morphine results in increased expression of NFKBIA mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKBIA mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NFKBIA protein]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in decreased expression of NFKBIA protein]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased degradation of NFKBIA protein]

PMID:11007951 PMID:15330761 PMID:16637064 PMID:21692457 PMID:22258905

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nerve growth factor

multiple interactions

ISO

Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]

NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834

G

NLR family, pyrin domain containing 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of NLRP3 protein]

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

nitric oxide synthase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [[Raloxifene Hydrochloride co-treated with 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid] results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS2 mRNA]

PMID:10760090 PMID:11007951 PMID:28138957

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nitric oxide synthase 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS3 mRNA]

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

neuropeptide Y receptor Y1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NPY1R mRNA]

NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387

G

NAD(P)H quinone dehydrogenase 1

decreases expression
multiple interactions

ISO
EXP

Cycloheximide results in decreased expression of NQO1 mRNA
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]]; Cycloheximide inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [arsenite results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Cadmium results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Chromium results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]

PMID:14510636 PMID:16243960 PMID:18474416 PMID:24437944

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 0, group B, member 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NR0B1 mRNA]

NCBI chr X:54,707,658...54,711,786
Ensembl chr X:54,707,639...54,712,083

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NR1H3 mRNA
Cycloheximide results in increased expression of NR1H3 mRNA

NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone binds to NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone results in increased degradation of NR3C1 protein]
Cycloheximide promotes the reaction [tubacin results in decreased expression of and results in increased degradation of NR3C1 mRNA]

PMID:21569845 PMID:31778773

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

EXP

Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA]

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

nuclear casein kinase and cyclin-dependent kinase substrate 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NUCKS1 mRNA

NCBI chr13:45,897,275...45,926,491
Ensembl chr13:45,897,248...45,923,101

G

ornithine decarboxylase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Paraquat results in increased activity of ODC1 protein]

NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146

G

OPA1, mitochondrial dynamin like GTPase

multiple interactions

EXP

Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of OPA1 protein alternative form]

NCBI chr11:84,612,943...84,690,025
Ensembl chr11:84,615,340...84,689,955

G

opioid receptor, kappa 1

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of OPRK1 mRNA
Cycloheximide results in increased expression of OPRK1 mRNA

NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671

G

opioid receptor, mu 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dronabinol results in increased expression of OPRM1 mRNA]

NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:45,565,371...45,638,756

G

orosomucoid 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dexamethasone results in increased expression of ORM1 mRNA]

NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667

G

proliferation-associated 2G4

multiple interactions

ISO

PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein]

NCBI chr 7:1,569,326...1,576,794
Ensembl chr 7:1,569,327...1,576,802

G

pappalysin 1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of PAPPA mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PAPPA mRNA

NCBI chr 5:83,513,358...83,751,364
Ensembl chr 5:83,513,358...83,751,361

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO
EXP

[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]
Cycloheximide inhibits the reaction [ammonium acetate results in increased expression of PARP1 protein]
Cycloheximide results in increased cleavage of PARP1 protein

PMID:12925536 PMID:15147502 PMID:16051428 PMID:18222423

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

paired box 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PAX3 mRNA]

NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141

G

polycomb group ring finger 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PCGF1 mRNA

NCBI chr 4:117,140,144...117,144,729
Ensembl chr 4:117,142,061...117,145,040

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of PCK1 mRNA]

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

proliferating cell nuclear antigen

multiple interactions

ISO

Cycloheximide inhibits the reaction [Vitamin K 3 results in decreased expression of PCNA protein]

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

programmed cell death 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PDCD2 mRNA]

NCBI chr 1:65,158,034...65,163,524
Ensembl chr 1:65,158,034...65,163,524

G

proenkephalin

multiple interactions

EXP

Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PENK mRNA]; Cycloheximide promotes the reaction [Colforsin results in increased expression of PENK mRNA]

NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:21,981,382...21,986,705

G

phosphatidylinositol 4-kinase alpha

multiple interactions

ISO

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PI4KA mRNA]

NCBI chr11:97,113,390...97,234,374
Ensembl chr11:97,113,245...97,228,315

G

phosphatidylinositol glycan anchor biosynthesis, class H

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGH mRNA]

NCBI chr 6:103,601,369...103,630,214
Ensembl chr 6:103,601,520...103,630,159

G

phosphatidylinositol glycan anchor biosynthesis, class K

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGK mRNA]

NCBI chr 2:244,289,928...244,375,394
Ensembl chr 2:244,250,621...244,376,030

G

phosphatidylinositol 3-kinase, catalytic subunit type 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3C3 mRNA]

NCBI chr18:22,119,677...22,203,546
Ensembl chr18:22,119,792...22,203,539

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3CG mRNA]

NCBI chr 6:54,494,247...54,529,563
Ensembl chr 6:54,478,603...54,529,509

G

paired immunoglobin-like type 2 receptor beta 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PILRB mRNA

NCBI chr12:24,220,304...24,239,811

G

phospholipase A2 group IB

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G1B mRNA]

NCBI chr12:46,802,932...46,814,511
Ensembl chr12:46,802,939...46,813,693

G

phospholipase A2 group 4A

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dexamethasone inhibits the reaction [Zymosan results in increased activity of PLA2G4A protein]]

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

plasminogen activator, tissue type

multiple interactions

EXP

Cycloheximide promotes the reaction [Isoproterenol results in increased expression of PLAT mRNA]

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696

G

plasminogen activator, urokinase receptor

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with IFNA2 protein] results in increased expression of PLAUR mRNA; [Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA
Cycloheximide results in increased expression of PLAUR mRNA

NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130

G

phospholipase D family, member 3

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of PLD3 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA

NCBI chr 1:91,949,465...91,971,834
Ensembl chr 1:91,949,467...91,961,207

G

phospholamban

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PLN mRNA]

NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241

G

proteolipid protein 1

multiple interactions
increases expression

EXP

Cycloheximide promotes the reaction [Tretinoin results in increased expression of PLP1 mRNA]
Cycloheximide results in increased expression of PLP1 mRNA

NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Fenretinide results in increased expression of PMAIP1 protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PMAIP1 protein]

NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382

G

PML nuclear body scaffold

decreases degradation
multiple interactions

ISO

Cycloheximide results in decreased degradation of PML protein modified form
Cycloheximide inhibits the reaction [arsenic trioxide results in increased degradation of PML protein]

PMID:20943951 PMID:26049103

NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083

G

patatin-like phospholipase domain containing 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PNPLA2 protein]

NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359

G

patatin-like phospholipase domain containing 6

multiple interactions

ISO

Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein]

NCBI chr12:6,372,284...6,401,632
Ensembl chr12:6,372,293...6,401,631

G

proopiomelanocortin

multiple interactions

EXP

Cycloheximide inhibits the reaction [POMC protein modified form results in increased chemical synthesis of Adrenal Cortex Hormones]

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

cytochrome p450 oxidoreductase

multiple interactions
decreases expression

ISO

POR protein mutant form promotes the reaction [Cycloheximide results in decreased expression of POR protein]

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

POU class 5 homeobox 1

multiple interactions

ISO

Cycloheximide promotes the reaction [Cobalt results in increased expression of POU5F1 protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of POU5F1 protein]

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598

G

peter pan homolog

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPAN mRNA

NCBI chr 8:27,700,147...27,704,127
Ensembl chr 8:27,700,152...27,704,128

G

protein phosphatase 1, regulatory subunit 15A

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of PPP1R15A protein
arsenite inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; Cycloheximide affects the reaction [arsenite results in increased expression of PPP1R15A protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PPP1R15A protein]

NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774

G

protein phosphatase 3 catalytic subunit beta

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPP3CB mRNA]

NCBI chr15:3,809,182...3,854,204
Ensembl chr15:3,809,262...3,854,203

G

protein phosphatase 4, regulatory subunit 3B

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPP4R3B mRNA

NCBI chr14:107,118,116...107,166,121
Ensembl chr14:107,118,131...107,166,134

G

peroxiredoxin 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRDX4 mRNA]

NCBI chr X:43,876,374...43,893,815
Ensembl chr X:43,876,417...43,893,812

G

protein kinase C, beta

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of PRKCB mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PRKCB mRNA

NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740

G

protein kinase C, delta

multiple interactions

EXP

Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCD protein]

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839

G

protein kinase C, epsilon

multiple interactions

EXP

Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCE protein]

NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288

G

protein kinase C, zeta

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRKCZ mRNA]

NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:171,101,774...171,212,674

G

presenilin 1

multiple interactions

ISO

[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189

G

presenilin 2

multiple interactions

ISO

Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]

NCBI chr13:94,499,451...94,528,419
Ensembl chr13:94,499,928...94,525,116

G

proteasome 26S subunit, non-ATPase 1

multiple interactions

ISO

PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]

NCBI chr 9:94,157,971...94,233,218
Ensembl chr 9:94,157,971...94,233,218

G

proteasome activator subunit 3

multiple interactions

ISO

PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein]

NCBI chr10:86,757,933...86,765,719
Ensembl chr10:86,757,899...86,818,033

G

phosphatase and tensin homolog

multiple interactions

ISO

Cycloheximide affects the reaction [sodium arsenite affects the expression of PTEN protein]; Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; Cycloheximide inhibits the reaction [Rosiglitazone results in increased expression of PTEN protein]

PMID:16425225 PMID:33256086

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

prostaglandin-endoperoxide synthase 2

multiple interactions
affects expression
increases expression

ISO
EXP

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of PTGS2 mRNA; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein]; Cycloheximide inhibits the reaction [Tretinoin results in increased expression of PTGS2 protein]
Cycloheximide affects the expression of PTGS2 mRNA
Cycloheximide results in increased expression of PTGS2 mRNA
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]

PMID:7575673 PMID:11112151 PMID:11286988 PMID:16696851 PMID:16894348 More...

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

pleiotrophin

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of PTN mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTN mRNA

NCBI chr 4:66,260,764...66,342,614
Ensembl chr 4:66,260,764...66,342,482

G

protein tyrosine phosphatase 4A1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]]; Cycloheximide promotes the reaction [Estradiol results in increased expression of PTP4A1 mRNA]

NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:40,710,250...40,718,176

G

protein tyrosine phosphatase 4A3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTP4A3 mRNA

NCBI chr 7:107,518,220...107,549,949
Ensembl chr 7:107,541,047...107,549,949

G

protein tyrosine phosphatase, non-receptor type 5

multiple interactions

EXP

Cycloheximide inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein]

NCBI chr 1:106,756,896...106,817,369
Ensembl chr 1:106,756,896...106,816,828

G

Rab9 effector protein with kelch motifs

affects response to substance

ISO

RABEPK gene SNP affects the susceptibility to Cycloheximide

NCBI chr 3:38,460,205...38,481,077
Ensembl chr 3:38,460,206...38,480,688

G

Rap guanine nucleotide exchange factor 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RAPGEF1 mRNA

NCBI chr 3:33,296,211...33,414,119
Ensembl chr 3:33,296,230...33,414,119

G

retinoic acid receptor, beta

multiple interactions
increases expression

EXP

Cycloheximide promotes the reaction [Tretinoin results in increased expression of RARB mRNA]
Cycloheximide results in increased expression of RARB mRNA

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040

G

retinoic acid receptor responder 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of RARRES2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RARRES2 mRNA

NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:78,853,453...78,856,457

G

RB transcriptional corepressor 1

multiple interactions

ISO

RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RB transcriptional corepressor like 1

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RBL1 mRNA]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]

PMID:11007951 PMID:20100483

NCBI chr 3:166,226,187...166,289,862
Ensembl chr 3:166,226,198...166,289,376

G

recombination signal binding protein for immunoglobulin kappa J region

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of RBPJ protein
[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; Cycloheximide inhibits the reaction [Ammonium Chloride results in increased expression of RBPJ protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]

NCBI chr14:61,551,366...61,736,220
Ensembl chr14:61,551,366...61,736,307

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
affects localization

ISO

[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein]
Cycloheximide affects the localization of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased secretion of REN protein]

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

ret proto-oncogene

decreases expression

EXP

Cycloheximide results in decreased expression of RET protein

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556

G

regucalcin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RGN mRNA]

NCBI chr X:4,172,537...4,190,112
Ensembl chr X:4,172,537...4,190,251

G

ras homolog family member B

multiple interactions

ISO

Cycloheximide inhibits the reaction [cytotoxic necrotizing factor type 1 results in increased expression of RHOB protein]

NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772

G

ras homolog family member C

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of RHOC protein
RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein]

NCBI chr 2:194,975,586...194,981,637
Ensembl chr 2:194,975,242...194,983,745

G

RPTOR independent companion of MTOR, complex 2

multiple interactions

ISO

Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein]
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA]

PMID:25897075 PMID:29576526

NCBI chr 2:57,539,279...57,631,291
Ensembl chr 2:57,539,311...57,631,288

G

ring finger protein 168

multiple interactions

ISO

RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein]

NCBI chr11:81,991,352...82,013,306
Ensembl chr11:81,991,360...82,013,306

G

ring finger protein 4

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of RNF4 protein
Cycloheximide inhibits the reaction [TAK-243 affects the localization of RNF4 protein]

PMID:20943951 PMID:31285264

NCBI chr14:80,625,864...80,647,138
Ensembl chr14:80,625,866...80,647,148

G

ribosomal protein S27-like

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RPS27L mRNA

NCBI chr 8:76,443,658...76,448,593
Ensembl chr12:33,713,661...33,714,130
Ensembl chr 8:33,713,661...33,714,130

G

ribosomal protein S6 kinase B1

multiple interactions

EXP

Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

RUNX family transcription factor 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]

PMID:15962303 PMID:18327666

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

S100 calcium-binding protein A4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A4 mRNA]

NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837

G

S100 calcium binding protein B

decreases expression

EXP

Cycloheximide results in decreased expression of S100B mRNA

NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081

G

spermidine/spermine N1-acetyl transferase 1

multiple interactions

ISO

[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]

NCBI chr X:44,008,089...44,011,376
Ensembl chr X:44,006,781...44,011,374

G

stearoyl-CoA desaturase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Clofibrate results in increased expression of SCD1 mRNA]

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

SEC11 homolog C, signal peptidase complex subunit

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of SEC11C mRNA

NCBI chr18:61,590,905...61,607,247
Ensembl chr18:61,590,885...61,607,348

G

serpin family B member 9

multiple interactions

ISO

Cycloheximide promotes the reaction [moxestrol results in increased expression of SERPINB9 mRNA]

NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974

G

serpin family E member 1

multiple interactions

ISO
EXP

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA]
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA]
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA]

PMID:9798919 PMID:11007951 PMID:12111005

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357

G

serpin family E member 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SERPINE2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERPINE2 mRNA

NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202

G

SERTA domain containing 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SERTAD2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERTAD2 mRNA

NCBI chr14:98,935,428...99,039,536
Ensembl chr14:98,934,769...99,041,468

G

sestrin 2

multiple interactions
decreases expression

ISO

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of SESN2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of SESN2 protein]

NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255

G

serum/glucocorticoid regulated kinase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of SGK1 protein]

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

G

signal-regulatory protein alpha

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SIRPA mRNA]

NCBI chr 3:137,272,932...137,311,279
Ensembl chr 3:137,273,042...137,311,279

G

sirtuin 1

multiple interactions
decreases expression

ISO

Cycloheximide promotes the reaction [antimony trichloride results in decreased expression of SIRT1 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]]; Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]

PMID:30055241 PMID:31082419

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

SKI3 subunit of superkiller complex

multiple interactions

EXP

Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TNFRSF10B mRNA]

NCBI chr 2:7,363,417...7,526,351
Ensembl chr 2:7,363,535...7,483,496

G

src-like adaptor

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLA mRNA]

NCBI chr 7:100,423,467...100,473,840
Ensembl chr 7:100,424,169...100,473,684

G

solute carrier family 16 member 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC16A1 mRNA

NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:194,812,502...194,832,977

G

solute carrier family 1 member 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLC1A1 mRNA]

NCBI chr 1:235,963,455...236,043,572
Ensembl chr 1:235,963,437...236,045,469

G

solute carrier family 22 member 4

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SLC22A4 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC22A4 mRNA

NCBI chr10:38,634,098...38,687,409
Ensembl chr10:38,634,098...38,679,920

G

solute carrier family 25, member 27

increases expression

ISO

Cycloheximide results in increased expression of SLC25A27 mRNA

NCBI chr 9:24,804,183...24,831,219
Ensembl chr 9:24,804,185...24,831,217

G

solute carrier family 2 member 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC2A1 mRNA

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 2 member 4

multiple interactions

EXP

Cycloheximide inhibits the reaction [4-hydroxyisoleucine results in increased localization of SLC2A4 protein]

NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270

G

solute carrier family 2 member 5

multiple interactions

EXP

Cycloheximide inhibits the reaction [Fructose promotes the reaction [SLC2A5 protein results in increased uptake of Fructose]]

NCBI chr 5:165,857,412...165,892,928
Ensembl chr 5:165,866,172...165,894,038

G

solute carrier family 39 member 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Zinc deficiency results in increased expression of SLC39A4 mRNA]; Cycloheximide inhibits the reaction [Zinc results in decreased expression of SLC39A4 mRNA]

NCBI chr 7:110,214,017...110,218,202
Ensembl chr 7:110,214,017...110,218,202

G

solute carrier family 3 member 2

increases expression

ISO

Cycloheximide results in increased expression of SLC3A2 mRNA

NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064

G

solute carrier family 5 member 5

increases expression

ISO

Cycloheximide results in increased expression of SLC5A5 mRNA

NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691

G

solute carrier family 7 member 5

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412

G

survival of motor neuron 1, telomeric

multiple interactions

ISO

Cycloheximide inhibits the reaction [Paraquat results in increased expression of SMN1 mRNA alternative form]

NCBI chr 2:33,224,115...33,235,162
Ensembl chr 2:33,224,095...33,235,162

G

SNW domain containing 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SNW1 mRNA

NCBI chr 6:112,826,374...112,850,459
Ensembl chr 6:112,826,381...112,858,180

G

suppressor of cytokine signaling 1

multiple interactions
increases expression

ISO

[afimoxifene co-treated with Cycloheximide] results in increased expression of SOCS1 mRNA
Cycloheximide results in increased expression of SOCS1 mRNA

PMID:16849584 PMID:23237828

NCBI chr10:5,389,574...5,391,265
Ensembl chr10:5,389,334...5,391,847

G

suppressor of cytokine signaling 2

multiple interactions
increases expression

ISO

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS2 mRNA]
Cycloheximide results in increased expression of SOCS2 mRNA

PMID:15371557 PMID:23237828

NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:31,874,463...31,930,423

G

suppressor of cytokine signaling 3

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SOCS3 mRNA
Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]; U 0126 inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

suppressor of cytokine signaling 4

increases expression

ISO

Cycloheximide results in increased expression of SOCS4 mRNA

NCBI chr15:23,003,130...23,017,615
Ensembl chr15:23,002,883...23,022,499

G

suppressor of cytokine signaling 5

increases expression

ISO

Cycloheximide results in increased expression of SOCS5 mRNA

NCBI chr 6:13,235,157...13,266,161
Ensembl chr 6:13,234,062...13,273,883

G

suppressor of cytokine signaling 6

increases expression

ISO

Cycloheximide results in increased expression of SOCS6 mRNA

NCBI chr18:84,386,587...84,413,927
Ensembl chr18:84,384,573...84,414,053

G

suppressor of cytokine signaling 7

increases expression

ISO

Cycloheximide results in increased expression of SOCS7 mRNA

NCBI chr10:82,848,525...82,885,201
Ensembl chr10:82,848,612...82,885,201

G

superoxide dismutase 2

multiple interactions
increases expression

ISO

Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]; Cycloheximide inhibits the reaction [polysaccharide-K results in increased expression of SOD2]
Cycloheximide results in increased expression of SOD2 mRNA
Cycloheximide promotes the reaction [Paclitaxel results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vincristine results in increased expression of SOD2 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased expression of SOD2 mRNA]

PMID:8037686 PMID:9852137 PMID:11154046 PMID:15330761 PMID:20495008

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

sortilin 1

multiple interactions
increases degradation

EXP
ISO

SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]
Cycloheximide results in increased degradation of SORT1 protein mutant form
Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]; Docosahexaenoic Acids inhibits the reaction [Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]]

PMID:22555848 PMID:24986865 PMID:25805502

NCBI chr 2:198,609,466...198,690,481
Ensembl chr 2:198,612,148...198,690,481

G

SOS Ras/Rac guanine nucleotide exchange factor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOS1 mRNA]

NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:20,286,117...20,363,350

G

spectrin, alpha, non-erythrocytic 1

multiple interactions

ISO

[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein]

NCBI chr 3:33,639,020...33,703,890
Ensembl chr 3:33,607,210...33,703,889

G

sequestosome 1

multiple interactions
decreases expression

ISO

[sodium arsenite results in increased abundance of arsenite] inhibits the reaction [Cycloheximide results in decreased expression of SQSTM1 protein]; Cycloheximide promotes the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]

PMID:31781319 PMID:34405320

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

SRC proto-oncogene, non-receptor tyrosine kinase

increases localization

EXP

Cycloheximide results in increased localization of SRC protein

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

serine racemase

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [methyllycaconitine results in increased expression of SRR protein]

NCBI chr10:60,267,936...60,285,094
Ensembl chr10:60,268,859...60,285,100

G

single stranded DNA binding protein 1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SSBP1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SSBP1 mRNA

NCBI chr 4:70,232,740...70,242,824
Ensembl chr 4:70,232,794...70,243,700

G

ST18 C2H2C-type zinc finger transcription factor

increases expression

ISO

Cycloheximide results in increased expression of ST18 mRNA

NCBI chr 5:17,369,383...17,701,094
Ensembl chr 5:17,371,000...17,458,676

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ST8SIA1 mRNA
Cycloheximide results in increased expression of ST8SIA1 mRNA

NCBI chr 4:177,513,966...177,651,553
Ensembl chr 4:177,520,926...177,651,553

G

serine/threonine kinase 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STK3 mRNA]

NCBI chr 7:67,938,341...68,208,472
Ensembl chr 7:67,938,378...68,208,508

G

syntaxin 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STX2 mRNA]

NCBI chr12:33,315,447...33,350,788
Ensembl chr12:33,315,750...33,350,788

G

sulfotransferase family 1A member 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 mRNA]

NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131

G

sulfotransferase family 2B member 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SULT2B1 mRNA]

NCBI chr 1:105,336,614...105,397,744
Ensembl chr 1:105,336,614...105,397,744

G

SPT4 homolog, DSIF elongation factor subunit

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SUPT4H1 mRNA]

NCBI chr10:73,036,560...73,042,821
Ensembl chr10:73,036,343...73,043,088

G

synaptopodin

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SYNPO mRNA
Cycloheximide results in increased expression of SYNPO mRNA

NCBI chr18:56,326,369...56,347,359
Ensembl chr18:56,319,571...56,353,306

G

tachykinin, precursor 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein]

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546

G

transforming, acidic coiled-coil containing protein 1

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of TACC1 mRNA
Cycloheximide results in increased expression of TACC1 mRNA

NCBI chr16:73,515,016...73,598,395
Ensembl chr16:73,514,889...73,598,394

G

TAR DNA binding protein

multiple interactions
decreases expression

ISO

Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein]

NCBI chr 5:164,330,452...164,348,435
Ensembl chr 5:164,334,924...164,345,204

G

taste receptor, type 2, member 106

multiple interactions

ISO

TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]; TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]

NCBI chr 4:167,044,628...167,045,551
Ensembl chr 4:167,044,628...167,045,551

G

T-box transcription factor 3

increases expression

ISO

cycloheximide co-treated with all-trans-retinoic acid increases expression of TBX3 mRNA in melanoma cells

RGD

NCBI chr12:42,540,378...42,555,490
Ensembl chr12:42,540,378...42,554,171

G

testin gene

multiple interactions
decreases secretion
decreases expression

EXP

Cycloheximide inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]; Cycloheximide inhibits the reaction [lonidamine results in increased secretion of TESTIN protein]
Cycloheximide results in decreased secretion of TESTIN protein
Cycloheximide results in decreased expression of TESTIN mRNA

NCBI chr17:3,829,012...3,864,995
Ensembl chr17:3,852,404...3,864,993

G

transcription factor AP-2 alpha

decreases stability
multiple interactions

ISO

Cycloheximide results in decreased stability of TFAP2A protein
LINC-ROR promotes the reaction [Cycloheximide results in decreased stability of TFAP2A protein]

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

trefoil factor 1

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in increased expression of TFF1 mRNA; Cycloheximide inhibits the reaction [bisphenol A results in increased expression of TFF1 mRNA]
Cycloheximide results in increased expression of TFF1 mRNA

PMID:15072547 PMID:20875696

NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,237,095...9,240,956

G

transforming growth factor alpha

increases expression

ISO

Cycloheximide results in increased expression of TGFA mRNA

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

transforming growth factor, beta 1

multiple interactions
decreases activity

EXP
ISO

Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]
Cycloheximide results in decreased activity of TGFB1 protein
Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA]

PMID:9145908 PMID:9790906 PMID:9798919 PMID:21303922 PMID:31652400

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta receptor 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [tolfenamic acid results in decreased expression of TGFBR2 protein]

NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469

G

thrombomodulin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THBD mRNA]

NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:156,306,632...156,320,582

G

thrombospondin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Testosterone results in decreased expression of THBS1 mRNA]

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

Thy-1 cell surface antigen

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THY1 mRNA]

NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:53,286,148...53,291,540

G

TIA1 cytotoxic granule-associated RNA binding protein

multiple interactions

EXP

Cycloheximide inhibits the reaction [sodium arsenite affects the localization of TIA1 protein]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]

PMID:19171178 PMID:22555848

NCBI chr 4:120,410,180...120,440,676
Ensembl chr 4:120,410,251...120,440,665

G

translocase of inner mitochondrial membrane 17A

multiple interactions
decreases expression

ISO

Cycloheximide results in decreased expression of and results in increased degradation of TIMM17A protein; YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein]
Cycloheximide results in decreased expression of TIMM17A protein

NCBI chr13:49,282,918...49,296,363
Ensembl chr13:49,282,918...49,307,904

G

TIMP metallopeptidase inhibitor 1

decreases response to substance

EXP

TIMP1 protein results in decreased susceptibility to Cycloheximide

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

TCDD-inducible poly(ADP-ribose) polymerase

multiple interactions
increases expression

ISO

AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]

NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:152,063,751...152,090,406

G

tight junction protein 1

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein]
Cycloheximide results in decreased expression of TJP1 protein

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

transmembrane 7 superfamily member 3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TM7SF3 mRNA

NCBI chr 4:181,248,819...181,280,844
Ensembl chr 4:181,248,822...181,280,844

G

transmembrane protein 263

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of TMEM263 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TMEM263 mRNA

NCBI chr 7:20,497,852...20,516,011
Ensembl chr 7:20,497,852...20,516,428

G

tumor necrosis factor

increases response to substance
multiple interactions

ISO
EXP

TNF protein results in increased susceptibility to Cycloheximide
[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; [TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; [TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of TNF protein]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Cycloheximide inhibits the reaction [SM 164 results in increased expression of TNF mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; Cycloheximide inhibits the reaction [Zinc deficiency promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA]
Cycloheximide inhibits the reaction [TNF protein results in decreased export of Potassium]; Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]
[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; Cycloheximide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Cycloheximide promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein]

PMID:8037686 PMID:8071060 PMID:12185005 PMID:12812920 PMID:12925536 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF alpha induced protein 1

multiple interactions

ISO

TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]

NCBI chr10:63,915,824...63,930,514
Ensembl chr10:63,915,825...63,930,514

G

TNF alpha induced protein 3

multiple interactions

ISO

[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA]

NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979

G

TNF receptor superfamily member 10b

multiple interactions

ISO

Cycloheximide inhibits the reaction [Docetaxel results in increased expression of TNFRSF10A protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10A protein]

NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082

G

TNF receptor superfamily member 11B

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of TNFRSF11B mRNA

NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075

G

TNF receptor superfamily member 8

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNFRSF8 mRNA]

NCBI chr 5:162,406,387...162,451,620
Ensembl chr 5:162,406,387...162,451,620

G

TNF superfamily member 10

multiple interactions

ISO

[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide]; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF10 mRNA]

PMID:11007951 PMID:18222423 PMID:22343715

NCBI chr 2:112,136,550...112,155,903

G

TNF superfamily member 11

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF11 mRNA]
Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of TNFSF11 mRNA]

PMID:11007951 PMID:17295206 PMID:18327666 PMID:18636177

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

troponin C1, slow skeletal and cardiac type

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNNC1 mRNA]

NCBI chr16:6,408,607...6,412,070
Ensembl chr16:6,408,607...6,412,070

G

tumor protein p53

increases response to substance
increases degradation
decreases expression
multiple interactions

ISO
EXP

TP53 mutant form results in increased susceptibility to Cycloheximide
Cycloheximide results in increased degradation of TP53 protein
Cycloheximide results in decreased expression of TP53 protein
Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of TRP53 protein]
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]
Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein]; Cycloheximide promotes the reaction [Chlorpyrifos results in decreased expression of TP53 protein]; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein]

PMID:9790906 PMID:10760090 PMID:15016801 PMID:20943951 PMID:21875941 More...

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tumor protein p53 inducible protein 11

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of TP53I11 mRNA]
Cycloheximide results in decreased expression of TP53I11 mRNA

NCBI chr 3:99,600,213...99,615,462
Ensembl chr 3:99,600,159...99,615,432

G

tumor protein p63

multiple interactions

ISO

Cycloheximide inhibits the reaction [trichostatin A results in increased expression of TP63 protein alternative form]

NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177

G

transient receptor potential cation channel, subfamily V, member 4

increases degradation
multiple interactions

ISO

Cycloheximide results in increased degradation of TRPV4 protein
tanshinone inhibits the reaction [Cycloheximide results in increased degradation of TRPV4 protein]

NCBI chr12:47,599,161...47,638,143
Ensembl chr12:47,599,035...47,638,143

G

tubulin gamma complex component 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TUBGCP3 mRNA]

NCBI chr16:83,553,950...83,614,626
Ensembl chr16:83,553,959...83,614,623

G

thioredoxin reductase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Acrolein results in increased expression of TXNRD1 mRNA]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of TXNRD1 mRNA]

PMID:12663510 PMID:15652504

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

thymidine phosphorylase

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of TYMP protein
salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]]

NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003

G

thymidylate synthetase

multiple interactions
decreases expression

ISO

cinobufagin promotes the reaction [Cycloheximide results in decreased expression of TYMS protein]; Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA]

PMID:17172411 PMID:35427566

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097

G

tyrosinase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Quercetin results in increased activity of TYR protein]
[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein; SB 203580 inhibits the reaction [[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein]

PMID:14717847 PMID:29621941

NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857

G

ubiquitin C-terminal hydrolase L1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Mevinphos results in increased expression of UCHL1 protein]

NCBI chr14:41,838,859...41,849,743
Ensembl chr14:41,838,861...41,849,417

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions
decreases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of UGT1A1 mRNA
Cycloheximide results in decreased expression of UGT1A1 mRNA

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A6a

multiple interactions

EXP

Cycloheximide inhibits the reaction [Paraquat results in increased expression of UGT1A6 mRNA]

NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

unc-51 like autophagy activating kinase 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of ULK1 protein
Antimycin A inhibits the reaction [Cycloheximide results in decreased expression of ULK1 protein]; Cycloheximide inhibits the reaction [Antimycin A results in increased expression of ULK1 protein]

NCBI chr12:51,511,492...51,537,746
Ensembl chr12:51,511,492...51,537,746

G

ubiquitin specific peptidase 7

multiple interactions

ISO

USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein]

NCBI chr10:7,335,508...7,432,018
Ensembl chr10:7,367,604...7,432,013

G

vasodilator-stimulated phosphoprotein

multiple interactions

ISO

VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein]

NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650

G

vascular cell adhesion molecule 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

multiple interactions
increases expression

EXP
ISO

Cycloheximide promotes the reaction [Estradiol results in increased expression of VEGFA mRNA alternative form]
Cycloheximide results in increased expression of VEGFA mRNA
Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]
[Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA

PMID:8344219 PMID:8537383 PMID:10788502 PMID:11641398

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vascular endothelial growth factor D

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VEGFD mRNA]

NCBI chr X:33,704,582...33,740,305
Ensembl chr X:33,706,055...33,740,167

G

vir like m6A methyltransferase associated

affects response to substance

ISO

VIRMA gene SNP affects the susceptibility to Cycloheximide

NCBI chr 5:29,758,529...29,822,030
Ensembl chr 5:29,758,147...29,822,156

G

very low density lipoprotein receptor

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VLDLR mRNA]

NCBI chr 1:234,239,769...234,272,150
Ensembl chr 1:234,240,121...234,272,154

G

visinin-like 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VSNL1 mRNA]

NCBI chr 6:39,757,721...39,878,556
Ensembl chr 6:39,757,722...39,878,556

G

WW domain-containing oxidoreductase

affects response to substance

ISO

WWOX gene SNP affects the susceptibility to Cycloheximide

NCBI chr19:59,338,402...60,269,323
Ensembl chr19:59,341,233...60,269,441

G

X-linked inhibitor of apoptosis

multiple interactions

ISO

Cycloheximide inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA]

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

Yes1 associated transcriptional regulator

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of YAP1 mRNA

NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:13,380,551...13,451,437

G

YME1-like 1 ATPase

multiple interactions

ISO

YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein]

NCBI chr17:90,195,485...90,235,675
Ensembl chr17:90,195,584...90,356,331

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

Cycloserine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

DNA-damage inducible transcript 3

multiple interactions

ISO

Cycloserine inhibits the reaction [resveratrol results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

early growth response 1

increases expression

EXP

Cycloserine results in increased expression of EGR1 protein

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

Cycloserine promotes the reaction [Clozapine results in increased expression of FOS mRNA]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

homer scaffold protein 1

multiple interactions

EXP

Cycloserine inhibits the reaction [Clozapine results in increased expression of HOMER1 mRNA]; Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA]

NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:26,278,105...26,381,657

G

mitogen activated protein kinase 1

multiple interactions

EXP

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

EXP

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

poly (ADP-ribose) polymerase 1

multiple interactions

ISO

Cycloserine inhibits the reaction [resveratrol results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

ISO

Dicloxacillin results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

advanced glycosylation end product-specific receptor

multiple interactions
increases expression

ISO

AGER protein affects the reaction [Dicloxacillin results in increased expression of GPT protein]
Dicloxacillin results in increased expression of AGER mRNA

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

ISO

[Progesterone co-treated with Dicloxacillin] results in increased expression of CXCL2 mRNA
Dicloxacillin results in increased expression of CXCL2 mRNA

PMID:22157104 PMID:24747151

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

increases expression
multiple interactions

ISO

Dicloxacillin results in increased expression of CXCL1 mRNA
Progesterone promotes the reaction [Dicloxacillin results in increased expression of CXCL1 mRNA]

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

ISO

Dicloxacillin results in increased expression of and results in increased activity of CYP3A4 protein
Dicloxacillin results in increased expression of CYP3A4 mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

glutamic--pyruvic transaminase

multiple interactions
increases expression

ISO

AGER protein affects the reaction [Dicloxacillin results in increased expression of GPT protein]; eritoran inhibits the reaction [Dicloxacillin results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

high mobility group box 1

increases expression

ISO

Dicloxacillin results in increased expression of HMGB1 protein

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

intercellular adhesion molecule 1

increases expression

ISO

Dicloxacillin results in increased expression of ICAM1 protein

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interleukin 1 beta

increases expression

ISO

Dicloxacillin results in increased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 4

increases response to substance
increases expression

ISO

IL4 results in increased susceptibility to Dicloxacillin
Dicloxacillin results in increased expression of IL4 protein

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

NLR family, pyrin domain containing 3

increases expression

ISO

Dicloxacillin results in increased expression of NLRP3 mRNA

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

nuclear receptor subfamily 1, group I, member 2

increases activity

ISO

Dicloxacillin results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

S100 calcium binding protein A8

increases expression

ISO

Dicloxacillin results in increased expression of S100A8 mRNA

PMID:24747151 PMID:28138970

NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:178,464,702...178,465,221

G

S100 calcium binding protein A9

increases expression

ISO

Dicloxacillin results in increased expression of S100A9 mRNA

NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

difloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
affects binding
decreases activity

ISO
EXP

Enoxacin inhibits the reaction [CYP1A2 protein affects the metabolism of Fluvoxamine]; Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]
Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin]
Enoxacin binds to CYP1A2 protein
Enoxacin results in decreased activity of CYP1A2 protein

PMID:7946932 PMID:8905919 PMID:15905806

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

glutathione S-transferase pi 1

multiple interactions

ISO

Enoxacin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

Enoxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

nitric oxide synthase 1

multiple interactions

ISO

7-nitroindazole inhibits the reaction [[Enoxacin co-treated with fenbufen] results in increased activity of NOS1 protein]; [Enoxacin co-treated with fenbufen] results in increased activity of NOS1 protein

NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

Fleroxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

ISO

Floxacillin results in decreased activity of ABCB11 protein
Floxacillin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

aldo-keto reductase family 1 member B10

increases expression

ISO

Floxacillin results in increased expression of AKR1B10 mRNA

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

G

albumin

affects binding

ISO

Floxacillin binds to ALB protein

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

caspase 3

increases activity
multiple interactions

ISO

Floxacillin results in increased activity of CASP3 protein
[Floxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Floxacillin co-treated with IL1B protein] results in increased activity of CASP3 protein; [Floxacillin co-treated with IL6 protein] results in increased activity of CASP3 protein; [Floxacillin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Floxacillin results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

C-C motif chemokine ligand 2

increases expression

ISO

Floxacillin results in increased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

Cd69 molecule

multiple interactions

ISO

[Floxacillin co-treated with CpG ODN 1826] results in decreased expression of CD69 protein

NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:164,411,485...164,419,509

G

carboxylesterase 1D

affects binding

ISO

Floxacillin binds to CES1 protein

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carbamoyl-phosphate synthase 1

affects binding

ISO

Floxacillin binds to CPS1 protein

NCBI chr 9:76,063,863...76,186,739
Ensembl chr 9:76,000,754...76,186,734

G

C-reactive protein

multiple interactions

ISO

[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

C-X-C motif chemokine ligand 2

increases expression

ISO

Floxacillin results in increased expression of CXCL2 mRNA

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

increases expression

ISO

Floxacillin results in increased expression of CXCL1 mRNA

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing

ISO

CYP3A4 results in increased metabolism of Floxacillin

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

Fas ligand

multiple interactions

ISO

[Floxacillin co-treated with CpG ODN 1826] results in decreased expression of FASL protein; FASL protein affects the reaction [[Floxacillin co-treated with CpG ODN 1826] results in increased expression of GPT protein]

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

glutamate dehydrogenase 1

affects binding

ISO

Floxacillin binds to GLUD1 protein

NCBI chr16:9,646,569...9,680,215
Ensembl chr16:9,646,509...9,680,210

G

glutamic--pyruvic transaminase

multiple interactions
increases expression

ISO

[Floxacillin co-treated with alpha-galactosylceramide] results in increased expression of GPT protein; [Floxacillin co-treated with CpG ODN 1826] results in increased expression of GPT protein; FASL protein affects the reaction [[Floxacillin co-treated with CpG ODN 1826] results in increased expression of GPT protein]; IL17A protein promotes the reaction [Floxacillin results in increased expression of GPT protein]

PMID:24652713 PMID:30993380

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

hemoglobin alpha, adult chain 3

affects binding

ISO

Floxacillin binds to HBA2 protein

NCBI chr10:15,816,099...15,816,943
Ensembl chr10:15,816,096...15,817,167

G

hemoglobin subunit beta

affects binding

ISO

Floxacillin binds to HBB protein

NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:167,630,245...167,663,873

G

high mobility group box 1

increases secretion
increases expression

ISO

Floxacillin results in increased secretion of HMGB1 protein
Floxacillin results in increased expression of HMGB1 protein

PMID:24652713 PMID:28444390

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

interleukin 17A

multiple interactions

ISO

[IL17A protein co-treated with Floxacillin] results in increased expression of MPO protein; IL17A protein promotes the reaction [Floxacillin results in increased expression of GPT protein]

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 1 alpha

increases secretion

ISO

Floxacillin results in increased secretion of IL1A protein

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

increases secretion
multiple interactions
increases expression

ISO

Floxacillin results in increased secretion of IL1B protein
[Floxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Floxacillin co-treated with IL1B protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Floxacillin results in increased activity of CASP3 protein]
Floxacillin results in increased expression of IL1B mRNA

PMID:24652713 PMID:28444390 PMID:30876886

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 5

increases expression

ISO

Floxacillin results in increased expression of IL5 mRNA

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

increases secretion
multiple interactions
increases expression

ISO

Floxacillin results in increased secretion of IL6 protein
[Floxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Floxacillin co-treated with IL6 protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Floxacillin results in increased activity of CASP3 protein]
Floxacillin results in increased expression of IL6 mRNA

PMID:24652713 PMID:28444390 PMID:30876886

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

myeloperoxidase

multiple interactions

ISO

[IL17A protein co-treated with Floxacillin] results in increased expression of MPO protein

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

RAR-related orphan receptor C

increases expression

ISO

Floxacillin results in increased expression of RORC mRNA

NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:184,698,818...184,724,566

G

S100 calcium binding protein A8

increases expression

ISO

Floxacillin results in increased expression of S100A8 mRNA

NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:178,464,702...178,465,221

G

S100 calcium binding protein A9

increases expression

ISO

Floxacillin results in increased expression of S100A9 mRNA

NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870

G

sulfiredoxin 1

increases expression

ISO

Floxacillin results in increased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

T-box transcription factor 21

decreases expression

ISO

Floxacillin results in decreased expression of TBX21 mRNA

NCBI chr10:82,578,751...82,595,253
Ensembl chr10:82,578,751...82,595,253

G

tumor necrosis factor

increases secretion
multiple interactions
increases expression

ISO

Floxacillin results in increased secretion of TNF protein
[Floxacillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Floxacillin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Floxacillin results in increased activity of CASP3 protein]
Floxacillin results in increased expression of TNF mRNA

PMID:24652713 PMID:28444390 PMID:30876886

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tRNA splicing endonuclease subunit 2

affects binding

ISO

Floxacillin binds to TSEN2 protein

NCBI chr 4:150,275,389...150,310,846
Ensembl chr 4:150,275,501...150,313,013

G

thioredoxin reductase 1

increases expression

ISO

Floxacillin results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

UDP-glucose pyrophosphorylase 2

affects binding

ISO

Floxacillin binds to UGP2 protein

NCBI chr14:99,657,637...99,698,573
Ensembl chr14:99,657,639...99,698,002

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta

affects binding

ISO

Floxacillin binds to YWHAB protein

NCBI chr 3:173,078,904...173,101,508
Ensembl chr 3:173,079,041...173,101,854

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of ABCB11 mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of ABCB11 mRNA]

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

albumin

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of ALB protein

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

C-C motif chemokine ligand 2

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL3 mRNA

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL4 mRNA

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 7

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCL7 mRNA

NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,514,091...67,515,947

G

cyclin A2

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNB1 mRNA; flumequine promotes the reaction [estragole results in increased expression of CCNB1 mRNA]

PMID:23681119 PMID:31029721

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin B2

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNB2 mRNA

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682

G

cyclin D1

multiple interactions
increases expression

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCND1 mRNA
flumequine results in increased expression of CCND1 mRNA

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin E1

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCNE1 mRNA; [flumequine co-treated with estragole] results in increased expression of CCNE1 mRNA

PMID:23681119 PMID:31029721

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

C-C motif chemokine receptor 2

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCR2 mRNA

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059

G

C-C motif chemokine receptor 7

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CCR7 mRNA

NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,593,594...84,604,501

G

cyclin-dependent kinase 1

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

checkpoint kinase 1

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CHEK1 mRNA

NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A1 mRNA

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A2 mRNA; [flumequine co-treated with estragole] results in increased expression of CYP1A2 mRNA

PMID:23681119 PMID:31029721

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of CYP27A1 mRNA; [Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP2B10 mRNA

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of CYP7A1 mRNA; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of CYP7A1 mRNA]

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804

G

exonuclease 1

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of EXO1 mRNA

NCBI chr13:90,341,947...90,366,861
Ensembl chr13:90,342,018...90,366,861

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of FOS mRNA

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GAPDH mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GAPDH mRNA]

NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377

G

glutamic--pyruvic transaminase

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of GPT protein; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 1

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GPX1 mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GPX1 mRNA]

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glutathione peroxidase 3

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of GPX3 mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of GPX3 mRNA]

NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405

G

glutathione peroxidase 4

multiple interactions

ISO

[Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of GPX4 mRNA

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of HMGCR mRNA; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of HMGCR mRNA]

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

heme oxygenase 1

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of HMOX1 mRNA; [Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

interleukin 1 beta

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 36, beta

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of IL36B mRNA

NCBI chr 3:27,422,980...27,521,344
Ensembl chr 3:27,423,171...27,428,678

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

metallothionein 1A

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of MT1 mRNA; [Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of MT1 mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

metallothionein 2

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of MT2 mRNA; [Sodium Selenite co-treated with Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of MT2 mRNA

NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709

G

nuclear factor kappa B subunit 2

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of NFKB2 mRNA

NCBI chr 1:255,106,010...255,114,649
Ensembl chr 1:255,107,374...255,114,637

G

phosphofructokinase, liver type

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of PFKL mRNA; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of PFKL mRNA]

NCBI chr20:10,663,907...10,685,967
Ensembl chr20:10,663,955...10,685,966

G

pyruvate kinase L/R

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of PKLR mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of PKLR mRNA]

NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:176,840,764...176,849,644

G

RAD18 E3 ubiquitin protein ligase

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of RAD18 mRNA

NCBI chr 4:147,291,463...147,376,904
Ensembl chr 4:147,291,276...147,376,869

G

RAD51 recombinase

multiple interactions

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of RAD51 mRNA

NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469

G

superoxide dismutase 1

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of SOD1 mRNA; Sodium Selenite promotes the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in decreased expression of SOD1 mRNA]

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

sterol regulatory element binding transcription factor 2

multiple interactions

ISO

[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of SREBF2 mRNA; Sodium Selenite inhibits the reaction [[Cadmium co-treated with Arsenic co-treated with Mercury co-treated with Diclofenac co-treated with flumequine] results in increased expression of SREBF2 mRNA]

NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:115,543,290...115,600,943

G

tumor necrosis factor

multiple interactions
increases expression

ISO

[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of TNF mRNA; [flumequine co-treated with estragole] results in increased expression of TNF mRNA
flumequine results in increased expression of TNF mRNA

PMID:23681119 PMID:31029721

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

UDP glucuronosyltransferase family 1 member A1

decreases expression
multiple interactions

ISO

flumequine results in decreased expression of UGT1A1 mRNA
[flumequine co-treated with estragole] results in decreased expression of UGT1A1 mRNA

PMID:23681119 PMID:31029721

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase 2 family, polypeptide B1

decreases expression
multiple interactions

ISO

flumequine results in decreased expression of UGT2B1 mRNA
[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of UGT2B1 mRNA

NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Furazolidone results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Furazolidone results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

BRCA1, DNA repair associated

multiple interactions
increases expression

ISO

Curcumin inhibits the reaction [Furazolidone results in increased expression of BRCA1 protein]

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763

G

caspase 3

multiple interactions
increases activity

ISO

CDKN1A protein inhibits the reaction [Furazolidone results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

cyclin D1

multiple interactions
increases expression

ISO

Curcumin inhibits the reaction [Furazolidone results in increased expression of CCND1 protein]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CCND1 mRNA]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND1 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND1 protein]
Furazolidone results in increased expression of CCND1 mRNA; Furazolidone results in increased expression of CCND1 protein

PMID:23112108 PMID:26095818 PMID:27996348

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D3

multiple interactions
increases expression

ISO

GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CCND3 mRNA]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CCND3 protein]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND3 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND3 protein]
Furazolidone results in increased expression of CCND3 mRNA; Furazolidone results in increased expression of CCND3 protein

PMID:23112108 PMID:26095818

NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033

G

cyclin-dependent kinase 6

increases expression
multiple interactions

ISO

Furazolidone results in increased expression of CDK6 mRNA; Furazolidone results in increased expression of CDK6 protein
GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CDK6 mRNA]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CDK6 protein]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CDK6 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CDK6 protein]

PMID:23112108 PMID:26095818

NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression
decreases expression

ISO

CDKN1A mutant form inhibits the reaction [Furazolidone results in increased expression of HMOX1 protein]; CDKN1A mutant form inhibits the reaction [Furazolidone results in increased expression of NFE2L2 protein]; CDKN1A protein inhibits the reaction [Furazolidone results in increased activity of CASP3 protein]; CDKN1A protein inhibits the reaction [Furazolidone results in increased phosphorylation of PARP1 protein]; CDKN1A protein promotes the reaction [Furazolidone results in increased expression of HMOX1 protein]; CDKN1A protein promotes the reaction [Furazolidone results in increased expression of NFE2L2 protein]; Furazolidone promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]
Furazolidone results in increased expression of CDKN1A mRNA
Furazolidone results in decreased expression of CDKN1A protein

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

checkpoint kinase 1

multiple interactions
increases expression

ISO

Curcumin inhibits the reaction [Furazolidone results in increased expression of CHEK1 protein]

NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity

EXP

Furazolidone results in increased activity of CYP1A1 protein

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

ISO

Curcumin inhibits the reaction [Furazolidone results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions
increases expression

ISO

GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CCND1 mRNA]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CCND1 protein]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CCND3 mRNA]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CCND3 protein]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CDK6 mRNA]; GADD45A mutant form inhibits the reaction [Furazolidone results in increased expression of CDK6 protein]
Furazolidone results in increased expression of GADD45A

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

heme oxygenase 1

multiple interactions
increases expression

ISO

CDKN1A mutant form inhibits the reaction [Furazolidone results in increased expression of HMOX1 protein]; CDKN1A protein promotes the reaction [Furazolidone results in increased expression of HMOX1 protein]; Curcumin promotes the reaction [Furazolidone results in increased expression of HMOX1 protein]

PMID:26687534 PMID:27996348

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heat shock protein family A (Hsp70) member 5

increases expression
multiple interactions

ISO

Furazolidone results in increased expression of HSPA5 protein
Curcumin inhibits the reaction [Furazolidone results in increased expression of HSPA5 protein]

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

insulin-like growth factor 1

multiple interactions

ISO

IGF1 protein inhibits the reaction [Furazolidone results in decreased phosphorylation of AKT1 protein]

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

ISO

Furazolidone results in increased phosphorylation of MAPK1 protein
Curcumin inhibits the reaction [Furazolidone results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression

ISO

CDKN1A mutant form inhibits the reaction [Furazolidone results in increased expression of NFE2L2 protein]; CDKN1A protein promotes the reaction [Furazolidone results in increased expression of NFE2L2 protein]; Curcumin promotes the reaction [Furazolidone results in increased expression of NFE2L2 protein]

PMID:26687534 PMID:27996348

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO

CDKN1A protein inhibits the reaction [Furazolidone results in increased phosphorylation of PARP1 protein]
Furazolidone results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glucagon

increases secretion
increases expression
multiple interactions

ISO
EXP

gatifloxacin results in increased secretion of GCG protein
gatifloxacin results in increased expression of GCG protein
[gatifloxacin co-treated with GCG protein] affects the secretion of INS1 protein; GCG protein affects the reaction [gatifloxacin results in decreased expression of INS2 mRNA]; GCG protein promotes the reaction [gatifloxacin affects the expression of GCGR mRNA]
Diazoxide inhibits the reaction [gatifloxacin results in increased secretion of GCG protein]
gatifloxacin results in increased expression of GCG mRNA

NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:67,522,489...67,531,533

G

glucagon receptor

multiple interactions
affects expression

EXP

GCG protein promotes the reaction [gatifloxacin affects the expression of GCGR mRNA]

NCBI chr10:106,306,803...106,314,970
Ensembl chr10:106,306,559...106,314,969

G

insulin 1

multiple interactions
affects secretion

EXP

[Gatifloxacin co-treated with GCG protein] affects the secretion of INS1 protein
Gatifloxacin affects the secretion of INS1 protein

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin 2

multiple interactions
decreases expression

EXP

GCG protein affects the reaction [gatifloxacin results in decreased expression of INS2 mRNA]

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

ISO

[Gatifloxacin binds to and results in decreased activity of KCNH2 protein] which results in decreased export of Potassium; Gatifloxacin binds to and results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

matrix metallopeptidase 2

increases expression
increases activity

EXP

Gatifloxacin results in increased expression of MMP2 mRNA
Gatifloxacin results in increased activity of MMP2 protein

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

increases expression
increases activity

EXP

Gatifloxacin results in increased expression of MMP9 mRNA
Gatifloxacin results in increased activity of MMP9 protein

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

proprotein convertase subtilisin/kexin type 1

increases expression

ISO

gatifloxacin results in increased expression of PCSK1 mRNA

NCBI chr 2:6,130,045...6,176,974
Ensembl chr 2:6,129,592...6,176,974

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

affects export

ISO

ABCC1 protein affects the export of grepafloxacin

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

grepafloxacin results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

solute carrier family 22 member 5

multiple interactions

ISO

grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]

NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

ISO

UGT1A1 protein results in increased glucuronidation of grepafloxacin

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

ISO

UGT1A3 protein results in increased glucuronidation of grepafloxacin

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

ISO

UGT1A9 protein results in increased glucuronidation of grepafloxacin

NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264

imipenem hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in increased expression of ABCB11 mRNA

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in decreased expression of ABCB1A mRNA

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 2

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] affects the expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in decreased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily G member 5

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] affects the expression of ABCG5 mRNA

NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376

G

ATP binding cassette subfamily G member 8

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] affects the expression of ABCG8 mRNA

NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:15,698,448...15,717,730

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in decreased expression of BAAT mRNA

NCBI chr 5:68,647,166...68,656,137
Ensembl chr 5:68,646,203...68,656,181

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in decreased expression of CYP7A1 mRNA

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in decreased expression of NPC1L1 mRNA

NCBI chr14:85,285,387...85,305,050
Ensembl chr14:85,285,390...85,305,050

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in increased expression of NR0B2 mRNA

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

nuclear receptor subfamily 1, group I, member 2

increases activity

ISO

Imipenem results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in increased expression of NR5A2 mRNA

NCBI chr13:50,865,253...50,985,107
Ensembl chr13:50,867,920...50,984,938

G

solute carrier family 10 member 1

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in increased expression of SLC10A1 mRNA

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 27 member 5

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in increased expression of SLC27A5 mRNA

NCBI chr 1:82,688,742...82,699,335
Ensembl chr 1:82,688,750...82,699,358

G

solute carrier family 51 member A

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in decreased expression of SLC51A mRNA

NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539

G

solute carrier organic anion transporter family, member 1a4

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in decreased expression of SLCO1A4 mRNA

NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816

G

solute carrier organic anion transporter family member 1B2

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in increased expression of SLCO1B2 mRNA

NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

ISO

[Vancomycin co-treated with Imipenem] results in increased expression of SLCO2B1 mRNA

NCBI chr 1:163,371,410...163,419,412
Ensembl chr 1:163,371,410...163,419,279

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 3

decreases activity

ISO

Levofloxacin results in decreased activity of ABCC3 protein

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 4

decreases activity

ISO

Levofloxacin results in decreased activity of ABCC4 protein

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

abhydrolase domain containing 1

decreases expression

EXP

Levofloxacin results in decreased expression of ABHD1 mRNA

NCBI chr 6:31,142,476...31,147,464
Ensembl chr 6:31,142,476...31,147,464

G

acyl-CoA synthetase family member 2

decreases expression

EXP

Levofloxacin results in decreased expression of ACSF2 mRNA

NCBI chr10:80,001,389...80,043,796
Ensembl chr10:80,001,389...80,045,050

G

acyl-CoA synthetase long-chain family member 5

decreases expression

EXP

Levofloxacin results in decreased expression of ACSL5 mRNA

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

actin, gamma 1

decreases expression

EXP

Levofloxacin results in decreased expression of ACTG1 mRNA

NCBI chr10:106,118,106...106,120,951
Ensembl chr10:106,118,108...106,120,951

G

aminoacylase 1

decreases expression

EXP

Levofloxacin results in decreased expression of ACY1 mRNA

NCBI chr 8:115,951,068...115,956,471
Ensembl chr 8:115,951,068...115,956,405

G

alpha-fetoprotein

decreases expression

EXP

Levofloxacin results in decreased expression of AFP mRNA

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

aldehyde dehydrogenase 1 family, member B1

decreases expression

EXP

Levofloxacin results in decreased expression of ALDH1B1 mRNA

NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365

G

angiopoietin-like 6

increases expression

EXP

Levofloxacin results in increased expression of ANGPTL6 mRNA

NCBI chr 8:27,689,804...27,696,172
Ensembl chr 8:27,689,806...27,696,111

G

annexin A1

decreases expression

EXP

Levofloxacin results in decreased expression of ANXA1 mRNA

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831

G

annexin A2

decreases expression

EXP

Levofloxacin results in decreased expression of ANXA2 mRNA

NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631

G

adaptor related protein complex 1 subunit sigma 1

decreases expression

EXP

Levofloxacin results in decreased expression of AP1S1 mRNA

NCBI chr12:25,261,958...25,272,483
Ensembl chr12:25,262,036...25,272,483

G

ARF like GTPase 4A

increases expression

EXP

Levofloxacin results in increased expression of ARL4A mRNA

NCBI chr 6:62,809,287...62,811,297
Ensembl chr 6:62,804,548...62,820,760

G

aspartoacylase

decreases expression

EXP

Levofloxacin results in decreased expression of ASPA mRNA

NCBI chr10:58,390,204...58,443,790
Ensembl chr10:58,379,410...58,443,769

G

autophagy related 2B

increases expression

EXP

Levofloxacin results in increased expression of ATG2B mRNA

NCBI chr 6:130,286,979...130,357,109
Ensembl chr 6:130,286,986...130,357,109

G

ATPase, H+ transporting V0 subunit e2

decreases expression

EXP

Levofloxacin results in decreased expression of ATP6V0E2 mRNA

NCBI chr 4:78,815,771...78,818,919
Ensembl chr 4:78,813,129...78,819,680

G

baculoviral IAP repeat-containing 2

multiple interactions

ISO

[Levofloxacin co-treated with TNF protein] results in increased expression of BIRC2 mRNA

NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911

G

bone morphogenetic protein 6

decreases expression

ISO

Levofloxacin results in decreased expression of BMP6 mRNA

NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261

G

bone marrow stromal cell antigen 2

decreases expression

EXP

Levofloxacin results in decreased expression of BST2 mRNA

NCBI chr16:18,250,593...18,254,967
Ensembl chr16:18,251,847...18,254,967

G

BTG anti-proliferation factor 1

increases expression

EXP

Levofloxacin results in increased expression of BTG1 mRNA

NCBI chr 7:33,228,149...33,230,406
Ensembl chr 7:33,227,833...33,230,406

G

C2 calcium-dependent domain containing 2

decreases expression

EXP

Levofloxacin results in decreased expression of C2CD2 mRNA

NCBI chr11:50,694,680...50,759,096
Ensembl chr11:50,694,563...50,759,016

G

complement C4B

increases expression

EXP

Levofloxacin results in increased expression of C4B mRNA

NCBI chr20:4,201,979...4,216,292
Ensembl chr20:4,201,961...4,216,289

G

complement C5

increases expression

EXP

Levofloxacin results in increased expression of C5 mRNA

NCBI chr 3:38,668,174...38,759,468
Ensembl chr 3:38,668,174...38,759,468

G

complement C5 like 1

increases expression

EXP

Levofloxacin results in increased expression of C5L1 mRNA

NCBI chr 3:38,799,165...38,818,443
Ensembl chr 3:38,799,731...38,817,527

G

similar to human chromosome 11 open reading frame 54

decreases expression

EXP

Levofloxacin results in decreased expression of C8H11ORF54 mRNA

NCBI chr 8:20,405,240...20,427,811
Ensembl chr 8:20,405,241...20,427,811

G

similar to human chromosome 11 open reading frame 65

increases expression

EXP

Levofloxacin results in increased expression of C8H11ORF65 mRNA

NCBI chr 8:62,692,123...62,720,951
Ensembl chr 8:62,692,568...62,720,946

G

carbonic anhydrase 14

decreases expression

EXP

Levofloxacin results in decreased expression of CAR14 mRNA

NCBI chr 2:186,131,196...186,138,164
Ensembl chr 2:186,129,341...186,138,863

G

caspase 3

multiple interactions

ISO

[Levofloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

coiled-coil domain containing 6

increases expression

EXP

Levofloxacin results in increased expression of CCDC6 mRNA

NCBI chr20:18,431,243...18,527,227
Ensembl chr20:18,431,243...18,527,227

G

coiled-coil domain containing 80

decreases expression

EXP

Levofloxacin results in decreased expression of CCDC80 mRNA

NCBI chr11:69,191,188...69,224,844
Ensembl chr11:69,191,189...69,224,844

G

CD302 molecule

increases expression

EXP

Levofloxacin results in increased expression of CD302 mRNA

NCBI chr 3:65,131,017...65,164,737
Ensembl chr 3:65,113,102...65,164,737

G

CDC42 effector protein 4

increases expression

EXP

Levofloxacin results in increased expression of CDC42EP4 mRNA

NCBI chr10:99,271,750...99,298,551
Ensembl chr10:99,267,540...99,300,168

G

cyclin-dependent kinase 1

decreases expression

EXP

Levofloxacin results in decreased expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase inhibitor 3

decreases expression

EXP

Levofloxacin results in decreased expression of CDKN3 mRNA

NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722

G

CCAAT/enhancer binding protein beta

increases expression

EXP

Levofloxacin results in increased expression of CEBPB mRNA

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

complement factor H-related 1

increases expression

EXP

Levofloxacin results in increased expression of CFHR1 mRNA

NCBI chr13:53,946,298...53,961,282
Ensembl chr13:53,919,927...53,961,303

G

cingulin

decreases expression

EXP

Levofloxacin results in decreased expression of CGN mRNA

NCBI chr 2:184,997,425...185,024,785
Ensembl chr 2:184,997,425...185,023,635

G

choline phosphotransferase 1

increases expression

EXP

Levofloxacin results in increased expression of CHPT1 mRNA

NCBI chr 7:24,753,880...24,802,529
Ensembl chr 7:24,750,343...24,802,521

G

CDC28 protein kinase regulatory subunit 2

decreases expression

EXP

Levofloxacin results in decreased expression of CKS2 mRNA

NCBI chr17:13,722,360...13,727,519
Ensembl chr17:13,722,361...13,727,519

G

C-type lectin domain containing 14A

increases expression

EXP

Levofloxacin results in increased expression of CLEC14A mRNA

NCBI chr 6:81,616,414...81,619,556
Ensembl chr 6:81,612,953...81,619,614

G

carboxymethylenebutenolidase homolog

decreases expression

EXP

Levofloxacin results in decreased expression of CMBL mRNA

NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880

G

carnitine palmitoyltransferase 1A

increases expression

EXP

Levofloxacin results in increased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases expression

EXP

Levofloxacin results in increased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

ISO

Levofloxacin results in decreased activity of CYP3A4 protein

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 4, subfamily b, polypeptide 1

increases expression

EXP

Levofloxacin results in increased expression of CYP4B1 mRNA

NCBI chr 5:134,375,807...134,413,635
Ensembl chr 5:134,375,807...134,393,116

G

cytochrome P450, family 51

increases expression

EXP

Levofloxacin results in increased expression of CYP51 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

dopa decarboxylase

decreases expression

EXP

Levofloxacin results in decreased expression of DDC mRNA

NCBI chr14:90,592,304...90,682,830
Ensembl chr14:90,592,304...90,682,806

G

DDHD domain containing 1

decreases expression

EXP

Levofloxacin results in decreased expression of DDHD1 mRNA

NCBI chr15:21,304,053...21,370,608
Ensembl chr15:21,303,826...21,370,608

G

dihydrofolate reductase

decreases activity

ISO

Levofloxacin results in decreased activity of DHFR protein

NCBI chr 2:25,320,895...25,346,004

G

DnaJ heat shock protein family (Hsp40) member C9

decreases expression

EXP

Levofloxacin results in decreased expression of DNAJC9 mRNA

NCBI chr15:3,970,843...4,003,009
Ensembl chr15:3,970,114...3,977,304

G

2'-deoxynucleoside 5'-phosphate N-hydrolase 1

decreases expression

EXP

Levofloxacin results in decreased expression of DNPH1 mRNA

NCBI chr 9:21,978,894...21,981,631
Ensembl chr 9:21,978,894...21,981,631

G

deoxythymidylate kinase

decreases expression

EXP

Levofloxacin results in decreased expression of DTYMK mRNA

NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:101,762,899...101,774,504

G

deoxyuridine triphosphatase

decreases expression

EXP

Levofloxacin results in decreased expression of DUT mRNA

NCBI chr 3:132,952,258...132,963,433
Ensembl chr 3:132,952,394...132,964,956

G

ER degradation enhancing alpha-mannosidase like protein 1

increases expression

EXP

Levofloxacin results in increased expression of EDEM1 mRNA

NCBI chr 4:143,350,989...143,385,693
Ensembl chr 4:143,353,624...143,388,060

G

ELOVL fatty acid elongase 5

decreases expression

EXP

Levofloxacin results in decreased expression of ELOVL5 mRNA

NCBI chr 8:87,671,164...87,737,618
Ensembl chr 8:87,671,159...87,737,616

G

ectodermal-neural cortex 1

increases expression

EXP

Levofloxacin results in increased expression of ENC1 mRNA

NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721

G

epoxide hydrolase 1

decreases expression

EXP

Levofloxacin results in decreased expression of EPHX1 mRNA

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

ergosterol biosynthesis 28 homolog

increases expression

EXP

Levofloxacin results in increased expression of ERG28 mRNA

NCBI chr 6:111,205,102...111,214,068
Ensembl chr 6:111,205,103...111,214,068

G

endoplasmic reticulum-golgi intermediate compartment 1

decreases expression

EXP

Levofloxacin results in decreased expression of ERGIC1 mRNA

NCBI chr10:17,035,615...17,131,411
Ensembl chr10:17,035,615...17,131,376

G

fibrinogen-like 1

increases expression

EXP

Levofloxacin results in increased expression of FGL1 mRNA

NCBI chr16:57,824,127...57,854,413
Ensembl chr16:57,824,200...57,854,429

G

FKBP prolyl isomerase 4

decreases expression

EXP

Levofloxacin results in decreased expression of FKBP4 mRNA

NCBI chr 4:163,389,464...163,397,918
Ensembl chr 4:163,389,464...163,397,918

G

FKBP prolyl isomerase 5

increases expression

EXP

Levofloxacin results in increased expression of FKBP5 mRNA

NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118

G

filamin A

decreases expression

EXP

Levofloxacin results in decreased expression of FLNA mRNA

NCBI chr X:157,159,051...157,185,559
Ensembl chr X:157,159,051...157,182,343

G

fibronectin type III domain containing 3B

increases expression

EXP

Levofloxacin results in increased expression of FNDC3B mRNA

NCBI chr 2:112,240,108...112,546,113
Ensembl chr 2:112,243,202...112,546,306

G

frizzled class receptor 8

increases expression

EXP

Levofloxacin results in increased expression of FZD8 mRNA

NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961

G

growth arrest specific 6

increases expression

EXP

Levofloxacin results in increased expression of GAS6 mRNA

NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088

G

glutamate-cysteine ligase, catalytic subunit

decreases expression

EXP

Levofloxacin results in decreased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glycine-N-acyltransferase-like 2

increases expression

EXP

Levofloxacin results in increased expression of GLYATL2 mRNA

NCBI chr 1:219,232,154...219,265,142
Ensembl chr 1:219,232,103...219,266,322

G

glycerol-3-phosphate dehydrogenase 1

decreases expression

EXP

Levofloxacin results in decreased expression of GPD1 mRNA

NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:132,721,915...132,730,368

G

3-hydroxyacyl-CoA dehydratase 3

decreases expression

EXP

Levofloxacin results in decreased expression of HACD3 mRNA

NCBI chr 8:74,396,441...74,433,700
Ensembl chr 8:74,396,442...74,433,700

G

HAUS augmin-like complex, subunit 4

decreases expression

EXP

Levofloxacin results in decreased expression of HAUS4 mRNA

NCBI chr15:31,964,555...31,976,853
Ensembl chr15:31,964,556...31,975,941

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

EXP

Levofloxacin results in increased expression of HERPUD1 mRNA

NCBI chr19:10,604,360...10,624,168
Ensembl chr19:10,604,362...10,624,081

G

high mobility group box 2

decreases expression

EXP

Levofloxacin results in decreased expression of HMGB2 mRNA

NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860

G

high mobility group nucleosomal binding domain 2

decreases expression

EXP

Levofloxacin results in decreased expression of HMGN2 mRNA

NCBI chr 5:151,475,907...151,479,361
Ensembl chr 5:151,475,909...151,479,397

G

HIV-1 Tat interactive protein 2

decreases expression

EXP

Levofloxacin results in decreased expression of HTATIP2 mRNA

NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815

G

intercellular adhesion molecule 1

decreases expression
multiple interactions

ISO

Levofloxacin results in decreased expression of ICAM1 mRNA
[Levofloxacin co-treated with TNF protein] results in increased expression of ICAM1 protein

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

isopentenyl-diphosphate delta isomerase 1

increases expression

EXP

Levofloxacin results in increased expression of IDI1 mRNA

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524

G

interferon gamma

increases expression

EXP

Levofloxacin results in increased expression of IFNG

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 1 alpha

increases expression

ISO

Levofloxacin results in increased expression of IL1A mRNA

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions

ISO

[Levofloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 24

increases expression

ISO

Levofloxacin results in increased expression of IL24 mRNA

NCBI chr13:44,905,362...44,910,760
Ensembl chr13:44,905,363...44,910,760

G

interleukin 6

multiple interactions

ISO

[Levofloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 receptor

increases expression

EXP

Levofloxacin results in increased expression of IL6R mRNA

NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221

G

inositol hexakisphosphate kinase 2

increases expression

EXP

Levofloxacin results in increased expression of IP6K2 mRNA

NCBI chr 8:118,362,154...118,388,668
Ensembl chr 8:118,362,795...118,388,667

G

influenza virus NS1A binding protein

increases expression

EXP

Levofloxacin results in increased expression of IVNS1ABP mRNA

NCBI chr13:65,977,069...65,996,685
Ensembl chr13:65,977,045...65,997,547

G

KLF transcription factor 15

increases expression

EXP

Levofloxacin results in increased expression of KLF15 mRNA

NCBI chr 4:124,522,652...124,535,613
Ensembl chr 4:124,522,909...124,542,373

G

KLF transcription factor 9

increases expression

EXP

Levofloxacin results in increased expression of KLF9 mRNA

NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641

G

karyopherin subunit alpha 2

decreases expression

EXP

Levofloxacin results in decreased expression of KPNA2 mRNA

NCBI chr10:92,433,678...92,445,841
Ensembl chr10:92,433,679...92,445,937

G

karyopherin subunit beta 1

decreases expression

EXP

Levofloxacin results in decreased expression of KPNB1 mRNA

NCBI chr10:82,642,082...82,670,856
Ensembl chr10:82,642,082...82,670,856

G

keratin 18

decreases expression

EXP

Levofloxacin results in decreased expression of KRT18 mRNA

NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848

G

lipopolysaccharide binding protein

increases expression

EXP

Levofloxacin results in increased expression of LBP mRNA

NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:167,373,924...167,401,518

G

leucine carboxyl methyltransferase 1

decreases expression

EXP

Levofloxacin results in decreased expression of LCMT1 mRNA

NCBI chr 1:187,335,173...187,391,195
Ensembl chr 1:187,327,706...187,391,516

G

lamin B1

decreases expression

EXP

Levofloxacin results in decreased expression of LMNB1 mRNA

NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283

G

LIM domain 7

decreases expression

EXP

Levofloxacin results in decreased expression of LMO7 mRNA

NCBI chr15:84,981,689...85,184,554
Ensembl chr15:84,981,735...85,184,551

G

lipin 1

increases expression

EXP

Levofloxacin results in increased expression of LPIN1 mRNA

NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991

G

leucine rich adaptor protein 1-like

increases expression

EXP

Levofloxacin results in increased expression of LURAP1L mRNA

NCBI chr 5:100,402,921...100,455,479
Ensembl chr 5:100,407,483...100,455,478

G

mannosidase beta

decreases expression

EXP

Levofloxacin results in decreased expression of MANBA mRNA

NCBI chr 2:226,583,968...226,676,520
Ensembl chr 2:226,583,917...226,676,517

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

ISO

[TNF protein co-treated with Levofloxacin] results in increased lipidation of MAP1LC3B protein; TNF protein promotes the reaction [Levofloxacin results in increased expression of MAP1LC3B protein]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

EXP

Levofloxacin results in increased expression of MFSD2A mRNA

NCBI chr 5:140,510,933...140,525,828
Ensembl chr 5:140,510,953...140,525,916

G

nicotinamide phosphoribosyltransferase

increases expression

EXP

Levofloxacin results in increased expression of NAMPT mRNA

NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544

G

neural precursor cell expressed, developmentally down-regulated 9

decreases expression

EXP

Levofloxacin results in decreased expression of NEDD9 mRNA

NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668

G

NFE2 like bZIP transcription factor 2

decreases expression

EXP

Levofloxacin results in decreased expression of NFE2L2 mRNA

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NFKB inhibitor alpha

increases expression
multiple interactions

EXP
ISO

Levofloxacin results in increased expression of NFKBIA mRNA
[Levofloxacin co-treated with TNF protein] results in increased expression of NFKBIA mRNA

PMID:24136188 PMID:32035082

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

NFKB inhibitor zeta

increases expression

EXP

Levofloxacin results in increased expression of NFKBIZ mRNA

NCBI chr11:58,251,720...58,279,767
Ensembl chr11:58,251,721...58,279,767

G

nuclear receptor binding protein 2

increases expression

EXP

Levofloxacin results in increased expression of NRBP2 mRNA

NCBI chr 7:109,679,330...109,685,656
Ensembl chr 7:109,679,330...109,685,588

G

nudix hydrolase 4

increases expression

EXP

Levofloxacin results in increased expression of NUDT4 mRNA

NCBI chr 7:32,074,978...32,091,491
Ensembl chr 7:32,075,002...32,091,491

G

nuclear protein 1, transcriptional regulator

increases expression

EXP

Levofloxacin results in increased expression of NUPR1 mRNA

NCBI chr 1:190,643,866...190,645,901
Ensembl chr 1:190,643,867...190,645,901

G

osteomodulin

increases expression

EXP

Levofloxacin results in increased expression of OMD mRNA

NCBI chr17:15,266,646...15,274,870
Ensembl chr17:15,266,646...15,274,870

G

oxysterol binding protein-like 1A

decreases expression

EXP

Levofloxacin results in decreased expression of OSBPL1A mRNA

NCBI chr18:4,178,734...4,383,511
Ensembl chr18:4,179,631...4,369,421

G

palmdelphin

decreases expression

EXP

Levofloxacin results in decreased expression of PALMD mRNA

NCBI chr 2:207,574,413...207,626,239
Ensembl chr 2:207,574,249...207,626,239

G

phenazine biosynthesis-like protein domain containing 1

increases expression

EXP

Levofloxacin results in increased expression of PBLD1 mRNA

NCBI chr20:25,549,974...25,565,390
Ensembl chr20:25,549,974...25,565,226

G

phosphotyrosine interaction domain containing 1

increases expression
decreases expression

EXP
ISO

Levofloxacin results in increased expression of PID1 mRNA
Levofloxacin results in decreased expression of PID1 mRNA

PMID:24136188 PMID:32816093

NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070

G

phosphatidylinositol glycan anchor biosynthesis, class U

increases expression

EXP

Levofloxacin results in increased expression of PIGU mRNA

NCBI chr 3:164,245,011...164,341,444
Ensembl chr 3:164,245,011...164,341,912

G

phospholipase A2, group XIIA

increases expression

EXP

Levofloxacin results in increased expression of PLA2G12A mRNA

NCBI chr 2:221,110,722...221,126,966
Ensembl chr 2:221,110,685...221,126,964

G

plasminogen receptor with a C-terminal lysine

decreases expression

EXP

Levofloxacin results in decreased expression of PLGRKT mRNA

NCBI chr 1:236,512,574...236,526,858
Ensembl chr 1:236,512,580...236,524,840

G

perilipin 3

decreases expression

EXP

Levofloxacin results in decreased expression of PLIN3 mRNA

NCBI chr 9:1,198,336...1,210,212
Ensembl chr 9:1,198,336...1,210,231

G

proteolipid protein 2

decreases expression

EXP

Levofloxacin results in decreased expression of PLP2 mRNA

NCBI chr X:17,506,153...17,509,552
Ensembl chr X:17,506,059...17,509,550

G

DNA polymerase gamma 2, accessory subunit

increases expression

EXP

Levofloxacin results in increased expression of POLG2 mRNA

NCBI chr10:92,212,303...92,222,849
Ensembl chr10:92,212,304...92,222,726

G

peroxisome proliferator activated receptor alpha

decreases expression

ISO

Levofloxacin results in decreased expression of PPARA mRNA

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

phosphopantothenoylcysteine synthetase

increases expression

EXP

Levofloxacin results in increased expression of PPCS mRNA

NCBI chr 5:138,308,394...138,312,047
Ensembl chr 5:138,308,397...138,312,012

G

peptidylprolyl isomerase F

decreases expression

EXP

Levofloxacin results in decreased expression of PPIF mRNA

NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954

G

protein phosphatase 1, regulatory (inhibitor) subunit 14A

decreases expression

EXP

Levofloxacin results in decreased expression of PPP1R14A mRNA

NCBI chr 1:93,708,269...93,718,218
Ensembl chr 1:93,708,218...93,719,147

G

protein kinase AMP-activated non-catalytic subunit gamma 2

decreases expression

EXP

Levofloxacin results in decreased expression of PRKAG2 mRNA

NCBI chr 4:10,744,695...10,985,939
Ensembl chr 4:10,744,588...10,985,939

G

proline and serine rich 2

increases expression

EXP

Levofloxacin results in increased expression of PROSER2 mRNA

NCBI chr17:77,061,371...77,096,788
Ensembl chr17:77,077,727...77,095,194

G

peroxiredoxin like 2B

increases expression

EXP

Levofloxacin results in increased expression of PRXL2B mRNA

NCBI chr 5:170,744,953...170,747,556
Ensembl chr 5:170,744,953...170,747,556

G

prostaglandin-endoperoxide synthase 2

decreases expression

ISO

Levofloxacin results in decreased expression of PTGS2 mRNA

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

PTTG1 regulator of sister chromatid separation, securin

decreases expression

EXP

Levofloxacin results in decreased expression of PTTG1 mRNA

NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309

G

Rap guanine nucleotide exchange factor 4

increases expression

EXP

Levofloxacin results in increased expression of RAPGEF4 mRNA

NCBI chr 3:77,217,024...77,509,933
Ensembl chr 3:77,217,039...77,509,978

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

[Levofloxacin co-treated with Lipopolysaccharides] affects the localization of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

reticulophagy regulator 1

increases expression

EXP

Levofloxacin results in increased expression of RETREG1 mRNA

NCBI chr 2:78,045,435...78,205,316
Ensembl chr 2:78,066,031...78,225,356

G

regulator of microtubule dynamics 2

decreases expression

EXP

Levofloxacin results in decreased expression of RMDN2 mRNA

NCBI chr 6:21,101,383...21,195,221
Ensembl chr 6:21,119,396...21,193,684

G

Rho family GTPase 2

increases expression

EXP

Levofloxacin results in increased expression of RND2 mRNA

NCBI chr10:86,899,395...86,902,992
Ensembl chr10:86,899,395...86,902,992

G

ring finger protein 4

decreases expression

EXP

Levofloxacin results in decreased expression of RNF4 mRNA

NCBI chr14:80,625,864...80,647,138
Ensembl chr14:80,625,866...80,647,148

G

arginyl aminopeptidase like 1

increases expression

EXP

Levofloxacin results in increased expression of RNPEPL1 mRNA

NCBI chr 9:100,921,053...100,933,748
Ensembl chr 9:100,923,856...100,933,485

G

replication protein A1

decreases expression

EXP

Levofloxacin results in decreased expression of RPA1 mRNA

NCBI chr10:60,647,185...60,698,279
Ensembl chr10:60,647,185...60,698,279

G

ribonucleotide reductase regulatory subunit M2

decreases expression

EXP

Levofloxacin results in decreased expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

arginine and serine rich protein 1

decreases expression

EXP

Levofloxacin results in decreased expression of RSRP1 mRNA

NCBI chr 5:152,431,448...152,435,202
Ensembl chr 5:152,431,478...152,435,126

G

retinoid X receptor alpha

increases expression

EXP

Levofloxacin results in increased expression of RXRA mRNA

NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417

G

sterol-C5-desaturase

increases expression

EXP

Levofloxacin results in increased expression of SC5D mRNA

NCBI chr 8:51,526,669...51,538,277
Ensembl chr 8:51,529,346...51,538,277

G

syndecan 4

increases expression

EXP

Levofloxacin results in increased expression of SDC4 mRNA

NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:173,574,239...173,593,670

G

serpin family A member 11

increases expression

EXP

Levofloxacin results in increased expression of SERPINA11 mRNA

NCBI chr 6:128,668,030...128,677,476
Ensembl chr 6:128,668,034...128,677,454

G

serpin family H member 1

decreases expression

EXP

Levofloxacin results in decreased expression of SERPINH1 mRNA

NCBI chr 1:163,055,630...163,063,177
Ensembl chr 1:163,055,630...163,062,976

G

sestrin 2

increases expression

EXP

Levofloxacin results in increased expression of SESN2 mRNA

NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255

G

splicing factor proline and glutamine rich

decreases expression

EXP

Levofloxacin results in decreased expression of SFPQ mRNA

NCBI chr 5:144,621,678...144,637,930
Ensembl chr 5:144,622,476...144,637,926

G

SH3-domain binding protein 5

increases expression

EXP

Levofloxacin results in increased expression of SH3BP5 mRNA

NCBI chr16:6,589,877...6,676,524
Ensembl chr16:6,589,877...6,655,211

G

solute carrier family 10 member 1

decreases activity

ISO

Levofloxacin results in decreased activity of SLC10A1 protein

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 13 member 3

increases expression

EXP

Levofloxacin results in increased expression of SLC13A3 mRNA

NCBI chr 3:174,561,174...174,623,893
Ensembl chr 3:174,561,168...174,623,895

G

solute carrier family 17 member 3

decreases expression

EXP

Levofloxacin results in decreased expression of SLC17A3 mRNA

NCBI chr17:41,698,679...41,729,057
Ensembl chr17:41,698,680...41,723,329

G

solute carrier family 38, member 2

increases expression

EXP

Levofloxacin results in increased expression of SLC38A2 mRNA

NCBI chr 7:129,730,450...129,742,619
Ensembl chr 7:129,730,450...129,742,619

G

solute carrier family 7 member 11

increases expression

ISO

Levofloxacin results in increased expression of SLC7A11 mRNA

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

solute carrier organic anion transporter family member 1B2

decreases activity

ISO

Levofloxacin results in decreased activity of SLCO1B3 protein

NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083

G

secretory leukocyte peptidase inhibitor

decreases expression

ISO

Levofloxacin results in decreased expression of SLPI mRNA

NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822

G

sperm autoantigenic protein 17

decreases expression

EXP

Levofloxacin results in decreased expression of SPA17 mRNA

NCBI chr 8:45,496,175...45,507,262
Ensembl chr 8:45,496,175...45,507,262

G

sulfiredoxin 1

decreases expression

EXP

Levofloxacin results in decreased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

SSX family member 2 interacting protein

decreases expression

EXP

Levofloxacin results in decreased expression of SSX2IP mRNA

NCBI chr 2:237,958,286...237,991,026
Ensembl chr 2:237,958,465...237,991,017

G

signal transducer and activator of transcription 3

increases expression

EXP

Levofloxacin results in increased expression of STAT3 mRNA

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

STEAP3 metalloreductase

decreases expression

EXP

Levofloxacin results in decreased expression of STEAP3 mRNA

NCBI chr13:33,904,710...33,950,100
Ensembl chr13:33,904,710...33,950,080

G

stathmin 1

decreases expression

EXP

Levofloxacin results in decreased expression of STMN1 mRNA

NCBI chr 5:151,964,308...151,970,843
Ensembl chr 5:151,964,351...151,970,842

G

sulfatase modifying factor 1

increases expression

EXP

Levofloxacin results in increased expression of SUMF1 mRNA

NCBI chr 4:142,634,766...142,716,726
Ensembl chr 4:142,634,767...142,716,712

G

synergin, gamma

increases expression

EXP

Levofloxacin results in increased expression of SYNRG mRNA

NCBI chr10:69,346,154...69,428,714
Ensembl chr10:69,322,114...69,428,714

G

synoviolin 1

increases expression

EXP

Levofloxacin results in increased expression of SYVN1 mRNA

NCBI chr 1:212,766,736...212,775,426
Ensembl chr 1:212,768,907...212,776,457

G

T-cell immune regulator 1, ATPase H+ transporting V0 subunit A3

decreases expression

EXP

Levofloxacin results in decreased expression of TCIRG1 mRNA

NCBI chr 1:210,556,270...210,568,021
Ensembl chr 1:210,556,270...210,568,033

G

TEF transcription factor, PAR bZIP family member

increases expression

EXP

Levofloxacin results in increased expression of TEF mRNA

NCBI chr 7:115,197,180...115,221,930
Ensembl chr 7:115,193,282...115,221,928

G

tight junction protein 2

decreases expression

EXP

Levofloxacin results in decreased expression of TJP2 mRNA

NCBI chr 1:231,136,218...231,264,750
Ensembl chr 1:231,136,243...231,264,750

G

transketolase

decreases expression

EXP

Levofloxacin results in decreased expression of TKT mRNA

NCBI chr16:5,729,381...5,755,170
Ensembl chr16:5,729,991...5,756,431

G

transmembrane protein 176B

increases expression

EXP

Levofloxacin results in increased expression of TMEM176B mRNA

NCBI chr 4:79,097,808...79,105,263
Ensembl chr 4:79,097,808...79,105,263

G

transmembrane protein 38B

increases expression

EXP

Levofloxacin results in increased expression of TMEM38B mRNA

NCBI chr 5:73,255,662...73,291,383
Ensembl chr 5:73,255,632...73,292,384

G

tumor necrosis factor

multiple interactions

ISO

[Levofloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Levofloxacin co-treated with TNF protein] results in increased expression of ICAM1 protein; [Levofloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 mRNA; [TNF protein co-treated with Levofloxacin] results in increased lipidation of MAP1LC3B protein; TNF protein promotes the reaction [Levofloxacin results in increased expression of MAP1LC3B protein]
[Levofloxacin co-treated with TNF protein] results in increased expression of BIRC2 mRNA; [Levofloxacin co-treated with TNF protein] results in increased expression of ICAM1 protein; [Levofloxacin co-treated with TNF protein] results in increased expression of NFKBIA mRNA; [Levofloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 mRNA

PMID:30876886 PMID:32035082 PMID:33609687

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF alpha induced protein 3

multiple interactions

ISO

[Levofloxacin co-treated with TNF protein] results in increased expression of TNFAIP3 mRNA

NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979

G

TNF alpha induced protein 6

decreases expression

ISO

Levofloxacin results in decreased expression of TNFAIP6 mRNA

NCBI chr 3:56,911,398...56,930,797
Ensembl chr 3:56,911,252...56,930,796

G

TNF receptor superfamily member 9

decreases expression

EXP

Levofloxacin results in decreased expression of TNFRSF9 mRNA

NCBI chr 5:166,664,494...166,690,834
Ensembl chr 5:166,664,494...166,690,831

G

transducer of ERBB2, 2

increases expression

EXP

Levofloxacin results in increased expression of TOB2 mRNA

NCBI chr 7:115,242,843...115,251,563
Ensembl chr 7:115,239,895...115,258,155

G

tropomyosin 3

decreases expression

EXP

Levofloxacin results in decreased expression of TPM3 mRNA

NCBI chr 2:177,812,534...177,842,661
Ensembl chr 2:177,814,883...177,842,660

G

TSC22 domain family, member 3

increases expression

EXP

Levofloxacin results in increased expression of TSC22D3 mRNA

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

thiosulfate sulfurtransferase like domain containing 3

decreases expression

EXP

Levofloxacin results in decreased expression of TSTD3 mRNA

NCBI chr 5:40,091,438...40,101,509
Ensembl chr 5:40,065,807...40,100,878

G

tubulin, alpha 1C

decreases expression

EXP

Levofloxacin results in decreased expression of TUBA1C mRNA

NCBI chr 7:131,636,974...132,078,589
Ensembl chr 7:132,070,536...132,079,311

G

tubulin, beta 4B class IVb

decreases expression

EXP

Levofloxacin results in decreased expression of TUBB4B mRNA

NCBI chr 3:28,435,999...28,438,455
Ensembl chr 3:28,435,148...28,439,719

G

tubulin, beta 5 class I

decreases expression

EXP

Levofloxacin results in decreased expression of TUBB5 mRNA

NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,917,539...2,921,726

G

tubulin, beta 6 class V

decreases expression

EXP

Levofloxacin results in decreased expression of TUBB6 mRNA

NCBI chr18:63,213,287...63,222,926
Ensembl chr18:63,213,279...63,224,303

G

UDP glucuronosyltransferase 1 family, polypeptide A2

decreases activity

ISO

Levofloxacin results in decreased activity of UGT1A3 protein

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 2 member B7

decreases activity

ISO

Levofloxacin results in decreased activity of UGT2B7 protein

NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451

G

ubiquitin specific peptidase 2

increases expression

EXP

Levofloxacin results in increased expression of USP2 mRNA

NCBI chr 8:53,308,264...53,336,800
Ensembl chr 8:53,308,303...53,336,794

G

vascular cell adhesion molecule 1

increases expression

EXP

Levofloxacin results in increased expression of VCAM1 mRNA

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vimentin

decreases expression

EXP

Levofloxacin results in decreased expression of VIM mRNA

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

vacuole membrane protein 1

increases expression

EXP

Levofloxacin results in increased expression of VMP1 mRNA

NCBI chr10:71,903,223...72,002,337
Ensembl chr10:71,903,227...72,002,319

G

WASP like actin nucleation promoting factor

increases expression

EXP

Levofloxacin results in increased expression of WASL mRNA

NCBI chr 4:54,049,081...54,097,653
Ensembl chr 4:54,049,082...54,097,570

G

WD repeat domain, phosphoinositide interacting 1

increases expression

EXP

Levofloxacin results in increased expression of WIPI1 mRNA

NCBI chr10:95,042,451...95,079,679
Ensembl chr10:95,042,441...95,079,293

G

exportin 1

decreases expression

EXP

Levofloxacin results in decreased expression of XPO1 mRNA

NCBI chr14:101,434,450...101,476,705
Ensembl chr14:101,434,517...101,476,714

G

zinc finger protein 354A

increases expression

EXP

Levofloxacin results in increased expression of ZFP354A mRNA

NCBI chr10:35,897,217...35,909,063
Ensembl chr10:35,897,228...35,909,510

G

zinc finger protein 446

increases expression

EXP

Levofloxacin results in increased expression of ZFP446 mRNA

NCBI chr 1:82,673,920...82,680,414
Ensembl chr 1:82,673,918...82,685,430

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

lomefloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

matrix metallopeptidase 2

increases expression
increases activity

EXP

lomefloxacin results in increased expression of MMP2 mRNA
lomefloxacin results in increased activity of MMP2 protein

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

increases expression
increases activity

EXP

lomefloxacin results in increased expression of MMP9 mRNA
lomefloxacin results in increased activity of MMP9 protein

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RT1 class II, locus DOb

affects expression

ISO

meropenem affects the expression of HLA-DOB mRNA

NCBI chr20:4,621,336...4,627,537
Ensembl chr20:4,619,694...4,627,523

G

RT1 class Ib, locus M3, gene 1

affects expression

ISO

Meropenem affects the expression of HLA-G mRNA

NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interferon gamma

decreases expression

ISO

moxifloxacin results in decreased expression of IFNG protein

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 1 beta

decreases secretion

ISO

moxifloxacin results in decreased secretion of IL1B protein

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 4

decreases expression

ISO

moxifloxacin results in decreased expression of IL4 protein

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

moxifloxacin results in decreased activity of KCNH2 protein

PMID:24052561 PMID:27553911

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

mitogen activated protein kinase 1

decreases phosphorylation

ISO

moxifloxacin results in decreased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation

ISO

moxifloxacin results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

matrix metallopeptidase 1

increases secretion
decreases secretion

ISO

Moxifloxacin results in increased secretion of MMP1 protein
Moxifloxacin results in decreased secretion of MMP1 protein

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 2

increases activity
increases expression

EXP

Moxifloxacin results in increased activity of MMP2 protein
Moxifloxacin results in increased expression of MMP2 mRNA

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 3

decreases secretion
increases secretion

ISO

Moxifloxacin results in decreased secretion of MMP3 protein
Moxifloxacin results in increased secretion of MMP3 protein

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826

G

matrix metallopeptidase 9

decreases secretion
increases activity
increases expression

ISO
EXP

Moxifloxacin results in decreased secretion of MMP9 protein
Moxifloxacin results in increased activity of MMP9 protein
Moxifloxacin results in increased expression of MMP9 mRNA

PMID:21058936 PMID:24890593

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

paraoxonase 1

decreases activity

ISO

Moxifloxacin results in decreased activity of PON1 protein

NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924

G

RELA proto-oncogene, NF-kB subunit

decreases expression

ISO

moxifloxacin results in decreased expression of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

tumor necrosis factor

decreases secretion

ISO

moxifloxacin results in decreased secretion of TNF protein

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

DNA topoisomerase I

multiple interactions

ISO

[moxifloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein

NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

ISO

UGT1A1 protein results in increased glucuronidation of moxifloxacin

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

ISO

UGT1A3 protein results in increased glucuronidation of moxifloxacin

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

ISO

UGT1A9 protein results in increased glucuronidation of moxifloxacin

NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

nadifloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity
multiple interactions

ISO

Nafcillin results in increased activity of CASP3 protein
[Nafcillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Nafcillin co-treated with IL1B protein] results in increased activity of CASP3 protein; [Nafcillin co-treated with IL6 protein] results in increased activity of CASP3 protein; [Nafcillin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Nafcillin results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

ISO

Nafcillin results in increased expression of CYP3A4 mRNA; Nafcillin results in increased expression of CYP3A4 protein

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

interleukin 1 beta

multiple interactions

ISO

[Nafcillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Nafcillin co-treated with IL1B protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Nafcillin results in increased activity of CASP3 protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

[Nafcillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Nafcillin co-treated with IL6 protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Nafcillin results in increased activity of CASP3 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

nuclear receptor subfamily 1, group I, member 2

increases activity

ISO

Nafcillin results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

tumor necrosis factor

multiple interactions

ISO

[Nafcillin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [Nafcillin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [Nafcillin results in increased activity of CASP3 protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 1 beta

multiple interactions

ISO

Nalidixic Acid inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

matrix metallopeptidase 13

multiple interactions
decreases expression

ISO

Nalidixic Acid inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]
Nalidixic Acid results in decreased expression of MMP13 mRNA

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

ISO

Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Nitrofurantoin results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 4

decreases activity

ISO

Nitrofurantoin results in decreased activity of ABCB4 protein

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily G member 2

affects transport
affects abundance
multiple interactions
increases secretion
increases transport
affects response to substance
increases export

ISO
EXP

ABCG2 protein affects the transport of Nitrofurantoin
ABCG2 protein affects the abundance of Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein affects the transport of Nitrofurantoin]; Elacridar inhibits the reaction [ABCG2 protein affects the transport of Nitrofurantoin]
ABCG2 protein results in increased secretion of Nitrofurantoin
ABCG2 protein results in increased transport of Nitrofurantoin
ABCG2 results in increased secretion of Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein results in increased transport of Nitrofurantoin]
ABCG2 affects the susceptibility to Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein results in increased transport of Nitrofurantoin]; Nitrofurantoin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]
ABCG2 protein results in increased export of Nitrofurantoin

PMID:15709111 PMID:15722455 PMID:17093006 PMID:17785426 PMID:18799806 More...

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

angiotensinogen

decreases activity

EXP

Nitrofurantoin results in decreased activity of AGT protein

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

aldolase, fructose-bisphosphate A

increases expression

EXP

Nitrofurantoin results in increased expression of ALDOA mRNA; Nitrofurantoin results in increased expression of ALDOA protein

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

catalase

decreases activity

ISO
EXP

Nitrofurantoin results in decreased activity of CAT protein

PMID:1313237 PMID:9000262

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

ciliary neurotrophic factor

multiple interactions

ISO

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]]

NCBI chr 1:219,312,512...219,314,535
Ensembl chr 1:219,312,512...219,314,488

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

ISO
EXP

Nitrofurantoin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO

Nitrofurantoin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
increases expression

ISO

NFE2L2 protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; POR protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutathione-disulfide reductase

decreases activity
multiple interactions

EXP
ISO

Nitrofurantoin results in decreased activity of GSR protein
[Nitrofurantoin co-treated with GSR protein] affects the metabolism of Glucose

PMID:1313237 PMID:1901343 PMID:9000262

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

hypoxia inducible factor 1 subunit alpha

increases activity

EXP

Nitrofurantoin results in increased activity of HIF1A protein

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

heme oxygenase 1

increases expression

EXP

Nitrofurantoin results in increased expression of HMOX1 mRNA

PMID:7626009 PMID:11841787

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heat shock transcription factor 1

increases activity

ISO

Nitrofurantoin results in increased activity of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

G

heat shock protein family A (Hsp70) member 8

increases expression

EXP

Nitrofurantoin results in increased expression of HSPA8 mRNA

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

EXP

Nitrofurantoin results in increased expression of JUN mRNA

PMID:7626009 PMID:11841787

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

LIM and cysteine-rich domains 1

increases expression

EXP

Nitrofurantoin results in increased expression of LMCD1 mRNA

NCBI chr 4:146,948,993...147,007,878
Ensembl chr 4:146,948,958...147,007,875

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO

NFE2L2 protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; Nitrofurantoin results in increased expression of and affects the localization of NFE2L2 protein; POR protein affects the reaction [Nitrofurantoin results in increased expression of NFE2L2 protein]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NAD(P)H quinone dehydrogenase 1

increases response to substance
affects reduction

ISO

NQO1 protein results in increased susceptibility to Nitrofurantoin
NQO1 protein affects the reduction of Nitrofurantoin

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

orosomucoid 1

increases expression

EXP

Nitrofurantoin results in increased expression of ORM1 mRNA; Nitrofurantoin results in increased expression of ORM1 protein

NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667

G

cytochrome p450 oxidoreductase

increases metabolic processing
multiple interactions
affects metabolic processing

ISO
EXP

POR protein results in increased metabolism of Nitrofurantoin
POR protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; POR protein affects the reaction [Nitrofurantoin results in increased expression of NFE2L2 protein]
diphenyleneiodonium inhibits the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; Nitrofurantoin inhibits the reaction [POR protein results in increased metabolism of Misonidazole]

PMID:6802140 PMID:18206659 PMID:34021431

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

signal transducer and activator of transcription 1

multiple interactions

ISO

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]]

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 3

multiple interactions
increases activity
increases expression

ISO
EXP

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]]
Nitrofurantoin results in increased activity of STAT3 protein
Nitrofurantoin results in increased expression of STAT3 mRNA

PMID:11841787 PMID:15748169

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

transforming growth factor, beta 2

increases expression

EXP

Nitrofurantoin results in increased expression of TGFB2 mRNA

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cyclin E1

multiple interactions
increases expression

EXP

Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of CCNE1 mRNA]

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

glycogen synthase kinase 3 beta

affects binding

EXP

Nitrofurazone binds to GSK3B protein

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

HRas proto-oncogene, GTPase

multiple interactions
increases expression

EXP

Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of HRAS mRNA]

NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590

G

interferon gamma

multiple interactions

ISO

[Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 1 beta

increases expression

ISO

Nitrofurazone results in increased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 2

multiple interactions

ISO

[Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

iodotyrosine deiodinase

multiple interactions

ISO

Nitrofurazone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:42,410,099...42,425,414
Ensembl chr 1:42,410,130...42,426,386

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

EXP

Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of JUN mRNA]

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

luteinizing hormone subunit beta

decreases expression

EXP

Nitrofurazone results in decreased expression of LHB protein

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

microRNA 128-1

increases expression

EXP

Nitrofurazone results in increased expression of MIR128-1 mRNA

NCBI chr13:42,251,884...42,251,965
Ensembl chr13:42,251,884...42,251,965

G

MYC proto-oncogene, bHLH transcription factor

increases expression
multiple interactions

EXP

Nitrofurazone results in increased expression of MYC mRNA
Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of MYC mRNA]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

cytochrome p450 oxidoreductase

multiple interactions

EXP

[Nitrofurazone co-treated with POR protein co-treated with Copper] results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; Nitrofurazone inhibits the reaction [POR protein results in increased metabolism of Misonidazole]

PMID:6802140 PMID:15488632

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

prolactin

decreases expression

EXP

Nitrofurazone results in decreased expression of PRL protein

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

transforming growth factor alpha

increases expression
multiple interactions

EXP

Nitrofurazone results in increased expression of TGFA mRNA
Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of TGFA mRNA]

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

tumor necrosis factor

multiple interactions
increases expression

EXP

Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of TNF mRNA]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tumor protein p53

increases mutagenesis

ISO

Nitrofurazone results in increased mutagenesis of TP53 gene

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis inducing factor, mitochondria associated 1

increases expression

ISO

Norfloxacin results in increased expression of AIFM1 protein

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237

G

BCL2-associated agonist of cell death

increases expression

ISO

Norfloxacin results in increased expression of BAD protein

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

Norfloxacin results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

decreases expression

ISO

Norfloxacin results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

caspase 2

affects activity

ISO

Norfloxacin affects the activity of CASP2 protein

NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:72,116,246...72,134,022

G

caspase 8

affects activity

ISO

Norfloxacin affects the activity of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects binding
multiple interactions

EXP

Norfloxacin binds to CYP1A2 protein
Norfloxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

interleukin 1 beta

multiple interactions

ISO
EXP

Norfloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Norfloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Norfloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Norfloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]
[biphenylylacetic acid co-treated with Norfloxacin] results in increased expression of IL1B mRNA; [biphenylylacetic acid co-treated with Norfloxacin] results in increased expression of IL1B protein

PMID:16148020 PMID:16824509

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

Norfloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

matrix metallopeptidase 1

multiple interactions

ISO

Norfloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Norfloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 13

multiple interactions
decreases expression

ISO

Norfloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Norfloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]
Norfloxacin results in decreased expression of MMP13 mRNA

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

matrix metallopeptidase 2

increases activity
increases expression

EXP

Norfloxacin results in increased activity of MMP2 protein
Norfloxacin results in increased expression of MMP2 mRNA

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

increases expression
increases activity

EXP

Norfloxacin results in increased expression of MMP9 mRNA
Norfloxacin results in increased activity of MMP9 protein

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

major histocompatibility complex, class I-related

affects expression

ISO

Norfloxacin affects the expression of MR1 mRNA

NCBI chr13:69,850,420...69,868,302
Ensembl chr13:69,850,420...69,868,502

G

solute carrier family 22 member 2

multiple interactions

ISO

Norfloxacin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

ISO

Ofloxacin results in decreased activity of ABCB11 protein
Ofloxacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

Rho GTPase activating protein 45

affects expression

ISO

Ofloxacin affects the expression of ARHGAP45 mRNA

NCBI chr 7:10,325,515...10,340,955
Ensembl chr 7:10,325,539...10,341,890

G

N-acylsphingosine amidohydrolase 1

increases expression

ISO

Ofloxacin results in increased expression of ASAH1 mRNA

NCBI chr16:57,669,927...57,701,349
Ensembl chr16:57,669,750...57,718,305

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO

[Ofloxacin co-treated with Clarithromycin] inhibits the reaction [CYP1A2 protein results in increased metabolism of Theophylline]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ISO

[Ofloxacin co-treated with Clarithromycin] inhibits the reaction [CYP3A4 protein results in increased metabolism of Theophylline]

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

DEPP autophagy regulator 1

increases expression

ISO

Ofloxacin results in increased expression of DEPP1 mRNA

NCBI chr 4:151,583,105...151,585,455
Ensembl chr 4:151,581,502...151,586,233

G

interleukin 1 beta

multiple interactions

ISO

Ofloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

insulin 1

increases expression

EXP

Ofloxacin results in increased expression of INS1 protein

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

integrin subunit beta 4

decreases expression

ISO

Ofloxacin results in decreased expression of ITGB4 protein

NCBI chr10:101,705,592...101,741,933
Ensembl chr10:101,705,587...101,741,932

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

Ofloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

matrix metallopeptidase 13

multiple interactions
decreases expression

ISO

Ofloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]
Ofloxacin results in decreased expression of MMP13 mRNA

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

matrix metallopeptidase 3

increases expression

EXP

Ofloxacin results in increased expression of MMP3 mRNA

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826

G

nuclear protein 1, transcriptional regulator

increases expression

ISO

Ofloxacin results in increased expression of NUPR1 mRNA

NCBI chr 1:190,643,866...190,645,901
Ensembl chr 1:190,643,867...190,645,901

G

phosphogluconate dehydrogenase

decreases activity

EXP

Ofloxacin results in decreased activity of PGD protein

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

phytanoyl-CoA 2-hydroxylase

decreases expression

ISO

Ofloxacin results in decreased expression of PHYH mRNA

NCBI chr17:78,238,747...78,255,645
Ensembl chr17:78,238,747...78,255,645

G

plasminogen activator, urokinase receptor

increases expression

EXP

Ofloxacin results in increased expression of PLAUR mRNA

NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130

G

prostaglandin-endoperoxide synthase 2

increases expression

EXP

Ofloxacin results in increased expression of PTGS2 mRNA

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RT1 class Ia, locus A2

affects expression

ISO

Ofloxacin affects the expression of HLA-E mRNA

NCBI chr20:4,872,720...4,876,425

G

solute carrier family 22 member 5

multiple interactions

ISO
EXP

Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]

NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077

G

solute carrier family 2 member 1

affects localization
decreases expression

ISO

Ofloxacin affects the localization of SLC2A1 mRNA
Ofloxacin results in decreased expression of SLC2A1 mRNA

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

TNF receptor superfamily member 12A

increases expression

EXP

Ofloxacin results in increased expression of TNFRSF12A mRNA

NCBI chr10:13,211,670...13,213,666
Ensembl chr10:13,211,673...13,213,704

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

ISO

UGT1A1 protein results in increased glucuronidation of Ofloxacin

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

ISO

UGT1A3 protein results in increased glucuronidation of Ofloxacin

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

ISO

UGT1A9 protein results in increased glucuronidation of Ofloxacin

NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

Pefloxacin metabolite results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

decreases expression

ISO

Pefloxacin metabolite results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

caspase 3

multiple interactions

ISO

Pefloxacin metabolite results in decreased cleavage of and results in increased expression of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

cytochrome c, somatic

increases secretion

ISO

Pefloxacin metabolite results in increased secretion of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

interleukin 6

decreases expression

ISO

Pefloxacin metabolite results in decreased expression of IL6 mRNA; Pefloxacin results in decreased expression of IL6 mRNA; Pefloxacin results in decreased expression of IL6 protein

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

potassium voltage-gated channel subfamily H member 2

affects binding

ISO

Pefloxacin binds to KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

nitric oxide synthase 2

decreases expression

ISO

Pefloxacin metabolite results in decreased expression of INOS mRNA

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

tumor necrosis factor

decreases expression

ISO

Pefloxacin metabolite results in decreased expression of TNF mRNA; Pefloxacin results in decreased expression of TNF mRNA; Pefloxacin results in decreased expression of TNF protein

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

phenoxymethylpenicillin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carboxylesterase 1D

increases expression

ISO

Penicillin V results in increased expression of CES1 mRNA

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

ISO

Penicillin V results in increased expression of CYP3A4 mRNA; Penicillin V results in increased expression of CYP3A4 protein

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

Penicillin V results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

microRNA 185

decreases expression

EXP

Penicillin V results in decreased expression of MIR185 mRNA

NCBI chr11:96,169,028...96,169,107
Ensembl chr11:96,169,028...96,169,107

G

microRNA 296

decreases expression

EXP

Penicillin V results in decreased expression of MIR296 mRNA

NCBI chr 3:183,470,069...183,470,146

G

microRNA 330

decreases expression

EXP

Penicillin V results in decreased expression of MIR330 mRNA

NCBI chr 1:87,961,207...87,961,303
Ensembl chr 1:87,961,207...87,961,303

G

microRNA 34c

decreases expression

EXP

Penicillin V results in decreased expression of MIR34C mRNA

NCBI chr 8:60,306,091...60,306,167

G

microRNA 433

decreases expression

EXP

Penicillin V results in decreased expression of MIR433 mRNA

NCBI chr 6:134,327,358...134,327,450
Ensembl chr 6:134,327,351...134,327,456

G

microRNA 434

decreases expression

EXP

Penicillin V results in decreased expression of MIR434 mRNA

NCBI chr 6:134,330,402...134,330,482

G

microRNA 484

decreases expression

EXP

Penicillin V results in decreased expression of MIR484 mRNA

NCBI chr10:1,394,905...1,394,981

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

Penicillin V results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

pirin

increases expression

ISO

Penicillin V results in increased expression of PIR mRNA

NCBI chr X:33,740,428...33,851,049
Ensembl chr X:33,740,429...33,851,049

G

tripartite motif-containing 16

increases expression

ISO

Penicillin V results in increased expression of TRIM16 mRNA

NCBI chr10:47,985,235...48,008,242
Ensembl chr10:47,958,677...48,051,136

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ISO

ABCC4 protein results in increased transport of Pipemidic Acid

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ISO

ABCC4 protein results in increased transport of Piperacillin

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity
multiple interactions

ISO

Piperacillin results in decreased activity of CYP2C8 protein
Piperacillin inhibits the reaction [CYP2C8 protein results in decreased methylation of Aminopyrine]

G

interferon gamma

increases secretion

ISO

Piperacillin results in increased secretion of IFNG protein

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 1 beta

multiple interactions

EXP

Ozone promotes the reaction [[tazobactam co-treated with Piperacillin] results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 22

increases secretion

ISO

Piperacillin results in increased secretion of IL22 protein

NCBI chr 7:55,687,061...55,691,526
Ensembl chr 7:55,686,896...55,692,201

G

microRNA 155

increases expression

ISO

Piperacillin results in increased expression of MIR155 mRNA

NCBI chr11:37,261,114...37,261,178
Ensembl chr11:37,261,114...37,261,178

G

microRNA 18a

increases expression

ISO

Piperacillin results in increased expression of MIR18A mRNA

NCBI chr15:98,587,984...98,588,079
Ensembl chr15:98,587,984...98,588,079

G

microRNA 21

increases expression

ISO

Piperacillin results in increased expression of MIR21 mRNA

NCBI chr10:71,902,600...71,902,691

G

major histocompatibility complex, class I-related

affects expression

ISO

Piperacillin affects the expression of MR1 mRNA

NCBI chr13:69,850,420...69,868,302
Ensembl chr13:69,850,420...69,868,502

G

RT1 class II, locus DMb

affects expression

ISO

Piperacillin affects the expression of HLA-DMB mRNA

NCBI chr20:4,695,009...4,702,560
Ensembl chr20:4,695,010...4,702,246

G

solute carrier family 25 member 20

multiple interactions

EXP

Piperacillin binds to and results in decreased activity of SLC25A20 protein; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

G

tumor necrosis factor

multiple interactions

EXP

Ozone promotes the reaction [[tazobactam co-treated with Piperacillin] results in increased expression of TNF mRNA]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects transport

EXP

ABCB1 protein affects the transport of prulifloxacin metabolite

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 2

affects transport

EXP

ABCC2 protein affects the transport of prulifloxacin metabolite

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

androgen receptor

affects localization
multiple interactions

ISO

prulifloxacin affects the localization of AR protein
prulifloxacin binds to and results in increased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

ISO

UGT1A1 protein results in increased glucuronidation of sitafloxacin

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

ISO

UGT1A3 protein results in increased glucuronidation of sitafloxacin

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

ISO

UGT1A9 protein results in increased glucuronidation of sitafloxacin

NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

matrix metallopeptidase 2

increases activity
increases expression

EXP

sparfloxacin results in increased activity of MMP2 protein
sparfloxacin results in increased expression of MMP2 mRNA

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

increases activity
increases expression

EXP

sparfloxacin results in increased activity of MMP9 protein
sparfloxacin results in increased expression of MMP9 mRNA

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ISO

ABCC4 protein results in increased transport of Sulbactam

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 1 beta

multiple interactions

EXP

Ozone promotes the reaction [[tazobactam co-treated with Piperacillin] results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

tumor necrosis factor

multiple interactions

EXP

Ozone promotes the reaction [[tazobactam co-treated with Piperacillin] results in increased expression of TNF mRNA]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alanyl-tRNA synthetase 1

decreases expression

ISO

trovafloxacin results in decreased expression of AARS1 mRNA

NCBI chr19:55,906,694...55,930,499
Ensembl chr19:55,906,702...55,930,497

G

alanyl-tRNA synthetase domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of AARSD1 mRNA

NCBI chr10:86,840,874...86,854,077
Ensembl chr10:86,840,874...86,849,734

G

apoptosis-associated tyrosine kinase

decreases expression

ISO

trovafloxacin results in decreased expression of AATK mRNA

NCBI chr10:105,789,171...105,825,634
Ensembl chr10:105,785,469...105,825,618

G

ATP binding cassette subfamily A member 2

decreases expression

ISO

trovafloxacin results in decreased expression of ABCA2 mRNA

NCBI chr 3:28,642,660...28,662,689
Ensembl chr 3:28,642,758...28,662,681

G

ATP binding cassette subfamily A member 5

decreases expression

ISO

trovafloxacin results in decreased expression of ABCA5 mRNA

NCBI chr10:95,739,610...95,808,633
Ensembl chr10:95,739,610...95,808,424

G

ATP binding cassette subfamily A member 7

decreases expression

ISO

trovafloxacin results in decreased expression of ABCA7 mRNA

NCBI chr 7:10,342,092...10,362,094
Ensembl chr 7:10,342,092...10,361,989

G

ATP binding cassette subfamily A member 8

decreases expression

ISO

trovafloxacin results in decreased expression of ABCA8B mRNA

NCBI chr10:95,416,984...95,490,647
Ensembl chr10:95,416,205...95,490,452

G

ATP binding cassette subfamily B member 7

decreases expression

ISO

trovafloxacin results in decreased expression of ABCB7 mRNA

NCBI chr X:73,361,296...73,502,464
Ensembl chr X:73,361,310...73,502,547

G

ATP binding cassette subfamily D member 2

decreases expression

ISO

trovafloxacin results in decreased expression of ABCD2 mRNA

NCBI chr 7:124,142,597...124,191,202
Ensembl chr 7:124,142,595...124,191,202

G

abhydrolase domain containing 15

decreases expression

ISO

trovafloxacin results in decreased expression of ABHD15 mRNA

NCBI chr10:62,861,335...62,866,726
Ensembl chr10:62,861,317...62,868,540

G

acetyl-CoA carboxylase alpha

decreases expression

EXP

trovafloxacin results in decreased expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 1

decreases expression

ISO

trovafloxacin results in decreased expression of ACAP1 mRNA

NCBI chr10:55,104,040...55,119,280
Ensembl chr10:55,104,040...55,118,185

G

atypical chemokine receptor 4

increases expression

ISO

trovafloxacin results in increased expression of ACKR4 mRNA

NCBI chr 8:113,595,325...113,599,762
Ensembl chr 8:113,595,293...113,602,372

G

acyl-CoA thioesterase 3

decreases expression

ISO

trovafloxacin results in decreased expression of ACOT3 mRNA

NCBI chr 6:109,413,617...109,419,840
Ensembl chr 6:109,413,534...109,421,427
Ensembl chr 6:109,413,534...109,421,427

G

acyl-CoA thioesterase 4

decreases expression

ISO

trovafloxacin results in decreased expression of ACOT4 mRNA

NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138

G

acrosin binding protein

increases expression

ISO

trovafloxacin results in increased expression of ACRBP mRNA

NCBI chr 4:159,537,395...159,550,454
Ensembl chr 4:159,537,391...159,550,454

G

acyl-CoA synthetase family member 2

decreases expression

EXP

trovafloxacin results in decreased expression of ACSF2 mRNA

NCBI chr10:80,001,389...80,043,796
Ensembl chr10:80,001,389...80,045,050

G

acyl-CoA synthetase family member 3

decreases expression

ISO

trovafloxacin results in decreased expression of ACSF3 mRNA

NCBI chr19:67,743,660...67,784,109
Ensembl chr19:67,743,490...67,784,084

G

acyl-CoA synthetase short-chain family member 1

decreases expression

ISO

trovafloxacin results in decreased expression of ACSS1 mRNA

NCBI chr 3:159,910,809...159,960,748
Ensembl chr 3:159,910,809...159,960,748

G

acyl-CoA synthetase short-chain family member 2

decreases expression

ISO

trovafloxacin results in decreased expression of ACSS2 mRNA

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830

G

actin, beta

decreases expression

EXP

trovafloxacin results in decreased expression of ACTB mRNA

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

actin, gamma 1

decreases expression

EXP

trovafloxacin results in decreased expression of ACTG1 mRNA

NCBI chr10:106,118,106...106,120,951
Ensembl chr10:106,118,108...106,120,951

G

actin related protein 3B

decreases expression

ISO

trovafloxacin results in decreased expression of ACTR3B mRNA

NCBI chr 4:9,995,553...10,089,422
Ensembl chr 4:9,996,155...10,089,553

G

activin A receptor like type 1

increases expression

ISO

trovafloxacin results in increased expression of ACVRL1 mRNA

NCBI chr 7:134,117,917...134,135,306
Ensembl chr 7:134,118,024...134,135,305

G

aminoacylase 1

decreases expression

EXP

trovafloxacin results in decreased expression of ACY1 mRNA

NCBI chr 8:115,951,068...115,956,471
Ensembl chr 8:115,951,068...115,956,405

G

ADAM metallopeptidase domain 1a

increases expression

ISO

trovafloxacin results in increased expression of ADAM1A mRNA

NCBI chr12:40,674,460...40,680,988
Ensembl chr12:40,676,918...40,684,619

G

ADAM metallopeptidase domain 22

increases expression

ISO

trovafloxacin results in increased expression of ADAM22 mRNA

NCBI chr 4:26,670,984...26,925,843
Ensembl chr 4:26,671,112...26,925,843

G

ADAM metallopeptidase domain 33

increases expression

ISO

trovafloxacin results in increased expression of ADAM33 mRNA

NCBI chr 3:138,715,428...138,736,392
Ensembl chr 3:138,724,046...138,736,347

G

ADAM metallopeptidase domain 3A

decreases expression

ISO

trovafloxacin results in decreased expression of ADAM3 mRNA

NCBI chr16:74,002,566...74,052,579
Ensembl chr16:74,002,410...74,052,578

G

ADAM metallopeptidase domain 8

increases expression

ISO

trovafloxacin results in increased expression of ADAM8 mRNA

NCBI chr 1:204,206,206...204,218,988
Ensembl chr 1:204,206,199...204,218,485

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

decreases expression

ISO

trovafloxacin results in decreased expression of ADAMTS4 mRNA

NCBI chr13:86,203,011...86,212,500
Ensembl chr13:86,202,642...86,212,514

G

ArfGAP with dual PH domains 2

increases expression
decreases expression

EXP
ISO

trovafloxacin results in increased expression of ADAP2 mRNA
trovafloxacin results in decreased expression of ADAP2 mRNA

PMID:24136188 PMID:35537566

NCBI chr10:65,635,891...65,665,019
Ensembl chr10:65,622,434...65,664,022

G

adducin 3

decreases expression

ISO

trovafloxacin results in decreased expression of ADD3 mRNA

NCBI chr 1:262,152,722...262,260,504
Ensembl chr 1:262,154,996...262,260,504

G

adhesion G protein-coupled receptor E4

increases expression

ISO

trovafloxacin results in increased expression of ADGRE4 mRNA

NCBI chr 9:10,085,258...10,240,346
Ensembl chr 9:10,085,352...10,240,229

G

adhesion G protein-coupled receptor L1

decreases expression

ISO

trovafloxacin results in decreased expression of ADGRL1 mRNA

NCBI chr19:41,107,162...41,148,752
Ensembl chr19:41,109,117...41,148,896

G

adhesion G protein-coupled receptor V1

decreases expression

ISO

trovafloxacin results in decreased expression of ADGRV1 mRNA

NCBI chr 2:13,067,149...13,647,407
Ensembl chr 2:13,067,150...13,647,372

G

alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide

decreases expression

ISO

trovafloxacin results in decreased expression of ADH7 mRNA

NCBI chr 2:229,422,125...229,436,584
Ensembl chr 2:229,421,252...229,436,691

G

adiponectin receptor 2

decreases expression

EXP

trovafloxacin results in decreased expression of ADIPOR2 mRNA

NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:154,172,567...154,231,666

G

adrenomedullin

decreases expression

ISO

trovafloxacin results in decreased expression of ADM mRNA

NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371

G

adrenoceptor alpha 1A

increases expression

ISO

trovafloxacin results in increased expression of ADRA1A mRNA

NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534

G

adrenoceptor beta 2

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ADRB2 mRNA

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

apoptosis enhancing nuclease

increases expression

ISO

trovafloxacin results in increased expression of AEN mRNA

NCBI chr 1:142,224,499...142,233,902
Ensembl chr 1:142,224,493...142,233,898

G

actin filament associated protein 1-like 1

decreases expression

ISO

trovafloxacin results in decreased expression of AFAP1L1 mRNA

NCBI chr18:57,454,120...57,514,584
Ensembl chr18:57,454,121...57,514,480

G

AGBL carboxypeptidase 3

decreases expression

ISO

trovafloxacin results in decreased expression of AGBL3 mRNA

NCBI chr 4:64,416,139...64,498,987
Ensembl chr 4:64,421,397...64,498,985

G

AGBL carboxypeptidase 5

decreases expression

ISO

trovafloxacin results in decreased expression of AGBL5 mRNA

NCBI chr 6:31,192,281...31,213,494
Ensembl chr 6:31,191,635...31,210,676

G

amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase

decreases expression

ISO

trovafloxacin results in decreased expression of AGL mRNA

NCBI chr 2:207,389,949...207,445,959
Ensembl chr 2:207,389,949...207,445,724

G

alkylglycerol monooxygenase

decreases expression

ISO

trovafloxacin results in decreased expression of AGMO mRNA

NCBI chr 6:59,713,495...60,044,851
Ensembl chr 6:59,713,467...60,044,854

G

ATP/GTP binding carboxypeptidase 1

decreases expression

ISO

trovafloxacin results in decreased expression of AGTPBP1 mRNA

NCBI chr17:5,092,108...5,244,414
Ensembl chr17:5,126,146...5,244,420

G

adenosylhomocysteinase-like 1

decreases expression

ISO

trovafloxacin results in decreased expression of AHCYL1 mRNA

NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:197,982,344...198,033,930

G

Abelson helper integration site 1

decreases expression

ISO

trovafloxacin results in decreased expression of AHI1 mRNA

NCBI chr 1:17,580,859...17,711,775
Ensembl chr 1:17,582,006...17,711,774

G

adenylate kinase 1

increases expression

ISO

trovafloxacin results in increased expression of AK1 mRNA

NCBI chr 3:36,310,113...36,320,760
Ensembl chr 3:36,310,197...36,320,757

G

adenylate kinase 6

increases expression

ISO

trovafloxacin results in increased expression of AK6 mRNA

NCBI chr 2:33,528,388...33,540,445
Ensembl chr 2:33,528,035...33,540,441
Ensembl chr20:33,528,035...33,540,441

G

A-kinase anchoring protein 7

decreases expression

ISO

trovafloxacin results in decreased expression of AKAP7 mRNA

NCBI chr 1:21,906,503...22,168,663
Ensembl chr 1:21,906,676...22,037,090

G

AT-hook transcription factor

decreases expression

ISO

trovafloxacin results in decreased expression of AKNA mRNA

NCBI chr 5:81,792,928...81,839,936
Ensembl chr 5:81,792,929...81,831,528

G

aldo-keto reductase family 1, member B7

decreases expression

ISO

trovafloxacin results in decreased expression of AKR1B7 mRNA

NCBI chr 4:64,043,901...64,083,751
Ensembl chr 4:64,020,686...64,064,909

G

aldo-keto reductase family 7 member A3

decreases expression

EXP

trovafloxacin results in decreased expression of AKR7A3 mRNA

NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

ISO

trovafloxacin results in increased phosphorylation of AKT1 protein
TNF protein promotes the reaction [trovafloxacin results in increased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 16 family, member A1

decreases expression

ISO

trovafloxacin results in decreased expression of ALDH16A1 mRNA

NCBI chr 1:104,763,200...104,776,270
Ensembl chr 1:104,763,055...104,776,270

G

aldehyde dehydrogenase 18 family, member A1

decreases expression

ISO

trovafloxacin results in decreased expression of ALDH18A1 mRNA

NCBI chr 1:249,325,082...249,357,383
Ensembl chr 1:249,325,082...249,357,383

G

aldehyde dehydrogenase 1 family, member A1

decreases expression

EXP

trovafloxacin results in decreased expression of ALDH1A1 mRNA

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

aldehyde dehydrogenase 1 family, member B1

decreases expression

EXP

trovafloxacin results in decreased expression of ALDH1B1 mRNA

NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365

G

aldehyde dehydrogenase 1 family, member L2

decreases expression

ISO

trovafloxacin results in decreased expression of ALDH1L2 mRNA

NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398

G

alkB homolog 4, lysine demethylase

increases expression

ISO

trovafloxacin results in increased expression of ALKBH4 mRNA

NCBI chr12:26,160,643...26,166,560
Ensembl chr12:26,160,643...26,166,560

G

ALMS1, centrosome and basal body associated protein

decreases expression

ISO

trovafloxacin results in decreased expression of ALMS1 mRNA

NCBI chr 4:119,683,085...119,783,471
Ensembl chr 4:119,683,076...119,783,471

G

alpha-methylacyl-CoA racemase

decreases expression

ISO

trovafloxacin results in decreased expression of AMACR mRNA

NCBI chr 2:61,673,291...61,685,381
Ensembl chr 2:61,670,475...61,685,379

G

adenosylmethionine decarboxylase 1

decreases expression

EXP

trovafloxacin results in decreased expression of AMD1 mRNA

NCBI chr20:45,250,289...45,324,939
Ensembl chr20:45,250,289...45,265,982

G

amidohydrolase domain containing 2

decreases expression

ISO

trovafloxacin results in decreased expression of AMDHD2 mRNA

NCBI chr10:13,692,136...13,700,632
Ensembl chr10:13,692,146...13,700,632

G

anti-Mullerian hormone

increases expression

ISO

trovafloxacin results in increased expression of AMH mRNA

NCBI chr 7:9,557,451...9,559,867
Ensembl chr 7:9,557,451...9,559,867

G

adhesion molecule with Ig like domain 3

increases expression

ISO

trovafloxacin results in increased expression of AMIGO3 mRNA

NCBI chr 8:117,620,499...117,622,025
Ensembl chr 8:117,616,629...117,626,577

G

AMMECR1 like

increases expression

EXP

trovafloxacin results in increased expression of AMMECR1L mRNA

NCBI chr18:23,661,649...23,685,391
Ensembl chr18:23,661,341...23,685,649

G

angiomotin-like 1

decreases expression

ISO

trovafloxacin results in decreased expression of AMOTL1 mRNA

NCBI chr 8:19,630,139...19,749,027
Ensembl chr 8:19,634,510...19,748,869

G

angiomotin like 2

decreases expression

ISO

trovafloxacin results in decreased expression of AMOTL2 mRNA

NCBI chr 8:112,182,060...112,198,032
Ensembl chr 8:112,181,863...112,198,030

G

archaelysin family metallopeptidase 1

decreases expression

ISO

trovafloxacin results in decreased expression of AMZ1 mRNA

NCBI chr12:19,000,448...19,038,625
Ensembl chr12:19,000,448...19,037,925

G

anaphase promoting complex subunit 1

decreases expression

ISO

trovafloxacin results in decreased expression of ANAPC1 mRNA

NCBI chr 3:136,303,350...136,383,464
Ensembl chr 3:136,303,413...136,383,464

G

anaphase-promoting complex subunit 5

decreases expression

ISO

trovafloxacin results in decreased expression of ANAPC5 mRNA

NCBI chr12:39,409,519...39,442,518
Ensembl chr12:39,385,399...39,442,762

G

angiogenin

decreases expression

ISO

trovafloxacin results in decreased expression of ANG mRNA

NCBI chr15:26,786,233...26,796,883
Ensembl chr15:26,786,065...26,801,106

G

angel homolog 1

decreases expression

ISO

trovafloxacin results in decreased expression of ANGEL1 mRNA

NCBI chr 6:112,080,074...112,117,178
Ensembl chr 6:112,080,075...112,113,453

G

angel homolog 2

decreases expression

ISO

trovafloxacin results in decreased expression of ANGEL2 mRNA

NCBI chr13:105,041,727...105,060,640
Ensembl chr13:105,041,728...105,060,640

G

angiopoietin-like 3

increases expression

ISO

trovafloxacin results in increased expression of ANGPTL3 mRNA

NCBI chr 5:118,818,494...118,825,531
Ensembl chr 5:118,818,499...118,826,444

G

angiopoietin-like 4

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ANGPTL4 mRNA

NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681

G

angiopoietin-like 6

decreases expression

ISO

trovafloxacin results in decreased expression of ANGPTL6 mRNA

NCBI chr 8:27,689,804...27,696,172
Ensembl chr 8:27,689,806...27,696,111

G

ankyrin repeat and LEM domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of ANKLE1 mRNA

NCBI chr16:18,109,865...18,116,999
Ensembl chr16:18,110,476...18,114,244

G

ankyrin repeat domain 23

increases expression

ISO

trovafloxacin results in increased expression of ANKRD23 mRNA

NCBI chr 9:46,269,107...46,274,578
Ensembl chr 9:46,269,107...46,274,510

G

ankyrin repeat domain 55

decreases expression

ISO

trovafloxacin results in decreased expression of ANKRD55 mRNA

NCBI chr 2:45,617,011...45,717,086
Ensembl chr 2:45,617,177...45,717,057

G

ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1

decreases expression

ISO

trovafloxacin results in decreased expression of ANKZF1 mRNA

NCBI chr 9:84,136,862...84,143,830
Ensembl chr 9:84,136,862...84,145,091

G

anillin, actin binding protein

decreases expression

ISO

trovafloxacin results in decreased expression of ANLN mRNA

NCBI chr 8:29,134,222...29,197,513
Ensembl chr 8:29,134,222...29,197,513

G

anoctamin 7

increases expression

ISO

trovafloxacin results in increased expression of ANO7 mRNA

NCBI chr 9:101,364,915...101,392,711
Ensembl chr 9:101,364,842...101,394,173

G

adenine nucleotide translocase lysine methyltransferase

decreases expression

ISO

trovafloxacin results in decreased expression of FAM173A mRNA

NCBI chr10:15,316,797...15,320,950
Ensembl chr10:15,316,772...15,318,656

G

ANTXR cell adhesion molecule 2

increases expression

ISO

trovafloxacin results in increased expression of ANTXR2 mRNA

NCBI chr14:11,845,774...11,986,166
Ensembl chr14:11,845,700...11,986,168

G

annexin A9

decreases expression

ISO

trovafloxacin results in decreased expression of ANXA9 mRNA

NCBI chr 2:185,562,174...185,572,560
Ensembl chr 2:185,562,174...185,572,560

G

adaptor related protein complex 1 subunit gamma 2

decreases expression

ISO

trovafloxacin results in decreased expression of AP1G2 mRNA

NCBI chr15:32,541,528...32,549,392
Ensembl chr15:32,541,528...32,549,280

G

adaptor related protein complex 1 subunit sigma 1

decreases expression

EXP

trovafloxacin results in decreased expression of AP1S1 mRNA

NCBI chr12:25,261,958...25,272,483
Ensembl chr12:25,262,036...25,272,483

G

adaptor related protein complex 5 subunit zeta 1

decreases expression

ISO

trovafloxacin results in decreased expression of AP5Z1 mRNA

NCBI chr12:17,207,315...17,222,975
Ensembl chr12:17,207,315...17,222,467

G

amyloid beta precursor protein binding family B member 3

increases expression

ISO

trovafloxacin results in increased expression of APBB3 mRNA

NCBI chr18:28,547,205...28,554,383
Ensembl chr18:28,547,205...28,554,383

G

APC regulator of WNT signaling pathway 2

increases expression

ISO

trovafloxacin results in increased expression of APC2 mRNA

NCBI chr 7:10,043,010...10,065,037
Ensembl chr 7:10,043,010...10,065,210

G

acylaminoacyl-peptide hydrolase

decreases expression

ISO

trovafloxacin results in decreased expression of APEH mRNA

NCBI chr 8:117,652,390...117,661,502
Ensembl chr 8:117,652,393...117,661,711

G

apurinic/apyrimidinic endodeoxyribonuclease 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of APEX1 mRNA

NCBI chr15:26,618,146...26,620,330
Ensembl chr15:26,618,224...26,620,329

G

apurinic/apyrimidinic endodeoxyribonuclease 2

increases expression

ISO

trovafloxacin results in increased expression of APEX2 mRNA

NCBI chr X:22,914,943...22,937,713
Ensembl chr X:22,914,944...22,936,011

G

apolipoprotein A5

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of APOA5 mRNA

NCBI chr 8:55,446,329...55,460,509
Ensembl chr 8:55,456,899...55,460,507

G

apolipoprotein E

increases expression

ISO

trovafloxacin results in increased expression of APOE mRNA

NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855

G

apolipoprotein N

increases expression

EXP

trovafloxacin results in increased expression of APON mRNA

NCBI chr 7:1,271,514...1,272,917
Ensembl chr 7:1,271,515...1,272,917

G

aquaporin 9

decreases expression

ISO

trovafloxacin results in decreased expression of AQP9 mRNA

NCBI chr 8:80,678,027...80,718,273
Ensembl chr 8:80,678,030...80,717,240

G

ADP-ribosylation factor 2

increases expression

ISO

trovafloxacin results in increased expression of ARF2 mRNA

NCBI chr10:89,367,843...89,389,644
Ensembl chr10:89,368,044...89,389,651

G

Rho GTPase activating protein 19

decreases expression

ISO

trovafloxacin results in decreased expression of ARHGAP19 mRNA

NCBI chr 1:250,519,703...250,566,705
Ensembl chr 1:250,530,214...250,580,190

G

Rho GTPase activating protein 24

decreases expression

EXP

trovafloxacin results in decreased expression of ARHGAP24 mRNA

NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950

G

Rho GTPase activating protein 26

decreases expression

ISO

trovafloxacin results in decreased expression of ARHGAP26 mRNA

NCBI chr18:30,702,602...31,489,047
Ensembl chr18:31,089,787...31,489,047

G

Rho GTPase activating protein 33

decreases expression

ISO

trovafloxacin results in decreased expression of ARHGAP33 mRNA

NCBI chr 1:94,903,566...94,917,074
Ensembl chr 1:94,902,922...94,917,684

G

Rho GTPase activating protein 6

decreases expression

ISO

trovafloxacin results in decreased expression of ARHGAP6 mRNA

NCBI chr X:28,525,912...29,062,344
Ensembl chr X:28,525,917...29,061,244

G

Rho guanine nucleotide exchange factor 17

decreases expression

ISO

trovafloxacin results in decreased expression of ARHGEF17 mRNA

NCBI chr 1:164,642,690...164,702,241
Ensembl chr 1:164,642,690...164,702,241

G

Rho guanine nucleotide exchange factor 3

decreases expression

ISO

trovafloxacin results in decreased expression of ARHGEF3 mRNA

NCBI chr16:2,308,311...2,588,634
Ensembl chr16:2,308,400...2,588,819

G

Rho guanine nucleotide exchange factor 39

decreases expression

ISO

trovafloxacin results in decreased expression of ARHGEF39 mRNA

NCBI chr 5:62,548,300...62,551,870
Ensembl chr 5:62,548,303...62,551,870

G

AT-rich interaction domain 5A

decreases expression

ISO

trovafloxacin results in decreased expression of ARID5A mRNA

NCBI chr 9:46,030,513...46,058,729
Ensembl chr 9:46,030,548...46,045,363

G

AT-rich interaction domain 5B

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ARID5B mRNA

NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686

G

ARF like GTPase 10

increases expression

ISO

trovafloxacin results in increased expression of ARL10 mRNA

NCBI chr17:10,035,320...10,043,732
Ensembl chr17:10,035,320...10,043,981

G

ARF like GTPase 11

decreases expression

ISO

trovafloxacin results in decreased expression of ARL11 mRNA

NCBI chr15:39,659,404...39,661,651
Ensembl chr15:39,656,050...39,664,105

G

ARF like GTPase 4C

decreases expression

ISO

trovafloxacin results in decreased expression of ARL4C mRNA

NCBI chr 9:96,748,075...96,751,510
Ensembl chr 9:96,745,069...96,752,772

G

ARF like GTPase 4D

increases expression

ISO

trovafloxacin results in increased expression of ARL4D mRNA

NCBI chr10:87,092,276...87,103,079
Ensembl chr10:87,077,523...87,106,199

G

ARF like GTPase 6 interacting protein 5

increases expression

ISO

trovafloxacin results in increased expression of ARL6IP5 mRNA

NCBI chr 4:131,365,320...131,395,311
Ensembl chr 4:131,367,289...131,400,130

G

armadillo repeat containing 2

decreases expression

ISO

trovafloxacin results in decreased expression of ARMC2 mRNA

NCBI chr20:46,976,442...47,083,888
Ensembl chr20:46,977,421...47,084,160

G

armadillo repeat containing 7

increases expression

ISO

trovafloxacin results in increased expression of ARMC7 mRNA

NCBI chr10:101,222,056...101,238,598
Ensembl chr10:101,222,067...101,238,597

G

acidic residue methyltransferase 1

decreases expression

EXP

trovafloxacin results in decreased expression of ARMT1 mRNA

NCBI chr 1:43,299,916...43,323,675
Ensembl chr 1:43,299,826...43,323,670

G

arrestin, beta 1

decreases expression

ISO

trovafloxacin results in decreased expression of ARRB1 mRNA

NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859

G

arylsulfatase A

decreases expression

ISO

trovafloxacin results in decreased expression of ARSA mRNA

NCBI chr 7:122,422,971...122,426,971
Ensembl chr 7:122,422,982...122,428,401

G

ARV1 homolog, fatty acid homeostasis modulator

increases expression

ISO

trovafloxacin results in increased expression of ARV1 mRNA

NCBI chr19:69,589,728...69,601,547
Ensembl chr19:69,589,328...69,601,537

G

ankyrin repeat and SOCS box-containing 10

decreases expression

ISO

trovafloxacin results in decreased expression of ASB10 mRNA

NCBI chr 4:11,522,531...11,531,946
Ensembl chr 4:11,522,887...11,531,505

G

ankyrin repeat and SOCS box-containing 6

increases expression

ISO

trovafloxacin results in increased expression of ASB6 mRNA

NCBI chr 3:34,508,390...34,513,033
Ensembl chr 3:34,508,140...34,513,033

G

anti-silencing function 1B histone chaperone

decreases expression

ISO

trovafloxacin results in decreased expression of ASF1B mRNA

NCBI chr19:41,085,786...41,100,352
Ensembl chr19:41,086,114...41,100,352

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

ISO

trovafloxacin results in decreased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

assembly factor for spindle microtubules

decreases expression

ISO

trovafloxacin results in decreased expression of ASPM mRNA

NCBI chr13:53,625,584...53,674,489
Ensembl chr13:53,625,584...53,674,489

G

ASPSCR1 tether for SLC2A4, UBX domain containing

decreases expression

ISO

trovafloxacin results in decreased expression of ASPSCR1 mRNA

NCBI chr10:106,450,600...106,488,231
Ensembl chr10:106,450,567...106,488,579

G

asparaginase and isoaspartyl peptidase 1

decreases expression

ISO

trovafloxacin results in decreased expression of ASRGL1 mRNA

NCBI chr 1:215,436,180...215,456,188
Ensembl chr 1:215,435,218...215,456,198

G

activating transcription factor 2

multiple interactions
increases phosphorylation

ISO

pyrazolanthrone inhibits the reaction [trovafloxacin results in increased phosphorylation of ATF2 protein]

NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745

G

activating transcription factor 4

decreases expression

ISO

trovafloxacin results in decreased expression of ATF4 mRNA

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

activating transcription factor 5

decreases expression

ISO

trovafloxacin results in decreased expression of ATF5 mRNA

NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:104,432,094...104,436,183

G

autophagy related 10

multiple interactions

ISO

[trovafloxacin co-treated with TNF protein] results in increased expression of ATG10 mRNA

NCBI chr 2:23,843,695...24,133,459
Ensembl chr 2:23,844,482...24,133,368

G

autophagy related 101

increases expression

ISO

trovafloxacin results in increased expression of ATG101 mRNA

NCBI chr 7:134,277,223...134,286,387
Ensembl chr 7:134,272,847...134,286,379

G

autophagy related 12

increases expression

ISO

trovafloxacin results in increased expression of ATG12 mRNA

PMID:33609687 PMID:35537566

NCBI chr18:41,638,841...41,649,311
Ensembl chr18:41,635,835...41,649,261

G

autophagy related 14

increases expression
multiple interactions

ISO

trovafloxacin results in increased expression of ATG14 mRNA
TNF protein inhibits the reaction [trovafloxacin results in increased expression of ATG14 mRNA]

NCBI chr15:23,275,457...23,306,817
Ensembl chr15:23,275,457...23,306,815

G

autophagy related 16-like 1

increases expression
multiple interactions

ISO

trovafloxacin results in increased expression of ATG16L1 mRNA
[trovafloxacin co-treated with TNF protein] results in increased expression of ATG16L1 mRNA

NCBI chr 9:95,869,839...95,905,354
Ensembl chr 9:95,869,865...95,905,357

G

autophagy related 16-like 2

decreases expression

ISO

trovafloxacin results in decreased expression of ATG16L2 mRNA

NCBI chr 1:165,100,946...165,123,307
Ensembl chr 1:165,102,936...165,115,473

G

autophagy related 2A

multiple interactions

ISO

[trovafloxacin co-treated with TNF protein] results in increased expression of ATG2A mRNA

NCBI chr 1:212,971,822...212,991,505
Ensembl chr 1:212,971,844...212,991,528

G

autophagy related 2B

increases expression

ISO

trovafloxacin results in increased expression of ATG2B mRNA

NCBI chr 6:130,286,979...130,357,109
Ensembl chr 6:130,286,986...130,357,109

G

autophagy related 3

increases expression
multiple interactions

ISO

trovafloxacin results in increased expression of ATG3 mRNA
[trovafloxacin co-treated with TNF protein] results in increased expression of ATG3 mRNA

NCBI chr11:69,130,948...69,159,280
Ensembl chr11:69,121,952...69,159,280

G

autophagy related 4A, cysteine peptidase

increases expression
multiple interactions

ISO

trovafloxacin results in increased expression of ATG4A mRNA
[trovafloxacin co-treated with TNF protein] results in increased expression of ATG4A mRNA

NCBI chr X:109,453,712...109,553,758
Ensembl chr X:109,453,689...109,553,760

G

autophagy related 4C, cysteine peptidase

multiple interactions

ISO

[trovafloxacin co-treated with TNF protein] results in decreased expression of ATG4C mRNA

NCBI chr 5:118,977,594...119,050,894
Ensembl chr 5:118,982,918...119,052,695

G

autophagy related 5

affects response to substance
increases expression
multiple interactions

ISO

ATG5 protein affects the susceptibility to trovafloxacin
trovafloxacin results in increased expression of ATG5 mRNA
ATG5 protein affects the reaction [trovafloxacin results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [trovafloxacin results in increased cleavage of PARP1 protein]; ATG5 protein affects the reaction [trovafloxacin results in increased phosphorylation of MAPK1 protein]; ATG5 protein affects the reaction [trovafloxacin results in increased phosphorylation of MAPK3 protein]; ATG5 protein affects the reaction [trovafloxacin results in increased phosphorylation of MAPK8 protein]; TNF protein inhibits the reaction [trovafloxacin results in increased expression of ATG5 mRNA]

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

autophagy related 9B

increases expression
multiple interactions

ISO

trovafloxacin results in increased expression of ATG9B mRNA
TNF protein promotes the reaction [trovafloxacin results in increased expression of ATG9B mRNA]; trovafloxacin promotes the reaction [TNF protein results in increased expression of ATG9B mRNA]

NCBI chr 4:11,678,548...11,686,097
Ensembl chr 4:11,678,299...11,686,079

G

ATM serine/threonine kinase

decreases expression

ISO

trovafloxacin results in decreased expression of ATM mRNA

NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629

G

atos homolog B

increases expression

ISO

trovafloxacin results in increased expression of ATOSB mRNA

NCBI chr 5:62,056,654...62,070,338
Ensembl chr 5:62,056,654...62,064,613

G

ATPase phospholipid transporting 11C

decreases expression

ISO

trovafloxacin results in decreased expression of ATP11C mRNA

NCBI chr X:143,600,763...143,788,407
Ensembl chr X:143,600,767...143,788,432

G

ATPase Na+/K+ transporting subunit alpha 3

decreases expression

ISO

trovafloxacin results in decreased expression of ATP1A3 mRNA

NCBI chr 1:89,700,645...89,729,782
Ensembl chr 1:89,700,649...89,729,825

G

ATP synthase membrane subunit c locus 3

increases expression

ISO

trovafloxacin results in increased expression of ATP5MC3 mRNA

NCBI chr 3:79,218,014...79,220,664
Ensembl chr 3:79,218,014...79,220,664

G

ATP synthase membrane subunit e

increases expression

ISO

trovafloxacin results in increased expression of ATP5ME mRNA

NCBI chr14:1,464,788...1,465,989
Ensembl chr14:1,464,800...1,465,988

G

ATP synthase membrane subunit K

increases expression

ISO

trovafloxacin results in increased expression of ATP5MK mRNA

NCBI chr 1:255,915,255...255,922,185
Ensembl chr 1:255,915,259...255,922,106
Ensembl chr10:255,915,259...255,922,106

G

ATPase, H+ transporting V0 subunit e2

decreases expression
increases expression

EXP
ISO

trovafloxacin results in decreased expression of ATP6V0E2 mRNA
trovafloxacin results in increased expression of ATP6V0E2 mRNA

PMID:24136188 PMID:35537566

NCBI chr 4:78,815,771...78,818,919
Ensembl chr 4:78,813,129...78,819,680

G

ATPase phospholipid transporting 8A1

decreases expression

ISO

trovafloxacin results in decreased expression of ATP8A1 mRNA

NCBI chr14:40,668,932...40,911,465
Ensembl chr14:40,731,846...40,911,463

G

ATR serine/threonine kinase

multiple interactions
decreases expression

ISO

4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of ATR protein]; 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine inhibits the reaction [trovafloxacin results in increased phosphorylation of ATR protein]; [trovafloxacin co-treated with TNF protein] results in increased phosphorylation of and results in increased activity of ATR protein; trovafloxacin results in increased phosphorylation of and results in increased activity of ATR protein; U 0126 inhibits the reaction [trovafloxacin results in increased activity of ATR protein]
trovafloxacin results in decreased expression of ATR mRNA

PMID:25748550 PMID:35537566

NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:105,306,305...105,403,718

G

attractin

increases expression

EXP

trovafloxacin results in increased expression of ATRN mRNA

NCBI chr 3:138,563,271...138,697,360
Ensembl chr 3:138,563,312...138,697,360

G

ataxin 7-like 3B

increases expression

ISO

trovafloxacin results in increased expression of ATXN7L3B mRNA

NCBI chr 7:50,208,666...50,212,190
Ensembl chr 7:50,208,676...50,212,190

G

aurora kinase A and ninein interacting protein

decreases expression

ISO

trovafloxacin results in decreased expression of AUNIP mRNA

NCBI chr 5:152,006,021...152,018,614
Ensembl chr 5:152,006,042...152,020,190

G

aurora kinase A

decreases expression

ISO

trovafloxacin results in decreased expression of AURKA mRNA

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

aurora kinase B

decreases expression

ISO

trovafloxacin results in decreased expression of AURKB mRNA

NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285

G

beta-2 microglobulin

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of B2M mRNA

NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356

G

beta-1,4-N-acetyl-galactosaminyl transferase 2

decreases expression

ISO

trovafloxacin results in decreased expression of B4GALNT2 mRNA

NCBI chr10:81,298,338...81,324,738
Ensembl chr10:81,299,421...81,382,557

G

BAR/IMD domain containing adaptor protein 2 like 1

decreases expression

ISO

trovafloxacin results in decreased expression of BAIAP2L1 mRNA

NCBI chr12:15,364,090...15,453,602
Ensembl chr12:15,364,109...15,453,605

G

BRCA1 associated RING domain 1

decreases expression

ISO

trovafloxacin results in decreased expression of BARD1 mRNA

NCBI chr 9:80,069,960...80,144,167
Ensembl chr 9:80,069,960...80,176,873

G

basic leucine zipper ATF-like transcription factor 2

increases expression

ISO

trovafloxacin results in increased expression of BATF2 mRNA

NCBI chr 1:212,897,076...212,905,740
Ensembl chr 1:212,875,148...212,905,831

G

Bardet-Biedl syndrome 9

increases expression

ISO

trovafloxacin results in increased expression of BBS9 mRNA

NCBI chr 8:29,288,846...29,713,889
Ensembl chr 8:29,289,997...29,713,880

G

BCAR3 adaptor protein, NSP family member

increases expression

ISO

trovafloxacin results in increased expression of BCAR3 mRNA

NCBI chr 2:213,209,907...213,323,305
Ensembl chr 2:213,209,893...213,323,302

G

branched chain amino acid transaminase 1

decreases expression

ISO

trovafloxacin results in decreased expression of BCAT1 mRNA

NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288

G

BCDIN3 domain containing RNA methyltransferase

decreases expression

ISO

trovafloxacin results in decreased expression of BCDIN3D mRNA

NCBI chr 7:132,484,404...132,488,998
Ensembl chr 7:132,484,431...132,488,998

G

beta-carotene oxygenase 2

decreases expression

ISO

trovafloxacin results in decreased expression of BCO2 mRNA

NCBI chr 8:59,778,571...59,803,597
Ensembl chr 8:59,778,575...59,799,168

G

3-hydroxybutyrate dehydrogenase 1

increases expression

ISO

trovafloxacin results in increased expression of BDH1 mRNA

NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636

G

3-hydroxybutyrate dehydrogenase 2

increases expression

ISO

trovafloxacin results in increased expression of BDH2 mRNA

NCBI chr 2:226,376,346...226,397,010
Ensembl chr 2:226,376,356...226,397,006

G

BEN domain containing 6

decreases expression

ISO

trovafloxacin results in decreased expression of BEND6 mRNA

NCBI chr 9:43,576,982...43,631,437
Ensembl chr 9:43,576,982...43,631,194

G

Bet1 golgi vesicular membrane trafficking protein-like

increases expression

ISO

trovafloxacin results in increased expression of BET1L mRNA

NCBI chr 1:205,361,041...205,365,036
Ensembl chr 1:205,361,041...205,364,706

G

basic helix-loop-helix family, member e40

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BHLHE40 mRNA

NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783

G

baculoviral IAP repeat-containing 2

multiple interactions
decreases expression

ISO

trovafloxacin inhibits the reaction [TNF protein results in increased expression of BIRC2 mRNA]
trovafloxacin results in decreased expression of BIRC2 protein
[trovafloxacin co-treated with TNF protein] results in decreased expression of BIRC2 mRNA
trovafloxacin results in decreased expression of BIRC2 mRNA

NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911

G

baculoviral IAP repeat-containing 3

multiple interactions
decreases expression

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BIRC3 mRNA
[trovafloxacin co-treated with TNF protein] results in increased expression of BIRC3 mRNA
trovafloxacin results in decreased expression of BIRC3 mRNA

PMID:18930950 PMID:32035082

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

baculoviral IAP repeat-containing 5

decreases expression

ISO

trovafloxacin results in decreased expression of BIRC5 mRNA

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

BLM RecQ like helicase

decreases expression

ISO

trovafloxacin results in decreased expression of BLM mRNA

NCBI chr 1:143,819,072...143,905,300
Ensembl chr 1:143,819,090...143,905,210

G

biogenesis of lysosomal organelles complex-1, subunit 2

increases expression

ISO

trovafloxacin results in increased expression of BLOC1S2 mRNA

NCBI chr 1:252,973,818...252,980,873
Ensembl chr 1:252,973,202...252,980,873

G

basic leucine zipper nuclear factor 1

increases expression

ISO

trovafloxacin results in increased expression of BLZF1 mRNA

NCBI chr13:79,174,898...79,190,116
Ensembl chr13:79,174,902...79,190,116

G

Bcl2 modifying factor

decreases expression

ISO

trovafloxacin results in decreased expression of BMF mRNA

NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258

G

BCL2 family apoptosis regulator BOK

decreases expression

ISO

trovafloxacin results in decreased expression of BOK mRNA

NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833

G

bora, aurora kinase A activator

decreases expression

ISO

trovafloxacin results in decreased expression of BORA mRNA

NCBI chr15:82,205,467...82,243,499
Ensembl chr15:82,205,697...82,244,052

G

BLOC-1 related complex subunit 5

decreases expression

ISO

trovafloxacin results in decreased expression of BORCS5 mRNA

NCBI chr 4:169,190,025...169,272,335
Ensembl chr 4:169,204,528...169,271,819

G

biphenyl hydrolase like

decreases expression

ISO

trovafloxacin results in decreased expression of BPHL mRNA

NCBI chr17:31,006,283...31,042,631
Ensembl chr17:31,004,972...31,042,632

G

3'(2'), 5'-bisphosphate nucleotidase 1

decreases expression

EXP

trovafloxacin results in decreased expression of BPNT1 mRNA

NCBI chr13:99,397,127...99,425,056
Ensembl chr13:99,400,115...99,425,053

G

BRCA1, DNA repair associated

decreases expression

ISO

trovafloxacin results in decreased expression of BRCA1 mRNA

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763

G

BRCA2, DNA repair associated

decreases expression

ISO

trovafloxacin results in decreased expression of BRCA2 mRNA

NCBI chr12:4,895,092...4,939,340
Ensembl chr12:4,895,447...4,936,194

G

bromodomain containing 2

increases expression

ISO

trovafloxacin results in increased expression of BRD2 mRNA

NCBI chr20:4,728,282...4,737,286
Ensembl chr20:4,728,951...4,737,290

G

bromodomain testis associated

decreases expression

ISO

trovafloxacin results in decreased expression of BRDT mRNA

NCBI chr14:2,532,275...2,590,780
Ensembl chr14:2,532,275...2,590,760

G

BRCA1 interacting DNA helicase 1

decreases expression

ISO

trovafloxacin results in decreased expression of BRIP1 mRNA

NCBI chr10:71,402,035...71,528,083
Ensembl chr10:71,401,151...71,575,206

G

BSD domain containing 1

increases expression

ISO

trovafloxacin results in increased expression of BSDC1 mRNA

NCBI chr 5:147,083,044...147,113,997
Ensembl chr 5:147,079,838...147,114,241

G

bone marrow stromal cell antigen 2

decreases expression
increases expression

EXP
ISO

trovafloxacin results in decreased expression of BST2 mRNA
trovafloxacin results in increased expression of BST2 mRNA

PMID:24136188 PMID:35537566

NCBI chr16:18,250,593...18,254,967
Ensembl chr16:18,251,847...18,254,967

G

BUB1 mitotic checkpoint serine/threonine kinase

decreases expression

ISO

trovafloxacin results in decreased expression of BUB1 mRNA

NCBI chr 3:135,473,525...135,504,921
Ensembl chr 3:135,472,582...135,504,921

G

BUB1 mitotic checkpoint serine/threonine kinase B

decreases expression

ISO

trovafloxacin results in decreased expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

similar to human chromosome 21 open reading frame 91

decreases expression

ISO

trovafloxacin results in decreased expression of D16ERTD472E mRNA

NCBI chr11:30,716,034...30,749,292
Ensembl chr11:30,716,034...30,749,415

G

C1D nuclear receptor corepressor

increases expression

ISO

trovafloxacin results in increased expression of C1D mRNA

NCBI chr14:95,862,550...95,874,796
Ensembl chr14:95,861,978...95,874,796

G

C1q and TNF related 12

increases expression

ISO

trovafloxacin results in increased expression of FAM132A mRNA

NCBI chr 5:171,833,854...171,838,229
Ensembl chr 5:171,833,854...171,838,800

G

C1q and TNF related 6

decreases expression

ISO

trovafloxacin results in decreased expression of C1QTNF6 mRNA

NCBI chr 7:111,958,348...111,964,948
Ensembl chr 7:111,958,350...111,966,871

G

complement C1r subcomponent like

decreases expression

ISO

trovafloxacin results in decreased expression of C1RL mRNA

NCBI chr 4:159,080,495...159,097,066
Ensembl chr 4:159,080,495...159,097,066

G

C2 calcium-dependent domain containing 5

decreases expression

ISO

trovafloxacin results in decreased expression of C2CD5 mRNA

NCBI chr 4:177,700,515...177,790,576
Ensembl chr 4:177,700,516...177,786,717

G

similar to human chromosome 4 open reading frame 33

decreases expression

ISO

trovafloxacin results in decreased expression of D3ERTD751E mRNA

NCBI chr 2:126,692,176...126,769,183
Ensembl chr 2:126,697,854...126,746,878

G

similar to human chromosome 1 open reading frame 50

increases expression

EXP

trovafloxacin results in increased expression of C5H1ORF50 mRNA

NCBI chr 5:138,122,595...138,126,973
Ensembl chr 5:138,122,236...138,127,240

G

complement C5 like 1

increases expression

EXP

trovafloxacin results in increased expression of C5L1 mRNA

NCBI chr 3:38,799,165...38,818,443
Ensembl chr 3:38,799,731...38,817,527

G

similar to human chromosome 11 open reading frame 54

decreases expression

EXP

trovafloxacin results in decreased expression of C8H11ORF54 mRNA

NCBI chr 8:20,405,240...20,427,811
Ensembl chr 8:20,405,241...20,427,811

G

carbonic anhydrase 12

decreases expression

ISO

trovafloxacin results in decreased expression of CAR12 mRNA

NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:76,169,815...76,225,465

G

calcium voltage-gated channel subunit alpha1 D

decreases expression

ISO

trovafloxacin results in decreased expression of CACNA1D mRNA

NCBI chr16:5,233,682...5,527,549
Ensembl chr16:5,233,690...5,674,692

G

carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase

decreases expression

ISO

trovafloxacin results in decreased expression of CAD mRNA

NCBI chr 6:31,012,091...31,035,098
Ensembl chr 6:31,012,091...31,035,297

G

calcium homeostasis modulator family member 2

decreases expression

ISO

trovafloxacin results in decreased expression of CALHM2 mRNA

NCBI chr 1:255,963,661...255,969,387
Ensembl chr 1:255,963,663...255,969,387

G

calcium homeostasis modulator family member 6

decreases expression

ISO

trovafloxacin results in decreased expression of FAM26F mRNA

NCBI chr20:26,638,721...26,640,466
Ensembl chr20:26,638,722...26,640,408

G

calcium/calmodulin-dependent protein kinase kinase 2

decreases expression

ISO

trovafloxacin results in decreased expression of CAMKK2 mRNA

NCBI chr12:39,451,828...39,505,719
Ensembl chr12:39,451,834...39,514,964

G

calmodulin regulated spectrin-associated protein family, member 3

increases expression

ISO

trovafloxacin results in increased expression of CAMSAP3 mRNA

NCBI chr12:6,440,959...6,464,582
Ensembl chr12:6,441,152...6,464,582

G

cell cycle associated protein 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CAPRIN1 mRNA

NCBI chr 3:110,606,489...110,685,408
Ensembl chr 3:110,606,489...110,685,562

G

carbonic anhydrase 7

decreases expression

ISO

trovafloxacin results in decreased expression of CAR7 mRNA

NCBI chr19:435,520...444,927
Ensembl chr19:435,522...452,384

G

caspase recruitment domain family, member 11

decreases expression

ISO

trovafloxacin results in decreased expression of CARD11 mRNA

NCBI chr12:18,735,088...18,872,045
Ensembl chr12:18,735,088...18,872,045

G

capping protein regulator and myosin 1 linker 2

increases expression

ISO

trovafloxacin results in increased expression of RLTPR mRNA

NCBI chr19:50,481,911...50,496,672
Ensembl chr19:50,484,324...50,496,669

G

cysteinyl-tRNA synthetase 1

decreases expression

ISO

trovafloxacin results in decreased expression of CARS1 mRNA

NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407

G

CAS1 domain containing 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASD1 mRNA

NCBI chr 4:33,613,805...33,705,821
Ensembl chr 4:33,613,450...33,705,821

G

caspase 3

multiple interactions
increases activity
increases cleavage

ISO

[TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [trovafloxacin results in increased activity of CASP3 protein]; [TNF protein co-treated with trovafloxacin] results in increased activity of CASP3 protein; [trovafloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL1B protein] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL6 protein] results in increased activity of CASP3 protein; [trovafloxacin co-treated with TNF protein] results in increased activity of CASP3 protein; ATG5 protein affects the reaction [trovafloxacin results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [[TNF protein co-treated with trovafloxacin] results in increased activity of CASP3 protein]
[TNF protein co-treated with trovafloxacin] results in increased cleavage of CASP3 protein

PMID:19638433 PMID:24097668 PMID:25748550 PMID:30876886 PMID:33609687

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 6

increases expression

EXP

trovafloxacin results in increased expression of CASP6 mRNA

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

caspase 7

decreases expression

EXP

trovafloxacin results in decreased expression of CASP7 mRNA

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

multiple interactions

ISO

[trovafloxacin co-treated with TNF protein] results in increased activity of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

multiple interactions

ISO

[trovafloxacin co-treated with TNF protein] results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

caveolin 1

increases expression

ISO

trovafloxacin results in increased expression of CAV1 mRNA

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

CBFA2/RUNX1 partner transcriptional co-repressor 3

decreases expression

ISO

trovafloxacin results in decreased expression of CBFA2T3 mRNA

NCBI chr19:67,584,319...67,658,533
Ensembl chr19:67,589,258...67,658,136

G

cystathionine beta synthase

decreases expression

ISO

trovafloxacin results in decreased expression of CBS mRNA

NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,709,395...9,734,066

G

coiled-coil and C2 domain containing 1B

decreases expression

ISO

trovafloxacin results in decreased expression of CC2D1B mRNA

NCBI chr 5:128,581,962...128,596,045
Ensembl chr 5:128,581,994...128,596,022

G

coiled-coil and C2 domain containing 2A

decreases expression

ISO

trovafloxacin results in decreased expression of CC2D2A mRNA

NCBI chr14:71,563,835...71,648,352
Ensembl chr14:71,563,835...71,648,331

G

coiled-coil domain containing 137

increases expression

ISO

trovafloxacin results in increased expression of CCDC137 mRNA

NCBI chr10:106,229,099...106,235,502
Ensembl chr10:106,229,099...106,235,502

G

coiled-coil domain containing 15

decreases expression

ISO

trovafloxacin results in decreased expression of CCDC15 mRNA

NCBI chr 8:45,165,297...45,257,641
Ensembl chr 8:45,134,596...45,277,989

G

coiled-coil domain containing 163

decreases expression

ISO

trovafloxacin results in decreased expression of CCDC163 mRNA

NCBI chr 5:135,408,981...135,415,574
Ensembl chr 5:135,409,003...135,415,577

G

coiled-coil domain containing 18

decreases expression

ISO

trovafloxacin results in decreased expression of CCDC18 mRNA

NCBI chr14:1,646,725...1,752,581
Ensembl chr14:1,646,809...1,750,470

G

coiled-coil domain containing 181

decreases expression

ISO

trovafloxacin results in decreased expression of CCDC181 mRNA

NCBI chr13:79,157,708...79,171,365
Ensembl chr13:79,157,697...79,171,364

G

coiled-coil domain containing 34

decreases expression

ISO

trovafloxacin results in decreased expression of CCDC34 mRNA

NCBI chr 3:117,007,652...117,042,885
Ensembl chr 3:117,005,760...117,042,226

G

coiled-coil domain containing 6

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCDC6 mRNA

NCBI chr20:18,431,243...18,527,227
Ensembl chr20:18,431,243...18,527,227

G

coiled-coil domain containing 62

decreases expression

ISO

trovafloxacin results in decreased expression of CCDC62 mRNA

NCBI chr12:38,284,089...38,320,828
Ensembl chr12:38,284,089...38,320,965

G

coiled-coil domain containing 74A

increases expression

ISO

trovafloxacin results in increased expression of CCDC74A mRNA

NCBI chr11:96,860,161...96,864,540
Ensembl chr11:96,860,161...96,864,540

G

coiled-coil domain containing 86

increases expression

ISO

trovafloxacin results in increased expression of CCDC86 mRNA

NCBI chr 1:217,015,059...217,021,439
Ensembl chr 1:217,014,848...217,021,468

G

coiled-coil domain containing 91

decreases expression

ISO

trovafloxacin results in decreased expression of CCDC91 mRNA

NCBI chr 4:182,132,931...182,304,948
Ensembl chr 4:182,132,942...182,304,948

G

C-C motif chemokine ligand 2

multiple interactions

ISO

trovafloxacin promotes the reaction [TNF protein results in increased expression of CCL2 protein]

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 22

increases expression

ISO

trovafloxacin results in increased expression of CCL22 mRNA

NCBI chr19:10,263,589...10,270,359
Ensembl chr19:10,263,589...10,270,359

G

C-C motif chemokine ligand 3

increases expression

ISO

trovafloxacin results in increased expression of CCL3 mRNA

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

trovafloxacin results in increased expression of CCL4 mRNA

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

cyclin A2

decreases expression

ISO

trovafloxacin results in decreased expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

decreases expression

ISO

trovafloxacin results in decreased expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin B2

decreases expression

EXP
ISO

trovafloxacin results in decreased expression of CCNB2 mRNA

PMID:24136188 PMID:35537566

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682

G

cyclin D1

decreases expression
increases expression

EXP
ISO

trovafloxacin results in decreased expression of CCND1 mRNA
trovafloxacin results in increased expression of CCND1 mRNA

PMID:24136188 PMID:35537566

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin G2

decreases expression

ISO

trovafloxacin results in decreased expression of CCNG2 mRNA

NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206

G

cyclin J

increases expression

ISO

trovafloxacin results in increased expression of CCNJ mRNA

NCBI chr 1:249,608,991...249,626,798
Ensembl chr 1:249,608,969...249,626,794

G

cyclin L1

increases expression

ISO

trovafloxacin results in increased expression of CCNL1 mRNA

NCBI chr 2:152,495,169...152,508,855
Ensembl chr 2:152,495,172...152,507,468

G

C-C motif chemokine receptor 10

increases expression

ISO

trovafloxacin results in increased expression of CCR10 mRNA

NCBI chr10:86,608,836...86,611,273
Ensembl chr10:86,608,836...86,611,273

G

centriole, cilia and spindle-associated protein

decreases expression

ISO

trovafloxacin results in decreased expression of CCSAP mRNA

NCBI chr19:68,722,417...68,740,908

G

CD101 molecule

decreases expression

ISO

trovafloxacin results in decreased expression of CD101 mRNA

NCBI chr 2:191,109,782...191,148,184
Ensembl chr 2:191,110,637...191,148,149

G

CD109 molecule

decreases expression

ISO

trovafloxacin results in decreased expression of CD109 mRNA

NCBI chr 8:88,334,736...88,449,463
Ensembl chr 8:88,334,736...88,449,462

G

CD200 receptor 1-like

decreases expression

ISO

trovafloxacin results in decreased expression of CD200R4 mRNA

NCBI chr11:69,348,638...69,366,916
Ensembl chr11:69,312,691...69,365,041

G

CD207 molecule

increases expression

ISO

trovafloxacin results in increased expression of CD207 mRNA

NCBI chr 4:117,712,879...117,719,191
Ensembl chr 4:117,712,879...117,719,191

G

CD24 molecule

decreases expression

ISO

trovafloxacin results in decreased expression of CD24A mRNA

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785

G

CD244 molecule

decreases expression

ISO

trovafloxacin results in decreased expression of CD244 mRNA

NCBI chr13:86,583,727...86,606,902
Ensembl chr13:86,584,826...86,616,009

G

CD27 molecule

decreases expression

ISO

trovafloxacin results in decreased expression of CD27 mRNA

NCBI chr 4:159,716,932...159,721,823
Ensembl chr 4:159,716,935...159,721,823

G

CD300 molecule-like family member b

increases expression

ISO

trovafloxacin results in increased expression of CD300LB mRNA

NCBI chr10:100,463,815...100,473,804
Ensembl chr10:100,463,815...100,473,804

G

CD33 molecule

decreases expression

ISO

trovafloxacin results in decreased expression of CD33 mRNA

NCBI chr 1:103,071,985...103,086,687
Ensembl chr 1:103,072,375...103,086,291

G

CD36 molecule

decreases expression

EXP

trovafloxacin results in decreased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142

G

Cd5 molecule

decreases expression

ISO

trovafloxacin results in decreased expression of CD5 mRNA

NCBI chr 1:216,790,245...216,811,209
Ensembl chr 1:216,790,245...216,811,209

G

Cd80 molecule

increases expression

ISO

trovafloxacin results in increased expression of CD80 mRNA

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

CD86 molecule

decreases expression

ISO

trovafloxacin results in decreased expression of CD86 mRNA

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

CD8 subunit beta

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CD8B mRNA

NCBI chr 4:104,870,911...104,886,838
Ensembl chr 4:104,870,893...104,886,868

G

cell division cycle 20

decreases expression

EXP
ISO

trovafloxacin results in decreased expression of CDC20 mRNA

PMID:24136188 PMID:35537566

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

cell division cycle 25B

decreases expression

ISO

trovafloxacin results in decreased expression of CDC25B mRNA

NCBI chr 3:138,860,148...138,870,287
Ensembl chr 3:138,860,130...138,870,492

G

cell division cycle 25C

decreases expression

ISO

trovafloxacin results in decreased expression of CDC25C mRNA

NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292

G

cell division cycle 26

increases expression

ISO

trovafloxacin results in increased expression of CDC26 mRNA

NCBI chr 5:80,861,658...80,875,326
Ensembl chr 5:80,861,659...80,875,326

G

cell division cycle 34, ubiquitin conjugating enzyme

increases expression

ISO

trovafloxacin results in increased expression of CDC34 mRNA

NCBI chr 7:10,668,209...10,674,206
Ensembl chr 7:10,668,210...10,674,526

G

CDC42 effector protein 4

increases expression

EXP

trovafloxacin results in increased expression of CDC42EP4 mRNA

NCBI chr10:99,271,750...99,298,551
Ensembl chr10:99,267,540...99,300,168

G

cell division cycle associated 2

decreases expression

ISO

trovafloxacin results in decreased expression of CDCA2 mRNA

NCBI chr15:46,071,360...46,117,524
Ensembl chr15:46,071,360...46,116,639

G

cell division cycle associated 3

decreases expression

ISO

trovafloxacin results in decreased expression of CDCA3 mRNA

NCBI chr 4:159,321,203...159,325,072
Ensembl chr 4:159,321,014...159,325,068

G

cell division cycle associated 5

decreases expression

ISO

trovafloxacin results in decreased expression of CDCA5 mRNA

NCBI chr 1:212,807,863...212,821,313
Ensembl chr 1:212,804,014...212,821,309

G

cell division cycle associated 8

decreases expression

ISO

trovafloxacin results in decreased expression of CDCA8 mRNA

NCBI chr 5:142,461,082...142,483,336
Ensembl chr 5:142,461,084...142,483,283

G

CDAN1 interacting nuclease 1

decreases expression

ISO

trovafloxacin results in decreased expression of CDIN1 mRNA

NCBI chr 3:122,895,754...123,101,099
Ensembl chr 3:122,895,824...123,101,099

G

cyclin-dependent kinase 1

decreases expression

EXP
ISO

trovafloxacin results in decreased expression of CDK1 mRNA

PMID:24136188 PMID:35537566

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase 10

decreases expression

ISO

trovafloxacin results in decreased expression of CDK10 mRNA

NCBI chr19:68,168,040...68,184,923
Ensembl chr19:68,169,874...68,177,599

G

cyclin-dependent kinase 16

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CDK16 mRNA

NCBI chr X:4,046,330...4,057,825
Ensembl chr X:4,026,866...4,057,380

G

cyclin-dependent kinase 2 associated protein 2

increases expression

ISO

trovafloxacin results in increased expression of CDK2AP2 mRNA

NCBI chr 1:210,819,155...210,822,604
Ensembl chr 1:210,820,507...210,823,010

G

CDK5 regulatory subunit associated protein 2

decreases expression

ISO

trovafloxacin results in decreased expression of CDK5RAP2 mRNA

NCBI chr 5:88,807,402...88,976,005
Ensembl chr 5:88,807,402...88,976,069

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CDKN1A mRNA
trovafloxacin results in increased expression of CDKN1A mRNA

PMID:18930950 PMID:25748550 PMID:35537566

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 2C

decreases expression

ISO

trovafloxacin results in decreased expression of CDKN2C mRNA

NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:129,639,736...129,644,891

G

cyclin dependent kinase inhibitor 2D

decreases expression

ISO

trovafloxacin results in decreased expression of CDKN2D mRNA

NCBI chr 8:28,108,036...28,110,809
Ensembl chr 8:28,108,044...28,110,809

G

cyclin-dependent kinase inhibitor 3

decreases expression

ISO
EXP

trovafloxacin results in decreased expression of CDKN3 mRNA

PMID:24136188 PMID:35537566

NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722

G

cysteine dioxygenase type 1

increases expression

ISO

trovafloxacin results in increased expression of CDO1 mRNA

NCBI chr18:41,619,076...41,633,719
Ensembl chr18:41,619,070...41,633,891

G

cell adhesion associated, oncogene regulated

decreases expression

ISO

trovafloxacin results in decreased expression of CDON mRNA

NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345

G

corneodesmosin

decreases expression

ISO

trovafloxacin results in decreased expression of CDSN mRNA

NCBI chr20:3,184,142...3,188,962
Ensembl chr20:3,183,808...3,188,962

G

CCAAT/enhancer binding protein alpha

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CEBPA mRNA

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein gamma

decreases expression

ISO

trovafloxacin results in decreased expression of CEBPG mRNA

NCBI chr 1:96,820,981...96,829,736
Ensembl chr 1:96,810,214...96,830,283

G

CUGBP, Elav-like family member 6

decreases expression

ISO

trovafloxacin results in decreased expression of CELF6 mRNA

NCBI chr 8:68,870,902...68,901,863
Ensembl chr 8:68,871,093...68,901,863

G

centrosomal AT-AC splicing factor

increases expression

ISO

trovafloxacin results in increased expression of CENATAC mRNA

NCBI chr 8:53,632,777...53,639,661
Ensembl chr 8:53,632,044...53,639,650

G

centromere protein A

decreases expression

ISO

trovafloxacin results in decreased expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703

G

centromere protein E

decreases expression

ISO

trovafloxacin results in decreased expression of CENPE mRNA

NCBI chr 2:226,310,970...226,369,636
Ensembl chr 2:226,300,798...226,369,636

G

centromere protein F

decreases expression

ISO

trovafloxacin results in decreased expression of CENPF mRNA

NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886

G

centromere protein I

decreases expression

ISO

trovafloxacin results in decreased expression of CENPI mRNA

NCBI chr X:101,809,192...101,860,935
Ensembl chr X:101,809,659...101,860,934

G

centromere protein K

decreases expression

ISO

trovafloxacin results in decreased expression of CENPK mRNA

NCBI chr 2:37,094,163...37,155,158
Ensembl chr 2:37,094,248...37,119,488

G

centromere protein L

decreases expression

ISO

trovafloxacin results in decreased expression of CENPL mRNA

NCBI chr13:75,870,479...75,885,466
Ensembl chr13:75,870,489...75,905,250

G

centromere protein M

decreases expression

ISO

trovafloxacin results in decreased expression of CENPM mRNA

NCBI chr 7:115,628,117...115,639,401
Ensembl chr 7:115,628,129...115,643,866

G

centromere protein N

decreases expression

ISO

trovafloxacin results in decreased expression of CENPN mRNA

NCBI chr19:61,880,101...61,902,850
Ensembl chr19:61,877,148...61,902,918

G

centromere protein P

decreases expression

ISO

trovafloxacin results in decreased expression of CENPP mRNA

NCBI chr17:15,220,521...15,395,741
Ensembl chr17:15,220,291...15,395,739

G

centromere protein Q

decreases expression

ISO

trovafloxacin results in decreased expression of CENPQ mRNA

NCBI chr 9:27,454,339...27,469,371
Ensembl chr 9:27,454,252...27,469,366

G

centromere protein U

decreases expression

ISO

trovafloxacin results in decreased expression of CENPU mRNA

NCBI chr16:52,448,446...52,471,662
Ensembl chr16:52,425,096...52,471,662

G

centrosomal protein 128

decreases expression

ISO

trovafloxacin results in decreased expression of CEP128 mRNA

NCBI chr 6:115,681,753...116,059,758
Ensembl chr 6:115,681,712...116,057,167

G

centrosomal protein 131

decreases expression

ISO

trovafloxacin results in decreased expression of CEP131 mRNA

NCBI chr10:105,844,433...105,868,811
Ensembl chr10:105,844,433...105,868,797

G

centrosomal protein 162

decreases expression

ISO

trovafloxacin results in decreased expression of CEP162 mRNA

NCBI chr 8:97,029,677...97,088,243
Ensembl chr 8:97,029,677...97,088,207

G

centrosomal protein 192

decreases expression

ISO

trovafloxacin results in decreased expression of CEP192 mRNA

NCBI chr18:63,643,816...63,728,264
Ensembl chr18:63,646,163...63,728,264

G

centrosomal protein 290

decreases expression

ISO

trovafloxacin results in decreased expression of CEP290 mRNA

NCBI chr 7:37,196,765...37,285,955
Ensembl chr 7:37,196,783...37,285,955

G

centrosomal protein 55

decreases expression

ISO

trovafloxacin results in decreased expression of CEP55 mRNA

NCBI chr 1:245,245,272...245,260,835
Ensembl chr 1:245,245,306...245,260,890

G

centrosomal protein 57-like 1

decreases expression

ISO

trovafloxacin results in decreased expression of CEP57L1 mRNA

NCBI chr20:46,820,350...46,876,911
Ensembl chr20:46,820,353...46,876,926

G

centrosomal protein 72

decreases expression

ISO

trovafloxacin results in decreased expression of CEP72 mRNA

NCBI chr 1:31,053,884...31,083,863
Ensembl chr 1:31,053,914...31,083,863

G

centrosomal protein 78

decreases expression

ISO

trovafloxacin results in decreased expression of CEP78 mRNA

NCBI chr 1:222,674,193...222,702,124
Ensembl chr 1:222,674,194...222,702,120

G

centrosomal protein 83

decreases expression

ISO

trovafloxacin results in decreased expression of CEP83 mRNA

NCBI chr 7:31,167,198...31,276,513
Ensembl chr 7:31,167,216...31,276,716

G

CERK like autophagy regulator

decreases expression

ISO

trovafloxacin results in decreased expression of CERKL mRNA

NCBI chr 3:84,641,121...84,747,999
Ensembl chr 3:84,645,696...84,747,688

G

cilia and flagella associated protein 184

increases expression

ISO

trovafloxacin results in increased expression of CCDC96 mRNA

NCBI chr14:78,501,256...78,503,715
Ensembl chr14:78,486,414...78,507,808

G

cofilin 2

increases expression

ISO

trovafloxacin results in increased expression of CFL2 mRNA

NCBI chr 6:78,090,843...78,094,888
Ensembl chr 6:78,090,843...78,094,888

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

decreases expression

ISO

trovafloxacin results in decreased expression of CHAC1 mRNA

NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361

G

chondroadherin-like

increases expression

ISO

trovafloxacin results in increased expression of CHADL mRNA

NCBI chr 7:115,085,447...115,097,565
Ensembl chr 7:115,085,165...115,097,435

G

chromodomain helicase DNA binding protein 5

decreases expression

ISO

trovafloxacin results in decreased expression of CHD5 mRNA

NCBI chr 5:168,130,851...168,181,705
Ensembl chr 5:168,130,575...168,179,441

G

checkpoint with forkhead and ring finger domains

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CHFR mRNA

NCBI chr12:52,164,214...52,197,860
Ensembl chr12:52,164,217...52,197,703

G

choline kinase alpha

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CHKA mRNA

NCBI chr 1:210,506,069...210,554,753
Ensembl chr 1:210,506,056...210,554,752

G

chondroitin polymerizing factor

increases expression

ISO

trovafloxacin results in increased expression of CHPF mRNA

NCBI chr 9:84,411,824...84,416,523
Ensembl chr 9:84,411,829...84,416,523

G

carbohydrate sulfotransferase 1

decreases expression

ISO

trovafloxacin results in decreased expression of CHST1 mRNA

NCBI chr 3:99,003,987...99,030,214
Ensembl chr 3:99,009,958...99,031,262

G

carbohydrate sulfotransferase 7

decreases expression

ISO

trovafloxacin results in decreased expression of CHST7 mRNA

NCBI chr X:4,949,810...4,986,372
Ensembl chr X:4,938,757...4,986,907

G

chromosome transmission fidelity factor 18

decreases expression

ISO

trovafloxacin results in decreased expression of CHTF18 mRNA

NCBI chr10:15,247,525...15,255,573
Ensembl chr10:15,246,362...15,255,685

G

calcium and integrin binding family member 2

decreases expression

ISO

trovafloxacin results in decreased expression of CIB2 mRNA

NCBI chr 8:63,826,410...63,843,301
Ensembl chr 8:63,826,411...63,843,277

G

cellular inhibitor of PP2A

decreases expression

ISO

trovafloxacin results in decreased expression of CIP2A mRNA

NCBI chr11:65,255,123...65,285,914
Ensembl chr11:65,255,123...65,285,914

G

citron rho-interacting serine/threonine kinase

decreases expression

ISO

trovafloxacin results in decreased expression of CIT mRNA

NCBI chr12:46,263,881...46,425,642
Ensembl chr12:46,266,369...46,424,656

G

cytoskeleton associated protein 2

decreases expression

ISO

trovafloxacin results in decreased expression of CKAP2 mRNA

NCBI chr16:76,542,114...76,567,297
Ensembl chr16:76,542,104...76,567,352

G

cytoskeleton associated protein 2-like

decreases expression

ISO

trovafloxacin results in decreased expression of CKAP2L mRNA

NCBI chr 3:136,950,390...136,977,503
Ensembl chr 3:136,950,381...136,977,565

G

cytoskeleton associated protein 5

decreases expression

ISO

trovafloxacin results in decreased expression of CKAP5 mRNA

NCBI chr 3:97,946,966...98,049,050
Ensembl chr 3:97,947,031...98,049,049

G

CDC28 protein kinase regulatory subunit 2

decreases expression

EXP

trovafloxacin results in decreased expression of CKS2 mRNA

NCBI chr17:13,722,360...13,727,519
Ensembl chr17:13,722,361...13,727,519

G

chloride voltage-gated channel 5

decreases expression

ISO

trovafloxacin results in decreased expression of CLCN5 mRNA

NCBI chr X:17,857,260...18,011,844
Ensembl chr X:17,857,260...18,011,844

G

claudin 11

decreases expression

ISO

trovafloxacin results in decreased expression of CLDN11 mRNA

NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:114,136,234...114,149,539

G

claudin 14

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CLDN14 mRNA

NCBI chr11:46,701,940...46,799,049
Ensembl chr11:46,701,940...46,799,096

G

C-type lectin domain family 2, member L

decreases expression

ISO

trovafloxacin results in decreased expression of CLEC2L mRNA

NCBI chr 4:68,359,021...68,381,431
Ensembl chr 4:68,358,973...68,381,432

G

C-type lectin domain family 4, member A1

decreases expression

ISO

trovafloxacin results in decreased expression of CLEC4A1 mRNA

NCBI chr 4:157,845,811...157,857,926
Ensembl chr 4:157,845,752...157,858,273

G

C-type lectin domain containing 7A

decreases expression

ISO

trovafloxacin results in decreased expression of CLEC7A mRNA

NCBI chr 4:164,588,737...164,599,953
Ensembl chr 4:164,588,754...164,599,919

G

clathrin interactor 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CLINT1 mRNA

NCBI chr10:30,799,936...30,854,513
Ensembl chr10:30,799,971...30,854,508

G

CAP-GLY domain containing linker protein 2

increases expression

ISO

trovafloxacin results in increased expression of CLIP2 mRNA

NCBI chr12:27,798,289...27,863,486
Ensembl chr12:27,799,524...27,863,484

G

CDC-like kinase 1

increases expression

ISO

trovafloxacin results in increased expression of CLK1 mRNA

NCBI chr 9:67,441,962...67,453,180
Ensembl chr 9:67,441,952...67,451,187

G

CLN6, transmembrane ER protein

decreases expression

ISO

trovafloxacin results in decreased expression of CLN6 mRNA

NCBI chr 8:72,198,773...72,213,777
Ensembl chr 8:72,198,712...72,213,776

G

claspin

decreases expression

ISO

trovafloxacin results in decreased expression of CLSPN mRNA

NCBI chr 5:144,134,619...144,169,531
Ensembl chr 5:144,134,632...144,169,530

G

cytidine monophospho-N-acetylneuraminic acid hydroxylase

decreases expression

ISO

trovafloxacin results in decreased expression of CMAH mRNA

NCBI chr17:40,985,129...41,070,317
Ensembl chr17:41,011,641...41,070,252

G

carboxymethylenebutenolidase homolog

decreases expression

ISO

trovafloxacin results in decreased expression of CMBL mRNA

NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880

G

cytidine/uridine monophosphate kinase 2

increases expression

ISO

trovafloxacin results in increased expression of CMPK2 mRNA

NCBI chr 6:48,802,150...48,813,652
Ensembl chr 6:48,802,321...48,813,652

G

centlein

decreases expression

ISO

trovafloxacin results in decreased expression of CNTLN mRNA

NCBI chr 5:104,340,801...104,622,491
Ensembl chr 5:104,342,173...104,630,976

G

centriolin

decreases expression

ISO

trovafloxacin results in decreased expression of CNTRL mRNA

NCBI chr 3:38,825,575...38,897,835
Ensembl chr 3:38,825,624...38,897,833

G

centrobin, centriole duplication and spindle assembly protein

decreases expression

ISO

trovafloxacin results in decreased expression of CNTROB mRNA

NCBI chr10:54,521,338...54,546,569
Ensembl chr10:54,521,663...54,543,657

G

Coenzyme A synthase

decreases expression

ISO

trovafloxacin results in decreased expression of COASY mRNA

NCBI chr10:86,514,850...86,519,130
Ensembl chr10:86,514,874...86,519,130

G

collagen type XIV alpha 1 chain

decreases expression

ISO

trovafloxacin results in decreased expression of COL14A1 mRNA

NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938

G

collagen type XV alpha 1 chain

decreases expression

ISO

trovafloxacin results in decreased expression of COL15A1 mRNA

NCBI chr 5:66,297,546...66,403,172
Ensembl chr 5:66,297,461...66,403,170

G

catechol-O-methyltransferase

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of COMT mRNA

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533

G

COPI coat complex subunit gamma 1

decreases expression

EXP

trovafloxacin results in decreased expression of COPG1 mRNA

NCBI chr 4:121,923,644...121,949,819
Ensembl chr 4:121,923,873...121,949,812

G

COP9 signalosome subunit 9

increases expression

ISO

trovafloxacin results in increased expression of MYEOV2 mRNA

NCBI chr 9:100,657,276...100,662,206
Ensembl chr 9:100,657,276...100,662,206

G

coenzyme Q10A

decreases expression

ISO

trovafloxacin results in decreased expression of COQ10A mRNA

NCBI chr 7:1,376,591...1,387,694
Ensembl chr 7:1,376,591...1,382,722

G

coenzyme Q2, polyprenyltransferase

decreases expression

ISO

trovafloxacin results in decreased expression of COQ2 mRNA

NCBI chr14:9,245,777...9,265,784
Ensembl chr14:9,245,803...9,265,783

G

coronin 1B

decreases expression

ISO

trovafloxacin results in decreased expression of CORO1B mRNA

NCBI chr 1:210,872,437...210,877,876
Ensembl chr 1:210,871,841...210,877,876

G

coronin 6

decreases expression

ISO

trovafloxacin results in decreased expression of CORO6 mRNA

NCBI chr10:62,808,172...62,817,788
Ensembl chr10:62,809,689...62,817,787

G

coronin 7

decreases expression

ISO

trovafloxacin results in decreased expression of CORO7 mRNA

NCBI chr10:11,386,683...11,447,422
Ensembl chr10:11,391,613...11,447,866

G

cytochrome c oxidase subunit 4i2

increases expression

ISO

trovafloxacin results in increased expression of COX4I2 mRNA

NCBI chr 3:161,686,193...161,699,605
Ensembl chr 3:161,689,017...161,699,602

G

cytochrome c oxidase subunit 6A2

decreases expression

ISO

trovafloxacin results in decreased expression of COX6A2 mRNA

NCBI chr 1:192,218,970...192,221,188
Ensembl chr 1:192,218,970...192,219,716

G

carboxypeptidase E

increases expression

ISO

trovafloxacin results in increased expression of CPE mRNA

NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524

G

cytoplasmic polyadenylation element binding protein 4

increases expression

ISO

trovafloxacin results in increased expression of CPEB4 mRNA

NCBI chr10:16,222,271...16,284,248
Ensembl chr10:16,225,672...16,283,787

G

cadherin-like and PC-esterase domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of CPED1 mRNA

NCBI chr 4:51,482,497...51,755,440
Ensembl chr 4:51,482,545...51,755,442

G

coproporphyrinogen oxidase

decreases expression

EXP

trovafloxacin results in decreased expression of CPOX mRNA

NCBI chr11:55,405,778...55,415,761
Ensembl chr11:55,405,784...55,415,761

G

cleavage and polyadenylation specific factor 1

decreases expression

ISO

trovafloxacin results in decreased expression of CPSF1 mRNA

NCBI chr 7:110,200,078...110,210,644
Ensembl chr 7:110,199,066...110,210,644

G

carnitine palmitoyltransferase 1A

increases expression

EXP

trovafloxacin results in increased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

CASP2 and RIPK1 domain containing adaptor with death domain

decreases expression

ISO

trovafloxacin results in decreased expression of CRADD mRNA

NCBI chr 7:31,827,131...31,839,796
Ensembl chr 7:31,685,622...31,874,512

G

CREB/ATF bZIP transcription factor

increases expression

ISO

trovafloxacin results in increased expression of CREBZF mRNA

NCBI chr 1:153,829,544...153,836,073
Ensembl chr 1:153,829,448...153,845,122

G

CRK proto-oncogene, adaptor protein

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CRK mRNA

NCBI chr10:61,028,736...61,054,971
Ensembl chr10:61,028,757...61,082,988

G

crystallin zeta like 1

decreases expression

ISO

trovafloxacin results in decreased expression of CRYZL1 mRNA

NCBI chr11:44,419,099...44,464,366
Ensembl chr11:44,419,103...44,463,793

G

citrate synthase

decreases expression

EXP

trovafloxacin results in decreased expression of CS mRNA

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

cysteine sulfinic acid decarboxylase

decreases expression

ISO

trovafloxacin results in decreased expression of CSAD mRNA

NCBI chr 7:135,187,175...135,216,495
Ensembl chr 7:135,187,175...135,215,581

G

cysteine and serine rich nuclear protein 1

increases expression

ISO

trovafloxacin results in increased expression of CSRNP1 mRNA

NCBI chr 8:128,582,364...128,594,163
Ensembl chr 8:128,582,365...128,588,469

G

cystatin F

decreases expression

ISO

trovafloxacin results in decreased expression of CST7 mRNA

NCBI chr 3:159,857,221...159,865,987
Ensembl chr 3:159,857,052...159,866,919

G

cleavage stimulation factor subunit 2, tau variant

increases expression

ISO

trovafloxacin results in increased expression of CSTF2T mRNA

NCBI chr 1:238,366,042...238,369,608
Ensembl chr 1:238,365,912...238,369,749

G

CTD small phosphatase 1

decreases expression

ISO

trovafloxacin results in decreased expression of CTDSP1 mRNA

NCBI chr 9:83,422,755...83,428,411
Ensembl chr 9:83,423,051...83,428,412

G

cystathionine gamma-lyase

decreases expression

ISO

trovafloxacin results in decreased expression of CTH mRNA

NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066

G

cathepsin C

decreases expression

ISO

trovafloxacin results in decreased expression of CTSC mRNA

NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:151,441,032...151,474,082

G

cathepsin E

decreases expression

ISO

trovafloxacin results in decreased expression of CTSE mRNA

NCBI chr13:45,644,168...45,666,722
Ensembl chr13:45,644,147...45,666,722

G

cathepsin F

decreases expression

ISO

trovafloxacin results in decreased expression of CTSF mRNA

NCBI chr 1:211,582,169...211,587,917
Ensembl chr 1:211,582,098...211,587,916

G

CTTNBP2 N-terminal like

increases expression

ISO

trovafloxacin results in increased expression of CTTNBP2NL mRNA

NCBI chr 2:195,196,318...195,244,792
Ensembl chr 2:195,196,318...195,243,181

G

cutC copper transporter

decreases expression

ISO

trovafloxacin results in decreased expression of CUTC mRNA

NCBI chr 1:252,571,489...252,586,269
Ensembl chr 1:252,571,521...252,597,272

G

cut-like homeobox 2

increases expression

ISO

trovafloxacin results in increased expression of CUX2 mRNA

NCBI chr12:40,168,402...40,368,303
Ensembl chr12:40,149,292...40,366,528

G

C-X-C motif chemokine ligand 2

increases expression
multiple interactions

ISO

trovafloxacin results in increased expression of CXCL2 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CXCL2 mRNA; trovafloxacin promotes the reaction [TNF protein results in increased expression of CXCL2 protein]

PMID:18930950 PMID:19638433 PMID:35537566

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CXCL3 mRNA; trovafloxacin promotes the reaction [TNF protein results in increased expression of CXCL1 protein]

PMID:18930950 PMID:19638433

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

cytochrome b5 type A

increases expression

ISO

trovafloxacin results in increased expression of CYB5A mRNA

NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094
Ensembl chr18:14,453,966...14,455,094

G

cytochrome b5 domain containing 1

increases expression

ISO

trovafloxacin results in increased expression of CYB5D1 mRNA

NCBI chr10:54,612,230...54,616,375
Ensembl chr10:54,612,230...54,616,713

G

cytochrome b5 reductase-like

decreases expression

ISO

trovafloxacin results in decreased expression of CYB5RL mRNA

NCBI chr 5:127,075,034...127,097,551
Ensembl chr 5:127,074,535...127,097,518

G

cytoplasmic FMR1 interacting protein 2

decreases expression

ISO

trovafloxacin results in decreased expression of CYFIP2 mRNA

NCBI chr10:31,122,653...31,242,440
Ensembl chr10:31,122,653...31,242,440

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

ISO

trovafloxacin results in decreased activity of CYP19A1 protein

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

ISO

trovafloxacin results in decreased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, family 2, subfamily b, polypeptide 12

decreases expression

EXP

trovafloxacin results in decreased expression of CYP2B12 mRNA

NCBI chr 1:91,135,294...91,147,094
Ensembl chr 1:91,135,294...91,208,159

G

cytochrome P450, family 2, subfamily u, polypeptide 1

decreases expression

ISO

trovafloxacin results in decreased expression of CYP2U1 mRNA

NCBI chr 2:222,523,516...222,541,055
Ensembl chr 2:222,523,518...222,541,124

G

cytochrome P450, family 4, subfamily f, polypeptide 39

decreases expression

ISO

trovafloxacin results in decreased expression of CYP4F39 mRNA

NCBI chr 7:12,082,821...12,156,076
Ensembl chr 7:12,083,888...12,156,076

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CYP7A1 mRNA

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 8 subfamily B member 1

increases expression

EXP

trovafloxacin results in increased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

cell cycle regulator of NHEJ

decreases expression

ISO

trovafloxacin results in decreased expression of CYREN mRNA

NCBI chr 4:64,514,477...64,519,896
Ensembl chr 4:64,514,477...64,518,742

G

CYFIP related Rac1 interactor A

decreases expression

ISO

trovafloxacin results in decreased expression of FAM49A mRNA

NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:40,774,171...40,881,860

G

cytohesin 4

increases expression

ISO

trovafloxacin results in increased expression of CYTH4 mRNA

NCBI chr 7:112,032,711...112,057,204
Ensembl chr 7:112,032,775...112,057,204

G

differentiation antagonizing non-protein coding RNA

increases expression

ISO

trovafloxacin results in increased expression of DANCR mRNA

NCBI chr14:34,481,052...34,482,032

G

death associated protein kinase 1

decreases expression

EXP

trovafloxacin results in decreased expression of DAPK1 mRNA

NCBI chr17:3,935,826...4,096,858
Ensembl chr17:3,935,625...4,096,581

G

aspartyl-tRNA synthetase 2 (mitochondrial)

decreases expression

ISO

trovafloxacin results in decreased expression of DARS2 mRNA

NCBI chr13:75,842,078...75,870,319
Ensembl chr13:75,836,565...75,869,904

G

death-domain associated protein

increases expression

ISO

trovafloxacin results in increased expression of DAXX mRNA

NCBI chr20:4,971,973...4,978,062
Ensembl chr20:4,971,941...4,977,720

G

DBF4-CDC7 kinase regulatory subunit

decreases expression

ISO

trovafloxacin results in decreased expression of DBF4 mRNA

NCBI chr 4:26,631,491...26,656,080
Ensembl chr 4:26,631,514...26,656,562

G

decapping mRNA 1B

decreases expression

ISO

trovafloxacin results in decreased expression of DCP1B mRNA

NCBI chr 4:154,030,181...154,068,038
Ensembl chr 4:154,030,690...154,068,035

G

DNA-damage inducible transcript 3

decreases expression

ISO

trovafloxacin results in decreased expression of DDIT3 mRNA

PMID:24136188 PMID:35537566

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DEAD-box helicase 1

decreases expression

EXP

trovafloxacin results in decreased expression of DDX1 mRNA

NCBI chr 6:41,725,365...41,756,236
Ensembl chr 6:41,725,367...41,758,302

G

DEAD-box helicase 17

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of DDX17 mRNA

NCBI chr 7:112,971,522...112,989,747
Ensembl chr 7:112,971,523...112,989,747

G

DEAD-box helicase 23

increases expression

ISO

trovafloxacin results in increased expression of DDX23 mRNA

NCBI chr 7:131,676,636...131,693,917
Ensembl chr 7:131,676,636...131,689,074

G

DEAD-box helicase 59

decreases expression

ISO

trovafloxacin results in decreased expression of DDX59 mRNA

NCBI chr13:50,427,940...50,452,893
Ensembl chr13:50,427,936...50,453,208

G

DEAD-box helicase 6

increases expression

ISO

trovafloxacin results in increased expression of DDX6 mRNA

NCBI chr 8:53,827,661...53,864,538
Ensembl chr 8:53,827,835...53,860,977

G

DEXD/H-box helicase 60

increases expression

ISO

trovafloxacin results in increased expression of DDX60 mRNA

NCBI chr16:33,087,940...33,208,843
Ensembl chr16:33,087,988...33,208,839

G

DEK proto-oncogene

decreases expression

ISO

trovafloxacin results in decreased expression of DEK mRNA

NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122

G

DENN domain containing 2D

decreases expression

ISO

trovafloxacin results in decreased expression of DENND2D mRNA

NCBI chr 2:196,661,465...196,680,505
Ensembl chr 2:196,661,345...196,682,397

G

DENN domain containing 4A

decreases expression

ISO

trovafloxacin results in decreased expression of DENND4A mRNA

NCBI chr 8:74,218,131...74,331,543
Ensembl chr 8:74,218,191...74,331,542

G

DENN domain containing 5B

increases expression

ISO

trovafloxacin results in increased expression of DENND5B mRNA

NCBI chr 4:183,688,039...183,821,012
Ensembl chr 4:183,692,227...183,820,508

G

DEP domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of DEPDC1A mRNA

NCBI chr 2:251,343,250...251,376,709
Ensembl chr 2:251,343,281...251,376,709

G

DEP domain containing 1B

decreases expression

ISO

trovafloxacin results in decreased expression of DEPDC1B mRNA

NCBI chr 2:41,605,686...41,697,207
Ensembl chr 2:41,624,922...41,697,202

G

DEP domain containing 7

decreases expression

ISO

trovafloxacin results in decreased expression of DEPDC7 mRNA

NCBI chr 3:111,554,701...111,575,979
Ensembl chr 3:111,554,706...111,575,979

G

DEP domain containing MTOR-interacting protein

decreases expression

ISO

trovafloxacin results in decreased expression of DEPTOR mRNA

NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041

G

derlin 2

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of DERL2 mRNA

NCBI chr10:56,226,340...56,238,038
Ensembl chr10:56,226,219...56,237,993

G

DET1 partner of COP1 E3 ubiquitin ligase

decreases expression

ISO

trovafloxacin results in decreased expression of DET1 mRNA

NCBI chr 1:142,159,120...142,175,366
Ensembl chr 1:142,127,876...142,175,336

G

DNA fragmentation factor subunit beta

increases expression

ISO

trovafloxacin results in increased expression of DFFB mRNA

NCBI chr 5:169,804,873...169,817,157
Ensembl chr 5:169,804,889...169,817,225

G

diacylglycerol O-acyltransferase 2

decreases expression

EXP
ISO

trovafloxacin results in decreased expression of DGAT2 mRNA

PMID:24136188 PMID:35537566

NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:162,866,237...162,896,566

G

diacylglycerol kinase epsilon

increases expression

ISO

trovafloxacin results in increased expression of DGKE mRNA

NCBI chr10:74,348,931...74,374,509
Ensembl chr10:74,350,246...74,374,478

G

diacylglycerol kinase, gamma

decreases expression

ISO

trovafloxacin results in decreased expression of DGKG mRNA

NCBI chr11:91,888,957...92,083,715
Ensembl chr11:91,888,782...92,082,105

G

deoxyguanosine kinase

decreases expression

ISO

trovafloxacin results in decreased expression of DGUOK mRNA

NCBI chr 4:117,544,784...117,572,414
Ensembl chr 4:117,544,773...117,572,414

G

dehydrogenase/reductase 3

decreases expression

ISO

trovafloxacin results in decreased expression of DHRS3 mRNA

NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653

G

dehydrogenase/reductase 4

decreases expression

ISO

trovafloxacin results in decreased expression of DHRS4 mRNA

NCBI chr15:32,924,482...32,948,103
Ensembl chr15:32,936,522...32,948,101

G

DEXH-box helicase 58

increases expression

ISO

trovafloxacin results in increased expression of DHX58 mRNA

NCBI chr10:86,120,677...86,132,095
Ensembl chr10:86,120,677...86,131,844

G

diaphanous-related formin 3

decreases expression

ISO

trovafloxacin results in decreased expression of DIAPH3 mRNA

NCBI chr15:68,951,992...69,421,623
Ensembl chr15:68,951,989...69,421,552

G

dispatched RND transporter family member 3

decreases expression

ISO

trovafloxacin results in decreased expression of DISP3 mRNA

NCBI chr 5:163,955,160...164,003,980
Ensembl chr 5:163,955,160...164,003,950

G

DIX domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of DIXDC1 mRNA

NCBI chr 8:59,904,218...59,977,595
Ensembl chr 8:59,904,218...59,978,447

G

DLG associated protein 5

decreases expression

ISO

trovafloxacin results in decreased expression of DLGAP5 mRNA

NCBI chr15:23,113,678...23,144,281
Ensembl chr15:23,113,678...23,144,176

G

dihydrolipoamide S-succinyltransferase

decreases expression

EXP

trovafloxacin results in decreased expression of DLST mRNA

NCBI chr 6:110,489,576...110,512,841
Ensembl chr 6:110,489,392...110,514,357

G

distal membrane arm assembly component 1

increases expression

ISO

trovafloxacin results in increased expression of DMAC1 mRNA

NCBI chr 5:94,288,900...94,290,053
Ensembl chr 5:94,280,654...94,290,119

G

DM1 protein kinase

increases expression

ISO

trovafloxacin results in increased expression of DMPK mRNA

NCBI chr 1:87,858,294...87,868,624
Ensembl chr 1:87,858,316...87,868,910

G

dynein, axonemal, heavy chain 17

increases expression

ISO

trovafloxacin results in increased expression of DNAH17 mRNA

NCBI chr10:103,748,033...103,862,009
Ensembl chr10:103,747,313...103,863,622

G

DnaJ heat shock protein family (Hsp40) member B2

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of DNAJB2 mRNA

NCBI chr 9:84,179,702...84,187,942
Ensembl chr 9:84,179,695...84,187,942

G

deoxyribonuclease 2, lysosomal

decreases expression

ISO

trovafloxacin results in decreased expression of DNASE2A mRNA

NCBI chr19:40,149,505...40,152,225
Ensembl chr19:40,149,505...40,152,225

G

DND microRNA-mediated repression inhibitor 1

increases expression

ISO

trovafloxacin results in increased expression of DND1 mRNA

NCBI chr18:28,652,712...28,655,336
Ensembl chr18:28,652,712...28,655,336

G

DNA methyltransferase 1

decreases expression

ISO

trovafloxacin results in decreased expression of DNMT1 mRNA

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119

G

DNA methyltransferase 3 like

decreases expression

ISO

trovafloxacin results in decreased expression of DNMT3L mRNA

NCBI chr20:10,614,591...10,628,989
Ensembl chr20:10,614,591...10,629,168

G

2'-deoxynucleoside 5'-phosphate N-hydrolase 1

decreases expression

EXP

trovafloxacin results in decreased expression of DNPH1 mRNA

NCBI chr 9:21,978,894...21,981,631
Ensembl chr 9:21,978,894...21,981,631

G

dedicator of cytokinesis 11

decreases expression

ISO

trovafloxacin results in decreased expression of DOCK11 mRNA

NCBI chr X:119,997,523...120,180,643
Ensembl chr X:119,997,552...120,180,634

G

dedicator of cytokinesis 2

decreases expression

ISO

trovafloxacin results in decreased expression of DOCK2 mRNA

NCBI chr10:19,331,412...19,748,987
Ensembl chr10:19,331,412...19,748,969

G

dedicator of cytokinesis 9

decreases expression

ISO

trovafloxacin results in decreased expression of DOCK9 mRNA

NCBI chr15:105,018,341...105,289,799
Ensembl chr15:105,024,912...105,289,799

G

DNA replication fork stabilization factor DONSON

decreases expression

ISO

trovafloxacin results in decreased expression of DONSON mRNA

NCBI chr11:44,405,794...44,419,099
Ensembl chr11:44,405,804...44,418,791

G

double PHD fingers 1

increases expression

ISO

trovafloxacin results in increased expression of DPF1 mRNA

NCBI chr 1:93,729,683...93,743,425
Ensembl chr 1:93,726,970...93,743,425

G

dynein regulatory complex subunit 3

decreases expression

ISO

trovafloxacin results in decreased expression of DRC3 mRNA

NCBI chr10:45,620,045...45,698,902
Ensembl chr10:45,648,410...45,698,900

G

DNA replication and sister chromatid cohesion 1

decreases expression

ISO

trovafloxacin results in decreased expression of DSCC1 mRNA

NCBI chr 7:88,372,349...88,390,815
Ensembl chr 7:88,372,146...88,387,973

G

DSN1 component of MIS12 kinetochore complex

decreases expression

ISO

trovafloxacin results in decreased expression of DSN1 mRNA

NCBI chr 3:166,072,775...166,089,029
Ensembl chr 3:166,074,033...166,085,890

G

dystrobrevin, beta

decreases expression

ISO

trovafloxacin results in decreased expression of DTNB mRNA

NCBI chr 6:32,286,022...32,483,007
Ensembl chr 6:32,285,941...32,485,872

G

dystrobrevin binding protein 1

decreases expression

ISO

trovafloxacin results in decreased expression of DTNBP1 mRNA

NCBI chr17:19,891,313...19,982,770
Ensembl chr17:19,891,337...19,984,418

G

deltex E3 ubiquitin ligase 1

decreases expression

ISO

trovafloxacin results in decreased expression of DTX1 mRNA

NCBI chr12:41,510,252...41,541,433
Ensembl chr12:41,510,264...41,541,430

G

deoxythymidylate kinase

decreases expression

EXP

trovafloxacin results in decreased expression of DTYMK mRNA

NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:101,762,899...101,774,504

G

dihydrouridine synthase 1-like

decreases expression

ISO

trovafloxacin results in decreased expression of DUS1L mRNA

NCBI chr10:106,553,841...106,560,977
Ensembl chr10:106,553,238...106,561,285

G

dihydrouridine synthase 4-like

decreases expression

ISO

trovafloxacin results in decreased expression of DUS4L mRNA

NCBI chr 6:53,955,609...53,970,050
Ensembl chr 6:53,955,609...53,970,087

G

dual specificity phosphatase 1

increases expression

ISO

trovafloxacin results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 16

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of DUSP16 mRNA

NCBI chr 4:169,278,118...169,361,508
Ensembl chr 4:169,278,118...169,361,508

G

dual specificity phosphatase 2

increases expression

ISO

trovafloxacin results in increased expression of DUSP2 mRNA

NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:135,009,590...135,011,809

G

dual specificity phosphatase 5

increases expression

ISO

trovafloxacin results in increased expression of DUSP5 mRNA

NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417

G

dual specificity phosphatase 8

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of DUSP8 mRNA

NCBI chr 1:206,596,912...206,613,728
Ensembl chr 1:206,598,942...206,612,441

G

deoxyuridine triphosphatase

decreases expression

EXP
ISO

trovafloxacin results in decreased expression of DUT mRNA

PMID:24136188 PMID:35537566

NCBI chr 3:132,952,258...132,963,433
Ensembl chr 3:132,952,394...132,964,956

G

dymeclin

decreases expression

ISO

trovafloxacin results in decreased expression of DYM mRNA

NCBI chr18:70,879,835...71,176,006
Ensembl chr18:70,880,255...71,176,004

G

dynein 2 intermediate chain 2

decreases expression

ISO

trovafloxacin results in decreased expression of DYNC2I2 mRNA

NCBI chr 3:33,703,882...33,719,960
Ensembl chr 3:33,703,882...33,719,960

G

dual specificity tyrosine phosphorylation regulated kinase 1B

increases expression

ISO

trovafloxacin results in increased expression of DYRK1B mRNA

NCBI chr 1:92,606,743...92,624,089
Ensembl chr 1:92,607,303...92,614,744

G

dual specificity tyrosine phosphorylation regulated kinase 3

increases expression

ISO

trovafloxacin results in increased expression of DYRK3 mRNA

NCBI chr13:45,146,383...45,157,082
Ensembl chr13:45,146,384...45,157,249

G

DAZ interacting zinc finger protein 3

decreases expression

ISO

trovafloxacin results in decreased expression of DZIP3 mRNA

NCBI chr11:65,286,190...65,356,314
Ensembl chr11:65,286,190...65,356,314

G

E2F transcription factor 1

decreases expression

ISO

trovafloxacin results in decreased expression of E2F1 mRNA

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563

G

E2F transcription factor 7

decreases expression

ISO

trovafloxacin results in decreased expression of E2F7 mRNA

NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:48,037,749...48,079,055

G

E2F transcription factor 8

decreases expression

ISO

trovafloxacin results in decreased expression of E2F8 mRNA

NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:107,701,985...107,720,009

G

ELL associated factor 1

increases expression

ISO

trovafloxacin results in increased expression of EAF1 mRNA

NCBI chr16:6,704,727...6,719,476
Ensembl chr16:6,704,727...6,719,476

G

glutamyl-tRNA synthetase 2, mitochondrial

decreases expression

ISO

trovafloxacin results in decreased expression of EARS2 mRNA

NCBI chr 1:186,025,740...186,057,165

G

enoyl CoA hydratase domain containing 2

decreases expression

ISO

trovafloxacin results in decreased expression of ECHDC2 mRNA

NCBI chr 5:128,144,241...128,163,611
Ensembl chr 5:128,144,425...128,163,610

G

enoyl CoA hydratase domain containing 3

decreases expression

ISO

trovafloxacin results in decreased expression of ECHDC3 mRNA

NCBI chr17:76,980,112...77,002,934
Ensembl chr17:76,980,083...77,002,934

G

enoyl-CoA delta isomerase 1

decreases expression

ISO

trovafloxacin results in decreased expression of ECI1 mRNA

NCBI chr10:13,961,250...13,974,595
Ensembl chr10:13,961,218...13,974,773

G

epithelial cell transforming 2

decreases expression

ISO

trovafloxacin results in decreased expression of ECT2 mRNA

NCBI chr 2:111,904,522...111,966,786
Ensembl chr 2:111,904,522...111,966,626

G

ectodysplasin A2 receptor

increases expression

ISO

trovafloxacin results in increased expression of EDA2R mRNA

NCBI chr X:66,225,557...66,280,674
Ensembl chr X:66,236,111...66,280,663

G

eukaryotic elongation factor-2 kinase

decreases expression

ISO

trovafloxacin results in decreased expression of EEF2K mRNA

NCBI chr 1:184,824,420...184,888,048
Ensembl chr 1:184,824,420...184,888,048

G

eukaryotic elongation factor 2 lysine methyltransferase

decreases expression

ISO

trovafloxacin results in decreased expression of EEF2KMT mRNA

NCBI chr10:10,843,429...10,853,800
Ensembl chr10:10,843,460...10,853,797

G

EF-hand calcium binding domain 11

decreases expression

ISO

trovafloxacin results in decreased expression of EFCAB11 mRNA

NCBI chr 6:124,738,531...124,892,623
Ensembl chr 6:124,738,542...124,891,675

G

EF-hand calcium binding domain 2

decreases expression

ISO

trovafloxacin results in decreased expression of EFCAB2 mRNA

NCBI chr13:92,683,182...92,769,939
Ensembl chr13:92,684,086...92,782,558

G

EF-hand calcium binding domain 5

decreases expression

ISO

trovafloxacin results in decreased expression of EFCAB5 mRNA

NCBI chr10:62,424,548...62,540,890
Ensembl chr10:62,423,629...62,540,994

G

ephrin B3

increases expression

ISO

trovafloxacin results in increased expression of EFNB3 mRNA

NCBI chr10:54,773,282...54,780,727
Ensembl chr10:54,773,282...54,797,651

G

EGF-like-domain, multiple 7

decreases expression

ISO

trovafloxacin results in decreased expression of EGFL7 mRNA

NCBI chr 3:29,802,481...29,814,966
Ensembl chr 3:29,802,690...29,814,951

G

epidermal growth factor receptor

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EGFR mRNA

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 3

decreases expression

ISO

trovafloxacin results in decreased expression of EGR3 mRNA

NCBI chr15:51,560,482...51,565,778
Ensembl chr15:51,560,344...51,565,712

G

EI24, autophagy associated transmembrane protein

increases expression

ISO

trovafloxacin results in increased expression of EI24 mRNA

NCBI chr 8:44,683,138...44,699,502
Ensembl chr 8:44,683,144...44,695,214

G

EP300 interacting inhibitor of differentiation 1

increases expression

ISO

trovafloxacin results in increased expression of EID1 mRNA

NCBI chr 3:133,376,389...133,378,108
Ensembl chr 3:133,370,474...133,378,434

G

EP300 interacting inhibitor of differentiation 2B

increases expression

ISO

trovafloxacin results in increased expression of EID2B mRNA

NCBI chr 1:92,673,119...92,674,899

G

eukaryotic translation initiation factor 2-alpha kinase 2

increases expression

ISO

trovafloxacin results in increased expression of EIF2AK2 mRNA

NCBI chr 6:21,941,147...21,977,115
Ensembl chr 6:21,952,631...21,977,116

G

eukaryotic translation initiation factor 2B subunit beta

decreases expression

ISO

trovafloxacin results in decreased expression of EIF2B2 mRNA

NCBI chr 6:110,597,979...110,604,403
Ensembl chr 6:110,597,729...110,604,403

G

eukaryotic translation initiation factor 2 subunit alpha

decreases expression

EXP

trovafloxacin results in decreased expression of EIF2S1 mRNA

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

eukaryotic translation initiation factor 2 subunit beta

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EIF2S2 mRNA

NCBI chr 3:163,834,846...163,855,733
Ensembl chr 3:163,834,851...163,855,570

G

eukaryotic translation initiation factor 3, subunit A

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of EIF3A mRNA

NCBI chr 1:269,888,730...269,925,785
Ensembl chr 1:269,888,615...269,919,025

G

eukaryotic translation initiation factor 3, subunit C

decreases expression

EXP

trovafloxacin results in decreased expression of EIF3C mRNA

NCBI chr 1:190,565,183...190,583,067
Ensembl chr 1:190,565,184...190,583,067

G

eukaryotic translation initiation factor 3, subunit L

decreases expression

EXP

trovafloxacin results in decreased expression of EIF3L mRNA

NCBI chr 7:112,522,222...112,544,063
Ensembl chr 7:112,507,831...112,544,062

G

eukaryotic translation initiation factor 4A2

increases expression

EXP
ISO

trovafloxacin results in increased expression of EIF4A2 mRNA

PMID:24136188 PMID:35537566

NCBI chr11:91,268,730...91,276,738
Ensembl chr11:91,268,731...91,275,323

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions
decreases expression

ISO

[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of EIF4EBP1 protein; Sirolimus inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of EIF4EBP1 protein]
trovafloxacin results in decreased expression of EIF4EBP1 mRNA

PMID:33609687 PMID:35537566

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

eukaryotic translation initiation factor 6

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EIF6 mRNA

NCBI chr 3:164,785,162...164,791,410
Ensembl chr 3:164,785,163...164,791,525

G

elongation factor for RNA polymerase II 2

increases expression

ISO

trovafloxacin results in increased expression of ELL2 mRNA

NCBI chr 2:6,910,446...6,990,654
Ensembl chr 2:6,921,771...7,016,199

G

engulfment and cell motility 3

increases expression

ISO

trovafloxacin results in increased expression of ELMO3 mRNA

NCBI chr19:50,091,883...50,096,324
Ensembl chr19:50,091,924...50,096,338

G

ELOVL fatty acid elongase 6

decreases expression

EXP

trovafloxacin results in decreased expression of ELOVL6 mRNA

NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:220,738,064...220,845,549

G

ER membrane protein complex subunit 1

decreases expression

EXP

trovafloxacin results in decreased expression of EMC1 mRNA

NCBI chr 5:156,891,773...156,917,092
Ensembl chr 5:156,891,773...156,917,092

G

essential meiotic structure-specific endonuclease 1

decreases expression

ISO

trovafloxacin results in decreased expression of EME1 mRNA

NCBI chr10:80,083,585...80,092,450
Ensembl chr10:80,083,585...80,092,301

G

EMAP like 6

decreases expression

ISO

trovafloxacin results in decreased expression of EML6 mRNA

NCBI chr14:107,651,893...108,006,792
Ensembl chr14:107,699,400...108,005,409

G

endonuclease G

decreases expression

ISO

trovafloxacin results in decreased expression of ENDOG mRNA

NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573

G

enolase 3

decreases expression

ISO

trovafloxacin results in decreased expression of ENO3 mRNA

NCBI chr10:55,868,880...55,876,099
Ensembl chr10:55,866,101...55,874,540

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

decreases expression

ISO

trovafloxacin results in decreased expression of ENPP1 mRNA

NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044

G

ectonucleotide pyrophosphatase/phosphodiesterase 6

decreases expression

ISO

trovafloxacin results in decreased expression of ENPP6 mRNA

NCBI chr16:51,898,557...52,026,789
Ensembl chr16:51,898,557...52,026,728

G

ectonucleoside triphosphate diphosphohydrolase 1

decreases expression

ISO

trovafloxacin results in decreased expression of ENTPD1 mRNA

NCBI chr 1:249,374,810...249,502,310
Ensembl chr 1:249,374,836...249,502,317

G

endosomal transmembrane epsin interactor 3

increases expression

ISO

trovafloxacin results in increased expression of FAM189B mRNA

NCBI chr 2:176,886,903...176,893,047
Ensembl chr 2:176,887,135...176,893,047

G

Eph receptor A2

increases expression

ISO

trovafloxacin results in increased expression of EPHA2 mRNA

NCBI chr 5:158,888,629...158,917,100
Ensembl chr 5:158,888,629...158,917,234

G

epoxide hydrolase 1

decreases expression

EXP

trovafloxacin results in decreased expression of EPHX1 mRNA

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

EPM2A glucan phosphatase, laforin

decreases expression

ISO

trovafloxacin results in decreased expression of EPM2A mRNA

NCBI chr 1:7,547,369...7,673,449
Ensembl chr 1:7,547,342...7,669,604

G

EPM2A interacting protein 1

increases expression

ISO

trovafloxacin results in increased expression of EPM2AIP1 mRNA

NCBI chr 8:120,112,265...120,119,613
Ensembl chr 8:120,112,084...120,121,458

G

glutamyl-prolyl-tRNA synthetase 1

decreases expression

ISO

trovafloxacin results in decreased expression of EPRS1 mRNA

NCBI chr13:99,431,955...99,503,510
Ensembl chr13:99,433,130...99,503,509

G

ERCC excision repair 1, endonuclease non-catalytic subunit

decreases expression

ISO

trovafloxacin results in decreased expression of ERCC1 mRNA

NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120

G

ERCC excision repair 6 like, spindle assembly checkpoint helicase

decreases expression

ISO

trovafloxacin results in decreased expression of ERCC6L mRNA

NCBI chr X:71,285,380...71,301,186
Ensembl chr X:71,285,380...71,301,186

G

endoplasmic reticulum-golgi intermediate compartment 1

decreases expression

EXP

trovafloxacin results in decreased expression of ERGIC1 mRNA

NCBI chr10:17,035,615...17,131,411
Ensembl chr10:17,035,615...17,131,376

G

endoplasmic reticulum metallopeptidase 1

decreases expression

ISO

trovafloxacin results in decreased expression of ERMP1 mRNA

NCBI chr 1:236,801,459...236,835,656
Ensembl chr 1:236,801,466...236,839,197

G

endoplasmic reticulum protein 29

decreases expression

EXP

trovafloxacin results in decreased expression of ERP29 mRNA

NCBI chr12:40,750,177...40,756,607
Ensembl chr12:40,750,314...40,757,010

G

ERBB receptor feedback inhibitor 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ERRFI1 mRNA

NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432

G

establishment of sister chromatid cohesion N-acetyltransferase 2

decreases expression

ISO

trovafloxacin results in decreased expression of ESCO2 mRNA

NCBI chr15:44,210,124...44,230,785
Ensembl chr15:44,210,641...44,231,304
Ensembl chr15:44,210,641...44,231,304

G

esterase D

increases expression

ISO

trovafloxacin results in increased expression of ESD mRNA

NCBI chr15:56,453,082...56,472,582
Ensembl chr15:56,453,044...56,473,508

G

extra spindle pole bodies like 1, separase

decreases expression

ISO

trovafloxacin results in decreased expression of ESPL1 mRNA

NCBI chr 7:135,302,460...135,329,570
Ensembl chr 7:135,302,716...135,329,570

G

estrogen receptor 1

decreases expression

ISO

trovafloxacin results in decreased expression of ESR1 mRNA

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

extended synaptotagmin 1

decreases expression

ISO

trovafloxacin results in decreased expression of ESYT1 mRNA

NCBI chr 7:1,513,381...1,530,836
Ensembl chr 7:1,513,381...1,530,732

G

extended synaptotagmin 2

decreases expression

ISO

trovafloxacin results in decreased expression of ESYT2 mRNA

NCBI chr 6:143,359,870...143,455,600
Ensembl chr 6:143,362,694...143,455,593

G

ETS proto-oncogene 2, transcription factor

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ETS2 mRNA

NCBI chr11:48,491,057...48,507,843
Ensembl chr11:48,491,394...48,507,842

G

ETS variant transcription factor 3

increases expression

ISO

trovafloxacin results in increased expression of ETV3 mRNA

NCBI chr 2:175,263,389...175,278,217
Ensembl chr 2:175,263,459...175,278,208

G

ecotropic viral integration site 2A

increases expression

ISO

trovafloxacin results in increased expression of EVI2A mRNA

NCBI chr10:64,983,727...64,987,627
Ensembl chr10:64,983,705...64,999,516

G

ecotropic viral integration site 5

decreases expression

ISO

trovafloxacin results in decreased expression of EVI5 mRNA

NCBI chr14:2,020,524...2,166,593
Ensembl chr14:2,020,581...2,166,593

G

exonuclease 3'-5' domain containing 2

decreases expression

ISO

trovafloxacin results in decreased expression of EXD2 mRNA

NCBI chr 6:105,847,931...105,881,780
Ensembl chr 6:105,848,305...105,883,665

G

exostosin-like glycosyltransferase 1

decreases expression

ISO

trovafloxacin results in decreased expression of EXTL1 mRNA

NCBI chr 5:151,857,629...151,872,830
Ensembl chr 5:151,857,629...151,872,830

G

EYA transcriptional coactivator and phosphatase 4

decreases expression

ISO

trovafloxacin results in decreased expression of EYA4 mRNA

NCBI chr 1:23,991,431...24,235,132
Ensembl chr 1:23,991,431...24,235,131

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

decreases expression

ISO

trovafloxacin results in decreased expression of EZH2 mRNA

NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:77,624,223...77,687,183

G

coagulation factor X

decreases expression

ISO

trovafloxacin results in decreased expression of F10 mRNA

NCBI chr16:83,170,973...83,190,280
Ensembl chr16:83,170,977...83,190,280

G

coagulation factor XII

increases expression

ISO

trovafloxacin results in increased expression of F12 mRNA

NCBI chr17:9,212,819...9,220,664
Ensembl chr17:9,212,819...9,220,664

G

coagulation factor II, thrombin

multiple interactions

ISO

[Lipopolysaccharides co-treated with trovafloxacin] results in increased activity of F2 protein

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

coagulation factor VII

decreases expression

ISO

trovafloxacin results in decreased expression of F7 mRNA

NCBI chr16:83,191,896...83,202,775
Ensembl chr16:83,191,914...83,202,738

G

fatty acid amide hydrolase

decreases expression

ISO

trovafloxacin results in decreased expression of FAAH mRNA

NCBI chr 5:134,716,545...134,735,396
Ensembl chr 5:134,716,545...134,735,396

G

FA core complex associated protein 100

decreases expression

ISO

trovafloxacin results in decreased expression of FAAP100 mRNA

NCBI chr10:106,140,820...106,152,500
Ensembl chr10:106,142,040...106,151,607

G

Fas associated factor 1

decreases expression

ISO

trovafloxacin results in decreased expression of FAF1 mRNA

NCBI chr 5:129,654,677...130,018,604
Ensembl chr 5:129,654,445...130,020,516

G

fumarylacetoacetate hydrolase domain containing 2A

decreases expression

ISO

trovafloxacin results in decreased expression of FAHD2A mRNA

NCBI chr 3:135,110,480...135,118,653
Ensembl chr 3:135,109,482...135,118,853

G

family with sequence similarity 120 member C

decreases expression

ISO

trovafloxacin results in decreased expression of FAM120C mRNA

NCBI chr X:23,765,089...23,922,059
Ensembl chr X:23,766,976...23,920,840

G

family with sequence similarity 131, member A

decreases expression

ISO

trovafloxacin results in decreased expression of FAM131A mRNA

NCBI chr11:93,715,979...93,725,930
Ensembl chr11:93,716,002...93,725,919

G

family with sequence similarity 13, member C

decreases expression

ISO

trovafloxacin results in decreased expression of FAM13C mRNA

NCBI chr20:18,064,706...18,186,888
Ensembl chr20:18,064,706...18,286,674

G

family with sequence similarity 171, member A2

decreases expression

ISO

trovafloxacin results in decreased expression of FAM171A2 mRNA

NCBI chr10:87,894,049...87,904,213
Ensembl chr10:87,893,543...87,904,247

G

family with sequence similarity 171, member B

decreases expression

ISO

trovafloxacin results in decreased expression of FAM171B mRNA

NCBI chr 3:89,337,566...89,392,973
Ensembl chr 3:89,337,661...89,392,971

G

family with sequence similarity 222, member B

increases expression

ISO

trovafloxacin results in increased expression of FAM222B mRNA

NCBI chr10:63,484,651...63,550,422
Ensembl chr10:63,484,652...63,550,288

G

family with sequence similarity 83, member D

decreases expression

ISO

trovafloxacin results in decreased expression of FAM83D mRNA

NCBI chr 3:167,841,748...167,861,062
Ensembl chr 3:167,841,791...167,861,061

G

family with sequence similarity 83, member H

increases expression

ISO

trovafloxacin results in increased expression of FAM83H mRNA

NCBI chr 7:109,597,129...109,605,317
Ensembl chr 7:109,597,129...109,609,188

G

family with sequence similarity 98, member A

decreases expression

EXP

trovafloxacin results in decreased expression of FAM98A mRNA

NCBI chr 6:25,626,108...25,640,767
Ensembl chr 6:25,625,984...25,640,767

G

FA complementation group A

decreases expression

ISO

trovafloxacin results in decreased expression of FANCA mRNA

NCBI chr19:68,210,562...68,271,080
Ensembl chr19:68,212,643...68,271,019

G

FA complementation group B

decreases expression

ISO

trovafloxacin results in decreased expression of FANCB mRNA

NCBI chr X:33,035,387...33,051,993
Ensembl chr X:33,035,387...33,051,808

G

FA complementation group C

decreases expression

ISO

trovafloxacin results in decreased expression of FANCC mRNA

NCBI chr17:1,686,374...1,818,672
Ensembl chr17:1,687,017...1,835,096

G

FA complementation group D2

decreases expression

ISO

trovafloxacin results in decreased expression of FANCD2 mRNA

NCBI chr 4:148,234,633...148,299,035
Ensembl chr 4:148,234,708...148,299,035

G

FA complementation group I

decreases expression

ISO

trovafloxacin results in decreased expression of FANCI mRNA

NCBI chr 1:142,736,636...142,792,999
Ensembl chr 1:142,736,653...142,792,999

G

fatty acid synthase

multiple interactions
decreases expression

ISO
EXP

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of FASN mRNA
trovafloxacin results in decreased expression of FASN mRNA

PMID:18930950 PMID:24136188

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

F-box and leucine-rich repeat protein 12

increases expression

ISO

trovafloxacin results in increased expression of FBXL12 mRNA

NCBI chr 8:27,453,042...27,459,136
Ensembl chr 8:27,445,823...27,457,772

G

F-box protein 15

decreases expression

ISO

trovafloxacin results in decreased expression of FBXO15 mRNA

NCBI chr18:80,594,444...80,909,549
Ensembl chr 6:51,576,566...51,577,639
Ensembl chr18:51,576,566...51,577,639

G

F-box protein 33

increases expression

ISO

trovafloxacin results in increased expression of FBXO33 mRNA

NCBI chr 6:82,635,509...82,669,441
Ensembl chr 6:82,635,521...82,667,440

G

F-box protein 36

increases expression

ISO

trovafloxacin results in increased expression of FBXO36 mRNA

NCBI chr 9:93,490,618...93,555,298
Ensembl chr 9:93,489,865...93,555,305

G

F-box protein 48

decreases expression

ISO

trovafloxacin results in decreased expression of FBXO48 mRNA

NCBI chr14:95,582,493...95,583,950
Ensembl chr14:95,581,279...95,587,616

G

F-box protein 5

decreases expression

ISO

trovafloxacin results in decreased expression of FBXO5 mRNA

NCBI chr 1:44,601,412...44,607,781
Ensembl chr 1:44,601,412...44,607,781

G

f-box protein 9

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of FBXO9 mRNA

NCBI chr 8:87,838,787...87,864,362
Ensembl chr 8:87,838,789...87,864,504

G

F-box and WD repeat domain containing 10

decreases expression

ISO

trovafloxacin results in decreased expression of FBXW10 mRNA

NCBI chr10:48,012,555...48,051,136
Ensembl chr10:47,958,677...48,051,136

G

Fcf1 rRNA-processing protein

increases expression

ISO

trovafloxacin results in increased expression of FCF1 mRNA

NCBI chr 6:110,348,854...110,360,715
Ensembl chr 6:110,348,845...110,372,221

G

Fc gamma receptor 2B

decreases expression

ISO

trovafloxacin results in decreased expression of FCGR2B mRNA

NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517

G

FCH and double SH3 domains 1

increases expression

ISO

trovafloxacin results in increased expression of FCHSD1 mRNA

NCBI chr18:30,043,466...30,056,326
Ensembl chr18:30,045,106...30,055,673

G

ferredoxin reductase

decreases expression

ISO

trovafloxacin results in decreased expression of FDXR mRNA

NCBI chr10:101,006,845...101,015,582
Ensembl chr10:101,006,849...101,015,542

G

free fatty acid receptor 4

decreases expression

ISO

trovafloxacin results in decreased expression of FFAR4 mRNA

NCBI chr 1:245,286,009...245,304,029
Ensembl chr 1:245,285,883...245,304,031

G

fibrinogen alpha chain

multiple interactions

ISO

[Lipopolysaccharides co-treated with trovafloxacin] results in increased expression of FGA protein

NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577

G

FYVE, RhoGEF and PH domain containing 4

decreases expression

ISO

trovafloxacin results in decreased expression of FGD4 mRNA

NCBI chr11:97,904,182...98,055,190
Ensembl chr11:97,904,182...98,055,190

G

fibroblast growth factor 22

increases expression

ISO

trovafloxacin results in increased expression of FGF22 mRNA

NCBI chr 7:10,598,254...10,600,945
Ensembl chr 7:10,597,538...10,600,945

G

fidgetin-like 2

increases expression

ISO

trovafloxacin results in increased expression of FIGNL2 mRNA

NCBI chr 7:134,038,734...134,066,626
Ensembl chr 7:134,038,672...134,067,893

G

filamin A interacting protein 1-like

decreases expression

ISO

trovafloxacin results in decreased expression of FILIP1L mRNA

NCBI chr11:56,403,467...56,646,422
Ensembl chr11:56,410,582...56,646,402

G

four-jointed box kinase 1

increases expression

EXP

trovafloxacin results in increased expression of ANKHD1-EIF4EBP3 mRNA

NCBI chr 3:109,229,223...109,231,324
Ensembl chr 3:109,227,170...109,232,479

G

FKBP prolyl isomerase 11

decreases expression

ISO

trovafloxacin results in decreased expression of FKBP11 mRNA

NCBI chr 7:131,750,828...131,757,784
Ensembl chr 7:131,750,672...131,770,123

G

FKBP prolyl isomerase family member 15

decreases expression

ISO

trovafloxacin results in decreased expression of FKBP15 mRNA

NCBI chr 5:80,766,356...80,830,622
Ensembl chr 5:80,766,356...80,830,565

G

FKBP prolyl isomerase 4

decreases expression

EXP

trovafloxacin results in decreased expression of FKBP4 mRNA

NCBI chr 4:163,389,464...163,397,918
Ensembl chr 4:163,389,464...163,397,918

G

FKBP prolyl isomerase 8

decreases expression

ISO

trovafloxacin results in decreased expression of FKBP8 mRNA

NCBI chr16:18,929,581...18,936,621
Ensembl chr16:18,929,582...18,936,543

G

FKBP prolyl isomerase like

decreases expression

ISO

trovafloxacin results in decreased expression of FKBPL mRNA

NCBI chr20:4,104,457...4,105,927
Ensembl chr20:4,104,019...4,105,615

G

fibronectin leucine rich transmembrane protein 2

increases expression

ISO

trovafloxacin results in increased expression of FLRT2 mRNA

NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004

G

flavin containing dimethylaniline monoxygenase 3

increases expression

EXP

trovafloxacin results in increased expression of FMO3 mRNA

NCBI chr13:77,838,899...77,868,869
Ensembl chr13:77,842,602...77,861,256

G

flavin containing dimethylaniline monoxygenase 5

decreases expression

ISO

trovafloxacin results in decreased expression of FMO5 mRNA

NCBI chr 2:187,885,741...187,938,468
Ensembl chr 2:187,910,964...187,938,464

G

formin binding protein 1-like

increases expression

ISO

trovafloxacin results in increased expression of FNBP1L mRNA

NCBI chr 2:213,331,871...213,432,821
Ensembl chr 2:213,318,662...213,423,051

G

formin binding protein 4

increases expression

ISO

trovafloxacin results in increased expression of FNBP4 mRNA

NCBI chr 3:97,188,852...97,218,916
Ensembl chr 3:97,188,884...97,219,435

G

fibronectin type III domain containing 8

increases expression

ISO

trovafloxacin results in increased expression of FNDC8 mRNA

NCBI chr10:68,323,500...68,331,638
Ensembl chr10:68,323,497...68,331,639

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of FOS mRNA
trovafloxacin results in increased expression of FOS mRNA

PMID:18930950 PMID:35537566

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FOS like 1, AP-1 transcription factor subunit

increases expression

ISO

trovafloxacin results in increased expression of FOSL1 mRNA

NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391

G

FOS like 2, AP-1 transcription factor subunit

increases expression

ISO

trovafloxacin results in increased expression of FOSL2 mRNA

NCBI chr 6:30,017,952...30,039,269
Ensembl chr 6:30,021,916...30,039,406

G

forkhead box M1

decreases expression

ISO

trovafloxacin results in decreased expression of FOXM1 mRNA

NCBI chr 4:163,325,628...163,338,100
Ensembl chr 4:163,325,614...163,337,172

G

FRAT regulator of WNT signaling pathway 2

decreases expression

ISO

trovafloxacin results in decreased expression of FRAT2 mRNA

NCBI chr 1:250,603,450...250,605,779
Ensembl chr 1:250,603,088...250,606,921

G

fibroblast growth factor receptor substrate 3

increases expression

ISO

trovafloxacin results in increased expression of FRS3 mRNA

NCBI chr 9:20,786,096...20,800,905
Ensembl chr 9:20,786,096...20,794,761

G

FRY microtubule binding protein

decreases expression

ISO

trovafloxacin results in decreased expression of FRY mRNA

NCBI chr12:9,530,360...9,773,391
Ensembl chr12:9,530,360...9,897,603

G

far upstream element binding protein 1

increases expression

ISO

trovafloxacin results in increased expression of FUBP1 mRNA

NCBI chr 2:243,819,529...243,846,544
Ensembl chr 2:243,819,218...243,846,428

G

fucosyltransferase 10

decreases expression

ISO

trovafloxacin results in decreased expression of POFUT3 mRNA

NCBI chr16:67,571,828...67,661,814
Ensembl chr16:67,581,565...67,661,753

G

fucosyltransferase 4

increases expression

ISO

trovafloxacin results in increased expression of FUT4 mRNA

NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436

G

fucosyltransferase 8

decreases expression

ISO

trovafloxacin results in decreased expression of FUT8 mRNA

NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:101,683,007...101,909,775

G

fuzzy planar cell polarity protein

decreases expression

ISO

trovafloxacin results in decreased expression of FUZ mRNA

NCBI chr 1:104,515,782...104,524,591
Ensembl chr 1:104,516,049...104,521,038

G

frizzled class receptor 7

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of FZD7 mRNA

NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585

G

frizzled class receptor 8

increases expression

ISO

trovafloxacin results in increased expression of FZD8 mRNA

NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961

G

G2/M-phase specific E3 ubiquitin protein ligase

decreases expression

ISO

trovafloxacin results in decreased expression of G2E3 mRNA

NCBI chr 6:74,498,801...74,530,703
Ensembl chr 6:74,503,109...74,528,198

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of G6PC1 mRNA

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033

G

glucose-6-phosphate dehydrogenase

decreases expression

EXP

trovafloxacin results in decreased expression of G6PD mRNA

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

alpha glucosidase

decreases expression

ISO

trovafloxacin results in decreased expression of GAA mRNA

NCBI chr10:105,028,106...105,045,365
Ensembl chr10:105,028,307...105,045,366

G

GABA type A receptor associated protein like 1

multiple interactions
increases expression

ISO

[trovafloxacin co-treated with TNF protein] results in increased expression of GABARAPL1 mRNA
trovafloxacin results in increased expression of GABARAPL1 mRNA

NCBI chr 4:164,666,332...164,675,474
Ensembl chr 4:164,666,246...164,674,578

G

GABA type A receptor associated protein like 2

multiple interactions
increases expression

ISO

TNF protein inhibits the reaction [trovafloxacin results in increased expression of GABARAPL2 mRNA]

NCBI chr19:56,819,826...56,830,662
Ensembl chr19:56,819,791...56,830,660

G

growth arrest and DNA-damage-inducible, alpha

decreases expression

ISO

trovafloxacin results in decreased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

growth arrest and DNA-damage-inducible, beta

increases expression

ISO

trovafloxacin results in increased expression of GADD45B mRNA

NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718

G

growth arrest and DNA-damage-inducible, gamma

decreases expression
increases expression

EXP
ISO

trovafloxacin results in decreased expression of GADD45G mRNA
trovafloxacin results in increased expression of GADD45G mRNA

PMID:24136188 PMID:35537566

NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,528,610...13,530,369

G

galactose-3-O-sulfotransferase 4

increases expression

ISO

trovafloxacin results in increased expression of GAL3ST4 mRNA

NCBI chr12:22,381,576...22,390,566
Ensembl chr12:22,381,576...22,390,824

G

galactosylceramidase

decreases expression

ISO

trovafloxacin results in decreased expression of GALC mRNA

NCBI chr 6:123,182,636...123,252,024
Ensembl chr 6:123,182,643...123,245,578

G

gigaxonin

increases expression

ISO

trovafloxacin results in increased expression of GAN mRNA

NCBI chr19:62,116,600...62,173,879
Ensembl chr19:62,116,600...62,163,083

G

glucosidase, alpha; neutral C

decreases expression

ISO

trovafloxacin results in decreased expression of GANC mRNA

NCBI chr 3:127,807,132...127,858,995
Ensembl chr 3:127,807,441...127,859,859

G

glyceraldehyde-3-phosphate dehydrogenase

decreases expression

EXP

trovafloxacin results in decreased expression of GAPDH mRNA

NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377

G

glyceraldehyde-3-phosphate dehydrogenase, spermatogenic

increases expression

ISO

trovafloxacin results in increased expression of GAPDHS mRNA

NCBI chr 1:95,106,516...95,125,918
Ensembl chr 1:95,106,518...95,121,055

G

glycyl-tRNA synthetase 1

decreases expression

ISO

trovafloxacin results in decreased expression of GARS1 mRNA

NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876

G

growth arrest-specific 2

decreases expression

ISO

trovafloxacin results in decreased expression of GAS2 mRNA

NCBI chr 1:110,587,952...110,721,572
Ensembl chr 1:110,717,312...110,718,541

G

growth arrest specific 5

increases expression

ISO

trovafloxacin results in increased expression of GAS5 mRNA

NCBI chr13:75,836,963...75,840,284

G

growth arrest specific 8

increases expression

ISO

trovafloxacin results in increased expression of GAS8 mRNA

NCBI chr19:68,461,280...68,480,810
Ensembl chr19:68,461,304...68,480,806

G

guanylate binding protein 1

increases expression

ISO

trovafloxacin results in increased expression of GBP2B mRNA

NCBI chr 2:234,071,366...234,106,012
Ensembl chr 2:234,190,708...234,206,802
Ensembl chr 2:234,190,708...234,206,802

G

guanylate binding protein 2

increases expression

ISO

trovafloxacin results in increased expression of GBP2 mRNA

NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810

G

guanylate binding protein family member 6

increases expression

ISO

trovafloxacin results in increased expression of GBP6 mRNA

NCBI chr14:5,034,999...5,062,023
Ensembl chr14:4,968,325...4,983,692
Ensembl chr14:4,968,325...4,983,692

G

guanylate binding protein 7

increases expression

ISO

trovafloxacin results in increased expression of GBP7 mRNA

NCBI chr 2:233,948,774...233,970,532
Ensembl chr 2:233,948,677...233,970,526

G

glycine C-acetyltransferase

decreases expression

ISO

trovafloxacin results in decreased expression of GCAT mRNA

NCBI chr 7:112,475,572...112,481,920
Ensembl chr 7:112,475,496...112,482,664

G

glucagon receptor

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GCGR mRNA

NCBI chr10:106,306,803...106,314,970
Ensembl chr10:106,306,559...106,314,969

G

glutamate-cysteine ligase, catalytic subunit

decreases expression
multiple interactions

EXP
ISO

trovafloxacin results in decreased expression of GCLC mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GCLC mRNA

PMID:18930950 PMID:24136188

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

GEN1 Holliday junction 5' flap endonuclease

decreases expression

ISO

trovafloxacin results in decreased expression of GEN1 mRNA

NCBI chr 6:39,666,675...39,697,480
Ensembl chr 6:39,667,286...39,697,480

G

guided entry of tail-anchored proteins factor 1

increases expression

ISO

trovafloxacin results in increased expression of WRB mRNA

NCBI chr11:48,915,298...48,929,235
Ensembl chr11:48,915,289...48,929,416

G

G elongation factor, mitochondrial 1

decreases expression

EXP

trovafloxacin results in decreased expression of GFM1 mRNA

NCBI chr 2:154,010,601...154,055,523
Ensembl chr 2:154,010,614...154,065,805

G

Gfo/Idh/MocA-like oxidoreductase domain containing 2

increases expression

ISO

trovafloxacin results in increased expression of GFOD2 mRNA

NCBI chr19:50,508,626...50,556,945
Ensembl chr19:50,513,709...50,557,132

G

gamma-glutamyl carboxylase

decreases expression

EXP

trovafloxacin results in decreased expression of GGCX mRNA

NCBI chr 4:106,027,918...106,043,653
Ensembl chr 4:106,027,912...106,043,923

G

GINS complex subunit 2

decreases expression

ISO

trovafloxacin results in decreased expression of GINS2 mRNA

NCBI chr19:65,535,492...65,548,270
Ensembl chr19:65,535,492...65,548,052

G

GIPC PDZ domain containing family, member 1

decreases expression

ISO

trovafloxacin results in decreased expression of GIPC1 mRNA

NCBI chr19:41,380,125...41,392,078
Ensembl chr19:41,380,125...41,391,725

G

gap junction protein, alpha 1

multiple interactions
increases expression

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GJA1 mRNA
trovafloxacin results in increased expression of GJA1 mRNA

PMID:18930950 PMID:35537566

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689

G

GLIS family zinc finger 2

increases expression

ISO

trovafloxacin results in increased expression of GLIS2 mRNA

NCBI chr10:11,457,594...11,484,948
Ensembl chr10:11,457,792...11,477,995

G

glycosylated lysosomal membrane protein

decreases expression

ISO

trovafloxacin results in decreased expression of GLMP mRNA

NCBI chr 2:176,092,098...176,095,688
Ensembl chr 2:176,091,839...176,097,208

G

glucagon-like peptide 2 receptor

increases expression

ISO

trovafloxacin results in increased expression of GLP2R mRNA

NCBI chr10:52,901,707...52,964,961
Ensembl chr10:52,900,706...52,964,961

G

glutaredoxin 3

decreases expression

EXP

trovafloxacin results in decreased expression of GLRX3 mRNA

NCBI chr 1:201,671,410...201,701,722
Ensembl chr 1:201,671,481...201,701,717

G

glutaminase 2

decreases expression

ISO

trovafloxacin results in decreased expression of GLS2 mRNA

NCBI chr 7:1,201,757...1,218,014
Ensembl chr 7:1,201,838...1,218,013

G

glycine-N-acyltransferase

increases expression

EXP

trovafloxacin results in increased expression of GLYAT mRNA

NCBI chr 1:219,128,798...219,149,615
Ensembl chr 1:219,128,811...219,150,774

G

glia maturation factor, beta

increases expression

ISO

trovafloxacin results in increased expression of GMFB mRNA

NCBI chr15:22,549,705...22,560,125
Ensembl chr15:22,547,034...22,560,308

G

G protein subunit alpha transducin 2

decreases expression

ISO

trovafloxacin results in decreased expression of GNAT2 mRNA

NCBI chr 2:198,414,568...198,431,532
Ensembl chr 2:198,414,920...198,424,022

G

G protein nucleolar 3

increases expression

EXP

trovafloxacin results in increased expression of GNL3 mRNA

NCBI chr16:6,213,844...6,220,029
Ensembl chr16:6,213,871...6,219,845

G

glyceronephosphate O-acyltransferase

decreases expression

ISO

trovafloxacin results in decreased expression of GNPAT mRNA

NCBI chr19:69,719,707...69,746,244
Ensembl chr19:69,719,394...69,746,244

G

glucosamine-phosphate N-acetyltransferase 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GNPNAT1 mRNA

NCBI chr15:21,076,129...21,088,526
Ensembl chr15:21,076,130...21,088,423

G

N-acetylglucosamine-1-phosphate transferase subunit gamma

decreases expression

ISO

trovafloxacin results in decreased expression of GNPTG mRNA

NCBI chr10:14,756,685...14,761,636

G

golgin A2

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GOLGA2 mRNA

NCBI chr 3:35,981,783...36,002,023
Ensembl chr 3:35,981,499...36,002,022

G

golgin A4

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of GOLGA4 mRNA

NCBI chr 8:127,085,830...127,163,227
Ensembl chr 8:127,085,848...127,163,603

G

glycosylphosphatidylinositol anchor attachment 1

decreases expression

ISO

trovafloxacin results in decreased expression of GPAA1 mRNA

NCBI chr 7:109,932,556...109,936,139
Ensembl chr 7:109,932,544...109,936,138

G

glycerol-3-phosphate acyltransferase, mitochondrial

decreases expression

EXP

trovafloxacin results in decreased expression of GPAM mRNA

NCBI chr 1:264,111,599...264,176,112
Ensembl chr 1:264,113,813...264,175,911

G

glycerol-3-phosphate acyltransferase 3

decreases expression

ISO

trovafloxacin results in decreased expression of AGPAT9 mRNA

NCBI chr14:9,018,762...9,072,552

G

G patch domain containing 3

increases expression

ISO

trovafloxacin results in increased expression of GPATCH3 mRNA

NCBI chr 5:151,083,970...151,093,382
Ensembl chr 5:151,083,961...151,093,537

G

glypican 1

increases expression

ISO

trovafloxacin results in increased expression of GPC1 mRNA

NCBI chr 9:100,843,645...100,871,458
Ensembl chr 9:100,843,645...100,879,933

G

gephyrin

decreases expression

ISO

trovafloxacin results in decreased expression of GPHN mRNA

NCBI chr 6:102,687,405...103,216,679
Ensembl chr 6:102,687,423...103,216,674

G

glycosylphosphatidylinositol specific phospholipase D1

increases expression

EXP

trovafloxacin results in increased expression of GPLD1 mRNA

NCBI chr17:40,512,659...40,560,483
Ensembl chr17:40,512,660...40,554,975

G

G protein-coupled receptor 155

decreases expression

ISO

trovafloxacin results in decreased expression of GPR155 mRNA

NCBI chr 3:78,623,931...78,677,803
Ensembl chr 3:78,607,976...78,677,803

G

G protein-coupled receptor 160

decreases expression

ISO

trovafloxacin results in decreased expression of GPR160 mRNA

NCBI chr 2:114,414,084...114,491,590
Ensembl chr 2:114,410,261...114,474,790

G

G protein-coupled receptor 17

increases expression

ISO

trovafloxacin results in increased expression of GPR17 mRNA

NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702

G

G protein-coupled receptor 176

decreases expression

ISO

trovafloxacin results in decreased expression of GPR176 mRNA

NCBI chr 3:125,690,750...125,791,172
Ensembl chr 3:125,690,751...125,791,172

G

G protein-coupled receptor 19

decreases expression

ISO

trovafloxacin results in decreased expression of GPR19 mRNA

NCBI chr 4:169,442,278...169,468,805
Ensembl chr 4:169,436,658...169,471,249

G

G protein-coupled receptor 34

decreases expression

ISO

trovafloxacin results in decreased expression of GPR34 mRNA

NCBI chr X:11,777,667...11,786,640
Ensembl chr X:11,776,371...11,843,240

G

G protein-coupled receptor 35

decreases expression

ISO

trovafloxacin results in decreased expression of GPR35 mRNA

NCBI chr 9:100,974,580...100,995,330
Ensembl chr 9:100,962,538...100,986,985

G

G-protein coupled receptor 65

decreases expression

ISO

trovafloxacin results in decreased expression of GPR65 mRNA

NCBI chr 6:123,245,534...123,262,758
Ensembl chr 6:123,219,633...123,266,285

G

G-protein signaling modulator 2

decreases expression

ISO

trovafloxacin results in decreased expression of GPSM2 mRNA

NCBI chr 2:199,015,250...199,063,788
Ensembl chr 2:199,015,250...199,063,056

G

glutamic--pyruvic transaminase 2

decreases expression

ISO

trovafloxacin results in decreased expression of GPT2 mRNA

NCBI chr19:37,700,023...37,734,551
Ensembl chr19:37,691,901...37,733,917

G

grainyhead-like transcription factor 1

increases expression

ISO

trovafloxacin results in increased expression of GRHL1 mRNA

NCBI chr 6:46,935,947...46,986,126
Ensembl chr 6:46,935,967...46,980,264

G

glutamate ionotropic receptor NMDA type subunit 3B

increases expression

ISO

trovafloxacin results in increased expression of GRIN3B mRNA

NCBI chr 7:10,381,495...10,387,817
Ensembl chr 7:10,381,496...10,387,817

G

glutamate-rich WD repeat containing 1

increases expression

ISO

trovafloxacin results in increased expression of GRWD1 mRNA

NCBI chr 1:105,437,708...105,443,410
Ensembl chr 1:105,437,709...105,443,825

G

glutathione-disulfide reductase

decreases expression

EXP

trovafloxacin results in decreased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione synthetase

decreases expression

EXP

trovafloxacin results in decreased expression of GSS mRNA

NCBI chr 3:164,508,005...164,538,343
Ensembl chr 3:164,508,005...164,538,306

G

glutathione S-transferase alpha 3

decreases expression

EXP

trovafloxacin results in decreased expression of GSTA3 mRNA

NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654

G

general transcription factor III A

decreases expression

ISO

trovafloxacin results in decreased expression of GTF3A mRNA

NCBI chr12:13,250,643...13,258,587
Ensembl chr12:13,250,644...13,258,587

G

GTP binding protein 2

decreases expression

ISO

trovafloxacin results in decreased expression of GTPBP2 mRNA

NCBI chr 9:22,311,532...22,321,405
Ensembl chr 9:22,311,158...22,321,441

G

GTP binding protein 6 (putative)

increases expression

ISO

trovafloxacin results in increased expression of GTPBP6 mRNA

NCBI chr12:52,234,646...52,238,578
Ensembl chr12:52,234,572...52,238,578

G

G-2 and S-phase expressed 1

increases expression

ISO

trovafloxacin results in increased expression of GTSE1 mRNA

NCBI chr 7:118,829,793...118,846,662
Ensembl chr 7:118,829,903...118,846,661

G

GTPase, very large interferon inducible 1

increases expression

ISO

trovafloxacin results in increased expression of GVIN2 mRNA

NCBI chr 1:169,689,178...169,718,522
Ensembl chr 1:169,691,586...169,718,522

G

H1.0 linker histone

decreases expression

ISO

trovafloxacin results in decreased expression of H1F0 mRNA

NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006

G

H1.10 linker histone

decreases expression

ISO

trovafloxacin results in decreased expression of H1F10 mRNA

NCBI chr 4:121,997,834...121,998,897
Ensembl chr 4:121,997,831...121,998,966

G

H1.2 linker histone, cluster member

decreases expression

ISO

trovafloxacin results in decreased expression of H1F2 mRNA

NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317

G

H1.4 linker histone, cluster member

decreases expression

ISO

trovafloxacin results in decreased expression of H1F4 mRNA

NCBI chr17:41,914,425...41,915,206
Ensembl chr17:41,914,431...41,916,129

G

H1.5 linker histone, cluster member

decreases expression

ISO

trovafloxacin results in decreased expression of H1F5 mRNA

NCBI chr17:47,421,875...47,422,905
Ensembl chr17:47,421,843...47,477,387

G

H2A clustered histone 10

decreases expression

ISO

trovafloxacin results in decreased expression of H2AC10 mRNA

NCBI chr17:41,998,567...41,999,055
Ensembl chr17:41,998,622...41,999,025

G

H2A clustered histone 13

decreases expression

ISO

trovafloxacin results in decreased expression of H2AC8 mRNA

NCBI chr17:41,807,261...41,807,653

G

H2A clustered histone 4

decreases expression

ISO

trovafloxacin results in decreased expression of H2AC4 mRNA

NCBI chr17:47,495,624...47,496,127
Ensembl chr17:47,495,546...47,496,173

G

H2A.X variant histone

multiple interactions
decreases expression
increases phosphorylation
increases expression

ISO

[TNF protein co-treated with trovafloxacin] results in increased expression of H2AX protein modified form; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[TNF protein co-treated with trovafloxacin] results in increased expression of H2AX protein modified form]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [trovafloxacin results in increased expression of H2AX protein modified form]; TNF protein promotes the reaction [trovafloxacin results in increased expression of H2AX protein modified form]
trovafloxacin results in decreased expression of H2AX mRNA
trovafloxacin results in increased phosphorylation of H2AX protein

PMID:24817034 PMID:25748550 PMID:35537566

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

H2B clustered histone 14

decreases expression

ISO

trovafloxacin results in decreased expression of H2BC14 mRNA

NCBI chr17:47,488,627...47,489,008

G

H2B clustered histone 18

decreases expression

ISO

trovafloxacin results in decreased expression of H2BC18 mRNA

NCBI chr 2:186,527,197...186,531,634

G

H2B clustered histone 3

decreases expression

ISO

trovafloxacin results in decreased expression of H2BC3 mRNA

NCBI chr17:41,807,913...41,808,543

G

H2B clustered histone 4

decreases expression

ISO

trovafloxacin results in decreased expression of H2BC4 mRNA

NCBI chr17:47,388,085...47,392,349
Ensembl chr17:47,404,375...47,419,020

G

H2B clustered histone 6

decreases expression

ISO

trovafloxacin results in decreased expression of H2BC6 mRNA

NCBI chr17:41,948,813...41,949,276
Ensembl chr17:47,392,229...47,449,312

G

H2B clustered histone 8

decreases expression

ISO

trovafloxacin results in decreased expression of H2BC8 mRNA

NCBI chr17:47,404,405...47,405,155

G

H2B clustered histone 9

decreases expression

ISO

trovafloxacin results in decreased expression of H2BC9 mRNA

NCBI chr17:47,166,372...47,174,369

G

H3 clustered histone 10

decreases expression

ISO

trovafloxacin results in decreased expression of H3C10 mRNA; trovafloxacin results in decreased expression of H3C6 mRNA

NCBI chr17:41,996,216...41,997,128
Ensembl chr17:47,493,820...47,494,861
Ensembl chr17:47,493,820...47,494,861

G

H3 clustered histone 15

decreases expression

ISO

trovafloxacin results in decreased expression of H3C11 mRNA

NCBI chr 2:186,526,162...186,526,587
Ensembl chr 2:186,521,116...186,550,846

G

H4 clustered histone 1

decreases expression

ISO

trovafloxacin results in decreased expression of H4C1 mRNA

NCBI chr17:47,393,764...47,394,168
Ensembl chr17:47,393,603...47,453,972
Ensembl chr17:47,393,603...47,453,972
Ensembl chr 4:47,393,603...47,453,972
Ensembl chr17:47,393,603...47,453,972
Ensembl chr17:47,393,603...47,453,972

G

H4 clustered histone 3

decreases expression

ISO

trovafloxacin results in decreased expression of H4C6 mRNA

NCBI chr17:41,796,600...41,860,389

G

H4 clustered histone 8

decreases expression

ISO

trovafloxacin results in decreased expression of H4C4 mRNA; trovafloxacin results in decreased expression of H4C9 mRNA

NCBI chr17:47,176,246...47,180,690
Ensembl chr17:41,797,152...41,806,539
Ensembl chr17:41,797,152...41,806,539
Ensembl chr17:41,797,152...41,806,539
Ensembl chr 4:41,797,152...41,806,539

G

H1.3 linker histone, cluster member

decreases expression

ISO

trovafloxacin results in decreased expression of H1F3 mRNA

NCBI chr17:41,979,562...41,980,341
Ensembl chr17:41,796,116...41,980,485

G

3-hydroxyacyl-CoA dehydratase 3

decreases expression

EXP

trovafloxacin results in decreased expression of HACD3 mRNA

NCBI chr 8:74,396,441...74,433,700
Ensembl chr 8:74,396,442...74,433,700

G

3-hydroxyacyl-CoA dehydratase 4

decreases expression

ISO

trovafloxacin results in decreased expression of HACD4 mRNA

NCBI chr 5:107,935,514...107,961,271
Ensembl chr 5:107,934,937...107,962,836

G

2-hydroxyacyl-CoA lyase 1

increases expression
decreases expression

EXP
ISO

trovafloxacin results in increased expression of HACL1 mRNA
trovafloxacin results in decreased expression of HACL1 mRNA

PMID:24136188 PMID:35537566

NCBI chr16:6,831,293...6,869,410
Ensembl chr16:6,833,268...6,869,410

G

hydroxyacid oxidase 2

increases expression

EXP

trovafloxacin results in increased expression of HAO2 mRNA

NCBI chr 2:188,888,848...188,921,567
Ensembl chr 2:188,889,212...188,913,133

G

histone H3 associated protein kinase

decreases expression

ISO

trovafloxacin results in decreased expression of GSG2 mRNA

NCBI chr10:58,246,244...58,249,031
Ensembl chr10:58,240,447...58,249,249

G

HAUS augmin-like complex, subunit 4

decreases expression

ISO

trovafloxacin results in decreased expression of HAUS4 mRNA

NCBI chr15:31,964,555...31,976,853
Ensembl chr15:31,964,556...31,975,941

G

HAUS augmin-like complex, subunit 5

decreases expression

ISO

trovafloxacin results in decreased expression of HAUS5 mRNA

NCBI chr 1:95,039,800...95,050,778
Ensembl chr 1:95,039,800...95,050,778

G

heparin-binding EGF-like growth factor

increases expression

ISO

trovafloxacin results in increased expression of HBEGF mRNA

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2

decreases expression

ISO

trovafloxacin results in decreased expression of HCN2 mRNA

NCBI chr 7:10,620,422...10,639,457
Ensembl chr 7:10,620,422...10,639,457

G

haloacid dehalogenase-like hydrolase domain containing 3

increases expression

ISO

trovafloxacin results in increased expression of HDHD3 mRNA

NCBI chr 5:80,966,878...80,970,345
Ensembl chr 5:80,954,610...80,970,854

G

high density lipoprotein binding protein

decreases expression

ISO

trovafloxacin results in decreased expression of HDLBP mRNA

NCBI chr 9:101,395,491...101,465,446
Ensembl chr 9:101,397,305...101,465,379

G

HemK methyltransferase family member 1

decreases expression

ISO

trovafloxacin results in decreased expression of HEMK1 mRNA

NCBI chr 8:116,878,317...116,889,342
Ensembl chr 8:116,878,318...116,888,873

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

decreases expression

ISO

trovafloxacin results in decreased expression of HERC1 mRNA

NCBI chr 8:75,796,347...75,965,347
Ensembl chr 8:75,796,357...75,965,347

G

homocysteine inducible ER protein with ubiquitin like domain 1

decreases expression

ISO

trovafloxacin results in decreased expression of HERPUD1 mRNA

NCBI chr19:10,604,360...10,624,168
Ensembl chr19:10,604,362...10,624,081

G

hypoxia inducible lipid droplet-associated

increases expression

ISO

trovafloxacin results in increased expression of HILPDA mRNA

NCBI chr 4:58,836,463...58,839,423
Ensembl chr 4:58,836,463...58,839,423

G

huntingtin interacting protein 1 related

decreases expression

ISO

trovafloxacin results in decreased expression of HIP1R mRNA

NCBI chr12:38,251,085...38,279,756
Ensembl chr12:38,251,086...38,279,654

G

HIRA interacting protein 3

decreases expression

ISO

trovafloxacin results in decreased expression of HIRIP3 mRNA

NCBI chr 1:190,903,065...190,905,610
Ensembl chr 1:190,902,593...190,905,607

G

helicase-like transcription factor

decreases expression

ISO

trovafloxacin results in decreased expression of HLTF mRNA

NCBI chr 2:104,478,725...104,538,531
Ensembl chr 2:104,478,772...104,538,818

G

high mobility group AT-hook 2

increases expression

ISO

trovafloxacin results in increased expression of HMGA2 mRNA

NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341

G

high mobility group box 2

decreases expression

ISO

trovafloxacin results in decreased expression of HMGB2 mRNA

NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860

G

high mobility group box 3

decreases expression

ISO

trovafloxacin results in decreased expression of HMGB3 mRNA

NCBI chr X:154,341,106...154,346,087
Ensembl chr X:154,340,935...154,346,097

G

high mobility group nucleosomal binding domain 3

decreases expression

EXP

trovafloxacin results in decreased expression of HMGN3 mRNA

NCBI chr 8:92,902,555...92,939,980

G

high mobility group nucleosome binding domain 5

decreases expression

ISO

trovafloxacin results in decreased expression of HMGN5 mRNA

NCBI chr X:78,161,439...78,170,613
Ensembl chr X:78,161,442...78,169,924

G

hyaluronan-mediated motility receptor

decreases expression

ISO

trovafloxacin results in decreased expression of HMMR mRNA

NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,635,915...25,665,390

G

heme oxygenase 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heterogeneous nuclear ribonucleoprotein A1

increases expression

ISO

trovafloxacin results in increased expression of HNRNPA1 mRNA

NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:136,253,278...136,260,085

G

heterogeneous nuclear ribonucleoprotein D-like

increases expression

ISO

trovafloxacin results in increased expression of HNRNPDL mRNA

NCBI chr14:9,861,716...9,867,945
Ensembl chr14:9,861,716...9,867,945

G

heterogeneous nuclear ribonucleoprotein F

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of HNRNPF mRNA

NCBI chr 4:152,755,668...152,776,867
Ensembl chr 4:152,722,617...152,815,769

G

heterogeneous nuclear ribonucleoprotein L

increases expression

ISO

trovafloxacin results in increased expression of HNRNPL mRNA

NCBI chr 1:93,226,373...93,239,084
Ensembl chr 1:93,235,729...93,239,061

G

homeo box B5

decreases expression

ISO

trovafloxacin results in decreased expression of HOXB5 mRNA

NCBI chr10:81,765,911...81,768,119

G

homeo box B8

increases expression

ISO

trovafloxacin results in increased expression of HOXB8 mRNA

NCBI chr10:81,745,430...81,747,181
Ensembl chr10:81,739,704...81,747,802

G

haptoglobin

decreases expression

ISO

trovafloxacin results in decreased expression of HP mRNA

NCBI chr19:54,449,151...54,453,701
Ensembl chr19:54,446,217...54,467,518

G

heparan sulfate-glucosamine 3-sulfotransferase 3B1

decreases expression

ISO

trovafloxacin results in decreased expression of HS3ST3B1 mRNA

NCBI chr10:49,060,693...49,093,185
Ensembl chr10:49,060,693...49,093,185

G

heat shock protein family B (small) member 6

decreases expression

ISO

trovafloxacin results in decreased expression of HSPB6 mRNA

NCBI chr 1:94,934,372...94,936,516
Ensembl chr 1:94,933,543...94,936,512

G

heat shock protein family B (small) member 7

decreases expression

ISO

trovafloxacin results in decreased expression of HSPB7 mRNA

NCBI chr 5:159,010,759...159,014,245
Ensembl chr 5:159,010,629...159,014,243

G

heat shock protein family H (Hsp110) member 1

decreases expression

EXP

trovafloxacin results in decreased expression of HSPH1 mRNA

NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891

G

HIV-1 Tat interactive protein 2

decreases expression

EXP

trovafloxacin results in decreased expression of HTATIP2 mRNA

NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815

G

HtrA serine peptidase 2

decreases expression

ISO

trovafloxacin results in decreased expression of HTRA2 mRNA

NCBI chr 4:117,114,631...117,117,793
Ensembl chr 4:117,114,633...117,117,793

G

HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1

decreases expression

ISO

trovafloxacin results in decreased expression of HUWE1 mRNA

NCBI chr X:24,350,708...24,480,798
Ensembl chr X:24,353,217...24,480,798

G

hydroxypyruvate isomerase

decreases expression

ISO

trovafloxacin results in decreased expression of HYI mRNA

NCBI chr 5:137,179,975...137,182,654
Ensembl chr 5:137,179,976...137,182,654

G

HYLS1, centriolar and ciliogenesis associated

decreases expression

ISO

trovafloxacin results in decreased expression of HYLS1 mRNA

NCBI chr 8:42,170,505...42,179,573
Ensembl chr 8:42,168,546...42,179,725

G

isoleucyl-tRNA synthetase 1

decreases expression

ISO

trovafloxacin results in decreased expression of IARS1 mRNA

NCBI chr17:15,147,357...15,193,716
Ensembl chr17:15,147,357...15,193,652

G

isoleucyl-tRNA synthetase 2, mitochondrial

decreases expression

ISO

trovafloxacin results in decreased expression of IARS2 mRNA

NCBI chr13:99,363,035...99,397,068
Ensembl chr13:99,362,696...99,397,068

G

intercellular adhesion molecule 1

multiple interactions
increases expression
decreases expression

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ICAM1 mRNA; trovafloxacin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]
trovafloxacin results in increased expression of ICAM1 mRNA
[trovafloxacin co-treated with TNF protein] results in increased expression of ICAM1 mRNA
trovafloxacin results in decreased expression of ICAM1 mRNA

PMID:18930950 PMID:32035082 PMID:35537566

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

intercellular adhesion molecule 2

decreases expression

ISO

trovafloxacin results in decreased expression of ICAM2 mRNA

NCBI chr10:91,808,449...91,819,319
Ensembl chr10:91,808,316...91,815,072

G

intercellular adhesion molecule 4, Landsteiner-Wiener blood group

decreases expression

ISO

trovafloxacin results in decreased expression of ICAM4 mRNA

NCBI chr 8:27,842,255...27,843,351
Ensembl chr 8:27,842,255...27,844,371

G

inhibitor of DNA binding 1

increases expression

ISO

trovafloxacin results in increased expression of ID1 mRNA

NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685

G

inhibitor of DNA binding 2

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of ID2 mRNA

NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:47,457,554...47,472,961

G

insulin degrading enzyme

decreases expression

EXP

trovafloxacin results in decreased expression of IDE mRNA

NCBI chr 1:244,415,495...244,516,925
Ensembl chr 1:244,416,343...244,514,526

G

isocitrate dehydrogenase (NADP(+)) 2

decreases expression

EXP
ISO

trovafloxacin results in decreased expression of IDH2 mRNA

PMID:24136188 PMID:35537566

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248

G

immediate early response 3

increases expression

ISO

trovafloxacin results in increased expression of IER3 mRNA

NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377

G

immediate early response 5-like

decreases expression

ISO

trovafloxacin results in decreased expression of IER5L mRNA

NCBI chr 3:34,141,866...34,143,457
Ensembl chr 3:34,139,672...34,144,452

G

interferon-induced protein 35

increases expression

ISO

trovafloxacin results in increased expression of IFI35 mRNA

NCBI chr10:86,881,270...86,889,523
Ensembl chr10:86,887,122...86,889,750

G

interferon-induced protein 44

increases expression

ISO

trovafloxacin results in increased expression of IFI44 mRNA

NCBI chr 2:243,286,050...243,303,869
Ensembl chr 2:243,286,052...243,306,877

G

interferon-induced protein 44-like

increases expression

ISO

trovafloxacin results in increased expression of IFI44L mRNA

NCBI chr 2:243,328,629...243,366,404
Ensembl chr 2:243,328,723...243,366,404

G

interferon-induced protein with tetratricopeptide repeats 1

increases expression

ISO

trovafloxacin results in increased expression of IFIT1 mRNA

NCBI chr 1:241,565,197...241,567,262
Ensembl chr 1:241,543,184...241,568,148

G

interferon-induced protein with tetratricopeptide repeats 2

increases expression

ISO

trovafloxacin results in increased expression of IFIT2 mRNA

NCBI chr 1:241,515,735...241,521,799
Ensembl chr 1:241,515,709...241,521,798

G

interferon-induced protein with tetratricopeptide repeats 3

increases expression

ISO

trovafloxacin results in increased expression of IFIT3 mRNA

NCBI chr 1:241,527,326...241,532,469
Ensembl chr 1:241,526,880...241,532,521

G

interferon induced transmembrane protein 3

increases expression

ISO

trovafloxacin results in increased expression of IFITM3 mRNA

NCBI chr 1:205,540,649...205,541,758
Ensembl chr 1:205,481,168...205,547,920

G

interferon gamma

multiple interactions

ISO
EXP

IFNG protein promotes the reaction [[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF protein]; IFNG protein results in increased susceptibility to [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5]; trovafloxacin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNG protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IFNG protein]
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin

PMID:18930950 PMID:19362101 PMID:19638433

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interferon-related developmental regulator 1

increases expression
decreases expression
multiple interactions

EXP
ISO

trovafloxacin results in increased expression of IFRD1 mRNA
trovafloxacin results in decreased expression of IFRD1 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IFRD1 mRNA

PMID:18930950 PMID:24136188 PMID:35537566

NCBI chr 6:62,996,560...63,044,996
Ensembl chr 6:62,996,562...63,016,131

G

interferon-related developmental regulator 2

decreases expression

ISO

trovafloxacin results in decreased expression of IFRD2 mRNA

NCBI chr 8:117,139,612...117,144,834
Ensembl chr 8:117,139,550...117,144,836

G

intraflagellar transport 140

decreases expression

ISO

trovafloxacin results in decreased expression of IFT140 mRNA

NCBI chr10:14,537,134...14,624,926
Ensembl chr10:14,537,466...14,624,926

G

intraflagellar transport 172

decreases expression

ISO

trovafloxacin results in decreased expression of IFT172 mRNA

NCBI chr 6:30,801,841...30,841,239
Ensembl chr 6:30,801,918...30,840,830

G

insulin-like growth factor 1

increases expression

ISO

trovafloxacin results in increased expression of IGF1 mRNA

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 2 mRNA binding protein 1

increases expression

ISO

trovafloxacin results in increased expression of IGF2BP1 mRNA

NCBI chr10:81,405,021...81,447,814
Ensembl chr10:81,404,797...81,447,846

G

insulin-like growth factor binding protein 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IGFBP1 mRNA

NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344

G

immunoglobulin mu DNA binding protein 2

increases expression

ISO

trovafloxacin results in increased expression of IGHMBP2 mRNA

NCBI chr 1:209,935,922...209,958,570
Ensembl chr 1:209,934,969...209,958,766

G

immunoglobulin superfamily, member 3

increases expression

ISO

trovafloxacin results in increased expression of IGSF3 mRNA

NCBI chr 2:191,499,972...191,588,249
Ensembl chr 2:191,500,045...191,588,249

G

inhibitor of nuclear factor kappa B kinase subunit beta

decreases expression

ISO

trovafloxacin results in decreased expression of IKBKB mRNA

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911

G

interleukin 12 receptor subunit beta 2

decreases expression

ISO

trovafloxacin results in decreased expression of IL12RB2 mRNA

NCBI chr 4:97,756,089...97,844,937
Ensembl chr 4:97,756,089...97,844,937

G

interleukin 15

increases expression

ISO

trovafloxacin results in increased expression of IL15 mRNA

NCBI chr19:42,536,160...42,611,349
Ensembl chr19:42,545,346...42,611,348

G

interleukin 16

decreases expression

ISO

trovafloxacin results in decreased expression of IL16 mRNA

NCBI chr 1:147,026,852...147,127,177
Ensembl chr 1:147,027,097...147,127,023

G

interleukin 17 receptor A

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL17RA mRNA

NCBI chr 4:155,339,742...155,362,382
Ensembl chr 4:155,339,400...155,362,382

G

interleukin 18

multiple interactions

ISO

IL18 protein results in increased susceptibility to [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5]; trovafloxacin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL18 protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IL18 protein]

PMID:18930950 PMID:19638433

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 18 binding protein

increases expression

ISO

trovafloxacin results in increased expression of IL18BP mRNA

NCBI chr 1:165,784,916...165,787,990
Ensembl chr 1:165,784,069...165,786,955

G

interleukin 18 receptor accessory protein

decreases expression

ISO

trovafloxacin results in decreased expression of IL18RAP mRNA

NCBI chr 9:50,263,723...50,296,583
Ensembl chr 9:50,263,733...50,296,583

G

interleukin 1 alpha

multiple interactions
increases expression

ISO
EXP

[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin; [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin
trovafloxacin results in increased expression of IL1A mRNA

PMID:19362101 PMID:35537566

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions

ISO

[TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [trovafloxacin results in increased activity of CASP3 protein]; [trovafloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL1B protein] affects the localization of SELE protein; [trovafloxacin co-treated with IL1B protein] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL1B protein] results in increased expression of SELE mRNA; trovafloxacin promotes the reaction [IL1B protein results in increased secretion of SELE protein]
trovafloxacin promotes the reaction [TNF protein results in increased expression of IL1B protein]

PMID:10822086 PMID:19638433 PMID:30876886

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 21 receptor

decreases expression

ISO

trovafloxacin results in decreased expression of IL21R mRNA

NCBI chr 1:189,598,682...189,626,340
Ensembl chr 1:189,598,558...189,626,342

G

interleukin 27

increases expression

ISO

trovafloxacin results in increased expression of IL27 mRNA

NCBI chr 1:190,603,684...190,609,292
Ensembl chr 1:190,603,522...190,609,258

G

interleukin 6

multiple interactions

ISO

[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacin; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] promotes the reaction [trovafloxacin results in increased activity of CASP3 protein]; [trovafloxacin co-treated with [TNF protein co-treated with IL6 protein co-treated with IL1B protein]] results in increased activity of CASP3 protein; [trovafloxacin co-treated with IL6 protein] results in increased activity of CASP3 protein
trovafloxacin promotes the reaction [TNF protein results in increased expression of IL6 protein]

PMID:19362101 PMID:19638433 PMID:30876886

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

inner mitochondrial membrane peptidase subunit 2

decreases expression

ISO

trovafloxacin results in decreased expression of IMMP2L mRNA

NCBI chr 6:63,797,189...64,696,906
Ensembl chr 6:63,797,237...64,697,749

G

inositol monophosphatase 2

decreases expression

ISO

trovafloxacin results in decreased expression of IMPA2 mRNA

NCBI chr18:63,104,113...63,135,232
Ensembl chr18:63,104,083...63,137,543

G

internexin neuronal intermediate filament protein, alpha

increases expression

ISO

trovafloxacin results in increased expression of INA mRNA

NCBI chr 1:255,838,129...255,849,680
Ensembl chr 1:255,838,129...255,849,680

G

inner centromere protein

decreases expression

ISO

trovafloxacin results in decreased expression of INCENP mRNA

NCBI chr 1:215,945,558...216,017,247
Ensembl chr 1:215,948,283...215,977,084

G

inka box actin regulator 2

increases expression

ISO

trovafloxacin results in increased expression of INKA2 mRNA

NCBI chr 2:195,873,617...195,888,983
Ensembl chr 2:195,873,497...195,893,605

G

integrator complex subunit 6 like

decreases expression

ISO

trovafloxacin results in decreased expression of DDX26B mRNA

NCBI chr X:139,295,490...139,363,090
Ensembl chr X:139,295,512...139,359,161

G

inversin

decreases expression

ISO

trovafloxacin results in decreased expression of INVS mRNA

NCBI chr 5:67,406,511...67,559,355
Ensembl chr 5:67,406,485...67,559,350

G

inositol hexakisphosphate kinase 2

increases expression

EXP

trovafloxacin results in increased expression of IP6K2 mRNA

NCBI chr 8:118,362,154...118,388,668
Ensembl chr 8:118,362,795...118,388,667

G

IQ motif containing D

increases expression

ISO

trovafloxacin results in increased expression of IQCD mRNA

NCBI chr12:41,616,107...41,633,244
Ensembl chr12:41,616,107...41,623,352

G

IQ motif containing GTPase activating protein 3

decreases expression

ISO

trovafloxacin results in decreased expression of IQGAP3 mRNA

NCBI chr 2:175,840,001...175,881,799
Ensembl chr 2:175,839,949...175,881,797

G

interferon regulatory factor 1

multiple interactions
decreases expression

ISO
EXP

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IRF1 mRNA
trovafloxacin results in decreased expression of IRF1 mRNA

PMID:18930950 PMID:24136188

NCBI chr10:38,417,935...38,424,946
Ensembl chr10:38,417,148...38,424,947

G

interferon regulatory factor 4

decreases expression

ISO

trovafloxacin results in decreased expression of IRF4 mRNA

NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,930,471...33,948,730

G

interferon regulatory factor 7

increases expression

ISO

trovafloxacin results in increased expression of IRF7 mRNA

NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:205,796,959...205,800,023

G

immunity-related GTPase M

increases expression

ISO

trovafloxacin results in increased expression of IRGM1 mRNA

NCBI chr10:33,734,640...33,742,720
Ensembl chr10:33,732,961...33,743,228

G

interferon stimulated exonuclease gene 20

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of ISG20 mRNA

NCBI chr 1:142,234,729...142,246,403
Ensembl chr 1:142,236,137...142,246,401

G

IST1 factor associated with ESCRT-III

increases expression

EXP

trovafloxacin results in increased expression of IST1 mRNA

NCBI chr19:54,558,353...54,580,551
Ensembl chr19:54,558,353...54,580,491

G

inositol-3-phosphate synthase 1

decreases expression

ISO

trovafloxacin results in decreased expression of ISYNA1 mRNA

NCBI chr16:18,873,119...18,876,116
Ensembl chr16:18,873,121...18,875,955

G

integrin subunit alpha X

decreases expression

ISO

trovafloxacin results in decreased expression of ITGAX mRNA

NCBI chr 1:192,140,089...192,171,151
Ensembl chr 1:192,149,905...192,171,151

G

integrin subunit beta 5

decreases expression

ISO

trovafloxacin results in decreased expression of ITGB5 mRNA

NCBI chr11:80,333,588...80,449,373
Ensembl chr11:80,333,590...80,449,373

G

inositol 1,4,5-trisphosphate receptor, type 1

decreases expression

ISO

trovafloxacin results in decreased expression of ITPR1 mRNA

NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504

G

inositol 1,4,5-trisphosphate receptor, type 2

decreases expression

ISO

trovafloxacin results in decreased expression of ITPR2 mRNA

NCBI chr 4:180,759,325...181,165,361
Ensembl chr 4:180,760,442...181,164,763

G

influenza virus NS1A binding protein

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IVNS1ABP mRNA

NCBI chr13:65,977,069...65,996,685
Ensembl chr13:65,977,045...65,997,547

G

IZUMO family member 4

decreases expression

ISO

trovafloxacin results in decreased expression of IZUMO4 mRNA

NCBI chr 7:9,657,975...9,661,699
Ensembl chr 7:9,657,203...9,660,794

G

jade family PHD finger 1

decreases expression

ISO

trovafloxacin results in decreased expression of JADE1 mRNA

NCBI chr 2:126,471,124...126,524,252
Ensembl chr 2:126,471,124...126,524,252

G

jagged canonical Notch ligand 1

increases expression

ISO

trovafloxacin results in increased expression of JAG1 mRNA

NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872

G

Janus kinase 3

decreases expression

ISO

trovafloxacin results in decreased expression of JAK3 mRNA

NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,420,415...18,433,222

G

junction adhesion molecule like

decreases expression

ISO

trovafloxacin results in decreased expression of JAML mRNA

NCBI chr 8:54,281,596...54,313,655
Ensembl chr 8:54,281,644...54,313,500

G

Jun dimerization protein 2

increases expression

ISO

trovafloxacin results in increased expression of JDP2 mRNA

NCBI chr 6:110,988,927...111,033,392
Ensembl chr 6:110,992,806...111,033,392

G

JPX transcript, XIST activator

decreases expression

ISO

trovafloxacin results in decreased expression of JPX mRNA

NCBI chr X:72,577,163...72,730,887

G

junctional sarcoplasmic reticulum protein 1

increases expression

ISO

trovafloxacin results in increased expression of JSRP1 mRNA

NCBI chr 7:9,539,997...9,556,730
Ensembl chr 7:9,552,324...9,557,137

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of JUNB mRNA

NCBI chr19:40,081,126...40,082,910
Ensembl chr19:40,073,541...40,085,218

G

KAT8 regulatory NSL complex subunit 1-like

decreases expression

ISO

trovafloxacin results in decreased expression of KANSL1L mRNA

NCBI chr 9:75,660,865...75,766,730
Ensembl chr 9:75,661,233...75,766,745

G

kelch repeat and BTB domain containing 11

increases expression

ISO

trovafloxacin results in increased expression of KBTBD11 mRNA

NCBI chr16:81,318,596...81,340,334
Ensembl chr16:81,313,093...81,340,390

G

kelch repeat and BTB domain containing 6

decreases expression

ISO

trovafloxacin results in decreased expression of KBTBD6 mRNA

NCBI chr15:61,257,360...61,259,117

G

kelch repeat and BTB domain containing 8

increases expression

ISO

trovafloxacin results in increased expression of KBTBD8 mRNA

NCBI chr 4:129,232,781...129,245,608
Ensembl chr 4:129,232,027...129,245,605

G

potassium voltage-gated channel subfamily A member 3

decreases expression

ISO

trovafloxacin results in decreased expression of KCNA3 mRNA

NCBI chr 2:197,320,324...197,322,277
Ensembl chr 2:197,318,134...197,350,739

G

potassium voltage-gated channel subfamily A regulatory beta subunit 2

decreases expression

ISO

trovafloxacin results in decreased expression of KCNAB2 mRNA

NCBI chr 5:168,182,228...168,270,760
Ensembl chr 5:168,184,613...168,270,760

G

potassium voltage-gated channel subfamily E regulatory subunit 3

decreases expression

ISO

trovafloxacin results in decreased expression of KCNE3 mRNA

NCBI chr 1:163,936,035...163,942,998
Ensembl chr 1:163,935,991...163,950,162

G

potassium calcium-activated channel subfamily N member 4

increases expression

ISO

trovafloxacin results in increased expression of KCNN4 mRNA

NCBI chr 1:89,084,306...89,102,279
Ensembl chr 1:89,086,814...89,102,275

G

potassium channel tetramerization domain containing 12b

decreases expression

ISO

trovafloxacin results in decreased expression of KCTD12B mRNA

NCBI chr X:20,989,053...21,000,208
Ensembl chr X:20,989,164...21,000,207

G

kinase insert domain receptor

decreases expression

ISO

trovafloxacin results in decreased expression of KDR mRNA

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

KH domain containing 4, pre-mRNA splicing factor

increases expression

ISO

trovafloxacin results in increased expression of KHDC4 mRNA

NCBI chr 2:176,446,895...176,475,405
Ensembl chr 2:176,446,910...176,475,392

G

ketohexokinase

decreases expression

ISO

trovafloxacin results in decreased expression of KHK mRNA

NCBI chr 6:31,165,246...31,175,779
Ensembl chr 6:31,165,248...31,175,481

G

KIAA0232 homolog

increases expression

ISO

trovafloxacin results in increased expression of D5ERTD579E mRNA

NCBI chr14:78,318,660...78,384,012
Ensembl chr14:78,319,105...78,384,014

G

kinesin family member 13A

decreases expression

ISO

trovafloxacin results in decreased expression of KIF13A mRNA

NCBI chr17:17,972,227...18,154,763
Ensembl chr17:17,972,325...18,154,760

G

kinesin family member 14

decreases expression

ISO

trovafloxacin results in decreased expression of KIF14 mRNA

NCBI chr13:50,478,646...50,542,256
Ensembl chr13:50,478,721...50,542,248

G

kinesin family member 15

decreases expression

ISO

trovafloxacin results in decreased expression of KIF15 mRNA

NCBI chr 8:131,479,340...131,550,209
Ensembl chr 8:131,479,337...131,550,202

G

kinesin family member 18A

decreases expression

ISO

trovafloxacin results in decreased expression of KIF18A mRNA

NCBI chr 3:116,219,007...116,279,378
Ensembl chr 3:116,219,007...116,279,227

G

kinesin family member 18B

decreases expression

ISO

trovafloxacin results in decreased expression of KIF18B mRNA

NCBI chr10:88,370,520...88,392,388
Ensembl chr10:88,370,524...88,389,691

G

kinesin family member 20A

decreases expression

ISO

trovafloxacin results in decreased expression of KIF20A mRNA

NCBI chr18:26,504,422...26,512,908
Ensembl chr18:26,504,072...26,512,909

G

kinesin family member 20B

decreases expression

ISO

trovafloxacin results in decreased expression of KIF20B mRNA

NCBI chr 1:241,840,898...241,896,451
Ensembl chr 1:241,840,987...241,896,451

G

kinesin family member 21B

decreases expression

ISO

trovafloxacin results in decreased expression of KIF21B mRNA

NCBI chr13:50,127,842...50,177,822
Ensembl chr13:50,127,842...50,177,822

G

kinesin family member 22

decreases expression

ISO

trovafloxacin results in decreased expression of KIF22 mRNA

NCBI chr 1:191,065,875...191,080,955
Ensembl chr 1:191,065,875...191,080,878

G

kinesin family member 23

decreases expression

ISO

trovafloxacin results in decreased expression of KIF23 mRNA

NCBI chr 8:71,293,439...71,321,911
Ensembl chr 8:71,293,482...71,320,856

G

kinesin family member 24

decreases expression

ISO

trovafloxacin results in decreased expression of KIF24 mRNA

NCBI chr 5:61,357,078...61,423,882
Ensembl chr 5:61,357,940...61,399,379

G

kinesin family member 2C

decreases expression

ISO

trovafloxacin results in decreased expression of KIF2C mRNA

NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:135,873,925...135,899,212

G

kinesin family member 4A

decreases expression

ISO

trovafloxacin results in decreased expression of KIF4 mRNA

NCBI chr X:69,761,803...69,864,335
Ensembl chr X:69,761,883...69,864,335

G

KIT ligand

increases expression

ISO

trovafloxacin results in increased expression of KITL mRNA

NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793

G

KLF transcription factor 11

decreases expression

ISO

trovafloxacin results in decreased expression of KLF11 mRNA

NCBI chr 6:47,014,312...47,026,152
Ensembl chr 6:47,014,326...47,037,044

G

KLF transcription factor 4

decreases expression

ISO

trovafloxacin results in decreased expression of KLF4 mRNA

NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592

G

KLF transcription factor 9

increases expression

EXP

trovafloxacin results in increased expression of KLF9 mRNA

NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641

G

kelch domain containing 8B

increases expression

ISO

trovafloxacin results in increased expression of KLHDC8B mRNA

NCBI chr 8:118,020,136...118,025,102
Ensembl chr 8:118,020,376...118,025,102

G

kelch-like family member 12

increases expression

ISO

trovafloxacin results in increased expression of KLHL12 mRNA

NCBI chr13:48,451,920...48,485,638
Ensembl chr13:48,455,227...48,485,641

G

kelch-like family member 24

increases expression
decreases expression

EXP
ISO

trovafloxacin results in increased expression of KLHL24 mRNA
trovafloxacin results in decreased expression of KLHL24 mRNA

PMID:24136188 PMID:35537566

NCBI chr11:94,348,024...94,382,085
Ensembl chr11:94,351,157...94,382,050

G

kelch-like family member 33

decreases expression

ISO

trovafloxacin results in decreased expression of KLHL33 mRNA

NCBI chr15:26,579,473...26,589,766
Ensembl chr15:26,580,639...26,590,387

G

kelch-like family, member 42

increases expression

ISO

trovafloxacin results in increased expression of KLHL42 mRNA

NCBI chr 4:181,730,343...181,760,899
Ensembl chr 4:181,735,244...181,757,013

G

kinetochore scaffold 1

decreases expression

ISO

trovafloxacin results in decreased expression of KNL1 mRNA

NCBI chr 3:126,483,498...126,545,774
Ensembl chr 3:126,483,544...126,545,774

G

kinetochore-localized astrin/SPAG5 binding protein

decreases expression

ISO

trovafloxacin results in decreased expression of KNSTRN mRNA

NCBI chr 3:126,254,633...126,274,412
Ensembl chr 3:126,254,663...126,274,418

G

kinetochore associated 1

decreases expression

ISO

trovafloxacin results in decreased expression of KNTC1 mRNA

NCBI chr12:38,429,925...38,500,564
Ensembl chr12:38,429,925...38,500,457

G

karyopherin subunit alpha 2

decreases expression

EXP

trovafloxacin results in decreased expression of KPNA2 mRNA

NCBI chr10:92,433,678...92,445,841
Ensembl chr10:92,433,679...92,445,937

G

karyopherin subunit beta 1

decreases expression

EXP

trovafloxacin results in decreased expression of KPNB1 mRNA

NCBI chr10:82,642,082...82,670,856
Ensembl chr10:82,642,082...82,670,856

G

kaptin (actin binding protein)

decreases expression

ISO

trovafloxacin results in decreased expression of KPTN mRNA

NCBI chr 1:85,936,922...85,937,716

G

keratin 18

decreases expression

EXP

trovafloxacin results in decreased expression of KRT18 mRNA

NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848

G

kinase suppressor of ras 1

decreases expression

ISO

trovafloxacin results in decreased expression of KSR1 mRNA

NCBI chr10:64,459,786...64,596,083
Ensembl chr10:64,459,786...64,596,082

G

L1 cell adhesion molecule

decreases expression

ISO

trovafloxacin results in decreased expression of L1CAM mRNA

NCBI chr X:156,748,597...156,775,116
Ensembl chr X:156,748,597...156,775,077

G

trans-L-3-hydroxyproline dehydratase

decreases expression

ISO

trovafloxacin results in decreased expression of L3HYPDH mRNA

NCBI chr 6:96,372,243...96,383,039

G

lactamase, beta 2

decreases expression

ISO

trovafloxacin results in decreased expression of LACTB2 mRNA

NCBI chr 5:10,352,165...10,374,928
Ensembl chr 5:10,352,154...10,379,255

G

lysosomal protein transmembrane 4 beta

decreases expression

EXP

trovafloxacin results in decreased expression of LAPTM4B mRNA

NCBI chr 7:67,319,438...67,362,547
Ensembl chr 7:67,319,542...67,363,258

G

leucyl-tRNA synthetase 1

decreases expression

ISO

trovafloxacin results in decreased expression of LARS1 mRNA

NCBI chr18:34,452,567...34,507,030
Ensembl chr18:34,452,561...34,506,938

G

LIM and SH3 protein 1

increases expression

ISO

trovafloxacin results in increased expression of LASP1 mRNA

NCBI chr10:83,290,820...83,331,989
Ensembl chr10:83,290,865...83,331,988

G

lamin B receptor

decreases expression

ISO

trovafloxacin results in decreased expression of LBR mRNA

NCBI chr13:96,071,058...96,095,709
Ensembl chr13:96,071,081...96,095,709

G

lecithin cholesterol acyltransferase

increases expression

ISO

trovafloxacin results in increased expression of LCAT mRNA

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:50,744,601...50,748,081

G

lactate dehydrogenase A-like 6B

increases expression

ISO

trovafloxacin results in increased expression of LDHAL6B mRNA

NCBI chr 1:48,402,997...48,404,420
Ensembl chr 1:48,403,012...48,404,851

G

low density lipoprotein receptor

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of LDLR mRNA

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

low density lipoprotein receptor class A domain containing 3

decreases expression

ISO

trovafloxacin results in decreased expression of LDLRAD3 mRNA

NCBI chr 3:108,694,528...108,936,330
Ensembl chr 3:108,694,528...108,936,368

G

low density lipoprotein receptor adaptor protein 1

increases expression

ISO

trovafloxacin results in increased expression of LDLRAP1 mRNA

NCBI chr 5:152,239,296...152,262,290
Ensembl chr 5:152,229,505...152,262,290

G

leucine, glutamate and lysine rich 1

increases expression

ISO

trovafloxacin results in increased expression of LEKR1 mRNA

NCBI chr 2:152,195,003...152,376,389
Ensembl chr 2:152,201,182...152,370,542

G

lens epithelial protein

increases expression

ISO

trovafloxacin results in increased expression of LENEP mRNA

NCBI chr 2:177,117,171...177,117,859
Ensembl chr 2:177,117,171...177,117,859

G

leucine zipper and EF-hand containing transmembrane protein 1

decreases expression

EXP

trovafloxacin results in decreased expression of LETM1 mRNA

NCBI chr14:81,167,268...81,206,776
Ensembl chr14:81,162,309...81,209,459

G

galectin 9

increases expression

ISO

trovafloxacin results in increased expression of LGALS9 mRNA

NCBI chr10:64,405,044...64,428,249
Ensembl chr10:64,405,044...64,428,070

G

galectin-like

decreases expression

EXP

trovafloxacin results in decreased expression of LGALSL mRNA

NCBI chr14:99,198,340...99,205,846
Ensembl chr14:99,198,339...99,206,487

G

leucine-rich repeat-containing G protein-coupled receptor 4

increases expression

ISO

trovafloxacin results in increased expression of LGR4 mRNA

NCBI chr 3:116,901,968...117,004,584
Ensembl chr 3:116,901,968...117,004,153

G

LIM homeobox 2

decreases expression

ISO

trovafloxacin results in decreased expression of LHX2 mRNA

NCBI chr 3:42,523,345...42,553,646
Ensembl chr 3:42,535,744...42,553,645

G

LIF, interleukin 6 family cytokine

increases expression

ISO

trovafloxacin results in increased expression of LIF mRNA

NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053

G

DNA ligase 1

decreases expression

ISO

trovafloxacin results in decreased expression of LIG1 mRNA

NCBI chr 1:83,243,043...83,281,707
Ensembl chr 1:83,219,545...83,281,708

G

leukocyte immunoglobulin like receptor B4

increases expression

ISO

trovafloxacin results in increased expression of LILRB4B mRNA

NCBI chr 1:78,847,685...78,853,294
Ensembl chr 1:78,847,685...78,853,326

G

lin-54 DREAM MuvB core complex component

decreases expression

ISO

trovafloxacin results in decreased expression of LIN54 mRNA

NCBI chr14:9,434,093...9,514,091
Ensembl chr14:9,434,112...9,492,106

G

lipase, family member N

decreases expression

ISO

trovafloxacin results in decreased expression of LIPN mRNA

NCBI chr 1:240,998,154...241,016,658
Ensembl chr 1:240,998,154...241,016,658

G

lipopolysaccharide-induced TNF factor

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of LITAF mRNA

NCBI chr10:5,163,258...5,199,930
Ensembl chr10:5,163,242...5,199,930

G

limb and CNS expressed 1

decreases expression

ISO

trovafloxacin results in decreased expression of LIX1 mRNA

NCBI chr 1:66,802,044...66,859,040
Ensembl chr 1:66,802,272...66,860,627

G

LLGL scribble cell polarity complex component 2

increases expression

ISO

trovafloxacin results in increased expression of LLGL2 mRNA

NCBI chr10:101,549,911...101,585,466
Ensembl chr10:101,549,862...101,585,464

G

lamin A/C

decreases expression
increases expression

EXP
ISO

trovafloxacin results in decreased expression of LMNA mRNA
trovafloxacin results in increased expression of LMNA mRNA

PMID:24136188 PMID:35537566

NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072

G

lamin B1

decreases expression

ISO

trovafloxacin results in decreased expression of LMNB1 mRNA

NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283

G

LIM domain only 4

decreases expression

ISO

trovafloxacin results in decreased expression of LMO4 mRNA

NCBI chr 2:235,924,574...235,941,609
Ensembl chr 2:235,924,403...235,941,275

G

lon peptidase 1, mitochondrial

decreases expression

ISO

trovafloxacin results in decreased expression of LONP1 mRNA

NCBI chr 9:1,534,581...1,546,908
Ensembl chr 9:1,534,584...1,547,427

G

lipin 1

increases expression

EXP

trovafloxacin results in increased expression of LPIN1 mRNA

NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991

G

lipin 3

increases expression

ISO

trovafloxacin results in increased expression of LPIN3 mRNA

NCBI chr 3:169,953,479...169,978,034
Ensembl chr 3:169,960,522...169,978,031

G

LDL receptor related protein 6

increases expression

EXP

trovafloxacin results in increased expression of LRP6 mRNA

NCBI chr 4:168,997,937...169,131,716
Ensembl chr 4:169,000,968...169,131,716

G

LDL receptor related protein 8

decreases expression

ISO

trovafloxacin results in decreased expression of LRP8 mRNA

NCBI chr 5:127,792,236...127,864,207
Ensembl chr 5:127,792,299...127,864,207

G

leucine rich repeat containing 41

increases expression

ISO

trovafloxacin results in increased expression of LRRC41 mRNA

NCBI chr 5:134,791,256...134,812,177
Ensembl chr 5:134,791,256...134,812,177

G

leucine rich repeat containing 63

decreases expression

ISO

trovafloxacin results in decreased expression of LRRC63 mRNA

NCBI chr15:56,809,629...56,846,831
Ensembl chr15:56,809,630...56,846,749

G

leucine rich repeat containing 75A

decreases expression

ISO

trovafloxacin results in decreased expression of LRRC75A mRNA

NCBI chr10:47,798,028...47,842,577
Ensembl chr10:47,798,028...47,842,577

G

leucine rich repeat containing 8 VRAC subunit C

decreases expression

ISO

trovafloxacin results in decreased expression of LRRC8C mRNA

NCBI chr14:4,528,721...4,621,259
Ensembl chr14:4,531,823...4,620,049

G

leucine rich repeat and coiled-coil centrosomal protein 1

decreases expression

ISO

trovafloxacin results in decreased expression of LRRCC1 mRNA

NCBI chr 2:88,746,904...88,781,532
Ensembl chr 2:88,746,443...88,781,542

G

leucine-rich repeat kinase 2

decreases expression

ISO

trovafloxacin results in decreased expression of LRRK2 mRNA

NCBI chr 7:124,706,246...124,867,234
Ensembl chr 7:124,706,080...124,867,239

G

LRRN4 C-terminal like

decreases expression

ISO

trovafloxacin results in decreased expression of LRRN4CL mRNA

NCBI chr 1:215,172,689...215,192,627
Ensembl chr 1:215,174,216...215,198,343

G

leucine-rich repeats and WD repeat domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of LRWD1 mRNA

NCBI chr12:26,166,648...26,179,689
Ensembl chr12:26,166,648...26,185,200

G

LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated

decreases expression

EXP

trovafloxacin results in decreased expression of LSM4 mRNA

NCBI chr16:18,789,466...18,795,164
Ensembl chr16:18,789,467...18,794,886

G

LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

ISO

trovafloxacin results in increased expression of LSM6 mRNA

NCBI chr19:46,002,592...46,017,152

G

leukotriene A4 hydrolase

decreases expression

EXP

trovafloxacin results in decreased expression of LTA4H mRNA

NCBI chr 7:29,856,846...29,888,642
Ensembl chr 7:29,856,802...29,888,641

G

latent transforming growth factor beta binding protein 2

decreases expression

ISO

trovafloxacin results in decreased expression of LTBP2 mRNA

NCBI chr 6:110,161,029...110,261,586
Ensembl chr 6:110,161,029...110,257,298

G

latent transforming growth factor beta binding protein 4

decreases expression

ISO

trovafloxacin results in decreased expression of LTBP4 mRNA

NCBI chr 1:91,727,769...91,759,822
Ensembl chr 1:91,727,769...91,760,006

G

LUC7 pre-mRNA splicing factor like 1

increases expression

ISO

trovafloxacin results in increased expression of LUC7L mRNA

NCBI chr10:15,777,837...15,811,586
Ensembl chr10:15,777,829...15,817,940

G

LYL1, basic helix-loop-helix family member

decreases expression

ISO

trovafloxacin results in decreased expression of LYL1 mRNA

NCBI chr19:40,356,967...40,359,834
Ensembl chr19:40,354,819...40,359,834

G

lysozyme 2

decreases expression
increases expression

EXP
ISO

trovafloxacin results in decreased expression of LYZ2 mRNA
trovafloxacin results in increased expression of LYZ2 mRNA

PMID:24136188 PMID:35537566

NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011

G

microtubule-actin crosslinking factor 1

decreases expression

ISO

trovafloxacin results in decreased expression of MACF1 mRNA

NCBI chr 5:140,908,829...141,234,127
Ensembl chr 5:140,908,837...141,233,890

G

mitotic arrest deficient 2 like 1

decreases expression

ISO

trovafloxacin results in decreased expression of MAD2L1 mRNA

NCBI chr 4:97,236,419...97,247,603
Ensembl chr 4:97,236,503...97,243,222

G

MAF bZIP transcription factor

decreases expression

ISO

trovafloxacin results in decreased expression of MAF mRNA

NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378

G

mal, T-cell differentiation protein 2

decreases expression

EXP

trovafloxacin results in decreased expression of MAL2 mRNA

NCBI chr 7:87,790,239...87,823,219
Ensembl chr 7:87,790,239...87,850,403

G

mannosidase, alpha, class 2A, member 1

decreases expression

ISO

trovafloxacin results in decreased expression of MAN2A1 mRNA

NCBI chr 9:111,698,913...111,855,257
Ensembl chr 9:111,698,913...111,867,850

G

mannosidase, alpha, class 2A, member 2

decreases expression

ISO

trovafloxacin results in decreased expression of MAN2A2 mRNA

NCBI chr 1:143,712,157...143,736,624
Ensembl chr 1:143,716,072...143,736,562

G

mannosidase beta like

increases expression

ISO

trovafloxacin results in increased expression of MANBAL mRNA

NCBI chr 3:166,455,067...166,484,652
Ensembl chr 3:166,455,066...166,487,431

G

mesencephalic astrocyte-derived neurotrophic factor

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MANF mRNA

NCBI chr 8:116,427,053...116,430,259
Ensembl chr 8:116,427,048...116,429,910

G

microtubule-associated protein 1 light chain 3 alpha

multiple interactions
increases expression

ISO

TNF protein inhibits the reaction [trovafloxacin results in increased expression of MAP1LC3A mRNA]

NCBI chr 3:164,243,204...164,244,850
Ensembl chr 3:164,243,093...164,244,850

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

ISO

[trovafloxacin co-treated with TNF protein] results in increased expression of MAP1LC3B mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trovafloxacin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; TNF protein inhibits the reaction [trovafloxacin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; trovafloxacin results in increased expression of and results in increased lipidation of MAP1LC3B protein
trovafloxacin results in increased expression of MAP1LC3B mRNA

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen-activated protein kinase kinase 6

decreases expression

ISO

trovafloxacin results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721

G

mitogen activated protein kinase kinase 7

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MAP2K7 mRNA

NCBI chr12:7,389,032...7,398,377
Ensembl chr12:7,389,155...7,398,377

G

mitogen-activated protein kinase kinase kinase 8

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAP3K8 mRNA

NCBI chr17:58,078,175...58,098,455
Ensembl chr17:58,078,320...58,098,452

G

mitogen activated protein kinase 1

increases activity
increases phosphorylation
multiple interactions

ISO

trovafloxacin results in increased activity of MAPK1 protein
trovafloxacin results in increased phosphorylation of MAPK1 protein
[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of MAPK1 protein; ATG5 protein affects the reaction [trovafloxacin results in increased phosphorylation of MAPK1 protein]
U 0126 inhibits the reaction [trovafloxacin results in increased activity of MAPK1 protein]

PMID:24525298 PMID:32035082 PMID:33609687

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases activity
increases phosphorylation
multiple interactions

ISO

trovafloxacin results in increased activity of MAPK3 protein
trovafloxacin results in increased phosphorylation of MAPK3 protein
[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of MAPK3 protein; ATG5 protein affects the reaction [trovafloxacin results in increased phosphorylation of MAPK3 protein]
U 0126 inhibits the reaction [trovafloxacin results in increased activity of MAPK3 protein]

PMID:24525298 PMID:32035082 PMID:33609687

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

increases phosphorylation
multiple interactions

ISO

trovafloxacin results in increased phosphorylation of MAPK8 protein
ATG5 protein affects the reaction [trovafloxacin results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 8 interacting protein 3

increases expression

ISO

trovafloxacin results in increased expression of MAPK8IP3 mRNA

NCBI chr10:14,422,936...14,463,387
Ensembl chr10:14,422,936...14,462,812

G

MAPK activated protein kinase 2

multiple interactions
increases phosphorylation

ISO

SB 203580 inhibits the reaction [trovafloxacin results in increased phosphorylation of MAPKAPK2 protein]

NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326

G

MARCKS-like 1

increases expression

ISO

trovafloxacin results in increased expression of MARCKSL1 mRNA

NCBI chr 5:147,135,827...147,138,150
Ensembl chr 5:147,134,514...147,138,417

G

microtubule associated serine/threonine kinase-like

decreases expression

ISO

trovafloxacin results in decreased expression of MASTL mRNA

NCBI chr17:90,158,592...90,195,550
Ensembl chr17:90,160,068...90,195,564

G

mitochondrial antiviral signaling protein

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MAVS mRNA

NCBI chr 3:138,904,673...138,919,129
Ensembl chr 3:138,904,771...138,919,126

G

MYC associated zinc finger protein

decreases expression

ISO

trovafloxacin results in decreased expression of MAZ mRNA

NCBI chr 1:191,060,271...191,065,722
Ensembl chr 1:191,060,280...191,065,339

G

metallo-beta-lactamase domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of MBLAC1 mRNA

NCBI chr12:22,185,142...22,186,404
Ensembl chr12:22,184,917...22,200,899

G

melanoma cell adhesion molecule

decreases expression

ISO

trovafloxacin results in decreased expression of MCAM mRNA

NCBI chr 8:53,376,225...53,384,407
Ensembl chr 8:53,376,197...53,384,406

G

MCF.2 cell line derived transforming sequence-like

decreases expression

ISO

trovafloxacin results in decreased expression of MCF2L mRNA

NCBI chr16:83,209,277...83,355,683
Ensembl chr16:83,209,280...83,354,956

G

minichromosome maintenance complex component 5

decreases expression

ISO

trovafloxacin results in decreased expression of MCM5 mRNA

NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758

G

minichromosome maintenance complex component 7

decreases expression

ISO

trovafloxacin results in decreased expression of MCM7 mRNA

NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771

G

minichromosome maintenance 8 homologous recombination repair factor

decreases expression

ISO

trovafloxacin results in decreased expression of MCM8 mRNA

NCBI chr 3:140,539,590...140,569,891
Ensembl chr 3:140,539,647...140,569,891

G

minichromosome maintenance 9 homologous recombination repair factor

decreases expression

ISO

trovafloxacin results in decreased expression of MCM9 mRNA

NCBI chr20:33,369,325...33,472,243
Ensembl chr20:33,387,611...33,472,243

G

mediator of DNA damage checkpoint 1

decreases expression

ISO

trovafloxacin results in decreased expression of MDC1 mRNA

NCBI chr20:2,898,496...2,914,960
Ensembl chr20:2,900,308...2,914,960

G

malate dehydrogenase 2

decreases expression

EXP

trovafloxacin results in decreased expression of MDH2 mRNA

NCBI chr12:26,530,886...26,543,841
Ensembl chr12:26,530,881...26,543,841

G

Mdm1 nuclear protein

decreases expression

ISO

trovafloxacin results in decreased expression of MDM1 mRNA

NCBI chr 7:55,615,459...55,651,889
Ensembl chr 7:55,615,608...55,651,888

G

MDM2 proto-oncogene

multiple interactions
increases expression

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MDM2 mRNA
trovafloxacin results in increased expression of MDM2 mRNA

PMID:18930950 PMID:35537566

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791

G

malic enzyme 1

decreases expression

EXP

trovafloxacin results in decreased expression of ME1 mRNA

NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275

G

mediator complex subunit 10

increases expression

ISO

trovafloxacin results in increased expression of MED10 mRNA

NCBI chr 1:35,298,494...35,310,163
Ensembl chr 1:35,298,495...35,304,154

G

mediator complex subunit 14

decreases expression

ISO

trovafloxacin results in decreased expression of MED14 mRNA

NCBI chr X:12,709,406...12,800,642
Ensembl chr X:12,709,472...12,800,640

G

mediator complex subunit 20

increases expression
multiple interactions

ISO

trovafloxacin results in increased expression of MED20 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MED20 mRNA

PMID:18930950 PMID:35537566

NCBI chr 9:20,867,681...20,880,288
Ensembl chr 9:20,867,681...20,880,011

G

mediator complex subunit 22

increases expression

ISO

trovafloxacin results in increased expression of MED22 mRNA

NCBI chr 3:30,631,829...30,636,911
Ensembl chr 3:30,631,829...30,636,911

G

mediator complex subunit 29

increases expression

ISO

trovafloxacin results in increased expression of MED29 mRNA

NCBI chr 1:92,805,505...92,810,908

G

multiple EGF-like-domains 9

decreases expression

ISO

trovafloxacin results in decreased expression of MEGF9 mRNA

NCBI chr 5:89,008,679...89,120,731
Ensembl chr 5:89,008,679...89,120,731

G

maternal embryonic leucine zipper kinase

decreases expression

ISO

trovafloxacin results in decreased expression of MELK mRNA

NCBI chr 5:63,336,151...63,396,254
Ensembl chr 5:63,336,106...63,396,247

G

major facilitator superfamily domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of MFSD1 mRNA

NCBI chr 2:154,156,167...154,176,209
Ensembl chr 2:154,156,166...154,177,086

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

ISO

trovafloxacin results in increased expression of MFSD2A mRNA

NCBI chr 5:140,510,933...140,525,828
Ensembl chr 5:140,510,953...140,525,916

G

major facilitator superfamily domain containing 3

decreases expression

ISO

trovafloxacin results in decreased expression of MFSD3 mRNA

NCBI chr 7:110,300,254...110,304,108
Ensembl chr 7:110,302,018...110,304,112

G

major facilitator superfamily domain containing 4B3

decreases expression

ISO

trovafloxacin results in decreased expression of MFSD4B3-PS mRNA

NCBI chr20:44,923,703...44,948,921
Ensembl chr20:44,925,502...44,949,154

G

mitochondria-localized glutamic acid-rich protein

decreases expression

ISO

trovafloxacin results in decreased expression of MGARP mRNA

NCBI chr 2:137,582,152...137,590,294
Ensembl chr 2:137,582,152...137,590,481

G

monoglyceride lipase

decreases expression

EXP

trovafloxacin results in decreased expression of MGLL mRNA

NCBI chr 4:122,749,436...122,851,440
Ensembl chr 4:122,749,436...122,851,440

G

O-6-methylguanine-DNA methyltransferase

increases expression

ISO

trovafloxacin results in increased expression of MGMT mRNA

NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482

G

MICAL-like 1

increases expression

ISO

trovafloxacin results in increased expression of MICALL1 mRNA

NCBI chr 7:112,557,192...112,587,618
Ensembl chr 7:112,557,192...112,587,618

G

MICAL-like 2

increases expression

ISO

trovafloxacin results in increased expression of MICALL2 mRNA

NCBI chr12:20,013,037...20,041,795
Ensembl chr12:20,012,985...20,041,795

G

midnolin

increases expression

ISO

trovafloxacin results in increased expression of MIDN mRNA

NCBI chr 7:10,198,761...10,210,563
Ensembl chr 7:10,200,306...10,207,203

G

mitochondrial elongation factor 2

increases expression

ISO

trovafloxacin results in increased expression of MIEF2 mRNA

NCBI chr10:45,907,576...45,913,658
Ensembl chr10:45,908,706...45,913,658

G

migration and invasion inhibitory protein

decreases expression

ISO

trovafloxacin results in decreased expression of MIIP mRNA

NCBI chr 5:163,575,689...163,582,739
Ensembl chr 5:163,575,437...163,582,873

G

microRNA 877

increases expression

ISO

trovafloxacin results in increased expression of MIR877 mRNA

NCBI chr20:2,816,284...2,816,368
Ensembl chr20:2,816,284...2,816,368

G

Mirlet7b host gene

increases expression

ISO

trovafloxacin results in increased expression of LNCPPARA mRNA

G

MIS18 kinetochore protein A

decreases expression

ISO

trovafloxacin results in decreased expression of MIS18A mRNA

NCBI chr11:43,454,129...43,467,157
Ensembl chr11:43,454,161...43,476,264

G

MIS18 binding protein 1

decreases expression

ISO

trovafloxacin results in decreased expression of MIS18BP1 mRNA

NCBI chr 6:88,918,743...88,968,225
Ensembl chr 6:88,918,745...88,967,629

G

mitochondrial matrix import factor 23

increases expression

ISO

trovafloxacin results in increased expression of MIX23 mRNA

NCBI chr11:78,166,038...78,186,323
Ensembl chr11:78,166,038...78,186,323

G

marker of proliferation Ki-67

decreases expression

ISO

trovafloxacin results in decreased expression of MKI67 mRNA

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

MAPK interacting serine/threonine kinase 1

decreases expression

ISO

trovafloxacin results in decreased expression of MKNK1 mRNA

NCBI chr 5:134,554,881...134,594,392
Ensembl chr 5:134,554,943...134,594,393

G

makorin, ring finger protein, 2

decreases expression

ISO

trovafloxacin results in decreased expression of MKRN2 mRNA

NCBI chr 4:150,334,164...150,352,271
Ensembl chr 4:150,334,142...150,352,263

G

makorin, ring finger protein, 3

increases expression

ISO

trovafloxacin results in increased expression of MKRN3 mRNA

NCBI chr 1:125,338,664...125,341,178
Ensembl chr 1:125,338,564...125,341,164

G

myeloid leukemia factor 1

decreases expression

ISO

trovafloxacin results in decreased expression of MLF1 mRNA

NCBI chr 2:153,958,060...153,991,705
Ensembl chr 2:153,958,546...153,994,220

G

MLX interacting protein-like

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MLXIPL mRNA

NCBI chr12:27,178,158...27,213,675
Ensembl chr12:27,178,158...27,213,660

G

matrix metallopeptidase 13

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MMP13 mRNA

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

meiotic nuclear divisions 1

decreases expression

ISO

trovafloxacin results in decreased expression of MND1 mRNA

NCBI chr 2:171,731,523...171,794,124
Ensembl chr 2:171,731,523...171,794,095

G

myeloid cell nuclear differentiation antigen

increases expression

ISO

trovafloxacin results in increased expression of MNDA mRNA; trovafloxacin results in increased expression of PYHIN1 mRNA

NCBI chr13:88,550,224...88,567,892
Ensembl chr13:88,550,228...88,566,537

G

MOB kinase activator 3B

decreases expression

ISO

trovafloxacin results in decreased expression of MOB3B mRNA

NCBI chr 5:54,342,509...54,534,164
Ensembl chr 5:54,338,056...54,454,678

G

mannosyl-oligosaccharide glucosidase

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MOGS mRNA

NCBI chr 4:117,179,335...117,182,738
Ensembl chr 4:117,179,335...117,182,744

G

MOK protein kinase

increases expression

ISO

trovafloxacin results in increased expression of MOK mRNA

NCBI chr 6:135,645,018...135,675,894
Ensembl chr 6:135,645,018...135,676,174

G

macrophage expressed 1

increases expression

ISO

trovafloxacin results in increased expression of MPEG1 mRNA

NCBI chr 1:218,876,848...218,881,364
Ensembl chr 1:218,876,069...218,908,715

G

N-methylpurine-DNA glycosylase

decreases expression

ISO

trovafloxacin results in decreased expression of MPG mRNA

NCBI chr10:15,900,697...15,906,981
Ensembl chr10:15,899,635...15,907,052

G

M-phase phosphoprotein 8

increases expression

EXP

trovafloxacin results in increased expression of MPHOSPH8 mRNA

NCBI chr15:34,916,169...34,944,038
Ensembl chr15:34,816,701...34,944,433

G

major histocompatibility complex, class I-related

decreases expression

ISO

trovafloxacin results in decreased expression of MR1 mRNA

NCBI chr13:69,850,420...69,868,302
Ensembl chr13:69,850,420...69,868,502

G

mannose receptor, C type 1

decreases expression

ISO

trovafloxacin results in decreased expression of MRC1 mRNA

NCBI chr17:82,157,725...82,239,411
Ensembl chr17:82,157,705...82,239,410

G

MRN complex interacting protein

decreases expression

ISO

trovafloxacin results in decreased expression of MRNIP mRNA

NCBI chr10:35,002,440...35,026,555

G

maestro heat-like repeat family member 1

decreases expression

ISO

trovafloxacin results in decreased expression of MROH1 mRNA

NCBI chr 7:109,979,344...110,052,800
Ensembl chr 7:109,983,337...110,052,801

G

mitochondrial ribosomal protein L12

decreases expression

EXP

trovafloxacin results in decreased expression of MRPL12 mRNA

NCBI chr10:106,256,746...106,261,249
Ensembl chr10:106,256,547...106,263,088

G

mitochondrial ribosomal protein L38

decreases expression

ISO

trovafloxacin results in decreased expression of MRPL38 mRNA

NCBI chr10:101,864,242...101,871,048
Ensembl chr10:101,863,318...101,871,048

G

mitochondrial ribosomal protein S18B

decreases expression
increases expression

EXP
ISO

trovafloxacin results in decreased expression of MRPS18B mRNA
trovafloxacin results in increased expression of MRPS18B mRNA

PMID:24136188 PMID:35537566

NCBI chr20:2,842,978...2,849,065
Ensembl chr20:2,842,528...2,849,065

G

mutS homolog 3

decreases expression

ISO

trovafloxacin results in decreased expression of MSH3 mRNA

NCBI chr 2:25,179,400...25,320,857
Ensembl chr 2:25,179,400...25,321,102

G

mutS homolog 5

decreases expression

ISO

trovafloxacin results in decreased expression of MSH5 mRNA

NCBI chr20:3,779,180...3,797,996
Ensembl chr20:3,781,578...3,797,994

G

metallothionein 1A

increases expression

EXP

trovafloxacin results in increased expression of MT1A mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

metallothionein 2

decreases expression
multiple interactions

ISO

trovafloxacin results in decreased expression of MT2 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MT1E mRNA

PMID:18930950 PMID:35537566

NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709

G

MDM2 binding protein

decreases expression

ISO

trovafloxacin results in decreased expression of MTBP mRNA

NCBI chr 7:88,862,939...88,945,491
Ensembl chr 7:88,862,927...88,945,493

G

mitochondrial carrier 1

decreases expression

ISO

trovafloxacin results in decreased expression of MTCH1 mRNA

NCBI chr20:7,391,558...7,415,291
Ensembl chr20:7,391,565...7,415,042

G

mitochondrial fission regulator 2

decreases expression

ISO

trovafloxacin results in decreased expression of MTFR2 mRNA

NCBI chr 1:16,942,814...16,958,218

G

mitochondrial ribosome-associated GTPase 1

decreases expression

ISO

trovafloxacin results in decreased expression of MTG1 mRNA

NCBI chr 1:204,361,176...204,373,917
Ensembl chr 1:204,361,147...204,373,924

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

decreases expression

ISO

trovafloxacin results in decreased expression of MTHFD1L mRNA

NCBI chr 1:42,849,424...43,038,313
Ensembl chr 1:42,849,374...43,038,309

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases expression

ISO

trovafloxacin results in decreased expression of MTHFD2 mRNA

NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350

G

microsomal triglyceride transfer protein

decreases expression

EXP
ISO

trovafloxacin results in decreased expression of MTTP mRNA

PMID:24136188 PMID:35537566

NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650

G

microtubule associated scaffold protein 2

increases expression

ISO

trovafloxacin results in increased expression of MTUS2 mRNA

NCBI chr12:11,742,713...12,115,798
Ensembl chr12:11,742,713...11,787,314

G

mitochondrial E3 ubiquitin protein ligase 1

increases expression

ISO

trovafloxacin results in increased expression of MUL1 mRNA

NCBI chr 5:155,936,112...155,945,163
Ensembl chr 5:155,936,111...155,945,163

G

MUS81 structure-specific endonuclease subunit

decreases expression

ISO

trovafloxacin results in decreased expression of MUS81 mRNA

NCBI chr 1:212,219,793...212,225,214
Ensembl chr 1:212,219,795...212,225,068

G

musculoskeletal, embryonic nuclear protein 1

increases expression

ISO

trovafloxacin results in increased expression of MUSTN1 mRNA

NCBI chr16:6,079,355...6,081,608
Ensembl chr16:6,079,277...6,081,586

G

mutY DNA glycosylase

decreases expression

ISO

trovafloxacin results in decreased expression of MUTYH mRNA

NCBI chr 5:135,510,666...135,522,777
Ensembl chr 5:135,517,695...135,522,776

G

Max dimerization protein 3

decreases expression

ISO

trovafloxacin results in decreased expression of MXD3 mRNA

NCBI chr17:9,306,552...9,310,278
Ensembl chr17:9,302,321...9,310,278

G

myeloid-associated differentiation marker-like 2

decreases expression

ISO

trovafloxacin results in decreased expression of MYADML2 mRNA

NCBI chr10:106,420,856...106,425,899
Ensembl chr10:106,421,419...106,426,224

G

MYB proto-oncogene like 2

decreases expression

ISO

trovafloxacin results in decreased expression of MYBL2 mRNA

NCBI chr 3:172,124,765...172,153,221
Ensembl chr 3:172,116,550...172,153,221

G

myosin binding protein C3

increases expression

ISO

trovafloxacin results in increased expression of MYBPC3 mRNA

NCBI chr 3:97,550,974...97,569,216
Ensembl chr 3:97,551,061...97,569,216

G

MYC proto-oncogene, bHLH transcription factor

increases expression

ISO

trovafloxacin results in increased expression of MYC mRNA

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

Myc binding protein

increases expression

ISO

trovafloxacin results in increased expression of MYCBP mRNA

NCBI chr 5:141,420,727...141,427,938
Ensembl chr 5:141,420,707...141,430,681

G

MYC binding protein 2

decreases expression

ISO

trovafloxacin results in decreased expression of MYCBP2 mRNA

NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325

G

MYCL proto-oncogene, bHLH transcription factor

increases expression

ISO

trovafloxacin results in increased expression of MYCL mRNA

NCBI chr 5:140,559,843...140,566,704
Ensembl chr 5:140,560,152...140,566,699

G

MYD88, innate immune signal transduction adaptor

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MYD88 mRNA

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

myosin heavy chain 10

increases expression

ISO

trovafloxacin results in increased expression of MYH10 mRNA

NCBI chr10:53,891,955...54,024,032
Ensembl chr10:53,893,166...54,024,036

G

myosin heavy chain 14

decreases expression

ISO

trovafloxacin results in decreased expression of MYH14 mRNA

NCBI chr 1:104,232,778...104,295,369
Ensembl chr 1:104,232,778...104,323,404

G

myosin heavy chain 7B

decreases expression

ISO

trovafloxacin results in decreased expression of MYH7B mRNA

NCBI chr 3:164,537,211...164,582,441
Ensembl chr 3:164,558,340...164,582,094

G

myosin light chain 11

decreases expression

ISO

trovafloxacin results in decreased expression of MYLPF mRNA

NCBI chr 1:191,257,432...191,263,046
Ensembl chr 1:191,256,196...191,263,045

G

myosin IXA

decreases expression

ISO

trovafloxacin results in decreased expression of MYO9A mRNA

NCBI chr 8:69,044,853...69,248,094
Ensembl chr 8:69,044,885...69,245,231

G

myomesin 1

decreases expression

ISO

trovafloxacin results in decreased expression of MYOM1 mRNA

NCBI chr 9:118,362,547...118,485,954
Ensembl chr 9:118,362,621...118,485,952

G

myozenin 1

decreases expression

ISO

trovafloxacin results in decreased expression of MYOZ1 mRNA

NCBI chr15:3,693,576...3,700,831
Ensembl chr15:3,693,613...3,700,826

G

myeloid zinc finger 1

decreases expression

ISO

trovafloxacin results in decreased expression of MZF1 mRNA

NCBI chr 1:82,742,709...82,755,069
Ensembl chr 1:82,742,726...82,753,820

G

NEDD4 binding protein 2-like 1

decreases expression

ISO

trovafloxacin results in decreased expression of N4BP2L1 mRNA

NCBI chr12:4,938,199...4,965,003
Ensembl chr12:4,927,142...4,963,045

G

Nedd4 binding protein 3

decreases expression

ISO

trovafloxacin results in decreased expression of N4BP3 mRNA

NCBI chr10:36,400,053...36,407,609
Ensembl chr10:36,400,057...36,407,637

G

N(alpha)-acetyltransferase 15, NatA auxiliary subunit

decreases expression

EXP

trovafloxacin results in decreased expression of NAA15 mRNA

NCBI chr 2:137,608,883...137,671,618
Ensembl chr 2:137,608,797...137,671,619

G

N-acetyl-alpha-glucosaminidase

decreases expression

ISO

trovafloxacin results in decreased expression of NAGLU mRNA

NCBI chr10:86,501,864...86,509,333
Ensembl chr10:86,501,836...86,509,315

G

NSF attachment protein beta

increases expression

ISO

trovafloxacin results in increased expression of NAPB mRNA

NCBI chr 3:156,585,394...156,632,418
Ensembl chr 3:156,585,394...156,632,418

G

nicotinate phosphoribosyltransferase

increases expression

ISO

trovafloxacin results in increased expression of NAPRT mRNA

NCBI chr 7:109,457,328...109,460,817
Ensembl chr 7:109,457,378...109,460,817

G

asparaginyl-tRNA synthetase 1

decreases expression

ISO

trovafloxacin results in decreased expression of NARS1 mRNA

NCBI chr18:60,259,506...60,275,782
Ensembl chr18:60,259,516...60,275,782

G

nuclear autoantigenic sperm protein

decreases expression

ISO

trovafloxacin results in decreased expression of NASP mRNA

NCBI chr 5:135,294,599...135,319,992
Ensembl chr 5:135,294,032...135,319,591

G

NAD(P)HX dehydratase

decreases expression

ISO

trovafloxacin results in decreased expression of NAXD mRNA

NCBI chr16:84,689,776...84,706,256
Ensembl chr16:84,688,243...84,706,411

G

NBAS subunit of NRZ tethering complex

decreases expression

ISO

trovafloxacin results in decreased expression of NBAS mRNA

NCBI chr 6:41,777,253...42,081,895
Ensembl chr 6:41,755,851...42,081,895

G

non-SMC condensin I complex, subunit D2

decreases expression

ISO

trovafloxacin results in decreased expression of NCAPD2 mRNA

NCBI chr 4:159,655,051...159,677,938
Ensembl chr 4:159,655,051...159,677,938

G

non-SMC condensin II complex, subunit D3

decreases expression

ISO

trovafloxacin results in decreased expression of NCAPD3 mRNA

NCBI chr 8:33,696,214...33,765,520
Ensembl chr 8:33,696,270...33,765,518

G

non-SMC condensin I complex, subunit G

decreases expression

ISO

trovafloxacin results in decreased expression of NCAPG mRNA

NCBI chr14:69,616,473...69,645,445
Ensembl chr14:69,616,473...69,645,445

G

non-SMC condensin II complex, subunit G2

decreases expression

ISO

trovafloxacin results in decreased expression of NCAPG2 mRNA

NCBI chr 6:143,484,651...143,561,850
Ensembl chr 6:143,485,944...143,560,249

G

non-SMC condensin I complex, subunit H

decreases expression

ISO

trovafloxacin results in decreased expression of NCAPH mRNA

NCBI chr 3:134,825,271...134,852,502
Ensembl chr 3:134,825,271...134,852,502

G

non-SMC condensin II complex, subunit H2

decreases expression

ISO

trovafloxacin results in decreased expression of NCAPH2 mRNA

NCBI chr 7:122,302,550...122,319,570
Ensembl chr 7:122,300,252...122,319,569

G

nuclear cap binding subunit 3

decreases expression

ISO

trovafloxacin results in decreased expression of NCBP3 mRNA

NCBI chr10:58,164,241...58,193,952
Ensembl chr10:58,164,234...58,193,964

G

NDC80 kinetochore complex component

decreases expression

ISO

trovafloxacin results in decreased expression of NDC80 mRNA

NCBI chr 9:118,853,806...118,887,582
Ensembl chr 9:118,853,806...118,887,568

G

nudE neurodevelopment protein 1

decreases expression

ISO

trovafloxacin results in decreased expression of NDE1 mRNA

NCBI chr10:1,347,010...1,391,167
Ensembl chr10:1,347,018...1,383,447

G

N-myc downstream regulated 1

decreases expression

ISO

trovafloxacin results in decreased expression of NDRG1 mRNA

NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913

G

NADH:ubiquinone oxidoreductase complex assembly factor 4

decreases expression

EXP

trovafloxacin results in decreased expression of NDUFAF4 mRNA

NCBI chr 5:43,401,795...43,406,967

G

NADH:ubiquinone oxidoreductase core subunit V1

decreases expression

ISO

trovafloxacin results in decreased expression of NDUFV1 mRNA

NCBI chr 1:210,729,856...210,735,103
Ensembl chr 1:210,729,858...210,734,949

G

nuclear paraspeckle assembly transcript 1

increases expression

ISO

trovafloxacin results in increased expression of NEAT1 mRNA

NCBI chr 1:212,507,512...212,568,055

G

nebulin

increases expression

ISO

trovafloxacin results in increased expression of NEB mRNA

NCBI chr 3:57,022,822...57,220,752
Ensembl chr 3:57,022,822...57,220,709

G

NECAP endocytosis associated 1

increases expression

ISO

trovafloxacin results in increased expression of NECAP1 mRNA

NCBI chr 4:157,775,890...157,790,992
Ensembl chr 4:157,775,896...157,790,984

G

NEDD4 like E3 ubiquitin protein ligase

multiple interactions
decreases expression

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NEDD4L mRNA
trovafloxacin results in decreased expression of NEDD4L mRNA

PMID:18930950 PMID:35537566

NCBI chr18:60,663,918...60,996,824
Ensembl chr18:60,663,970...60,996,824

G

neural precursor cell expressed, developmentally down-regulated 9

decreases expression
multiple interactions

ISO

trovafloxacin results in decreased expression of NEDD9 mRNA
[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NEDD9 mRNA

PMID:18930950 PMID:35537566

NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668

G

nei-like DNA glycosylase 3

decreases expression

ISO

trovafloxacin results in decreased expression of NEIL3 mRNA

NCBI chr16:45,091,401...45,151,419
Ensembl chr16:45,092,200...45,151,205

G

NIMA-related kinase 1

decreases expression

ISO

trovafloxacin results in decreased expression of NEK1 mRNA

NCBI chr16:34,009,092...34,137,418
Ensembl chr16:34,009,094...34,128,576

G

NIMA-related kinase 8

decreases expression

ISO

trovafloxacin results in decreased expression of NEK8 mRNA

NCBI chr10:63,558,940...63,570,954
Ensembl chr10:63,558,788...63,570,488

G

nuclear envelope integral membrane protein 1

decreases expression

ISO

trovafloxacin results in decreased expression of NEMP1 mRNA

NCBI chr 7:65,399,297...65,424,054
Ensembl chr 7:65,399,381...65,424,055

G

neogenin 1

decreases expression

ISO

trovafloxacin results in decreased expression of NEO1 mRNA

NCBI chr 8:68,169,711...68,322,158
Ensembl chr 8:68,169,716...68,322,152

G

nestin

decreases expression

ISO

trovafloxacin results in decreased expression of NES mRNA

NCBI chr 2:175,735,715...175,745,631
Ensembl chr 2:175,736,551...175,746,228

G

neuralized E3 ubiquitin protein ligase 1B

decreases expression

ISO

trovafloxacin results in decreased expression of NEURL1B mRNA

NCBI chr10:17,258,317...17,289,362
Ensembl chr10:17,258,328...17,289,362

G

nexilin (F actin binding protein)

decreases expression

ISO

trovafloxacin results in decreased expression of NEXN mRNA

NCBI chr 2:243,846,736...243,878,268
Ensembl chr 2:243,846,433...243,887,114

G

nuclear factor of activated T-cells 1

increases expression

ISO

trovafloxacin results in increased expression of NFATC1 mRNA

NCBI chr18:76,321,386...76,430,997
Ensembl chr18:76,321,386...76,430,990

G

nuclear factor I/A

decreases expression

ISO

trovafloxacin results in decreased expression of NFIA mRNA

NCBI chr 5:117,359,006...117,897,391
Ensembl chr 5:117,359,077...117,891,395

G

nuclear factor, interleukin 3 regulated

decreases expression

ISO

trovafloxacin results in decreased expression of NFIL3 mRNA

NCBI chr17:12,432,376...12,447,605
Ensembl chr17:12,432,198...12,450,826

G

NFKB inhibitor alpha

multiple interactions
increases expression

ISO

[Lipopolysaccharides co-treated with trovafloxacin] results in increased expression of NFKBIA mRNA; [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFKBIA mRNA; [trovafloxacin co-treated with TNF protein] results in decreased expression of NFKBIA protein; trovafloxacin promotes the reaction [TNF protein results in increased expression of NFKBIA mRNA]
[trovafloxacin co-treated with TNF protein] results in increased expression of NFKBIA mRNA
trovafloxacin results in increased expression of NFKBIA mRNA; trovafloxacin results in increased expression of NFKBIA protein

PMID:18930950 PMID:32035082 PMID:35537566

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

NFKB inhibitor delta

increases expression

ISO

trovafloxacin results in increased expression of NFKBID mRNA

NCBI chr 1:94,808,459...94,824,726
Ensembl chr 1:94,808,453...94,817,861

G

NFKB inhibitor zeta

multiple interactions
increases expression

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFKBIZ mRNA
trovafloxacin results in increased expression of NFKBIZ mRNA

PMID:18930950 PMID:35537566

NCBI chr11:58,251,720...58,279,767
Ensembl chr11:58,251,721...58,279,767

G

nerve growth factor receptor

increases expression

ISO

trovafloxacin results in increased expression of TNFRSF10B mRNA

NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305

G

NHERF family PDZ scaffold protein 1

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NHERF1 mRNA

NCBI chr10:100,902,165...100,919,265
Ensembl chr10:100,901,227...100,919,579

G

NHS-like 2

decreases expression

ISO

trovafloxacin results in decreased expression of NHSL2 mRNA

NCBI chr X:71,009,940...71,249,427
Ensembl chr X:71,009,949...71,241,289

G

niban apoptosis regulator 2

increases expression

ISO

trovafloxacin results in increased expression of FAM129B mRNA

NCBI chr 3:36,572,356...36,621,968
Ensembl chr 3:36,572,377...36,621,967

G

nidogen 2

decreases expression

ISO

trovafloxacin results in decreased expression of NID2 mRNA

NCBI chr15:4,507,224...4,562,949
Ensembl chr15:4,506,756...4,562,949

G

Sodium/potassium transporting ATPase interacting 1

increases expression

ISO

trovafloxacin results in increased expression of NKAIN1 mRNA

NCBI chr 5:148,031,685...148,076,834
Ensembl chr 5:148,031,338...148,076,834

G

NLR family member X1

decreases expression

ISO

trovafloxacin results in decreased expression of NLRX1 mRNA

NCBI chr 8:53,486,866...53,503,498
Ensembl chr 8:53,486,867...53,503,523

G

NME/NM23 nucleoside diphosphate kinase 1

decreases expression

EXP

trovafloxacin results in decreased expression of NME1 mRNA

NCBI chr10:79,403,939...79,426,620
Ensembl chr10:79,403,940...79,413,310

G

NME/NM23 nucleoside diphosphate kinase 2

decreases expression

EXP

trovafloxacin results in decreased expression of NME2 mRNA

NCBI chr10:79,394,999...79,400,418
Ensembl chr20:11,179,066...11,179,497
Ensembl chr10:11,179,066...11,179,497

G

NmrA like redox sensor 1

decreases expression

ISO

trovafloxacin results in decreased expression of NMRAL1 mRNA

NCBI chr10:11,348,080...11,356,621
Ensembl chr10:11,348,213...11,356,620

G

neuronatin

increases expression

ISO

trovafloxacin results in increased expression of NNAT mRNA

NCBI chr 3:166,646,373...166,648,845
Ensembl chr 3:166,646,384...166,649,086

G

nicotinamide nucleotide transhydrogenase

decreases expression

ISO

trovafloxacin results in decreased expression of NNT mRNA

NCBI chr 2:53,144,157...53,237,857
Ensembl chr 2:53,144,160...53,237,310

G

nocturnin

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NOCT mRNA

NCBI chr 2:137,422,074...137,442,282
Ensembl chr 2:137,422,074...137,442,282

G

nitric oxide synthase 1

decreases expression

ISO

trovafloxacin results in decreased expression of NOS1 mRNA

NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837

G

nitric oxide synthase 2

decreases expression

ISO

trovafloxacin results in decreased expression of NOS2 mRNA

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

notch receptor 2

decreases expression

EXP

trovafloxacin results in decreased expression of NOTCH2 mRNA

NCBI chr 2:188,299,336...188,432,823
Ensembl chr 2:188,299,336...188,432,823

G

NADP-dependent oxidoreductase domain containing 1

decreases expression

ISO

trovafloxacin results in decreased expression of NOXRED1 mRNA

NCBI chr 6:112,593,296...112,619,113
Ensembl chr 6:112,592,353...112,619,081

G

nephrocystin 4

decreases expression

ISO

trovafloxacin results in decreased expression of NPHP4 mRNA

NCBI chr 5:168,270,522...168,356,393
Ensembl chr 5:168,271,073...168,358,242

G

nephronectin

decreases expression

ISO

trovafloxacin results in decreased expression of NPNT mRNA

NCBI chr 2:224,065,191...224,133,567
Ensembl chr 2:224,065,191...224,133,435

G

nuclear receptor subfamily 1, group D, member 1

increases expression

ISO

trovafloxacin results in increased expression of NR1D1 mRNA

NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812

G

nuclear receptor subfamily 2, group F, member 6

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of NR2F6 mRNA

NCBI chr16:18,080,003...18,087,449
Ensembl chr16:18,080,003...18,087,449

G

nuclear receptor subfamily 3, group C, member 1

increases expression

EXP

trovafloxacin results in increased expression of NR3C1 mRNA

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 4, group A, member 1

increases expression

ISO

trovafloxacin results in increased expression of NR4A1 mRNA

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

nuclear receptor subfamily 4, group A, member 2

increases expression

ISO

trovafloxacin results in increased expression of NR4A2 mRNA

NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769

G

neurotrophin receptor associated death domain

increases expression

ISO

trovafloxacin results in increased expression of NRADD mRNA

NCBI chr 8:119,478,055...119,481,336
Ensembl chr 8:119,477,240...119,481,214

G

NSL1 component of MIS12 kinetochore complex

decreases expression

ISO

trovafloxacin results in decreased expression of NSL1 mRNA

NCBI chr13:105,176,163...105,205,179
Ensembl chr13:105,180,183...105,196,117

G

5'-nucleotidase domain containing 2

decreases expression

ISO

trovafloxacin results in decreased expression of NT5DC2 mRNA

NCBI chr16:6,328,925...6,336,978
Ensembl chr16:6,328,523...6,336,980

G

NUAK family kinase 2

increases expression

ISO

trovafloxacin results in increased expression of NUAK2 mRNA

NCBI chr13:46,305,744...46,322,755
Ensembl chr13:46,305,975...46,322,748

G

nudix hydrolase 22

increases expression

ISO

trovafloxacin results in increased expression of NUDT22 mRNA

NCBI chr 1:213,612,008...213,615,626
Ensembl chr 1:213,612,009...213,615,713

G

nudix hydrolase 6

decreases expression

ISO

trovafloxacin results in decreased expression of NUDT6 mRNA

NCBI chr 2:122,218,031...122,234,488
Ensembl chr 2:122,217,861...122,234,344

G

nudix hydrolase 7

multiple interactions

ISO

[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of NUDT7 mRNA

NCBI chr19:59,034,808...59,049,148
Ensembl chr19:59,034,839...59,063,994

G

NUF2 component of NDC80 kinetochore complex

decreases expression

ISO

trovafloxacin results in decreased expression of NUF2 mRNA

NCBI chr13:84,226,448...84,290,957
Ensembl chr13:84,226,509...84,255,598

G

nucleoporin 205

decreases expression

ISO

trovafloxacin results in decreased expression of NUP205 mRNA

NCBI chr 4:64,822,051...64,887,996
Ensembl chr 4:64,822,065...64,887,988

G

nucleoporin 210

decreases expression

ISO

trovafloxacin results in decreased expression of NUP210 mRNA

NCBI chr 4:125,068,736...125,167,238
Ensembl chr 4:125,068,736...125,167,047

G

nucleoporin 98 and 96 precursor

increases expression

EXP

trovafloxacin results in increased expression of NUP98 mRNA

NCBI chr 1:165,906,405...166,003,366
Ensembl chr 1:165,906,405...166,003,366